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1.1 ViruSeS aS bionanoTechnoLogicaL TeMPLaTeS
Viruses are arguably among the most abundant biological entities on earth.1 Since the 
discovery of the first non-bacterial pathogen infecting tobacco plants in 1892, over 5000 
virus species have been discovered and described in detail. It is estimated, however, that 
millions of viral species exist.2 Viruses are infectious agents, which can only replicate inside 
living cells of an organism. In order to perform this function, a virus minimally consists of 
nucleic acid, i.e. the viral genome, and a protein-based shell composed of a fixed amount 
of so-called capsid proteins. Enveloped viruses have an additional lipid membrane that 
surrounds the protein capsid when it is not present in a cell. The genome can be either 
DNA or RNA and encodes for all the proteins required for virus replication. 
Generally, viruses are associated with terrible diseases, such as Ebola and HIV/AIDS.3,4 
Since viruses are programmed for the delivery of cargo to cells, however, they have also 
been recognized as suitable templates for bionanotechnological applications. Special 
attention has been given to plant viruses and virus-like particles (VLPs), i.e. viruses 
devoid of their viral genome, as these particles pose less risk to humans. Several examples 
of viruses are known, which can be produced in their natural host and subsequently 
extracted and purified. Alternatively, heterologous expression protocols have been 
developed for the production of viral capsid proteins in yeast or bacteria.5 This has allowed 
scientists to use viruses and virus capsids as delivery vehicles, biotemplates in materials 
science, and nanoreactors.6–8 A wide range of differently shaped and sized viruses exist, 
e.g. icosahedrons, prolates and helices. In terms of the applications of these particles, this 
is a convenient advantage, as it allows the selection of a virus with the exact shape and 
size, suitable for a specific application. Additional advantages of the use of virus capsids in 
bionanotechnology are their monodispersity, highly symmetrical and ordered structure, 
biocompatibility, and stability towards variations in pH, temperature and solvent. 
Over the years, both genetic and chemical methods have been developed for the selective 
modification of VLPs. It was recognized that the particles have three surfaces which can be 
addressed independently: the exterior, interior and interface between the protein subunits.9 
This has allowed the alteration of the interactions of the VLPs with the environment through 
ligand display, the encapsulation of cargo and the manipulation of the protein subunit 
interactions, and thus the architecture and stability of the resulting capsids, respectively. 
Icosahedral viruses have especially drawn our attention, due to the fact that they possess an 
isolated inner cavity which can serve purpose in several applications (Figure 1.1).10
1.2 ouTLine of The TheSiS
The research described in this thesis is aimed at the construction of cowpea chlorotic 
mottle virus (CCMV)-based protein nanoparticles, which can serve a purpose as artificial 
organelles or drug delivery vehicles in living systems. Several aspects have been investigated 
in this context, i.e. (i) the development of robust techniques for the covalent modification 
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figure 1.1 Overview of the 200 icosahedral viruses, whose structures have been solved and included in the 
protein data bank (PDB). Adapted from the PDB.10
of the interior of the CCMV capsids, to enable modular and reproducible encapsulation 
of the desired cargoes, (ii) the application of the loaded CCMV capsids as nanoreactors, 
as a proof-of-principle for the functionality of the cargo after encapsulation in the CCMV 
capsid interior, and (iii) the expansion of the assembly profile of the CCMV capsid proteins, 
towards the creation of CCMV capsids that are stable at physiological conditions.
Chapter 2 of this thesis is a literature survey on the applications of several types of protein-
based nanocages in drug delivery and nanoreactor applications. It entails a brief introduction 
of the protein cages and VLPs which are most often used in bionanotechnological 
applications, followed by a description of several common methods to functionalize these 
particles. A number of examples of the modification of protein nanocages for drug delivery 
purposes, as well as their application as nanoreactors are given. Additionally, some relevant 
aspects for in vivo application of these particles, such as toxicity and biodistribution, are 
discussed.
In Chapter 3, a new enzymatic method is described for the modular, covalent modification 
of the N-terminus of the CCMV capsid proteins. As the N-termini of the capsid proteins 
are positioned on the inside of the capsids, attachment of a cargo to this terminus will lead 
to encapsulation of the cargo upon capsid assembly. In Chapter 4, a functional enzyme was 
covalently attached to the capsid protein N-terminus and subsequently encapsulated. It 
was shown that the activity of the enzyme was not affected by encapsulation and that the 
capsid offers a protective environment for the enzyme. This strategy was taken one step 
further in Chapter 5, which reports on the covalent encapsulation of lysozyme using the 
same enzymatic method, after which the resulting capsids were stabilized and used for 
catalysis under reaction conditions close to physiological conditions.
Chapter 6 describes the finding that hexahistidine tags, which are generally introduced in 
protein sequences for purification purposes, are able to act as catalysts in ester hydrolysis. 
This applies to the commonly used green fluorescent protein (GFP), but also to the CCMV 
capsid proteins. In addition, the equipment of an enzyme with a His-tag resulted in the 
formation of a dual-active enzyme, which was able to catalyze a two-step cascade reaction.
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Enzymatic modification of the CCMV capsid protein N-terminus, e.g. as described 
in Chapters 3, 4 and 5, is a very effective method to encapsulate peptides and proteins. 
Synthetic organic compounds, on the other hand, would have to be functionalized with a 
recognition peptide before being applicable as a cargo for this strategy. Therefore, a more 
convenient method for selective N-terminal protein modification using solely organic 
reactions was applied to the proteins in Chapter 7. In contrast to previous attempts to 
chemically modify the N-terminus of the CCMV capsid protein, this method was found 
to be mild enough and allowed the attachment of a fluorescent dye and an organocatalyst, 
without the need for an additional enzyme or catalyst.
In Chapter 8, attempts to fabricate nanoreactors without the aid of covalent interactions to 
force encapsulation of cargo are discussed. Inspired by nature, where viruses are packaged 
with nucleic acid material, the possibility of encapsulating a DNA-based catalyst inside 
CCMV capsids using only ionic interactions between the negatively charged DNA and the 
positively charged N-terminus of the capsid proteins was exploited.
Chapter 9 describes the expansion of the assembly profile of CCMV capsid proteins, 
modified with a short elastin-like polypeptide (ELP) at the N-terminus. By changing the 
guest residues in the ELP sequence, the hydrophobicity of this stimuli-responsive peptide 
block was increased. This allowed capsid protein assembly at lower salt concentrations, 
compared to the original construct, and thus, at conditions more similar to physiological 
conditions.
As a proof-of-principle for the potential use of CCMV capsids in nanotechnological 
applications, they were used as supramolecular and functional crosslinks in a biomimetic 
hydrogel in Chapter 10. By introducing these relatively complex crosslinking nodes into 
the gel, the mechanical behavior of the gel could be tuned. In addition, observed energy 
dissipation in the gel indicated that the capsids can be degraded under stress, offering 
opportunities for future applications of these types of crosslinked gels in e.g. drug delivery 
or stress sensor applications.
Finally, Chapter 11 reflects on the progress achieved in the application of VLPs for 
bionanotechnological applications, both based on the work described in this thesis, and in 
a broader context. Additionally, an outlook is given for the feasibility of the application of 
CCMV in biological systems, taking into account the achievements made so far for other 
types of VLPs.
Chapter 1
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abSTracT
Self-assembling protein-based nanocages are common features 
in nature, and serve as sources of inspiration in the field of 
bionanotechnology. Here, an overview is given of the protein-
based nanocages that are most commonly used for these types of 
studies, making a distinction between containers of viral origin and 
other types of nanocages. In particular, relevant examples of their 
application for both drug delivery and nanoreactor applications are 
discussed. To this end, emphasis is also given on the modification 
strategies that are most commonly used to modify the exterior and 
interior surfaces of these types of particles. Lastly, an overview is 
given of studies investigating the in vivo fate of protein-based 
nanocages, e.g. toxicity and biodistribution.
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figure 2.1 Schematic representation of a nanoparticle platform for drug delivery, featuring a core, corona, cargo 
and targeting ligands.
2.1 inTroDucTion 
2.1.1  nanoparticles in drug delivery
Conventional drug molecules diffuse throughout the body where they can affect normal 
cells next to their intended targets, leading to undesired side effects. In fact, less than 5% 
of all new potential therapeutics have favorable pharmacokinetic and bio-pharmaceutical 
properties.1 Recent nanotechnological advances have led to the development of smart 
nanoparticles which are able to selectively target tissues and deliver therapeutics. These 
nanosystems may be produced either by breaking down large structures into smaller pieces 
by techniques such as etching (top-down approach), or by assembling small components 
into supramolecular structures (bottom-up approach). The main advantage of applying 
nanoparticles in drug delivery is the ability to combine multiple functionalities into one 
therapeutic (Figure 2.1). Modifications to the exterior surface can impart a preferred 
distribution of drugs to the desired site of action compared to healthy tissues and thus 
drastically reduce side effects. To this end, targeting groups that bind specifically to the 
surface of the target cell type can be attached. The additional advantage of doing this 
on the surface of a nanoparticle is the potential increase of binding avidity through 
multivalency effects. In addition, a protecting layer (corona) can be attached to increase 
blood circulation times and reduce non-specific interactions. Simultaneously, multiple 
copies of a drug cargo can be delivered to a target tissue through encapsulation of the drug 
into the interior of the particles. Control over the time and location of cargo release can 
be obtained by integrating disassembly and degradation mechanisms that are activated 
under the desired conditions.
2.1.2  compartmentalized catalysis
Compartmentalization and positional assembly are two of the main methodologies found 
12
Chapter 2
in living cells that enable spatiotemporal control over multi-step biological processes. 
Many scientists have become intrigued over the years by these regulatory mechanisms and 
have explored possibilities to apply or mimic the organized complexity of the living cell.2,3 
In particular compartmentalization has become a topic of intense investigations, and has 
been targeted by a multidisciplinary group of scientists, from the fields of supramolecular 
catalysis to synthetic biology. For cells to function properly, compartmentalization is 
crucial; an internal structure is required which ensures temporal and positional control 
over the executed biological processes, which is particularly apparent in eukaryotic cells by 
the presence of organelles. Compartmentalization of a catalytic cycle prevents interference 
of other compounds and enables regulation of the flux of molecules in and out of the 
microenvironment. Moreover, a cell as a whole can be regarded as a compartment where 
the cell membrane takes care of regulating external stimuli to the correct internal response.
Over the years many different approaches have been followed to mimic the 
compartmentalization of catalytic processes found in nature with synthetic analogues. 
This research has been motivated by mainly four goals: (i) from a synthetic perspective, 
nanoreactors in which catalysis is performed in confined space can be useful to improve the 
efficiency and selectivity of the catalytic process, which could find its benefits in the fine-
chemical industry, (ii) biomimetic, catalytically active compartments can serve as a platform 
to study and understand complex multi-step biosynthetic pathways, such as protein 
expression and DNA replication, (iii) supramolecular chemists aim to push the boundaries 
of self-assembly by translating the design rules nature applies to the construction of well-
defined artificial nanocompartments, and (iv) biomimetic compartments and scaffolds 
can be employed to serve as artificial organelles, in order to yield a therapeutic effect in 
dysfunctional cells or to extend the biosynthetic pathways in living cells.
2.1.3  Protein-based nanoparticles
Over the past decades, substantial steps have been taken in the field of nanoscale engineering. 
This has allowed chemists to develop and utilize many different kinds of nanoparticles 
for various applications. For instance, a number of nanoparticle-based therapeutics and 
diagnostic agents have been developed to combat diseases such as cancer.4–6 Nanoparticles 
based on synthetic materials are often utilized, e.g. micelles, liposomes, polymersomes 
and layer-by-layer-capsules. The use of synthetic materials is attractive, as these can often 
be produced in high quantities and allow for facile modification for specific purposes. The 
architectures of the resulting nanoparticles, however, are often very disperse and have a 
relatively high size distribution.
On the other hand, protein-based cage structures are symmetrical, monodisperse and 
robust assemblies consisting of a limited number of protein subunits. They are highly 
promising for drug delivery purposes due to their stability, low toxicity, biocompatibility 
and biodegradability. Moreover, due to the highly repetitive structure, one single 
modification is identically displayed in a controlled fashion around the entire particle. 
The often spherical protein cages offer the opportunity of separate interior and exterior 
modification through biological and chemical approaches. This offers various possibilities, 
such as selective encapsulation of therapeutic drugs or catalytic systems.
13
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2.1.4  outline
In this chapter, commonly used methods for functionalization of protein-based nanocages 
will be discussed. Subsequently, modifications which we deem valuable for drug 
delivery applications will be mentioned. The emphasis will be on genetic and synthetic 
modification strategies for the attachment of molecules relevant to drug delivery, for 
instance therapeutic cargo or targeting moieties. Additionally, recent developments in the 
application of protein-based nanocages as nanoreactors will be illustrated. Lastly, we will 
evaluate the toxicity, immunology and biodistribution of the discussed nanoparticles, as 
these aspects are crucial for their in vivo application.
2.2 ProTein-baSeD nanocageS
In this section, the different protein-based cages will be introduced that have been 
applied in biomedical settings and as nanoreactors. A distinction will be made between 
nanocapsules of viral and non-viral origin.
2.2.1  Protein cages
In nature, a variety of proteins exist that self-assemble into capsule-like architectures. 
These protein cages function as carriers and storage devices for minerals and metal ions 
or hosts for biomineralization reactions. A well-known example is ferritin, an iron-storage 
protein, which is produced in almost all living organisms. Other proteins that self-assemble 
into cages are, for instance, the ferritin-like DNA-binding proteins from starved cells and 
small heat shock proteins.
Ferritin
Apoferritins, i.e. ferritins that have not yet been combined with iron, consist of 24 subunits 
which assemble into nanoparticles of approximately 450 kDa,7 with outer and inner 
diameters of 12 nm and 8 nm, respectively (Figure 2.2).8 The natural functions of apoferritin 
are binding of FeII, oxidation to FeIII and biomineralization towards ferric oxide clusters.9,10 
Ferritins are robust proteins; they can withstand high temperatures (85 °C) and high pH 
values (8.5–9.0) for a relatively long period of time without significant loss of structure. 
Also, ferritins are biocompatible and non-immunogenic. Therefore, these protein cages 
have been studied extensively as biomineralization scaffolds and MRI contrast agents.11
Small heat shock protein
Heat shock proteins are expressed in organisms in response to elevated temperatures and 
other types of cellular stress. Their main function is the facilitation of the correct synthesis 
and folding of proteins, by forming stable complexes with folding intermediates of their 
protein substrates. One class of heat shock proteins consists of the small heat shock 
proteins (sHsps). In this section we will focus on the sHsp from Methanococcus jannaschii 
14
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figure 2.2 Ribbon diagrams of the exterior surface view and interior cavity of wild-type human heavy chain ferritin 
(HFn). Reproduced from Uchida et al. with permission from Elsevier, Copyright (2010).11
figure 2.3	 Space	filling	model	of	the	interior	of	16.5	kDa	MjHsp,	viewed	along	the	crystallographic	three-fold	axis	
(left) and four-fold axis (right). Obtained from the Protein Data Bank (PDB 1SHS). Reproduced from Kim et al. with 
permission	from	Macmillan	Publishers	Ltd:	Nature,	Copyright	(1998).12
(MjHsp). This protein cage consists of 24 subunits, which self-assemble into an octahedral 
cage of 16.5 kDa with an outer diameter of 12 nm and an inner cavity of 6.5 nm (Figure 
2.3).12–14 This cage is also quite robust, as it is stable in the pH range 5–11 and at temperatures 
of up to 70 °C. The major difference between MjHsp and ferritin is the presence of large 3 
nm pores in MjHsp, which allow small molecules to diffuse in and out of the cage.
2.2.2  Virus-like particles
Viruses in their most simplistic form consist of a protein coat (capsid), which stores and 
protects viral nucleic acids (DNA or RNA). Their natural purpose is to infect plants, bacteria 
or animal cells in order to replicate and assemble new particles. Viral capsids have appealing 
properties for use in nanotechnology, one of which is their wide variety in sizes and shapes 
(Figure 2.4). Icosahedral particles ranging from circa 18–500 nm and rod-shaped particles 
with lengths of >2 µm exist. Their ability to form robust and monodisperse structures with 
15
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figure 2.4	 Virus(-like)	particles	which	are	used	in	nanotechnology.	Icosahedral	plant	viruses:	brome	mosaic	virus	
(BMV,	PDB	1JS9),31	cowpea	chlorotic	mottle	virus	(CCMV,	PDB	1CWP),27	cucumber	mosaic	virus	(CMV,	PDB	1F15),32 
cowpea	mosaic	 virus	 (CPMV,	PDB	2BFU),28,29	 turnip	 yellow	mosaic	 virus	 (TYMV,	PDB	1AUY).30 Icosahedral animal 
viruses:	 human	 hepatitis	 B	 (HBV,	 PDB	 1QGT),34 murine polyomavirus (PDB 1SID).33	 Icosahedral	 bacteriophages:	
HK97	(PDB	1OHG),37	MS2	(PDB	2MS2),35 P22 (PDB 2XYY),38	Qβ	(PDB	1QBE)36	(tails	not	shown).	Rod-shaped	viruses:	
tobacco	mosaic	virus	(TMV),	bacteriophage	M13.	Images	of	the	icosahedral	viruses	were	reproduced	from	the	VIPER	
database	(http://www.viperdb.scripps.edu).	The	structure	of	TMV	was	reproduced	from	Sachse	et al. with permission 
from Elsevier, Copyright (2007).40	The	structure	of	M13	was	reproduced	from	Khalil	et al.	with	permission	from	National	
Academy of Sciences, Copyright (2007).39
a high degree of symmetry makes them unique nanocontainers.15 For some viruses, it has 
been observed that their capsid proteins can self-assemble into stable virus-like particles 
(VLPs), in the absence of their corresponding genetic material. These particles are non-
infectious and have proven to be very suited for nanotechnological applications, such as 
vaccine development,16–18 biomedical imaging,19,20 synthesis of inorganic materials,21 gene 
therapy22,23 and development of arrays and films for electronics and tissue engineering.24–26
Icosahedral plant viruses
The cowpea chlorotic mottle virus (CCMV) capsid consists of 180 identical 20 kDa capsid 
proteins, which assemble into an icosahedral protein cage with T = 3 symmetry. The 
assembled cage has outer and inner diameters of 28 nm and 18 nm, respectively.27 CCMV 
can be obtained from its natural host, Vigna unguiculata, in yields of approximately 1–2 
mg per gram of infected leaves. Its coat proteins can also be obtained using expression 
systems based on yeast or Escherichia coli (E. coli), with good yields. The N-termini of the 
capsid proteins are located on the inside of the viral capsid, providing a suitable location 
for functionalization. The residues at this terminus are predominantly positively charged, 
allowing the encapsulation of negatively charged species, e.g. RNA or DNA. An attractive 
feature of CCMV is its ability to undergo a reversible, pH-dependent swelling. This results 
in the formation of 60 openings of 2 nm in diameter.
Cowpea mosaic virus (CPMV) has a 28 nm sized capsid composed of 60 subunits, which are 
made up of a small (24 kDa) and a large (41 kDa) subunit.28,29 CPMV has been widely used 
as protein-based nanoreactor due to its non-toxicity and stability in a wide range of pH, 
temperatures and solvents. It also has the natural capacity to bind and enter mammalian 
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cells, which has already proven useful in intravital imaging of vascular development. 
CPMV is commonly produced from infected black eyed pea plant leaves in approximately 
0.9 mg/g yields.
Red clover necrotic mosaic virus (RCNMV) is a T = 3 icosahedral virus with an outer 
diameter of 36 nm and an inner diameter of 17 nm. Its capsid is composed of 180 identical 
capsid proteins of 37 kDa. RCNMV can be obtained by inoculation on Nicotiana clevelandii 
plants, followed by collection and purification. Similar to CCMV, it can undergo a structural 
transition resulting in the formation of pores in its capsid. 
The icosahedral turnip yellow mosaic virus (TYMV) capsid is 28 nm in diameter and 
composed of 180 protein subunits which self-assemble into a capsid with T = 3 symmetry.30 
It can be isolated from turnip or Chinese cabbage. TYMV is stable in a broad range of pH’s, 
at high temperature and in various chemical environments.
Studies on several other icosahedral plant viruses, such as brome mosaic virus (BMV),31 
cucumber mosaic virus (CMV)32 and hibiscus chlorotic ringspot virus (HCRSV) have also 
been reported.
Icosahedral animal viruses
The Polyomaviridae family consists of many icosahedral animal viruses of 40–50 nm in 
diameter. They have been extensively studied as tumor viruses in humans and animals. 
Three species in particular have also been functionalized for biomedical applications: 
murine polyomavirus, Simian vacuolating virus 40 (SV40) and human polyoma JC virus. 
The murine polyomavirus is composed of an outer layer, composed of 72 VP1 capsid proteins, 
and an inner layer, consisting of capsid proteins VP2 and VP3.33 VP1 can be separately 
expressed and purified from E. coli and spontaneously forms capsids in the absence of 
VP2 and VP3. The structure of SV40 is very similar to that of the murine polyomavirus. 
The human polyoma JC virus consists of two viral proteins: the major coat protein VP1 and 
inner core protein VP2.
The rotavirus consists of a three-layered protein capsid of 77 nm in diameter. This 
surrounds its viral DNA, which is composed of 11 identical double helixes coding for 12 
different proteins. Six structural proteins are involved in the formation of the capsid (VP1, 
VP2, VP3, VP4, VP6 and VP7), whereas six other non-structural proteins are only produced 
in cells after infection by the rotavirus.
The human hepatitis B virus (HBV) is a human-specific liver virus composed of three 
different types of proteins: the small, medium and large proteins.34
Icosahedral bacteriophages
MS2 is an RNA-containing bacteriophage with an icosahedral phage head of 27 nm 
consisting of 180 identical capsid proteins.35 These subunits spontaneously self-assemble 
into genome-free, non-infectious hollow particles, independently of the phage tail. The 32 
pores in MS2 of ~2 nm wide enable interior functionalization without disassembly of the 
capsid. The MS2 VLPs can withstand pH’s from 3 to 10, making them a versatile platform 
for chemical modification. The viral capsid proteins of MS2 can be expressed in E. coli, 
after which the capsids can be assembled towards VLPs. Yields of 30 mg/L of bacterial 
culture have been reported for this procedure. 
17
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E. coli bacteriophage Qβ is a 28 nm T = 3 icosahedral particle composed of 180 identical 
coat proteins of 14 kDa, which can be obtained by bacterial expression.36 The virus strongly 
resembles bacteriophage MS2. Due to strong non-covalent interactions between the 
subunits, however, the viral capsid is more stable than MS2 under extreme temperature, 
pH and chemical reagent conditions.
Bacteriophage HK97, known to infect E. coli, is a large phage with a spherical phage head 
consisting of 415 capsid proteins with a double-stranded DNA genome.37 A mature virus 
head is formed during a series of maturation steps, during which the capsid expands from 
56 to 66 nm. A library of HK97 particles with different sizes and stabilities can be created 
by trapping them in different maturation stages.
The Salmonella typhimurium bacteriophage P22 has a 60 nm icosahedral T = 7 head and a 
short tail. The capsid consists 420 copies of the 47 kDa coat protein, which self-assemble 
around approximately 300 copies of a scaffolding protein (SP).38 Similar to HK97, the 
structure of P22 can undergo maturation. Additionally, maturation can be mimicked by 
extended heating. In this case a wiffle-ball capsid is formed, which is identical in structure 
to the mature capsid, except for the presence of 12 holes of 10 nm.
Rod-shaped viruses
Bacteriophage M13 is a commonly used rod-shaped display system, composed of five 
different proteins. It is 880 nm long and 7 nm in diameter.39 The virus is composed of a 
piece of circular, single-stranded DNA surrounded by 2700 copies of major coat protein P8. 
Its ends are capped with five copies of four different minor coat proteins. These proteins are 
utilized in a technique called phage display, in which peptides that can recognize specific 
targets are presented on the virus ends.
The tobacco mosaic virus (TMV) is a 300 nm rod-shaped virus with a helical capsid 
symmetry.40 It is built up from 2130 identical proteins of 17.5 kDa, which assemble around 
the viral DNA. The resulting helix has an outer diameter of 18 nm and a 4 nm wide core. In 
1999, TMV was used as a template for biomineralization for the first time.41 Since then, TMV 
has often been employed for the production of conductive polymers and metal nanowires. 
TMV is commonly obtained from infected tobacco plants in high yields.
The potato virus X (PVX) has a rod-like structure of approximately 500 nm in length and 13 
nm in diameter composed of 1270 identical 25 kDa capsid proteins.42
2.3 coVaLenT funcTionaLizaTion STraTegieS 
Several chemical methods exist which can be used for the selective modification of certain 
amino acids in virus particles (Figure 2.5). In most cases, endogenous lysines, cysteines and 
glutamic and aspartic acids are targeted.
Lysine residues, which possess a primary amine residue, are mostly reacted with 
N-hydroxy-succinimide esters (NHS esters) (Figure 2.5A). The advantage of this residue 
is that it is often solvent-exposed, due to its hydrophilicity. At the same time, targeting 
of specific lysine residues can be quite complicated. N-termini can be derivatized using 
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figure 2.5 Depiction of the most predominantly used internal and external chemical functionalization strategies 
of protein-based nanocages. a)	Lysine,	N-terminus:	conjugation	to	N-hydroxysuccinimide esters. b)	Cysteine:	thiol–
maleimide coupling or coupling with halogen-substituted acetamides. c)	Glutamic	and	aspartic	acid:	amide	formation	
through activation with a carbodiimide. D)	Tyrosine:	oxidative	coupling	of	a	phenylene	diamine	derivative	or	oxidation	
through a diazonium coupling reaction. e)	Tryptophan:	oxidative	coupling	of	a	phenylene	diamine	derivative,	similar	to	
that shown for tyrosine. f) para-Amino-l-phenylalanine:	oxidative	coupling	of	a	phenylene	diamine	derivative,	similar	
to that shown for tyrosine and tryptophan. g)	Homopropargylglycine:	click	chemistry	between	the	alkyne	and	an	azide.	
h)	Azidohomoalanine:	click	chemistry	between	the	azide	and	an	alkyne,	similar	to	G.
similar chemistry. These amines are not necessarily solvent-exposed, however, thus 
N-terminal modification with NHS esters is not applicable to all protein nanocages. A 
general limitation of NHS chemistry in general is a side hydrolysis reaction in water, which 
competes with nucleophilic attack of primary amines.
Two popular modification strategies exist for solvent-exposed cysteine residues, which 
provide reactive thiols (Figure 2.5B). Maleimide-thiol Michael-type couplings are most 
often used in cysteine-targeted functionalization, but halogen-substituted acetamides 
have also been used as reaction partners.
Aspartic and glutamic acids provide free acid moieties, which can be addressed by primary 
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amines in the presence of carbodiimides such as N-ethyl-N’-(3-dimethylaminopropyl)-
carbodiimide (EDC) (Figure 2.5C). The disadvantage of this type of functionalization is 
the use of primary amines, which are ubiquitous when working with proteins and/or in 
biological systems.
Tyrosine residues have been both utilized in their endogenous form, as well as after genetic 
introduction. Oxidative coupling of a phenylene diamine derivative with (NH4)2Ce(NO3)6 
as the oxidant has been used to functionalize tyrosine residues (Figure 2.5D). Alternatively, 
benzenediazonium derivatives have been obtained via a diazonium coupling. The former 
has also been done for genetically introduced tryptophan residues (Figure 2.5E) and para-
amino-l-phenylalanine residues (Figure 2.5F).
Another useful approach for functionalization is the reaction between alkynes and azides, 
as these react in an orthogonal fashion with each other. Therefore, homopropargylglycine 
(HPG) (Figure 2.5G) and azidohomoalanine (AHA) (Figure 2.5H) have been incorporated 
into protein nanocages. Generally, copper(I) is used to catalyze the azide–alkyne 
cycloaddition (copper(I)-catalyzed azide–alkyne cycloaddition, CuAAC). More recently, 
several types of strained alkynes have been developed which react with azides without the 
need of a copper catalyst (copper-free click chemistry). This approach can be useful when 
AHA is incorporated into the target protein.
2.4 ProTein-baSeD nanocageS in Drug DeLiVery 
In this section we describe the different modification strategies that have been followed to 
introduce biological functions to protein cages for a biomedical purpose. This entails both 
genetic methods and the chemical strategies depicted in Figure 2.5.
2.4.1  Protein cages
Ferritin
Douglas et al. were the first to introduce a modification onto the exterior of ferritin, while 
maintaining the overall cage architecture and the ability to form ferromagnetic iron oxide 
nanoparticles.43 The authors attached the amino acid sequence RGD-4C (CDCRGDCFC)44 
to the exterior N-terminus of human heavy chain ferritin (HFn) via a genetic modification 
strategy. This peptide selectively binds integrins αvβ3 and αvβ5, which are known to play 
an important role in the initial phases of some human diseases such as rheumatoid 
arthritis and cancer.45,46 The RGD-4C-HFn mutant showed increased specific targeting to 
amelanotic melanoma cells, compared to control HFn. In a separate study, the same authors 
proved that RGD-4C-HFn was able to specifically target THP-1 human acute monocytic-
leukemia cells.47 Additionally, it was found that the HFn mutant was internalized much 
more efficiently than the control. Xie et al. showed that a hybrid ferritin nanocage can 
be constructed by a pH-dependent disassembly and reassembly of two differently 
functionalized protein cages.48 This methodology was also used to construct fluorescently 
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labeled RGD-4C-functionalized HFn.49 The advantage of this method is the possibility to 
functionalize the exterior of ferritin with multiple types of functional groups. Recently, the 
authors showed that, after being pre-complexed with Cu(II), the chemotherapeutic agent 
doxorubicin (Dox) could be loaded into RGD-4C-HFn with high efficiency.50 Compared 
to free Dox, the drug-loaded capsules showed an extended circulation time and reduced 
cardiotoxicity, while maintaining integrin selectivity imposed by RGD-4C.
A melanoma-targeting HFn platform, functionalized with α-melanocyte-stimulating 
hormone, was developed by Ceci et al.51 The nanoparticles were specifically taken up by 
melanoma cells and not by other types of cancer cells. By masking the ferritin cage with 
polyethylene glycol (PEG) molecules, non-specific recognition was significantly reduced 
and the circulation times were improved.
Another biochemically interesting target is the epidermal growth factor receptor (EGFR), 
which is overexpressed in a number of cancers, such as lung and breast cancer.52 Cao et al. 
produced EGF-HFn nanoparticles by genetic fusion of the growth factor to recombinant 
ferritin proteins, followed by self-assembly into the apoferritin structure.53 These particles 
were efficiently and specifically taken up by breast cancer MCF-10A and MDA-MB-231 cells. 
Additionally, in vivo studies showed accumulation of EGF-HFn particles in mouse breast 
tumors.
Kang et al. genetically modified HFn to provide reactive cysteine residues on its exterior 
surface. These were functionalized with 24 β-cyclodextrins (β-CD) through a thiol-
maleimide addition, followed by CuAAC.54 The resulting β-CD–HFn complexes could 
form inclusion complexes with hydrophobic molecules such as adamantanes. These guest 
molecules were released slowly in a buffer solution, illustrating the potential of these 
systems for the delivery of hydrophobic drugs.
The same authors developed a stimuli-responsive delivery platform based on ferritin from 
hyperthermophilic archaeon Pyrococcus furiosus (PfFn).55 The C-terminal glycine in the 
interior cavity could be substituted with cysteine (G173C) for site-specific conjugation 
of cargo molecules. Furthermore, a thrombin cleavage peptide was introduced on the 
outer surface, which could be selectively cleaved by thrombin resulting in the release of 
the C-terminal helix, including cysteine 173 and its attached cargo. Specific recognition 
by MDA-MB-231 cells was achieved by the attachment of 48 biotins per cage on average. 
Kang and co-workers achieved tumor targeting of PfFn by genetically introducing the Fc-
binding peptide of IgG into a flexible loop region between two helices and mixing the 
modified protein with the natural protein subunits.56 Binding to breast cancer cells and 
folate receptor overexpressing cells was demonstrated.
Another member of the ferritin superfamily is the DNA-binding protein from Listeria 
innocua (LiDps). This nanocontainer is composed of 12 identical 18 kDa subunits and has 
inner and outer diameters of 9 and 5 nm, respectively. Janus-like particles were created 
with this protein cage by toposelective modification of its surface by a masking/unmasking 
method on a solid support (Figure 2.6).57 Two different moieties could be attached to 
different sides of the cage, allowing for sophisticated drug delivery through a polarized 
orientation with respect to the cell surface. As a proof of concept, the particles were loaded 
with monoclonal antibodies against Staphylococcus aureus (S. aureus).58
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figure 2.6	 Surface-masking	approach	for	toposelective	modification	of	the	surface	of	LiDps	towards	Janus-like	
particles. Adapted from Suci et al.	with	permission	from	the	American	Chemical	Society,	Copyright	(2009).58
Small heat shock protein
MjHsp has been proven to be a versatile platform for interior and exterior modification, 
pioneered by Douglas et al. They first demonstrated that specific amino acid residues 
could be genetically replaced for the display of thiol and amine groups.59 This methodology 
was used to encapsulate and release Dox in a controlled and selective manner.60 Mass 
spectrometry confirmed the attachment of 24 molecules of Dox on the interior surface of 
MjHsp. A hydrazone linker was used, which could be hydrolyzed under acidic conditions, 
similar to the conditions in the endosome. Subsequent studies showed that the MjHsp 
nanocontainer could be functionalized with cell targeting peptides and antibodies.61 
The attachment of abovementioned αvβ3 and αvβ5 targeting RGD peptides imparted cell-
specific targeting capabilities.61,62
Douglas et al. also utilized LyP-1, a small peptide which targets tumor-associated lymphatic 
vessels and macrophages, as a targeting moiety.63,64 Macrophage-rich atherosclerotic lesions 
in mice were targeted by MjHsp cages with LyP-1 genetically attached to the C-terminus.65
Hashizume et al. used MjHsp to target hepatocellular carcinoma (HCC) cells, by 
functionalization with HCC-binding peptide SP94 (SFSIIHTPILPL).66 The authors reacted 
amine groups on the exterior of MjHsp with a bifunctional PEG linker and the SP94 peptide.67 
By fluorescence microscopy, it was shown that the nanocages bound specifically to HCC 
cells and not to other cell lines tested. Furthermore, the authors optimized the affinity of 
the cages for HCC cells by varying the amount of immobilized SP94, the conjugation site 
of SP94 and linker length. The most effective binding was found for conjugation of the 
N-terminus of SP94 to the protein cage with high SP94 levels and a longer linker length. 
The same authors also published a method by which the SP94-functionalized MjHsp cage 
can be made genetically.68 This way, the density of the SP94 peptide on the outer surface 
was easier to control, compared to the multi-step chemical process. Dox was conjugated to 
the interior of this cage via a hydrazone linker and its cytotoxic effects towards Huh-7 HCC 
cells were demonstrated. 
Furthermore, liver cell-specific targeting nanocages were developed by genetically 
modifying the outer surface of MjHsp with the preS1 peptide.69 This peptide is derived 
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figure 2.7	 Schematic	presentation	of	the	assembly	of	mixed	protein	cages.	Reproduced	from	Gillitzer	et al. with 
permission	from	John	Wiley	and	Sons,	Copyright	(2006).71
from HBV and is known to have a high affinity for liver tissue. The functionalized protein 
cages showed lower cytotoxicity and higher specificity towards human hepatocyte cell 
lines than other cell lines in vitro.
2.4.2  Virus-like particles
CCMV
One of the first examples of chemical modification of VLPs was reported for CCMV.70 
Douglas et al. addressed natural amines and carboxylic acids present on the surface for 
the attachment of functional molecules. In addition, the authors genetically engineered a 
mutant with two surface-exposed thiols per capsid protein, since the wild-type virus does 
not have reactive cysteine residues. It was found that up to 540 amines, 560 carboxylic 
acids and 100 thiols could be labeled with a fluorescent dye, without disrupting the cage 
structure. Moreover, surface-exposed thiols were chemically linked to an antitumor 24 
amino acid peptide sequence.
In order to control the attachment of different groups to the same VLP, Douglas and co-
workers constructed CCMV capsids through mixed self-assembly.71 Two populations of 
capsids were created by attaching different ligands to exterior lysine residues. The capsids 
were disassembled in vitro and the resulting subunits were separately purified by size 
exclusion chromatography. Then, the purified capsid proteins were mixed in defined ratios 
in order to precisely control the composition of the final capsids (Figure 2.7).
An application of the functional modification of CCMV came with the development of dual-
functionalized CCMV capsids for the treatment of bacterial infections via photodynamic 
therapy (PDT).72 In PDT, specific wavelengths are used to excite photosensitizers to 
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figure 2.8	 Schematic	presentation	of	the	formation	of	the	protein–capsid	complex	with	leucine	zippers.73
generate reactive oxygen species, thereby killing the target cells. A ruthenium complex, 
which acts as a photosensitizer, was chemically attached to exterior cysteine residues. To 
improve the PDT, specific antibodies were also linked to the capsid to target S. aureus cells. 
Killing of targeted cells increased up to 100-fold relative to the non-targeted cells or the free 
ruthenium complex.
In contrast to the abovementioned examples, methods have also been developed to 
selectively modify the interior of CCMV. Cornelissen et al. developed an encapsulation 
method based on non-covalent interactions between the capsid proteins and the cargo, 
as this eliminates the need for chemical reactions.73 The N-terminus of the capsid protein 
was modified with a positively charged leucine zipper and its negative complementary 
counterpart was attached to enhanced green fluorescent protein (EGFP) (Figure 2.8). 
By varying the ratio between wild-type and modified capsid protein, the amount of 
encapsulated EGFP could be precisely controlled and up to 15 EGFP molecules were 
encapsulated.
CPMV
A wide variety of targeting molecules have been attached to the CPMV capsid by chemical 
conjugation to either lysines or cysteines, using for instance NHS and maleimide 
conjugated ligands, respectively.74–83 Specific interior modification of the CPMV capsid 
has been performed by addressing the naturally occurring reactive interior cysteines.84 
Fluorophores, biotin affinity tags, PEG polymers and various peptides have been conjugated 
to the capsid interior in this way. Since native CPMV does not display reactive cysteines 
on its exterior surface, cysteines have been genetically inserted on the surface. A variety 
of ligands could be introduced to these inserted cysteines, including carbohydrates,76 
antibodies,75,77 oligonucleotides,79 organic dyes,75,85 biotin,85 peptides86 and proteins.80 A 
problem of genetic introduction of thiols, however, is the possibility of disulfide bond 
formation, followed by aggregation. Therefore, a chemical method was developed for the 
introduction of protected thiols in CPMV VLPs.87 Surface-exposed lysines were modified 
to thioacetate groups using N-succinimidyl-S-acetylthiopropionate. The protecting group 
could be easily removed with hydroxylamine hydrochloride. Surprisingly, no aggregation of 
the particles was observed after deprotection, probably due to the positioning of the thiol 
groups. Further mutagenesis studies showed that the exterior solvent-accessible lysines are 
addressable in a different degree.88 A series of CPMV mutants was produced where specific 
lysines were replaced by arginine residues, in order to determine the reactivity of each 
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individual lysine. This knowledge was applied for the specific attachment of a component 
of HER2 tyrosine kinase receptor to a single lysine.80 Additionally, histidines have been 
genetically introduced at various locations on the CPMV capsid.89 Their relative reactivity 
was confirmed by labeling of the histidines with nanogold.
Additionally, native CPMV possesses 180 accessible carboxylate groups which can be 
addressed, as shown by Evans et al.90 This method of modification is very valuable, as 
it provides chemists with coupling chemistry which can be independently used without 
affecting amines and cysteines on the CPMV surface.
Derivatization of the CPMV exterior has also been performed using CuAAC, which allows 
conjugation with different types or more challenging ligands, compared to abovementioned 
strategies. Another advantage of using click chemistry over direct functionalization of the 
lysines or cysteines is the selectivity. Both reaction components (azide and alkyne) are 
non-reactive, unless they are mixed in the presence of a Cu(I) catalyst. Finn et al. showed 
that azides and alkynes can be introduced on the CPMV capsid surface at both reactive 
lysine and cysteine residues.91 These handles were then used to incorporate a wide variety 
of ligands, including organic dyes, carbohydrates, peptides and PEG polymers.91–94 For 
tumor-targeted delivery, transferrin (Tfn) and glycopolymers were conjugated to CPMV 
using click chemistry, as the Tfn receptor and carbohydrate receptors are overexpressed 
on several types of tumor cells.92,95 Azides were also installed on the CPMV surface by 
addressing accessible tyrosines, followed by a click reaction to conjugate an organic dye.96 
This was only possible, however, if an inhibitor was added to prevent crosslinking of 
tyrosines after oxidation.
The abovementioned methods for CPMV derivatization have been applied in several 
studies towards CPMV drug carriers. For instance, PEGylation has been shown to reduce 
the interaction of CPMV with cells in vivo.97 When a targeting moiety is combined with PEG 
on the surface of CPMV, the desired cells are targeted while eliminating any background 
binding of the VLP to other cells. This was shown by Manchester and co-workers, who 
used folic acid (FA) in combination with PEG to specifically target tumor cells.98 Uptake 
of FA into cells is mediated by the folate receptor, which is overexpressed on the surface 
of many human cancers. PEGylation can also be applied to modulate binding of ligands to 
the surface of CPMV. For instance, the binding of Lerner–Janda blue fluorescent antibody 
to its antigen stilbene, which was bound to CPMV, could be blocked and controlled by 
PEGylation of the surface.77
CPMV decorated with peptide ligands has also been used for tumor targeting. Peptide 
F56 was conjugated to the surface of CPMV, which specifically binds vascular endothelial 
growth factor receptor 1.82 First, exposed lysine residues were converted into benzaldehyde 
groups, after which the peptide was ligated via a stable hydrazone linkage. In vitro specificity 
for tumors overexpressing the corresponding receptor was observed. Polyarginine cell 
penetrating peptides were attached to CPMV via a similar hydrazone ligation strategy.99 
Studies in vitro showed effective uptake by HeLa cells. Bombesin peptides were attached 
to CPMV via NHS acylation and click chemistry for targeting of tumor cells overexpressing 
the gastrin-releasing peptide receptors.83 Targeting and uptake in human prostate tumor 
cells was demonstrated in vitro. The same strategy was used for the attachment of a cyclic 
RGD-containing peptide.100 Selective binding and internalization into several cancer cell 
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lines expressing RGD-binding integrin receptors was shown in vitro.
A useful biomedical application of CPMV in PDT was described by Manchester et al. A 
popular photosensitizer of choice for applications in PDT is C60. C60 is very hydrophobic, 
however, which limits its application in aqueous systems. By attaching C60 to CPMV 
through its native lysine residues, the solubility of the photosensitizer was significantly 
enhanced.81 Furthermore, cellular uptake of CPMV by HeLa human cancer cells was not 
inhibited by the attachment of C60.
Utilizing both native carboxylic acid and amine groups on the exterior of CPMV, Evans and 
co-workers attached Dox to the capsid.101 The carboxylic acid groups were modified with 
NHS, followed by a reaction with Dox to create a stable amide linker. Lysines were attached 
to Dox through a linker containing a labile disulfide bond. The ability of CPMV to target 
cancer cells via surface-expressed vimentin102 was used to target the VLPs to HeLa cells. A 
higher cytotoxicity towards HeLa cells was observed compared to free Dox, when the amide 
linker was used. The VLP with disulfide linker was approximately as active as free Dox. This 
is the first example of a promising application of CPMV as a drug delivery vehicle.
Bacteriophage	MS2
The Stockley group was the first to chemically modify the MS2 capsid for encapsulation 
of cargo molecules. They utilized the natural affinity of the coat protein for a specific 
fragment in the viral RNA sequence for drug encapsulation. The specific RNA stemloop was 
attached to a plant toxin, ricin A chain and packaged into the VLP.103 To achieve targeting, 
surface-exposed lysines were modified to thiols with N-succinimidyl-S-acetylthioacetate 
for the attachment of Tfn.104 In vitro studies with the dual-functionalized MS2 capsids 
demonstrated cell-specific targeting and cytotoxicity. 
Additionally, exterior lysines have been used to attach the SP94 peptide for HCC cell 
targeting.105 The authors showed that VLPs modified with the targeting ligand exhibited 
a 104-fold higher avidity for HCC than for control tissues. Furthermore, these conjugates 
were used to deliver a variety of cargo molecules to HCC cells.
Cell targeting was also achieved through functionalization of the exterior of MS2 capsids 
with the cell penetrating HIV-1 Tat peptide.106 Amine groups were subsequently reacted with 
a heterobifunctional crosslinker and the N-terminal thiol side chain of the Tat peptide. The 
capsids were successfully delivered to human hepatoma Huh-7 cells. Covalent attachment 
of human transferrin to the MS2 surface induced targeting to HeLa cells.107 Other exterior 
residues have also been used to create functional handles onto the MS2 surface. For example, 
Francis and co-workers explored the reactivity of electron-rich amino acids tryptophan 
and tyrosine for exterior capsid functionalization.108 The majority of these native residues 
are not solvent-accessible and thus unlikely to be prone to modification. One exception is 
tyrosine 85, an interior amino acid. The authors envisioned that functionalization of this 
residue, however, would not be possible when large coupling partners were used. Tyrosine 
and tryptophan residues were thus introduced on external positions 19 and 15. As a proof-
of-principle, PEG and RGD derivatives were attached to the surface of MS2. Swartz et al. 
used a cell-free methionine replacement approach to introduce surface-exposed AHA and 
HPG residues containing reactive side chains.109 These could be reacted with alkyne- and 
azide-containing molecules, respectively. Proteins, nucleic acids and PEG chains were 
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figure 2.9	 Four-step	methodology	for	 the	attachment	of	olefin-containing	substrates	to	 tyrosine	residue	85	on	
the	interior	of	MS2.	a)	2	(5	eq.),	pH	9,	4	°C,	15	min;	b)	Na2S2O4	(100	mM),	pH	7.2,	rt,	2	h,	80-85%	protein	recovery,	2	
steps;	c)	NaIO4	(100	mM),	pH	6.5,	followed	by	D)	6	(10	mM),	2	h,	75%	protein	recovery.	Adapted	from	Hooker	et al. 
with permission from the American Chemical Society, Copyright (2004).116
conjugated in a controlled fashion. This technology was applied to both bacteriophages 
MS2 and the bacteriophage Qβ (see also next section). Peabody showed that an exterior 
threonine could be substituted by cysteine.110
An alternative functionalization approach was introduced by Francis and co-workers. 
They implemented the procedure for unnatural amino acid incorporation, developed by 
Schultz et al.,111 to introduce an orthogonal functional handle in MS2. A para-amino-l-
phenylalanine (pAF) residue was introduced in each capsid monomer using the amber 
codon suppression method.125 In this method, the target codon is mutated to an amber 
stop codon in the mRNA. Suppressor tRNA aminoacylated with the unnatural amino 
acid recognizes the amber codon as a sense codon, allowing for the incorporation of any 
unnatural amino acid. The resulting 180 copies of the aniline group could then be reacted 
with specific cell targeting peptides and DNA aptamers.112,113 Subsequently, the aptamer-
conjugated MS2 cages were loaded with porphyrins for PDT and targeted to Jurkat leukemia 
T cells.114 The dual-functionalized particles were able to kill the Jurkat cells selectively 
in only 20 minutes by PDT. Recently, Francis et al. reported a more efficient version of 
the aniline oxidation reaction under similar conditions.115 High levels of conversion and 
equivalent chemoselectivities were achieved in <2 minutes, using aminophenols instead 
of phenylene diamines for the coupling with aniline side chains.
The Francis group was also the first to modify the MS2 interior. They developed an 
orthogonal four-step methodology for the attachment of olefin-containing substrates to 
modified tyrosine residues in the capsid.116 Key steps were a diazonium coupling reaction, 
followed by a hetero-Diels-Alder reaction (Figure 2.9). A similar strategy was also applied 
for the attachment of 50–70 dyes inside MS2, demonstrating the ability to encapsulate 
large drug molecules.117 In the same paper, the authors showed that the particles could 
be subsequently functionalized with PEG chains to improve the circulation times in vivo. 
Interior modification was also achieved by mutating an asparagine residue to a cysteine.118 
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figure 2.10	 Schematic	 presentation	 of	 the	 production	 of	 Qβ	 particles	 partially	 displaying	 EGF	 at	 the	 exterior	
C-terminus. Reproduced from Pokorski et al.	with	permission	from	John	Wiley	and	Sons,	Copyright	(2011).122
To this handle, taxol was attached, which is a potent chemotherapeutic agent used in the 
treatment of several cancers. Upon incubation with breast cancer MCF-7 cells, the linker 
was cleaved, thereby releasing the drug. Surprisingly, this was achieved without the use of 
targeting groups.
Bacteriophage	Qβ
The field of Qβ functionalization was pioneered by the Finn group. Their first paper on this 
topic comprised the replacement of an exterior methionine for AHA and HPG via the sense 
codon technique.119 They also showed that a functional handle inside the capsid could be 
introduced by mutation of Thr93 to an azidohomoalanine.120 Using click chemistry, both of 
these functional groups could be addressed without loss of the capsid stability.
Cell targeting was achieved for the first time when human transferrin was conjugated to 
Qβ particles.121 The authors used a strategy they previously had used for the attachment of 
Tfn to CPMV.92 Only in this case, Tfn was not derivatized at the cysteine residues, allowing 
for controlled derivatization and preservation of protein function. Here, the sialic acid 
residues on Tfn were oxidized, followed by introduction of a reactive alkyne functionality. 
Exterior lysine residues on the Qβ capsid were exposed to a succinimidyl ester activated 
alkylazide to introduce the complementary reaction partner. The Qβ–Tfn conjugate, 
formed by CuAAC, showed specific recognition and internalization by Tfn-receptor-
bearing cells. The uptake rate turned out to be proportional to the ligand density and was 
inhibited by the presence of free Tfn.
Finn et al. modified Qβ such, that its exterior displayed 5–12 copies of EGF for cancer cell 
targeting.122 A two-plasmid system was used to produce a mixture of a C-terminal truncated 
version of the native coat protein and a version with EGF fused to the C-terminus (Figure 
2.10). The functionalized particles were still prone to bioconjugation by click chemistry, 
without disruption of the ability to interact with the EGF receptor. Furthermore, apoptosis 
of A431 epidermoid carcinoma cells could be induced by interaction with EGFR.
In another application, cell targeting was achieved by conjugation of Qβ to a modified sialic 
acid which selectively binds to CD22.123 The imparted targeting capabilities were combined 
with cytotoxic activity through the attachment of a metalloporphyrin derivative for PDT. 
Both ligands were provided with an azide functionality and alkynes were attached to the 
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surface through acylation of the 720 surface-exposed amine groups for functionalization 
by means of a CuAAC reaction. Successful targeting, internalization and phototoxicity of 
the modified particles was detected.
Photodynamically active VLPs have also been obtained by attachment of photosensitizer 
C60 to Qβ.
81 Conjugation of fullerenes to VLPs was already mentioned above for CPMV.81 
In this case, C60 was attached to Qβ via two different methods: directly to the native lysine 
residues and via click chemistry with azides conjugated to the Qβ surface via a linker. The 
authors showed that the Qβ–C60 complex was internalized by breast cancer cells. It was 
also proven that cell uptake and cell killing in prostate cancer cells is possible using white 
light therapy.124
Qβ nanoparticles were also used for the display of cationic motifs that act as heparin 
antagonists. Heparin stimulates thrombin inhibition by antithrombin and is therefore 
often used as an anticoagulant. Normally, high doses are administered to prevent 
thrombosis, which can lead to uncontrolled bleeding in some cases. Protamine, which 
is highly positively charged, is the only FDA-approved agent for heparin neutralization, 
but its adverse effects are significant. Therefore, in order to develop an alternative for 
protamine, several point mutations on the exterior surface of Qβ were used to introduce a 
spectrum of particles with different surface charges. The VLPs appeared to bind and block 
the anticoagulant function of heparin more effectively than protamine in a biochemical 
assay.125 In patient samples, the modified Qβ capsids also showed heparin reversal, even if 
high doses of heparin were administered to the patients.126 Compared to protamine, more 
consistent results were obtained for the VLPs.
In order to improve the pharmacokinetic properties of Qβ, Finn and co-workers prepared 
polymer-coated Qβ VLPs.127 Atom transfer radical polymerization (ATRP) initiators were 
attached to the exterior surface of Qβ via click chemistry, after which oligo(ethylene glycol)-
methacrylate and its azido-functionalized analogue were polymerized on the surface. The 
resulting particles retained a low polydispersity and allowed conjugation of e.g. Dox via 
CuAAC.
TMV
Mutants of TMV displaying lysine and cysteine residues on the outer surface have been 
made for functionalization via selective amine and thiol chemistry.128,129 Francis et al. utilized 
naturally occurring external tyrosine residues for an efficient diazonium coupling/oxime 
formation sequence, similar to the abovementioned strategy for MS2 functionalization.130 
This approach was used to decorate the surface with >1000 copies of PEG MW 2000 
and 5000. In addition, glutamic acid residues on the interior could be modified via a 
carbodiimide coupling reaction with several amines.130 The Wang group used the same 
diazonium chemistry in combination with CuAAC to modify the exterior tyrosines.131,132 
Instead of using diazonium salts bearing an ester-group, the authors used alkyne-
functionalized diazonium salts, which could be clicked to a wide range of compounds.
Miscellaneous	VLPs
Several other types of VLPs have been applied in studies on the development of drug 
delivery vehicles. Below, we will discuss three examples which we deem the most valuable 
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in addition to the abovementioned VLPs. Less commonly applied VLPs are bacteriophage 
λ,133 BMV,134 HBV,135–137 CMV,138 HCRSV,139 HK97,153 PVX,141,142 RCNMV,143 rotavirus,144 and 
TYMV.145,146 The reader is referred to the given references for examples of their applications 
in nanotechnology.
Bacteriophage P22 was utilized by Prevelige et al. as a molecular display platform by 
genetically introducing a cysteine residue on its exterior.147 This cysteine proved reactive 
towards maleimide reagents. Non-covalent attachment of cargo to P22 was achieved using 
a stepwise addition protocol with the phage decoration protein (Dec).148 This protein binds 
selectively to the surface of mature capsids.149 Both termini of the bound Dec appeared 
available for cargo binding. Recently, the Douglas group found that the C-terminus of 
P22 extends towards the capsid exterior.150 They used this knowledge to e.g. introduce a 
cysteine on the exterior, which can serve as a handle for functionalization. The same group 
also investigated different strategies for interior modification of the P22 capsid. Genetic 
introduction of cysteine residues, followed by site-specific attachment of a maleimide–
biotin complex proved successful for both the empty capsid and the wiffle-ball structure.151 
Anchoring of streptavidin to the biotin molecules was possible for the wiffle-ball owing 
to its holes, providing a method for cargo loading. Site-selective initiation of ATRP on 
the interior of P22 was used to introduce handles for the attachment of small-molecule 
cargo as well.152 A new single point mutation was used to introduce an interior thiol, to 
which the ATRP initiator could be attached. After polymerization, the primary amine 
groups present on the side chains of the polymer were found reactive towards for instance 
fluorescent dyes. Finally, the authors used metal–ligand coordination to load cargo into 
P22.153 Again, cysteine residues were genetically introduced in the interior, followed by 
reaction with 5-iodoacetamido-1,10-phenanthroline, binding of metal ions and addition of 
phenanthroline ligands. By attaching a small molecule to the ligand, cargo loading could 
be achieved.
Bacteriophage M13 was first used by Chen et al. for drug delivery.154 They genetically 
produced chimeric phages by displaying RGD-4C and a streptavidin-binding peptide 
for tumor targeting and tracking, respectively. In vivo tumor targeting of the chimeric 
phage complexed with streptavidin-quantum dots was achieved. Chemical methods 
have also proven useful for the attachment of chemotherapeutic agents hygromycin and 
Dox to surface-exposed carboxylic acids.155,156 Chloramphenicol-loaded M13 phages have 
been used as antibacterial targeted delivery vehicles.157 Wang et al. explored the chemical 
modification of three reactive groups on M13: amino groups of lysine residues and the 
N-terminus, carboxylic acid groups of aspartic and glutamic acid residues and phenol 
groups of tyrosine residues.158 Fluorescent molecules and cancer cell targeting motifs such 
as FA could be attached. The reactive groups could also be addressed separately, creating 
new methods to selectively produce dual-functionalized M13 phages. Next, the authors 
used the folic acid-conjugated M13 to create a core-shell structure where the phage formed 
the shell and copolymer poly(capro-lactone-b-2-vinylpyridine) the core, incorporated 
with Dox.159 FA was in this case conjugated to free amines on the surface of M13 via an 
EDC coupling reaction. It was shown that the Dox-loaded particles were internalized more 
efficiently than free Dox, due to the presence of FA targeting groups.
As mentioned previously, three types of polyomaviruses have been applied in biomedical 
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applications: murine polyomavirus, SV40 and human polyoma JC virus. The VP1 capsid of 
murine polyomavirus has been genetically modified by Böhm et al. to display the sequence 
of a WW domain in its β-turns.160 WW domains are small protein domains named after the 
two conserved tryptophan residues which are essential for its folding and function.161 They 
specifically bind proline-rich peptide sequences. It was shown that one variant of the WW 
domain maintained its high selective binding affinity for proline-rich ligands. This allows 
for a short-term coupling of cargo to the exterior of the VP1 capsid. The same authors 
similarly introduced a WW domain in the interior of the VP1 capsid.162 Assembly of the VP1-
WW particles in the presence of proline-rich cargo resulted in an efficient encapsidation 
into the particles. Other methods of VP1 modification are based on the specific interaction 
between VP1 and the inner core proteins VP2 and VP3. Encapsulation can in this case be 
achieved by fusing the desired cargo to (parts of) VP2 or VP3. Following this strategy, 
green fluorescent protein (GFP)163,164 and antimetabolite methotrexate163 were enclosed 
in murine polyomavirus. In all cases, targeted drug delivery was achieved. The particles, 
however, were irregularly shaped and showed poor solubility. SV40 has been utilized for the 
encapsulation and delivery of EGFP and cytosine deaminase.165 In a separate study, several 
peptides were inserted into VP1 surface loops through mutagenesis.166 It was shown that 
introduction of foreign peptides, such as flag-tags, on the surface can reduce natural virus–
cell interactions. Also, the ability to bind new target tissues was introduced by insertion 
of RGD motifs. The same authors conjugated human EGF to the exterior of a cysteine-
containing mutant of SV40 through a thiol-maleimide coupling.167 They showed increased 
selectivity for cells displaying the EGF receptor. Human polyoma JC virus has been used to 
create a pH-responsive drug release vesicle.168 VP2 was modified to display hexahistidine 
tags inside the VLPs, which offered specific and reversible attachment of drug molecules 
containing a hexahistidine-targeting segment. As proof of concept, a fluorescent small 
molecule was encapsidated and released in mouse NIH 3T3 cells. A similar system, in 
which drug release is triggered by glutathione, was developed by the same authors.169 In 
this case, cyclodextrins were coupled to the inside of VP1 through a disulfide bond so that 
hydrophobic drugs could be encapsulated. Release of different types of dyes was shown 
to increase with glutathione concentration. Furthermore, anticancer drug paclitaxel was 
released inside the cytoplasm of NIH 3T3 cells, as the glutathione concentration in the 
cytoplasm is approximately three times higher than outside cells.
2.5 ProTein-baSeD nanocageS aS nanoreacTorS
Icosahedral virus particles have been one of the most studied classes of protein nanocages 
for nanoreactor applications. Reversible assembly and disassembly behavior of e.g. the 
CCMV virus capsid, can be used for the statistical encapsulation of enzymes. Nolte et al. 
used this method to, for instance, encapsulate horseradish peroxidase.170 Because of the low 
loading efficiency resulting from this encapsulation method, single enzyme nanoreactors 
were obtained which were used in single enzyme kinetics studies. Cornelissen et al. 
showed that this strategy can also be applied for the encapsulation of small heterogeneous 
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catalysts, such as colloidal gold nanoparticles.171
In order to improve on the loading, non-covalent interactions were introduced between 
the capsid proteins and the enzymes to be encapsulated. In one approach, complementary 
coiled-coil peptides capable of heterodimerization were employed, as mentioned above.73 
This strategy was also employed for the encapsulation of Candida antarctica lipase 
B (CalB).172 The enzymes were bound efficiently and the CCMV capsid could still be 
assembled. With this method the number of CalB enzymes inside could be much better 
controlled and this allowed the researchers to investigate the effect of enzyme confinement 
on activity. It was shown that encapsulated enzymes were more active than the free CalB. 
This was explained by the high local enzyme concentration in confined space which leads 
to a very efficient reaction between substrate molecules that have entered the capsid and 
the enzymes inside. This hypothesis was supported by the fact that encapsulation of 
multiple enzymes in the capsid did not lead to rate increase, since only one enzyme in the 
capsid is sufficient to convert the substrate entering the nanoreactor.
In an alternative approach, Glasgow et al. modified the enzyme alkaline phosphatase 
with a DNA oligomer, which binds to the RNA-binding domain of the MS2 bacteriophage 
capsid proteins.173 Due to this non-covalent interaction, the enzymes were conveniently 
encapsulated. More recently, Silver et al. made use of the SpyTag/SpyCatcher system 
to non-covalently encapsulate active enzymes in the MS2 capsid.174,175 This method also 
proved useful for in vivo loading of cargo during capsid assembly. Inspired by nature, 
non-covalent encapsulation is often achieved using interactions between the charged 
interior of a capsid and the oppositely charged cargo. For example, Hilvert et al. developed 
a variant of the non-viral enzyme lumazine synthase from Aquifex aeolicus (AaLS), where 
interior surface residues were mutated to negatively charged residues. Subsequently, single 
enzymes or enzyme cascades could be encapsulated by fusion to highly positively charged 
proteins.176,177
Douglas et al. have taken the non-covalent encapsulation strategy to a next level by 
encapsulating three enzymes in a P22 bacteriophage capsid.178 By performing an expression 
of a three-enzyme construct linked by flexible oligoglycine spacers and with the SP 
moiety at the C-terminus, the metabolon-like fusion proteins were efficiently connected 
to the inside of the P22 capsid (Figure 2.11). The enzymes involved: CelB, a tetrameric 
β-glucosidase enzyme, galactokinase and glucokinase, cooperated to convert lactose into 
galactose-1-phosphate and glucose-6-phosphate. 
In addition to their use as nanoreactors, virus particles have also been used as scaffolds for 
the immobilization of proteins on their exterior.179,180 For example, a genetic fusion between 
CalB and the capsid protein of the rod-like potato virus X particle was expressed in plants 
and yielded enzyme-decorated particles of 500 nm in size.179 In order to prevent problems 
with assembly, the genetic construct was designed in such a way that expression was halted 
in a number of occasions, leading to the production of the separate enzyme and capsid 
protein, besides the entire fusion protein. As this expression in plants turned out to be 
toxic for the host, an alternative route was devised based on non-covalent interactions. 
Antibodies were raised against the capsid protein of another rod-like virus, zucchini yellow 
mosaic virus (ZYMV), and were assembled on the virus particle surface. Subsequently, 
proteins modified with the generic antibody binding domain Z33 (derived from protein A) 
32
Chapter 2
figure 2.11	 Three	enzymes	involved	in	a	cascade	reaction	are	expressed	with	the	scaffold	protein	SP.	SP	interacts	
with	the	capsid	protein	of	the	P22	bacteriophage	to	yield	enzyme-filled	nanoreactors.	Adapted	from	Patterson	et al. 
with permission from the American Chemical Society, Copyright (2014).178
figure 2.12	 A	 rod-like	plant	 virus	 (ZYMV)	 is	decorated	 in	a	2-step	supramolecular	 approach.	Antibodies	 raised	
against	the	capsid	protein	adhere	first	to	the	particles	and	are	functionalized	next	with	enzymes	with	an	antibody-
binding domain (Z33). Reproduced from Pille et al. with permission from the American Chemical Society, Copyright 
(2013).180
adhered to the antibodies and thus to the virus scaffold (Figure 2.12).180
Another type of protein nanoreactor was reported by Bruns et al.181 They used a thermosome 
(THS), a chaperonin from the archaea Thermoplasma acidophilum for controlled radical 
polymerization experiments. THS is a hexadecameric protein complex that consists of 
eight a and eight b subunits. In its closed conformation it is a spherical protein cage about 
16 nm in diameter that encloses two cavities. Using thiol-maleimide chemistry a multi-
amine ligand was attached to the inside of the chaperonin via a cysteine introduced by a 
mutation strategy. To the ligand Cu(II) was bound. In the next step initiator and monomer 
(N-isopropylacrylamide) were added, together with ascorbic acid to reduce Cu(II) to 
the active Cu(I) species. The polymers obtained were of low molecular weight and low 
polydispersity, both explained by the confinement effect. This effect namely leads to the 
growing polymer chain staying in close proximity to the catalyst and it creates a diffusion 
barrier for monomers to enter the cavity.
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2.6 PharMacokineTicS, bioDiSTribuTion anD ToxiciTy
Most of the abovementioned plant and animal VLPs are not human pathogens, which 
implies that these particles are less likely to interact with human surface receptor proteins, 
leading to toxicity. These viruses are considered much safer than for instance human 
adenoviruses, which are often used for gene delivery purposes and are associated with severe 
toxic effects.182 Unfortunately, there are only few studies describing the characteristics of 
plant and animal VLPs in vivo. The most important findings from these studies will be 
discussed below. Before testing VLPs for nanomedical applications, however, a better 
understanding of the influence of size, shape, composition, surface chemistry and physical 
properties on their in vivo behavior should be obtained.183,184
Animal studies have been carried out with bacteriophages M13, MS2 and Qβ and plant 
viruses CCMV, CPMV, HCRSV, PVX and TMV. Biodistribution studies showed that CPMV,185 
M13,186 MS2,187,188 Qβ,120 PVX142 and TMV189 accumulate mainly in the spleen and liver. 
Accumulation in these organs is expected, since they are part of the reticuloendothelial 
system and their function is to remove antigens from circulation, including nanoparticles. 
CCMV is distributed to a broad range of tissues throughout the body, including the 
bladder, thyroid gland, liver, spleen and salivary gland.190 Surprisingly, no signs of toxicity 
were observed for CCMV after a single injection, despite its broad distribution.190 Likewise, 
no apparent toxic effects were reported in vivo for CPMV,185,191 Qβ192 and TMV.189 HCRSV 
showed no cytotoxicity towards OVCAR-3 and CCL-186 cells.139
In addition to biodistribution and toxicology, pharmacokinetic properties of VLPs are also 
important, as there needs to be a good balance between tissue penetration and clearance 
from the body. Longer circulation times allow drugs to accumulate into the targeted 
tissue, but the chance of toxic side effects increases. It has been shown that circulation 
times depend on the surface chemistry, for instance surface charge. Positively charged 
nanoparticles exhibit longer half-lives than negatively charged particles. The same trend is 
observed for VLPs.193 CCMV, which has a negative outer surface, displays a short blood half-
life of less than 15 minutes. Within 24 h after administration, a high percentage (57–73%) 
is excreted.190 In addition, a test on mouse urine suggested in vivo degradation of at least a 
part of the capsids. Rapid blood clearance is also observed for CPMV (4–7 min half-life),185 
MS2 (4.5 min half-life)187 and TMV (3 min half-life).189 Long circulation times (>4 h) are 
observed for Qβ, which has a positive outer surface.120 M13 has a half-life of 4.5 h, which 
was reduced to several minutes for receptor-targeted phages.186 In case of MS2, substantial 
amounts of VLP remain in the bloodstream.188
Apart from the surface charge, it is known that the shape and flexibility of VLPs plays 
an important role in both cellular uptake and biodistribution. For instance, a direct 
comparison between spherical CPMV and rod-shaped TMV showed that TMV, with its 
high aspect ratio, had more advantageous flow and margination properties.194 This resulted 
in increased vascular targeting and tumor homing.
Even though abovementioned VLPs are not human pathogens, it has been shown that the 
regular structure of VLPs promotes immune responses.195 In particular, B-cells are activated, 
which will produce virus-specific antibodies. A possible explanation for this phenomenon 
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is that the regular array of capsid proteins can contact bivalent B-cell receptors efficiently, 
which already causes a response without the aid of T cells.
Many strategies are now being developed to overcome immunogenic responses in vivo, 
one of which is masking of the particle surface by PEGylation. This approach has already 
proven successful for adenoviruses.196,197 PEGylated versions of VLPs have already been 
generated for CPMV,77,78,83,84,92,97,142,198 MS2,108,109,115,117 PVX,141,142 Qβ109 and TMV.130,131 Studies 
with CPMV have shown that introduction of a PEG coating can inhibit the anti-VLP 
response in mice,78 as well as prevent internalization by several cell types in vitro and in 
vivo through non-specific binding.82,97,98,198,199 Also, the plasma circulation time increased 
upon PEGylation.185 Shielding efficiency was found to be dependent on polymer length, 
the number of PEG chains attached, the density on the surface and the location of 
conjugation.198 A higher efficiency was obtained for more and longer PEG chains. Also 
for MS2 and PVX, reduction of non-specific cellular uptake has been observed after 
PEGylation of their capsid surfaces.142,188 In the latter study, it was shown that the capsid 
could be simultaneously conjugated to a fluorescent dye. Thus, even though PEGylation 
might be required for successful in vivo applications in the future, this does not exclude 
other surface modification for, for instance, targeting purposes. A promising alternative to 
PEGylation is albumination, which has been used recently to enhance the pharmacokinetic 
properties of proteins and virus-based nanoparticles.200,201
2.7 concLuSionS
Nature has provided us with a wide variety of protein nanocages, all with different shapes, 
dimensions, and physical properties. These particles have the unique advantage of 
structural uniformity, in addition to the ease of functionalization and production on large 
scale.
Protein containers are especially useful for drug delivery purposes due to favorable 
properties such as water solubility, high uptake efficiency and biocompatibility. Many 
different modification strategies aimed at targeting specific tissue and delivering the 
required drug have been developed. Genetic tailoring has allowed the introduction of 
functional handles in protein nanocages and site-selective conjugation of e.g. targeting 
ligands, therapeutics and polymers. Cysteine, lysine and glutamic and aspartic acid have 
evidently been used mostly in functionalization of protein nanocages for drug delivery 
applications. These functionalization strategies have proven to be robust, applicable to 
many types of proteins and versatile regarding the type of desired cargo. Also, high loading 
efficiencies can be achieved using these types of modification. Moreover the introduction 
of non-natural amino acids is a very convenient method for orthogonal functionalization 
of protein nanocages at specific locations or with specific cargo densities.
The application of protein nanocages as nanoreactors underlines the versatility of 
protein-based nanoparticles. Due to their ease of modification and, in some cases, 
reversible assembly behavior, these particles are very suitable for the encapsulation or 
functionalization with catalytically active moieties. Since they are also based on biological 
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materials, we believe protein nanocages will continue to be important models in the study 
of compartmentalized catalytic processes found in nature.
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abSTracT
A new strategy is described for the modification of cowpea chlorotic 
mottle virus (CCMV) capsid proteins for loading of cargoes inside 
the viral capsid. Sortase A, an enzyme which is present in Gram-
positive bacteria, was used to attach cargo to the glycine-tagged 
N-termini of several CCMV variants. In particular, small molecules 
and proteins bearing the required C-terminal LPETG recognition 
motif were attached and encapsulated. This method allows for 
the site-specific, covalent, and orthogonal modification of CCMV 
capsids in a mild fashion, leading to high encapsulation efficiencies. 
This strategy can easily be expanded to other types of cargoes, 
labeled with an LPETG-tag. 
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3.1 inTroDucTion
Virus-like particles (VLPs) are protein assemblies, which have appealing features for 
use in bionanotechnology. They have a well-defined size and shape, are robust and 
biocompatible, and can be functionalized at both the interior and exterior faces.1–5 The 
cowpea chlorotic mottle virus (CCMV) capsid is especially interesting in this respect, as it 
is able to encapsulate relatively large cargoes compared to VLPs derived from other viruses. 
Also, CCMV capsids can undergo a reversible, pH-dependent assembly and disassembly, 
even in the absence of their viral RNA.6
The CCMV capsid consists of 180 identical 20 kDa capsid proteins. They form an icosahedral 
cage with T = 3 symmetry and inner and outer diameters of 18 and 28 nm, respectively.7,8 
CCMV VLPs have been modified in many different ways.9 The most popular method for 
functionalization of the CCMV capsid proteins is by addressing the amino acids which 
are naturally present on the capsid interior and exterior faces, as this method does not 
require prior modification of the capsid proteins themselves. Amine and carboxylic acid 
containing residues have been modified e.g. with fluorescent dyes, peptides, haptens, 
and biotin,10–12 and carboxylic acid groups have also been used to introduce alkyne groups 
which could subsequently react with azides using click chemistry via a cycloaddition.13 The 
disadvantage of addressing endogenous amino acids is the low selectivity of this process: 
functionalization of a specific residue requires the blockage or modification of residues 
that should not react with the group of interest. Furthermore, modifications to undesired 
positions can lead to protein deactivation or denaturation.
Cysteines are also often utilized for protein modification purposes. CCMV has two 
natives cysteines, but these are not susceptible to chemical modification.10 Therefore, 
surface-exposed cysteines have been genetically introduced to attach cargo using thiol-
maleimide or thiol-iodoacetamide chemistry.10,12,14 This method is more specific, as it allows 
site-selective cargo attachment. On the other hand, it can only be applied to proteins/
nanoparticles that do not have a reactive thiol group, limiting the applicability.
Modifications at the N-termini of CCMV proteins are particularly interesting, as these are 
located on the inside of the VLPs, allowing controlled encapsulation of chemotherapeutics 
and catalytically active species. Cornelissen et al. used a non-covalent method to attach 
cargo to the CCMV protein N-termini, by making use of coiled-coil peptides as linkers.15 
This method, however, requires targets to be attached to a rather large coiled-coil peptide. 
Moreover, attaching the target in a covalent fashion to CCMV has been shown to lead to 
higher encapsulation efficiencies.16
We set out to develop a generic strategy to modify the N-termini of CCMV proteins with a 
wide range of different species in a covalent way. This requires a broadly applicable method 
which can be used to specifically address the N-terminus over other free amine groups. 
Also, the method should not involve harsh conditions, as these might lead to denaturation/
deactivation of the CCMV protein and/or the cargo. Based on these considerations, we 
decided to explore the enzymatic modification of CCMV capsid proteins catalyzed by 
Sortase A (SrtA). SrtA is present in Gram-positive bacteria, where it is responsible for 
the anchoring of surface proteins to the bacterial cell wall. Proteins bearing the sorting 
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Scheme 3.1	 Schematic	representation	of	Sortase	A-mediated	N-terminal	functionalization	of	CCMV	capsid	protein	
dimers	with	an	LPETG-labeled	cargo,	followed	by	encapsulation	of	the	target	molecule	through	capsid	assembly.
signal LPXTG (where X = any amino acid) are recognized and the amide bond between Thr 
and Gly is cleaved. The new Thr C-terminal residue is then coupled to an N-terminal Gly 
residue of an oligoglycine peptidoglycan crossbridge.17 SrtA has been used for a wide variety 
of applications, ranging from protein labeling to surface anchoring and engineering of 
bacterial surfaces.18 Recently, SrtA was used to multifunctionalize protein nanoparticles on 
their exterior.19 Until now, however, it has not been explored for the modification of VLPs.
Here, we report the modification of the CCMV capsid protein at its N-terminus using a 
SrtA-based strategy (Scheme 3.1). We genetically modified the N-terminus of CCMV to 
display a glycine or triglycine motif. Using SrtA, we were able to covalently attach a peptide 
and a protein containing a C-terminal LPETG-tag. This method allows for the first time 
the site-specific, covalent, and orthogonal modification of CCMV VLPs under benign 
conditions, after expression of the capsid protein. This way, functionalized capsids with 
a specified amount of cargo inside can be produced after a minimal amount of processing 
steps. We believe that this strategy can be extended to the attachment of various types of 
targets, as long as they can be equipped with an LPXTG-tag. Even enzymes incompatible 
with other coupling methods might be employed to create catalytically active VLPs.
3.2 reSuLTS anD DiScuSSion
In this study, two types of CCMV were modified: the commonly used His-tagged CCMV 
capsid protein and a modified form, containing an N-terminal elastin-like polypeptide 
(ELP) tag.20 ELPs consist of repeating Val-Pro-Gly-Xaa-Gly (VPGXG) pentapeptides (where 
X = any amino acid).21 These responsive peptides can switch from a water-soluble state 
to a collapsed hydrophobic state by an increase in temperature or salt concentration, 
which is known as lower critical solution temperature behavior.22–24 These two CCMV 
variants show different assembly behaviors. The His-tagged CCMV capsid protein shows 
assembly upon decreasing the pH, i.e., into T = 3 particles. ELP-CCMV, on the other hand, 
assembles both via a conventional pH shift (CCMV-induced assembly) and by an increase 
of salt concentration or temperature (ELP-induced assembly) into T = 3 or T = 1 particles, 
respectively.20 To investigate the broad applicability of the coupling reaction for different 
CCMV forms, we set out to modify the N-termini of both CCMV and ELP-CCMV.
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The CCMV constructs were designed to display glycine residues at their N-termini. A 
hexahistidine tag was also included to facilitate purification of the proteins by affinity 
chromatography. In the literature it has been shown that in some cases the SrtA reaction 
is more effective when two or more glycines are present. This highly depends, however, 
on the accessibility of the N-terminus.25–27 Therefore, additional CCMV variants were 
cloned with three glycines to investigate the influence of the amount of glycines. Thus, 
four CCMV constructs were designed in total: G-CCMV 1a, G3-CCMV 1b, G-ELP-CCMV 
1c, and G3-ELP-CCMV 1d (Scheme 3.1). The addition of the small glycine-tags to CCMV 
did not affect the soluble expression of the capsid proteins in Escherichia coli (E. coli). 
All proteins were purified by Ni2+ affinity chromatography and, if necessary, preparative 
size exclusion chromatography (SEC), and were subsequently analyzed by polyacrylamide 
gel electrophoresis (SDS-PAGE). The molecular weights of the proteins were verified by 
electrospray ionization time-of-flight (ESI-TOF) mass spectrometry. The modified capsid 
proteins were assembled to show that they still formed T = 3 particles upon lowering the 
pH from 7.5 to 5.0. The particles eluted at approximately 10 mL on a Superose 6 column. 
Transmission electron microscopy (TEM) showed particles with an average diameter 
consistent with T = 3 shaped VLPs.
To evaluate the possibility of using the SrtA reaction for the labeling of the capsid proteins 
with small molecules, FITC-Anl-Ala-Leu-Pro-Glu-Thr-Gly-NH2 (FITC-LPETG) was 
employed, containing a fluorescein isothiocyanate (FITC)-modified azidonorleucine (Anl) 
amino acid. This reaction could be easily monitored using the fluorescence of the FITC-
modified product. The reaction was performed at rt, as the capsid protein dimer is unstable 
upon incubation for prolonged time periods at elevated temperatures. Both substrates 
were present at a concentration of 50 μM and different amounts of SrtA were added to 
determine the amount required to achieve high conversions. After addition of SrtA from 
Staphylococcus aureus to the substrates, the reaction mixtures were incubated for 24 h. 
SDS-PAGE analysis revealed that higher amounts of SrtA led to more product formation, 
as expected (Figure 3.1). The formation of the product was particularly visible when the 
fluorescence of the gel was measured. No conversion to the product was observed when 
no SrtA was added. Analysis of the reaction mixtures after 24 h by mass spectrometry 
confirmed the presence of the FITC-G-CCMV and FITC-G3-CCMV products in the mixtures 
to which SrtA had been added.
In order to compare the four different CCMV variants, quantitative analysis of the 
Coomassie-stained SDS-PAGE gels was performed. The conversions found for the 0.2 eq. 
SrtA reaction mixtures were compared, as these showed the least overlap of the SrtA band 
with the band of the coupled product. After 24 h, the conversions of all proteins were 
quite similar: CCMV conversions of 53%, 62%, 57%, and 50% were found for 1a, 1b, 1c, 
and 1d, respectively. Differences between the four CCMV variants were larger after 7 h, as 
conversions of 37%, 35%, 57%, and 41% were observed for 1a, 1b, 1c, and 1d, respectively. It 
is known that in the Sortase coupling reaction, an equilibrium is reached. This is due to the 
fact that a glycine nucleophile is also released upon cleavage of the threonine-glycine bond 
during the formation of the R-LPET-SrtA intermediate. This nucleophile can compete with 
the desired nucleophile during the attack on the intermediate. The conversions that were 
measured in this specific reaction were comparable to examples known from the literature. 
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figure 3.1	 SDS-PAGE	 analysis	 of	 SrtA-mediated	 N-terminal	 modification	 of	 four	 CCMV	 variants	 with	 FITC-
LPETG,	using	different	equivalents	of	SrtA.	Protein	bands	were	visualized	both	by	Coomassie	blue	staining	(top)	and	
by	in-gel	fluorescence	(bottom).	a)	Modification	of	1a, followed over time. b)	Modification	of	1b, followed over time. 
c)	Modification	of	1c, followed over time. D)	Modification	of	1d, followed over time.
There are some methods to improve the coupling yield, e.g., the use of depsipeptides or 
performing the reaction under dialysis.28,29 Luckily, for our application we do not need a 
high conversion, as we cannot entrap 180 pieces of large cargo anyhow inside the CCMV 
interior.
We can conclude from this data that having more N-terminal glycines does not necessarily 
improve the efficiency of the SrtA reaction in this case. Furthermore, it seems that the 
modification of 1c is the fastest reaction, as we did not observe an increase in yield anymore 
after 7 h. Additional advantages of using the ELP-tagged variants over the non-modified 
variants are the higher expression yields (~5-10 times higher) and the ability to use more 
triggers for capsid assembly besides a pH shift. Therefore, we chose to perform subsequent 
experiments with G-ELP-CCMV 1c.
Next, it was determined if and to what extent the modified capsid proteins could still be 
co-assembled into VLPs. For this purpose, SrtA reactions were carried out for 24 h, and the 
reaction mixtures were dialyzed to pH 5 buffer to induce capsid formation. The capsids 
were then isolated by preparative SEC and analyzed by SDS-PAGE (Figure 3.2).
ImageJ analysis revealed that the FITC-1c:1c ratio in the reaction mixtures was similar to 
that found in the purified capsids for each SrtA concentration, with a maximum of about 
57% incorporated FITC-CCMV. This corresponds to the encapsulation of approximately 103 
FITC fluorophores per capsid. The UV-vis absorbance of the capsids clearly showed that 
the protein absorbed not only at 280 nm, but also around 495 nm, which is the absorbance 
maximum of FITC (Figure 3.3A). Analysis of the capsid proteins by mass spectrometry 
confirmed the presence of FITC-G-ELP-CCMV in the capsids.
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figure 3.2 a)	Schematic	 representation	of	 the	use	of	SEC	for	 the	purification	of	modified	capsids	 from	a	SrtA	
reaction mixture. b)	Modification	of	1c:	 reaction	mixtures	 after	 24	h	before	preparative	SEC	purification	 (pre)	 and	
purified	 capsids	 (post),	with	 different	 equivalents	 of	SrtA.	Protein	 bands	were	 visualized	both	by	Coomassie	 blue	
staining	(top)	and	by	in-gel	fluorescence	(bottom).
figure 3.3 a)	 SEC	 chromatograms	 of	 G-ELP-CCMV	 capsids	 (blue line)	 and	 G-ELP-CCMV	 capsids	 after	
modification	with	FITC-LPETG	in	the	absence	(purple line) or presence (orange line) of SrtA. Solid line = absorbance 
at	280	nm,	dashed	line	=	absorbance	at	495	nm.	b)	Uranyl	acetate-stained	TEM	micrograph	of	FITC-modified	G-ELP-
CCMV	 (0.2	 eq.	 SrtA).	 Scale	 bar	 corresponds	 to	 200	 nm.	c)	 Size	 distribution	 of	 the	 FITC-modified	G-ELP-CCMV	
particles shown in B.
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figure 3.4	 SDS-PAGE	analysis	of	SrtA-mediated	N-terminal	modification	of	G-ELP-CCMV	1c	with	GFP-LPETG.	
a)	Conjugation	followed	over	time.	Proteins	bands	were	visualized	both	by	Coomassie	blue	staining	(top)	and	by	in-gel	
fluorescence	(bottom).	b)	Reaction	mixtures	after	24	h	before	preparative	SEC	purification	(pre)	and	purified	capsids	
(post). Protein bands were visualized by silver staining.
Subsequently, the capsids were analyzed with TEM. TEM micrographs of purified 1c VLPs 
showed particles with an average size of 29.4 ± 1.7 nm, which corresponds well with that 
of T = 3 particles. The FITC-modified capsids showed a broader size distribution and 
a slightly smaller average size of 23.3 ± 2.6 nm (Figure 3.3B and C). Interestingly, these 
smaller particles could already be observed after incubation of the capsid proteins and 
FITC-LPETG without SrtA. We hypothesize that the presence of ELP conjugated to CCMV 
could be the reason for this effect, as we did not observe this effect for G3-CCMV 1b. Here 
we found particles of about 28.3 ± 2.5 nm after the reaction with FITC, which corresponds 
well with T = 3 particles.
In order to demonstrate the applicability of this method to larger (bio)molecules, the SrtA 
reaction was used to couple a model protein to G-ELP-CCMV 1c. For this purpose, a green 
fluorescent protein (GFP) construct was modified to display the intended LPETG-tag at 
its C-terminus, as well as a hexahistidine tag for purification purposes. GFP-LPETG was 
expressed in E. coli and purified by Ni2+ affinity chromatography and preparative SEC. 
SDS-PAGE analysis showed that the protein was obtained in pure form. This was further 
confirmed by ESI-TOF and SEC analysis.
The coupling of GFP-LPETG to 1c was followed over time and visualized by SDS-PAGE 
analysis (Figure 3.4A). The product was observed as a band around 50 kDa which appeared 
slowly over time. A second band around 50 kDa was observed, which possibly corresponds 
to the GFP-SrtA intermediate. The presence of the product band could be confirmed by 
labeling CCMV with a DyLight 650 NHS ester prior to the Sortase-mediated coupling. The 
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figure 3.5 a)	SEC	chromatograms	of	G-ELP-CCMV	capsids	after	modification	with	GFP-LPETG	in	the	absence	
(purple line) or presence (orange line)	of	SrtA.	Solid	line	=	absorbance	at	280	nm,	dashed	line	=	absorbance	at	395	
nm. b)	Uranyl	acetate-stained	TEM	micrograph	of	GFP-modified	G-ELP-CCMV	(3.0	eq.	SrtA).	Scale	bar	corresponds	
to 200 nm. c)	Size	distribution	of	the	GFP-modified	G-ELP-CCMV	particles	shown	in	B.
labeling allowed for the imaging of both 1c and the desired product GFP-1c using in-gel 
fluorescence in addition to Coomassie staining (Figure 3.4A). When no SrtA was added, no 
product was formed, as expected. Evidence for the intended product GFP-ELP-CCMV was 
provided by ESI-TOF.
A CCMV conversion of 19% was observed after 24 h when 0.2 eq. SrtA was used as a catalyst. 
This conversion is relatively low compared to the reaction with FITC, where a conversion 
of 57% was achieved with 1c under the same reaction conditions (Figure 3.1C). This is not 
unexpected, as the conjugation of two proteins is less efficient than the coupling of a small 
molecule and a protein, due to for instance steric hindrance limiting the accessibility of the 
reactive moieties. As already mentioned, we however do not require a high conversion as 
the capsid interior can only accommodate a limited amount of cargo.
After coupling of GFP-LPETG to 1c, the reaction mixtures were dialyzed to pH 5 buffer 
and the capsids were isolated using preparative SEC (Figure 3.5A). SDS-PAGE analysis 
showed that both 1c and GFP-1c were present in the capsids (Figure 3.4B). Using ImageJ, 
it was determined that 4-8% of the CCMV proteins in the capsids was modified with GFP-
LPETG. This implies that approximately 8-14 GFP proteins had been encapsulated in 
the T = 3 capsids, depending on the SrtA concentration. This is quite comparable to the 
encapsulation yield of GFP that was achieved using a non-covalent strategy, where up to 15 
GFP proteins were encapsulated per capsid.15 With TEM analysis, particles of 26.1 ± 1.7 nm 
were found (Figure 3.5B and C).
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3.3 concLuSionS
We have described a method for the site-selective modification of the CCMV capsid interior 
in a covalent manner. SrtA was applied to attach small molecules and proteins, bearing a 
C-terminal LPETG-tag, to the CCMV capsid protein N-terminus. For small molecules, up 
to 57% of the CCMV capsid proteins could be modified and capsids were formed with an 
identical loading. An encapsulation efficiency of 8-14 proteins per capsid was achieved for 
GFP. Our method was found to be applicable to different types of CCMV, and can likely 
be extended to all kinds of cargoes, for instance, catalysts or drug molecules. As the SrtA-
based strategy is highly selective, it allows for the controlled encapsulation of cargo in 
CCMV and other VLPs.
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3.5 exPeriMenTaL SecTion
3.5.1  Materials and methods
Materials
Hot start II HF DNA polymerase, dNTPs, restriction enzymes, T4 DNA ligase and Antarctic 
phosphatase were obtained from New England Biolabs. The DNA oligos were synthesized by 
Biolegio. Ampicillin was purchased from MP Biomedicals. Chloramphenicol was obtained 
from Sigma-Aldrich. Isopropyl β-d-1-thiogalactopyranoside (IPTG) was purchased from 
Acros. Ni-NTA agarose beads were obtained from Qiagen. DyLight 650 NHS ester was 
purchased from ThermoFisher Scientific. DMSO-d6 was purchased at Cambridge Isotope 
Laboratories. The H6-SrtA and GFP-LPETG-H6 plasmids were a kind gift from Prof. Geerten 
Vuister.
Buffers
pH 5.0 capsid buffer: 50 mM NaOAc, 500 mM NaCl, 10 mM MgCl2, 1 mM EDTA, pH 5.0. 
pH 7.5 dimer buffer: 50 mM Tris·HCl, 500 mM NaCl, 10 mM MgCl2, 1 mM EDTA, pH 7.5.
PBS buffer: 10 mM Na2HPO4, 1.8 mM KH2PO4, 137 mM NaCl, 2.7 mM KCl, pH 7.2-7.4.
Sortase buffer: 50 mM HEPES, 150 mM NaCl, 5 mM CaCl2, pH 7.5.
All buffers were filtered over a 0.2 micron filter prior to use.
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UV-vis spectroscopy
Protein concentrations were measured on a Varian Cary 50 Conc UV-vis spectrometer 
using a quartz cuvette with a path length of 3 mm. Protein concentrations were calculated 
using the theoretical extinction coefficients.30 Samples were centrifuged prior to the 
measurements.
Mass	spectrometry
Protein mass characterization was performed by electrospray ionization time-of-flight 
(ESI-TOF) on a JEOL AccuTOF CS. Deconvoluted mass spectra were obtained using 
MagTran 1.03 b2. Isotopically averaged molecular weights were calculated using the 
‘Protein Calculator v3.4’ at http://protcalc.sourceforge.net. Protein samples were desalted 
by spin filtration to MQ (final concentrations 10-100 μM).
Liquid chromatography-mass spectrometry (LC-MS) was performed on a Thermo Finnigan 
LCQ-Fleet ESI-ion trap (Thermo Fischer) equipped with an Alltima C18 column (50 mm x 2 
mm, particle size 3 μm) (Alltech Applied Sciences B.V.). A CH3CN/H2O gradient containing 
0.1% HCO2H was used for elution (5-100%, over 15 min). Samples were diluted in MeOH to 
a concentration of 10-15 μM.
Size exclusion chromatography (SEC)
SEC was performed on a Superose 6 10/300 column or a Superdex 75 PC 10/300 column (GE 
Healthcare). Analytical and preparative SEC measurements were executed on a Shimadzu 
LC-2010AHT HPLC and Agilent 1260 bio-inert HPLC, respectively. Samples (50-200 μg) 
were separated on the column with a flow rate of 0.5 mL/min.
Transmission	electron	microscopy	(TEM)
TEM grids (FCF-200-Cu, EMS) were glow-discharged using a Cressington carbon coater 
and power unit. Protein samples (0.2 mg/mL, 5 μL) were applied on the glow-discharged 
grids and incubated for 1 min. The samples were carefully removed using a filter paper and 
the grid was allowed to dry for at least 15 minutes. Then the grid was negatively stained 
by applying 2% uranyl acetate in water (5 μL). The staining solution was removed after 15 
seconds and the grid was allowed to dry for at least 15 minutes. The samples were analyzed 
on a JEOL JEM-1010 TEM.
Reversed phase chromatography
Reversed phase HPLC purifications were performed on a Shimadzu LC-20A system equipped 
with a Reprosil C18 column, 250 x 10 mm (particle size: 5 μm) (Dr. Maisch GmbH). Elution 
was achieved using a CH3CN/H2O gradient containing 0.1% trifluoroacetic acid with a flow 
rate of 4 mL/min (5-100%, 5-55 min).
1H and 13C	NMR
1H and 13C NMR spectra were recorded on a Bruker Avance III 400 (400 MHz) spectrometer 
in DMSO-d6. The NMR solvent residual peak of DMSO-d6 was used as the internal 
reference. Proton coupling constants (Hz) of the phenyl protons were determined by 
computer simulation using MestReNova.
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3.5.2  experimental details
Protein	sequences
Table 3.1	 Amino	acid	sequences	of	the	proteins	used	in	this	chapter.
Name Sequence
H6-SrtA
TGSHHHHHHGSKPHIDNYLHDKDKDEKIEQYDKNVKEQASKDKKQQAKPQIPKDKSKVAGYIEIPDAD
IKEPVYPGPATPEQLNRGVSFAEENESLDDQNISIAGHTFIDRPNYQFTNLKAAKKGSMVYFKVGNET
RKYKMTSIRDVKPTDVGVLDEQKGKDKQLTLITCDDYNEKTGVWEKRKIFVATEVK
G-H6-CCMV
GSSHHHHHHSSGLVPRGSHMMSTVGTGKLTRAQRRAAARKNKRNTRVVQPVIVEPIASGQGKAIKAWT
GYSVSKWTASCAAAEAKVTSAITISLPNELSSERNKQLKVGRVLLWLGLLPSVSGTVKSCVTETQTTA
AASFQVALAVADNSKDVVAAMYPEAFKGITLEQLTADLTIYLYSSAALTEGDVIVHLEVEHVRPTFDD
SFTPVY
G3-H6-CCMV
GGGHHHHHHGGMSTVGTGKLTRAQRRAAARKNKRNTRVVQPVIVEPIASGQGKAIKAWTGYSVSKWTA
SCAAAEAKVTSAITISLPNELSSERNKQLKVGRVLLWLGLLPSVSGTVKSCVTETQTTAAASFQVALA
VADNSKDVVAAMYPEAFKGITLEQLTADLTIYLYSSAALTEGDVIVHLEVEHVRPTFDDSFTPVY
G-H6-ELP-CCMV
GHHHHHHVPGVGVPGLGVPGVGVPGLGVPGVGVPGLGVPGGGVPGVGVPGLGLEVVQPVIVEPIASGQ
GKAIKAWTGYSVSKWTASCAAAEAKVTSAITISLPNELSSERNKQLKVGRVLLWLGLLPSVSGTVKSC
VTETQTTAAASFQVALAVADNSKDVVAAMYPEAFKGITLEQLTADLTIYLYSSAALTEGDVIVHLEVE
HVRPTFDDSFTPVY
G3-H6-ELP-CCMV
GGGHHHHHHVPGVGVPGLGVPGVGVPGLGVPGVGVPGLGVPGGGVPGVGVPGLGLEVVQPVIVEPIAS
GQGKAIKAWTGYSVSKWTASCAAAEAKVTSAITISLPNELSSERNKQLKVGRVLLWLGLLPSVSGTVK
SCVTETQTTAAASFQVALAVADNSKDVVAAMYPEAFKGITLEQLTADLTIYLYSSAALTEGDVIVHLE
VEHVRPTFDDSFTPVY
GFP-LPETG-H6
SVSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTGKLPVPWPTLVTTLTYG
VQCFSRYPDHMKQHDFFKSAMPEGYVQERTIFFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKEDGN
ILGHKLEYNYNSHNVYIMADKQKNGIKVNFKIRHNIEDGSVQLADHYQQNTPIGDGPVLLPDNHYLST
QSALSKDPNEKRDHMVLLEFVTAAGITLGMDELYKLPETGENLYFQSLEHHHHHH
Expression of H6-SrtA
The pQE30-H6-SrtA vector encoding for the hexahistidine-tagged SrtA protein was 
previously constructed by the group of Geerten W. Vuister (Department of Biochemistry, 
University of Leicester) and kindly donated to our group.
E. coli BL21 AI cells were transformed with a pQE30 plasmid carrying the Sortase gene, 
followed by incubation in LB medium (1 mL) for 1h at 37 °C.31 After this short incubation 
phase, the cells were transferred into fresh LB medium (4 mL) with ampicillin (100 mg/L) 
and were incubated at 37 °C for 4h. This preculture was then transferred into TB medium 
(500 mL) with ampicillin (100 mg/L) and cells were incubated for 24h at 37 °C. Cells were 
pelleted and resuspended in lysis buffer (50 mM NaH2PO4, 300 mM NaCl, 5 mM imidazole 
and supplemented with 1 mM phenylmethanesulfonyl fluoride, pH 8.0) and lysed by 
sonication. The lysate was centrifuged (14.000 g, 30 min, 4 °C) and the supernatant was 
incubated with Ni-NTA beads for 2 h at 4 °C. Ni-NTA beads were washed with wash buffer 
(50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole, pH 8.0) and the purified protein 
was eluted from the beads with elution buffer (50 mM NaH2PO4, 300 mM NaCl, 500 mM 
imidazole, pH 8.0). The protein was dialyzed against Sortase buffer for storage purposes. 
The pure protein was obtained with a yield of 10-13 mg/L of culture. The purity was verified 
by SDS-PAGE. ESI-TOF: calculated 21947.5 Da, found 21948.7 Da.
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Synthesis of Boc-azidonorleucine
To a solution of Boc-protected l-lysine (2.5 g, 10.2 mmol) in MeOH (50 mL) was added 
K2CO3 (2.23 g, 18.1 mmol, 1.8 eq.), copper(II) sulfate pentahydrate (253 mg, 1.01 mmol, 0.1 
eq.) and imidazole-1-sulfonyl azide HCl salt (3.18 g, 15.2 mmol, 1.5 eq.). After stirring for 16 
h at rt, half of the solvent was evaporated in vacuo before the solution was acidified with 
2M HCl. The mixture was extracted with CH2Cl2 (3×100 mL) and the organic layer was 
dried with Na2SO4 and concentrated in vacuo. The crude product was then re-dissolved in 
CH2Cl2 (100 mL) and extracted with 5% aq. NaHCO3 (3×100 mL). The combined aqueous 
layers were washed twice with CH2Cl2 (100 mL), acidified with 1M HCl and extracted with 
CH2Cl2 (3×100 mL). The organic layer was dried with Na2SO4 and concentrated in vacuo 
to afford the product as a colorless oil (2.45 mg, 88%). R
f
 = 0.33 (MeOH/CH2Cl2 1/9, v/v). 
HRMS: m/z for C11H20N4O4Na
+ (M + Na+): calculated 295.13822, found 295.13910. 1H NMR 
(CDCl3, 400 MHz): δ 11.91 (broad s, 1H), 6.82-5.19 (m, 1H), 4.41-4.08 (m, 1H), 3.3 (t, J = 6.8 
Hz, 3H), 1.97-1.81 (m, 1H), 1.81-1.58 (m, 3H), 1.56-1.37 (m, 11H) ppm.32
Synthesis	of	FITC-Anl-Ala-Leu-Pro-Glu-Thr-Gly-NH2
Anl-Ala-Leu-Pro-Glu-Thr-Gly-NH2 was synthesized from 2.0 g Fmoc-4-methoxy-4’-(γ-
carboxypropyloxy)-benzhydrylamine linked to alanyl-aminomethyl resin (Bachem) using 
Fmoc solid-phase peptide synthesis (SPPS). The resin was swollen in DMF for 20 min prior 
to use. The Fmoc-groups from the resin were removed with piperidine in DMF (20%, v/v) 
for 30 min. Functionalization of the resin with the first Fmoc-protected amino acid was 
performed for 45 min with 3 eq. of Fmoc-Gly-OH, 3.3 eq. of N,N’-diisopropylcarbodiimide 
(DIPCDI) and 3.6 eq. of 1-hydroxybenzotriazole (HOBt) in DMF. Deprotection of the 
Fmoc-groups was done with piperidine in DMF (20%, v/v) for 30 min. For all subsequent 
coupling reactions, 3 eq. of the required Fmoc-protected amino acid, 3.3 eq. of DIPCDI 
and 3.6 eq. HOBt in DMF were added to the resin and allowed to react for 45 min. After 
each coupling reaction and Fmoc deprotection, a Kaiser test was performed to ensure 
completion of the reaction. Boc-azidonorleucine (3 eq.) was added as the final residue. 
The peptide was cleaved from the resin by treatment with a mixture of 1,2-ethanedithiol/
H2O/TFA 2.5/2.5/95 (v/v/v) for 3 h. The peptide was precipitated in Et2O and separated 
from solvent by centrifugation yielding a white solid. To a solution of crude peptide (20 
mg, 0.027 mmol) in DMF (2 mL) was added fluorescein isothiocyanate isomer I (11.6 mg, 
0.027 mmol, 1.0 eq.) and DIPEA (9.4 μL, 0.054 mmol, 2.0 eq.). After 2.5 h stirring at rt, 
the mixture was concentrated in vacuo. The crude peptide was purified by reversed phase 
HPLC. The fractions containing the peptide were combined and lyophilized yielding a 
yellow powder. LC-MS: m/z for C
52
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+: (M + H+) calculated 1130.2, found 1129.2 
(retention time: 8.32 min).
Cloning	of	G3-H6-CCMV	and	G3-H6-ELP-CCMV
The pET-15b-H6-CCMV vector encoding for the hexahistidine-tagged CCMV protein 
was previously constructed as described by Minten et al.15 The pET-15b-G-H6-[V4L4G1-
9]-CCMV(ΔN26) vector encoding for the hexahistidine-tagged ELP-CCMV protein was 
previously constructed as described by van Eldijk et al.20
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For the introduction of the G3-tags, two sets of DNA oligos were designed (Table 3.2). The 
oligos were annealed and the resulting inserts encoded for a G3-tag, a hexahistidine tag, 9 
ELP repeats in case of the G3-H6-ELP-CCMV primers, and the CCMV capsid protein with 
a 5’ NcoI and a 3’ BamHI restriction site. The products after PCR were purified by agarose 
gel electrophoresis. Both the purified inserts and the corresponding pET-15b vectors were 
digested with NcoI-HF® and BamHI-HF® and the products were again purified by agarose 
gel electrophoresis. Subsequently, the inserts were ligated into the corresponding digested 
vector to yield pET-15b-G3-H6-CCMV and pET-15b-G3-H6-[V4L4G1-9]-CCMV(ΔN26), 
respectively. These plasmids were transformed into E. coli XL1-BLUE cells, the DNA was 
extracted and the sequences were confirmed by DNA sequencing (Table 3.1). For expression, 
the plasmids were transformed into E. coli BLR(DE3)pLysS cells (Novagen, MERCK).
Table 3.2	 DNA	sequence	of	the	oligos	used	for	the	construction	of	the	required	expression	vectors.
Name Sequence
G3-H6-CCMV forward 5’-ATATATCCATGGGCGGTGGCCATCATCATCATCATCACGGTGGCATGTCTACAGTCGGA
G3-H6-CCMV reverse 5’-ATATATGGATCCCTAATACACCGGAGT
G3-H6-ELP-CCMV forward 5’-ATATATCCATGGGCGGTGGCCATCATCATCATCATCACGTTCCGGGCGTCGGTGTT
G3-H6-ELP-CCMV reverse 5’-ATATATGGATCCCTAATACACCGGAGT
General	protocol	for	the	expression	of	CCMV	capsid	proteins
The pET-15b-H6-CCMV vector encoding for bacterial expression of the hexahistidine-
tagged CCMV protein was previously constructed as described by Minten et al.15 The pET-
15b-G-H6-[V4L4G1-9]-CCMV(ΔN26) vector encoding for the hexahistidine-tagged ELP-
CCMV protein was previously constructed as described by van Eldijk et al.20
For a typical expression, LB medium (50 mL), containing ampicillin (100 mg/L) and 
chloramphenicol (50 mg/L), was inoculated with a single colony of E. coli BLR(DE3)pLysS 
containing the pET-15b vector encoding for the desired CCMV capsid protein, and was 
incubated overnight at 37 °C. This overnight culture was used to inoculate 2x TY medium 
(1 L), supplemented with ampicillin (100 mg/L). The culture was grown at 37 °C and protein 
expression was induced during logarithmic growth (OD600 = 0.4-0.6) by the addition of 
IPTG (1 mM). After 6 h of expression at 30 °C, the cells were harvested by centrifugation 
(2700 g, 15 min, 4 °C) and the pellets were stored overnight at -20 °C.
After thawing, the cell pellet was resuspended in lysis buffer (50 mM NaH2PO4, 1.5 M NaCl, 
10 mM imidazole, pH 8.0; 25 mL). The cells were lysed by ultrasonic disruption (2-3 times 
30 s, 100% duty cycle, output control 3, Branson Sonifier 250, Marius Instruments). In 
case of G-H6-CCMV and G3-H6-CCMV, the lysate was incubated with DNase (10 mg/L) and 
RNase A (5 mg/L) for 10 min at 4 °C. Then the lysate was centrifuged (16.400 g, 15 min, 4 
°C) to remove the cellular debris. The supernatant was incubated with Ni-NTA agarose 
beads (3 mL) for 1 h at 4 °C. The suspension was loaded onto a column, the flow-through 
was collected and the beads were washed twice with wash buffer (50 mM NaH2PO4, 1.5 M 
NaCl, 20 mM imidazole, pH 8.0; 20 mL). Then, the protein of interest was eluted from 
the column with elution buffer (50 mM NaH2PO4, 1.5 M NaCl, 250 mM imidazole, pH 8.0; 
1 time 0.5 mL, 5 times 1.5 mL). The purification was analyzed by SDS-PAGE. The elution 
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fractions containing the desired protein were combined and dialyzed against pH 7.5 dimer 
buffer to obtain the capsid protein dimers. For storage, the proteins were assembled by 
dialysis against pH 5.0 capsid buffer. The purity of the proteins was verified by SDS-PAGE. 
The assembly properties of the capsid proteins and the geometry of the resulting capsids 
were analyzed by SEC using a Superose 6 GL 10/300 column with pH 5.0 capsid buffer as 
the eluent, and TEM. The yields of the proteins after purification and the ESI-TOF results 
are listed in Table 3.3.
Table 3.3	 Expression	yields	and	ESI-TOF	results	of	the	CCMV	capsid	protein	variants	used	in	this	chapter.
Name Yield ESI-TOF
calculated mw observed mw
G-H6-CCMV 12-40 mg/L 22506.6 Da 22507.o Da
G3-H6-CCMV 3-35 mg/L 21451.4 Da 21451.7 Da
G-H6-ELP-CCMV 100-140 mg/L 22253.4 Da 22253.5 Da
G3-H6-ELP-CCMV 72 mg/L 22367.6 Da 22366.8 Da
Expression	of	GFP-LPETG-H6
The pLEICS-05-GFP-LPETG-H6 vector encoding for the hexahistidine-tagged GFP-LPETG 
protein was previously constructed by the group of Geerten W. Vuister (Department of 
Biochemistry, University of Leicester) and kindly donated to our group.
For a typical expression, LB medium (50 mL), containing ampicillin (100 mg/L) and 
chloramphenicol (50 mg/L), was inoculated with a single colony of E. coli BLR(DE3)
pLysS containing pLEICS-05-GFP-LPETG-H6 and was incubated overnight at 37 °C. This 
overnight culture was used to inoculate 2x TY medium (1 L), supplemented with ampicillin 
(100 mg/L) and chloramphenicol (50 mg/L). The culture was grown at 37 °C and protein 
expression was induced during logarithmic growth (OD600 = 0.4-0.6) by the addition of 
IPTG (1 mM). After 5-6 h of expression at 30 °C, the cells were harvested by centrifugation 
(2700 g, 15 min, 4 °C) and the pellets were stored overnight at -20 °C.
After thawing, the cell pellet was resuspended in lysis buffer (50 mM NaH2PO4, 0.5 M NaCl, 
10 mM imidazole, pH 8.0; 25 mL). The cells were lysed by ultrasonic disruption (5 times 30 
s, 100% duty cycle, output control 3, Branson Sonifier 250, Marius Instruments). Then the 
lysate was centrifuged (16.400 g, 15 min, 4 °C) to remove the cellular debris. The supernatant 
was incubated with Ni-NTA agarose beads (3 mL) for 1 h at 4 °C. The suspension was 
loaded onto a column, the flow-through was collected and the beads were washed twice 
with wash buffer (50 mM NaH2PO4, 0.5 M NaCl, 20 mM imidazole, pH 8.0; 20 mL). Then, 
the protein of interest was eluted from the column with elution buffer (50 mM NaH2PO4, 
0.5 M NaCl, 250 mM imidazole, pH 8.0; 1 time 0.5 mL, 7 times 1.5 mL). The purification was 
analyzed by SDS-PAGE. The elution fractions containing GFP-LPETG-H6 were combined 
and concentrated (Amicon® Ultra-15 Centrifugal Filter Device 10.000 NMWL). Further 
purification was performed by preparative SEC using a Superdex 200 10/300 column and 
PBS buffer as the eluent. The pure protein was obtained with a yield of 7.5 mg/L of culture. 
The purity was verified by SDS-PAGE and SEC using a Superose 6 10/300 GL column with 
PBS buffer as the eluent. ESI-TOF: calculated 29321.9 Da, found 29320.1 Da.
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SrtA-mediated coupling experiments
For a typical SrtA-mediated coupling experiment, stock solutions of SrtA, CCMV capsid 
protein and the LPETG-containing reactant were prepared in Sortase buffer. If a component 
had been dissolved in another buffer, it was spin filtrated to Sortase buffer (10 kDa MWCO, 
3 x 10 min). The components were added together to final concentrations of 0-100 μM SrtA, 
50 μM CCMV capsid protein and 50 μM LPETG-substrate. The solutions were shaken at 21 
°C for 24 h. The reaction progress was followed by SDS-PAGE analysis.
SrtA-mediated	coupling	experiments,	followed	by	capsid	purification
For a typical SrtA-mediated coupling experiment, stock solutions of SrtA, CCMV capsid 
protein and the LPETG-containing reactant were prepared in Sortase buffer. If a component 
had been dissolved in another buffer, it was spin filtrated to Sortase buffer (10 kDa MWCO, 
3 x 10 min). The components were added together to final concentrations of 0-150 μM SrtA, 
50 μM CCMV capsid protein and 50 μM LPETG-substrate. The solutions were shaken at 
21 °C for 3-24 h. Capsid assembly was induced by spin filtration to pH 5.0 capsid buffer (10 
kDa MWCO, 3 x 10 min). Subsequently, the capsids were isolated using preparative SEC. 
The capsid fractions were analyzed.
Fluorescent	labeling	of	CCMV
G-ELP-CCMV 1c (511.3 μM, 100 μL) was diluted with phosphate buffer (0.1 M NaH2PO4, 0.15 
M NaCl, pH 7.5) (400 μL) and dialyzed against the phosphate buffer (Spectra/Por 4 dialysis 
tubing, 12-14 kDa MWCO, 10 mm flat width, 3 × 30 min). The solution was added to a vial 
containing DyLight 650 NHS ester (50 μg) and shaken at 21 °C for 1 hour in the dark. The 
excess of dye was removed by spin filtration to Sortase buffer (10 kDa MWCO, 3 x 10 min). 
The labeling was confirmed by SDS-PAGE analysis and UV-vis spectroscopy.
Calculation	capsid	loading	based	on	ImageJ	analysis	of	SDS-PAGE
The intensities of the bands observed on an SDS-PAGE gel relate to the amount of protein 
loaded on the gel. Using ImageJ, these intensities can be calculated and they can be used to 
calculate the conversion. Note, however, that this conversion is a conversion in terms of the 
mass of the proteins. For the determination of the loading in the capsids, the SDS-PAGE 
intensities must be corrected with the molecular weights of the corresponding proteins:
Capsid loading = 
               moleproduct               
                    moleproduct + molestarting material
Capsid loading = 
                          gelproduct / mwproduct                             
                   gelproduct / mwproduct  + gelstarting material / mwstarting material
where gel = the intensity of the protein band on the SDS-PAGE gel, as calculated by ImageJ; 
mw = the molecular weight of the corresponding protein; product = CCMV capsid protein 
after the SrtA reaction; starting material = CCMV capsid protein before modification.
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abSTracT
The study of enzyme behavior in small nanocompartments is crucial 
for the understanding of biocatalytic processes in the cellular 
environment. We have developed an enzymatic conjugation strategy 
to attach a model enzyme to the interior of a cowpea chlorotic 
mottle virus (CCMV) capsid. It is shown that with this methodology 
high encapsulation efficiencies can be achieved. Additionally, we 
demonstrate that the encapsulation does not affect the enzyme 
performance in terms of a decreased activity or a hampered substrate 
diffusion. Finally, it is shown that the encapsulated enzymes are 
protected against proteases. We believe that our strategy can be 
used to study enzyme kinetics in an environment that approaches 
physiological conditions. 
Highly efficient enzyme encapsulation in a protein nanocage
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4.1 inTroDucTion
In a cellular environment, compartmentalization is crucial to make certain that catalytic 
processes proceed properly. It ensures protection against interfering compounds and allows 
regulation of the flux of molecules through the cell. Enzymes are for example spatially 
arranged in mitochondrial lipid membranes as part of the oxidative phosphorylation 
pathway, they are assembled in a modular fashion in non-ribosomal peptide synthetase 
complexes, or encapsulated in protein cages such as the ethanolamine utilization (Eut) 
and carboxysome systems.1–4 In order to mimic natural compartmentalization and to study 
enzymes in a more biologically relevant environment, several encapsulation strategies 
have been followed in the literature, involving a wide variety of different synthetic 
nanocompartments, e.g. micelles, liposomes, polymersomes, and layer-by-layer capsules.5,6 
The architectures of the resulting compartments, however, can only be controlled to a 
certain extent and they often have a relatively high size distribution, which may result in 
non-uniform environments and hence unreliable enzyme kinetics.
In contrast to the abovementioned architectures, protein cages are very monodisperse, 
biocompatible, and robust.7 In this connection virus capsids are especially interesting, as 
they are available in a wide variety of sizes and shapes.8–11 The cowpea chlorotic mottle 
virus (CCMV) is frequently used as a protein cage, due to its ability to reversibly assemble 
and disassemble upon a pH shift, even in the absence of its viral RNA. At pH 7.5, the 
capsids are disassembled into 90 capsid protein dimers. When the pH is decreased to 5.0, 
icosahedral capsids of approximately 28 nm in diameter with a triangulation number T = 3 
are formed.12,13 This behavior has been used to encapsulate different types of cargoes in the 
CCMV capsids, such as polymers, MRI contrast agents and proteins, including enzymes.14–17
Nolte and co-workers encapsulated horseradish peroxidase inside CCMV in a statistical 
fashion, i.e. by disassembling and assembling the capsid in the presence of free horseradish 
peroxidase.18 By tuning the enzyme concentration in the solution, only one or no enzyme was 
entrapped per capsid, which made this approach useful to study single enzyme processes 
inside the virus nanoreactor. Additional research on the behavior of entrapped enzymes 
was performed by the statistical encapsulation of CYP
BM3
 (a cytochrome P450 variant) and 
Candida antarctica lipase B (CalB) inside CCMV.19,20 The latter enzyme was bound via non-
covalent, leucine zipper mediated interactions, which led to a substantial increase in cargo 
loading. Although these investigations have given valuable insights into the activity of an 
enzyme in a small compartment, there are still some important limitations of the currently 
available biomimetic systems, making a comparison with the intracellular environment 
difficult. For instance, in most systems described above, the pH of the solution, which is 
usually around pH 5, does not match the physiological conditions of the cell. This might 
influence the kinetic properties of the enzymes and, therefore, provides an inaccurate 
impression of the activity of the enzyme in its biological environment.
Alternatively, negatively charged polymers such as nucleic acids, can be used to form 
capsids at physiological pH. For instance, recently, nucleic acids were attached to enzymes, 
resulting in spontaneous encapsulation inside CCMV capsids due to their negatively 
charged exterior.21 Even though cargo can be encapsulated at pH 7.5 in these types of 
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Scheme 4.1	 Schematic	representation	of	the	SrtA-mediated	N-terminal	functionalization	of	G-ELP-CCMV	with	the	
enzyme	construct	CalB-LPETG,	and	the	subsequent	enzyme	encapsulation	via	capsid	formation.	The	grey-colored	
proteins	are	the	CCMV	capsid	protein	dimers;	the	LPETG	tag	is	shown	in	blue	and	the	ELP	moieties	in	red.
systems, they require a negatively charged polymer to induce capsid formation. This limits 
the types of cargo that can be encapsulated and takes up part of the space in the interior 
of the capsid. 
A system that can operate under more physiologically relevant conditions, without the 
help of a negatively charged cargo, is the ELP-CCMV protein cage. In previous studies, the 
CCMV capsid protein was equipped with an N-terminal block consisting of an elastin-like 
polypeptide (ELP).22 ELPs are stimuli-responsive polymers that can be reversibly switched 
from a water-soluble to a collapsed, water-insoluble hydrophobic state upon changes in 
their environment, such as the salt concentration, temperature, or pH of the solution.23,24 
These ELPs consist of repeating Val-Pro-Gly-Xaa-Gly (VPGXG) pentapeptides (where X is 
any natural amino acid except proline). Using the advantageous properties of the ELPs, 
it was shown that the new ELP-CCMV block copolymer could form T = 1 capsids upon an 
increase of the salt concentration or temperature at pH 7.5, whereas the non-modified 
capsid protein was not able to form capsids under these conditions. We envisioned the 
use of the ELP-CCMV system to encapsulate enzymes in a more physiologically relevant 
manner and to investigate their kinetic behavior in a confined space.
Here, we show that it is possible to use a chemo-enzymatic coupling strategy based on 
Sortase A (SrtA) to construct an enzyme-ELP-CCMV conjugate, which upon assembly 
of the capsid proteins leads to internalization of the enzyme with a high encapsulation 
efficiency (Scheme 4.1). As a model enzyme we used the lipase CalB and we compared the 
activity of the encapsulated and non-encapsulated enzyme at physiologically relevant pH. 
Additionally, we explored the protective features of the viral capsid towards its cargo by the 
addition of proteases that are able to break down CalB.
4.2 reSuLTS anD DiScuSSion 
In order to encapsulate CalB, we used Sortase A to couple the enzyme molecules to the 
ELP-CCMV capsid protein N-termini, which are located in the interior of the capsids. 
Previously, we have shown that SrtA, a transpeptidase which is present in Gram-positive 
bacteria, can be used to covalently link peptides and proteins to the CCMV capsid protein 
(Chapter 3).25 SrtA recognizes proteins with the sorting signal LPXTG (where X is any 
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figure 4.1	 SDS-PAGE	 analysis	 of	 the	 SrtA-mediated	 coupling	 of	 CalB-LPETG	 to	 G-ELP-CCMV.	 a) The 
conjugation	was	performed	using	different	equivalents	of	SrtA,	and	followed	over	time.	Protein	bands	were	visualized	
by Coomassie blue staining. b)	Conversions	of	G-ELP-CCMV	to	CalB-LPETG-ELP-CCMV	after	7	and	24	hours,	based	
on	quantitative	ImageJ	analysis	of	the	SDS-PAGE	results	shown	in	A.
natural amino acid); it forms a thioester conjugate, thereby cleaving the bond between the 
threonine and glycine. Subsequently, a nucleophile containing an N-terminal glycine can 
attack the LPXT-SrtA intermediate to form the coupled product.26
The ELP-CCMV construct was designed to display an N-terminal glycine residue for the 
SrtA-mediated coupling reaction (G-ELP-CCMV). A CalB construct was modified to display 
the Sortase recognition sequence LPETG at its C-terminus (CalB-LPETG). Additionally, 
hexahistidine tags were included in both constructs for facile affinity chromatography 
purification. The newly introduced tags did not affect the soluble expression of the proteins 
in E. coli. The proteins were purified by Ni2+ affinity chromatography and, if necessary, 
additional preparative size exclusion chromatography (SEC).
To evaluate the possibility to couple CalB-LPETG to the N-terminus of G-ELP-CCMV, 
different equivalents of SrtA from Staphylococcus aureus were added to CalB-LPETG and 
G-ELP-CCMV, which were both present at a concentration of 50 μM. The coupling reaction 
was followed over time by polyacrylamide gel electrophoresis (SDS-PAGE) (Figure 4.1A). 
Quantitative analysis of the SDS-PAGE results confirmed that higher amounts of SrtA 
led to more product formation, as expected (Figure 4.1B). Furthermore, no product was 
observed when SrtA was omitted from the reaction mixture. Electrospray ionization time-
of-flight (ESI-TOF) mass spectrometry analysis of the reaction mixtures after 24 hours 
confirmed the presence of CalB-LPETG-ELP-CCMV.
Before testing the activity of the encapsulated CalB, we investigated to what extent the 
buffer composition influences the activity of CalB in solution. A frequently used buffer to 
monitor CalB lipase activity is the buffer that we labeled ‘CalB buffer’ (Buffer A) (Figure 
4.2A). In order to compare the activity between free and encapsulated CalB, however, the 
enzyme activity had to be measured under conditions at which the ELP-CCMV capsids 
remain assembled, i.e. in either pH 5.0 capsid buffer (Buffer B) or pH 7.5 capsid buffer 
(Buffer C) (Figure 4.2B). To investigate the influence of the individual components of 
the assembly buffers, CalB activity was measured in Buffer A supplemented with specific 
components of Buffer B or C (Figure 4.2C). The conversion of p-nitrophenyl acetate 
(p-NPA) to p-nitrophenol (p-NP) was chosen as the benchmark reaction, as this reaction 
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figure 4.2 a) Conversion of p-NPA	to	p-NP,	catalyzed	by	CalB.	The	activity	of	CalB	is	often	monitored	in	CalB	
buffer,	which	is	marked	as	Buffer	A.	b)	Assembly	of	G-ELP-CCMV	dimers	into	capsids,	by	changing	the	pH	or	salt	
concentration	of	the	buffer.	Buffers	B	and	C	can	be	used	to	assemble	G-ELP-CCMV	dimers	into	T = 3 or T = 1 capsids, 
respectively. c) The activity of CalB-H6	and	CalB-LPETG-H6	in	different	buffers,	expressed	in	U/mg.	The	activity	was	
measured by the conversion of p-NPA	into	p-NP	(see	A).
is easy to follow using the absorbance change at 405 nm due to the formation of p-NP. 
No significant negative effect on the CalB activity was observed upon the addition of 
extra sodium chloride (1.85 M, to a final concentration of 2 M), magnesium sulfate or 
ethylenediaminetetraacetic acid (EDTA) to buffer. The addition of sodium chloride in fact 
seemed to increase the activity of CalB. Next, CalB activity was measured in Buffers B and 
C. CalB retained a high level of activity in both buffer systems, which was even increased 
in the case of Buffer C, compared to the standard Buffer A conditions. Additionally, it was 
shown that the newly introduced C-terminal LPETG-tag did not impede the lipase activity 
of CalB-LPETG greatly (Figure 4.2C).
Like many other commonly used CalB substrates, p-NPA is not water-soluble. Therefore, 
these types of substrates are normally dissolved in DMSO and added to an aqueous 
solution of CalB. In the abovementioned assay of non-encapsulated CalB, we used a final 
DMSO content of 10%. Before investigating the activity of encapsulated CalB, the stability 
of the ELP-CCMV T = 1 capsids in the presence of DMSO was investigated. Dynamic light 
scattering (DLS) measurements were used to monitor the state of the capsid proteins in 
the presence of DMSO. G-ELP-CCMV in pH 7.5 capsid buffer yielded a uniform assembly 
product with an average size of 21 nm (Figure 4.3A). When 10% DMSO was added to this 
solution, however, large aggregates were already observed after 15 minutes (Figure 4.3B). 
Fortunately, when the DMSO content was lowered to 1% DMSO, the capsids remained 
stable for at least 4 hours at room temperature, based on DLS measurements (Figure 
4.3C). This was confirmed by a precipitation assay, followed by UV-vis absorbance analysis 
(Figure 4.3D). A solution of ELP-CCMV T = 1 capsids in the presence of 1% DMSO was 
stored at room temperature for 4 hours. At certain time points, a sample was removed and 
centrifuged to remove any aggregated material. The absorbance at 280 nm of the resulting 
solution was taken as a measure of soluble, and thus stable, protein material. Over time, 
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figure 4.3	 Analysis	of	ELP-CCMV	T	=	1	capsid	stability	in	pH	7.5	capsid	buffer	(Buffer	C)	in	the	presence	of	DMSO.	
a)	Intensity	distribution	of	ELP-CCMV	T	=	1	capsids	in	Buffer	C,	as	measured	by	DLS.	b)	Intensity	distribution	of	ELP-
CCMV	T	=	1	capsids	 in	Buffer	C	with	10%	DMSO	after	15	minutes,	as	measured	by	DLS.	c) Intensity distribution 
of	ELP-CCMV	T	=	1	capsids	 in	Buffer	C	with	1%	DMSO,	as	measured	by	DLS.	The	capsid	stability	was	 followed	
for a period of 4 hours. Capsids are expected around 20-30 nm, and dimers are expected below 10 nm. D) UV-vis 
absorbance	of	ELP-CCMV	T	=	1	capsids	in	Buffer	C	with	1%	DMSO.
no decrease in the 280 nm absorbance was observed, confirming the stability of the capsids 
in the presence of 1% DMSO.
Next, we investigated the co-assembly of CalB-ELP-CCMV and G-ELP-CCMV into capsids. 
First, SrtA coupling reactions were carried out for 3 hours, after which both pH- and salt-
induced assembly conditions were applied to form T = 3 and T = 1 capsids, respectively 
(Figure 4.4). The capsid assembly was analyzed by SEC using a Superose 6 increase 10/300 
column. The capsids eluted around 11–13 mL and the residual proteins in the reaction 
mixture at 16–20 mL (Figure 4.4A and B). It was observed that capsids were much more 
efficiently formed when the salt-induced assembly towards T = 1 particles was applied, 
which is probably due to the additional effects of ELP aggregation during capsid assembly. 
To this end, we decided to continue with salt-induced capsid formation, and thus T = 1 
particles, for the next experiments.
After preparative SEC of the reaction mixtures, the T = 1 capsid fractions could be isolated 
and analyzed by SDS-PAGE (Figure 4.4C). The percentage of CalB-ELP-CCMV in relation 
to G-ELP-CCMV was determined for both the initial reaction mixture and the isolated 
capsids (Figure 4.4D). It was observed that a conversion of 28% was achieved in the 
reaction mixture with 2.0 eq. SrtA after 3 hours. With regard to the isolated capsids, 8% of 
all ELP-CCMV capsid protein mass was modified with CalB. This corresponds to a loading 
of approximately 1-2 CalB enzymes per T = 1 capsid. As the amount of available CalB-CCMV 
protein is much higher than 8% it implies that the loading of 1-2 enzymes per capsid is 
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figure 4.4	 Purification	of	 the	ELP-CCMV	capsids	after	 the	SrtA-mediated	coupling	reaction	with	CalB-LPETG.	
a)	 SEC	 chromatogram	 of	 pH-induced	G-ELP-CCMV	 capsid	 assembly	 after	modification	with	 CalB-LPETG	 in	 the	
absence (purple line) or presence (blue line)	 of	 SrtA	 (2.0	 eq.).	 The	 capsid	 peak	 is	 indicated	 by	 an	 arrow.	b) SEC 
chromatogram	of	salt-induced	G-ELP-CCMV	capsid	assembly	after	modification	with	CalB-LPETG	 in	 the	absence	
(purple line) or presence (blue line)	of	SrtA	(2.0	eq.).	The	capsid	peak	is	indicated	by	an	arrow.	c)	SDS-PAGE	analysis	
of	3	hour	reaction	mixtures	before	(pre)	and	after	preparative	SEC	purification	of	salt-induced	capsids	(post),	both	in	
the	absence	(left)	or	presence	(right)	of	SrtA	(2.0	eq.).	Protein	bands	were	visualized	by	Coomassie	blue	staining	(left)	
and by silver staining (right). D)	Mass	percentages	of	CalB-ELP-CCMV	compared	 to	G-ELP-CCMV	 in	 the	 reaction	
mixtures	and	purified	capsids,	based	on	quantitative	ImageJ	analysis	of	the	SDS-PAGE	results	shown	in	C.	e) SDS-
PAGE	calibration	curve	of	G-ELP-CCMV.	f)	Comparison	using	SDS-PAGE	between	capsids	without	CalB,	without	
SrtA, or with both components present, after a reaction time of 3 hours. The calibration curve shown in E was used to 
calculate	the	amounts	of	G-ELP-CCMV	and	CalB-ELP-CCMV	in	the	capsid	fractions.
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figure 4.5 a)	Uranyl	acetate-stained	TEM	micrograph	of	G-ELP-CCMV	after	incubation	with	CalB-LPETG	(0	eq.	
SrtA). Scale bar corresponds to 200 nm. b)	Size	distribution	of	the	ELP-CCMV	particles	shown	in	A.	c) Uranyl acetate-
stained	TEM	micrograph	of	G-ELP-CCMV	after	reaction	with	CalB-LPETG	(2.0	eq.	SrtA).	Scale	bar	corresponds	to	200	
nm. D)	Size	distribution	of	the	CalB-modified	ELP-CCMV	particles	shown	in	C.	Scale	bars	correspond	to	200	nm.
the maximum tolerated capacity, caused by steric constraints. This is quite a remarkable 
encapsulation efficiency, considering that CalB has an estimated diameter of 5 nm, while 
the interior of T = 1 capsids has a diameter of approximately 8 nm, of which part is occupied 
by the condensed ELP layer in case of ELP-CCMV. Analysis of the capsid fractions by ESI-
TOF mass spectrometry confirmed the presence of CalB-ELP-CCMV in the capsids (data 
not shown). Transmission electron microscopy (TEM) analysis of the capsids showed that 
there was no size difference between the particles from the experiments with and without 
SrtA, indicating that the modification with CalB did not impart the structure of the capsids 
to a great extent (Figure 4.5). This was supported by the SEC traces, which showed a similar 
elution volume, regardless whether the particles were modified with CalB or not (Figure 
4.4B).
After having established that CalB-ELP-CCMV could indeed be incorporated into the 
capsids, three different coupling experiments were performed with the CCMV capsid 
proteins: one without CalB-LPETG present, one without SrtA present and one with 
both CalB-LPETG and SrtA present (++ capsid sample). All three protein samples were 
assembled into T = 1 capsids using the salt-induced protocol after the SrtA reaction 
and purified as described above. These capsids were used in an activity assay with the 
benchmark substrate p-NPA 1, which can diffuse into the capsids through its small pores 
(Figure 4.6A).13 To investigate background hydrolysis, buffer was added to the substrate 
instead of a capsid solution. Additionally, the activity of the encapsulated CalB in the 
++ mixture was compared to the activity of non-encapsulated CalB-LPETG at the same 
concentration. To this end, quantitative SDS-PAGE analysis of the reaction mixtures 
was used to determine the amount of CalB-ELP-CCMV in the sample (Figure 4.4E and 
F). The activity assay showed that encapsulated CalB performed equally well or slightly 
70
Chapter 4
figure 4.6 a) Substrates that were used in the CalB activity assays. b) Hydrolytic activity in the hydrolysis of 
substrates 1, 2 and 3.	 -CalB:	no	CalB	present	during	 the	SrtA-mediated	coupling	 reaction;	 -SrtA:	no	SrtA	present	
during	 the	 SrtA-mediated	 coupling	 reaction;	 ++:	 both	 CalB	 and	 SrtA	 present	 during	 the	 SrtA-mediated	 coupling	
reaction;	free	CalB:	non-encapsulated	CalB,	same	CalB	concentration	as	in	the	++	capsid	sample;	buffer:	buffer	C.	c) 
Kinetic data for non-encapsulated and encapsulated CalB.
figure 4.7 a)	Hydrolytic	activity	upon	incubation	with	protease	Glu-C	after	t	=	5	minutes	and	5	hours.	b) Hydrolytic 
activity upon incubation with protease trypsin after t	=	5	minutes	and	5	hours.	For	++	and	free	CalB,	the	activity	after	
5	hours	was	expressed	as	a	percentage	of	the	initial	activity	(see	numbers	below	the	graph).	-CalB:	no	CalB	present	
during	the	SrtA-mediated	coupling	reaction;	-SrtA:	no	SrtA	present	during	the	SrtA-mediated	coupling	reaction;	++:	
both	CalB	and	SrtA	present	during	 the	SrtA-mediated	coupling	 reaction;	 free	CalB:	non-encapsulated	CalB,	same	
CalB	concentration	as	in	the	++	capsid	sample;	buffer:	buffer	C.
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better than non-encapsulated CalB (Figure 4.6B). Detailed kinetic analysis of the reaction 
of encapsulated and non-encapsulated CalB confirmed that in both cases the enzyme’s 
K
M
 and kcat are rather similar (Figure 4.6C). Thus, encapsulation of the enzyme does not 
decrease its intrinsic activity and the substrate conversion is not hindered by diffusion over 
the CCMV capsid wall. As expected, hardly any conversion of the substrate was observed 
when CalB-LPETG or SrtA had been left out of the reaction mixture, compared to the 
background hydrolysis.
Substrates 2 and 3 with an incorporated polyethylene glycol (PEG) tail were used to 
investigate the influence of substrate size on the conversion. For the non-encapsulated 
CalB, a drop in activity was observed, compared to the smaller substrate 1. This might be 
due to shielding of the p-nitrophenyl moiety by the PEG chain. Similarly, a decrease in 
conversion of substrates 2 and 3 was observed for encapsulated CalB. Since the effect of 
an increase in substrate size has similar effects on both free CalB and encapsulated CalB, 
we cannot safely draw conclusions about the effect of substrate diffusion over the protein 
capsid membrane on the conversion of these substrates.
Lastly, the protective influence of the ELP-CCMV capsid on the encapsulated enzyme 
was investigated. To this end, CalB-modified ELP-CCMV capsids were incubated at room 
temperature with two different proteases: Glu-C and trypsin. Previous research had shown 
that protease Glu-C does not seem to affect the capsid protein, whereas upon incubation 
with protease trypsin, three stable degradation products of the CCMV capsid protein are 
formed.27 As expected, the activity of encapsulated CalB did not decrease greatly upon 
incubation with Glu-C, whereas non-encapsulated CalB was not active anymore after 
5 hours of incubation (Figure 4.7A). This proves that the capsid protects the enzyme 
efficiently. Incubation of these samples with trypsin, however, resulted in different behavior 
(Figure 4.7B). Non-encapsulated CalB was not as greatly affected by trypsin as by Glu-C, 
which could be due to a lower activity of trypsin at room temperature, compared to Glu-C. 
Surprisingly, the activity of encapsulated CalB increased upon 5 hours of incubation with 
trypsin. A possible explanation could be partial degradation of the ELP-CCMV capsid 
protein in this time, allowing easier diffusion of the substrates into the capsid.
4.3 concLuSionS
We have described an efficient method to encapsulate enzymes in an ELP-CCMV protein 
capsid. An encapsulation efficiency of approximately 1-2 enzymes per T = 1 capsid was 
achieved. The capsids could easily be separated from the other proteins in the reaction 
mixture, after which the activity of the encapsulated CalB was measured. The encapsulated 
enzyme was found to be equally active as the non-encapsulated enzyme and its activity 
did not seem to be hampered by substrate diffusion effects. While studying the effect of 
substrate size on its diffusion, we found that non-encapsulated CalB already converts 
larger substrates much more slowly. Therefore, this enzyme is not useful when studying 
the effect of substrate size on the conversion. To investigate this further, other types of 
enzymes should be encapsulated. It was also shown that the capsid is able to protect its 
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cargo against proteases. Thus, this system allows the study of enzymatic activity in the 
presence of harmful compounds.
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4.5 exPeriMenTaL SecTion
4.5.1  Materials and methods
Materials
Hot start II HF DNA polymerase, restriction enzymes, T4 DNA ligase and Antarctic 
phosphatase were obtained from New England Biolabs. The DNA oligos were synthesized 
by Biolegio. Ampicillin was purchased from MP Biomedicals. Chloramphenicol was 
obtained from Sigma-Aldrich. Isopropyl β-d-1-thiogalactopyranoside (IPTG) and DMSO 
were purchased from Acros. Ni-NTA agarose beads were obtained from Qiagen. CH2Cl2 
was dried by purging it over an activated alumina column utilizing an MBraun MB 
SPS800 system under nitrogen atmosphere. p-Nitrophenol and p-nitrophenyl acetate 
were purchased from Aldrich. EDC·HCl and MeO-PEG-NHCO-C2H4-COOH MW 750 and 
MW 2000 were obtained from Iris Biotech GmbH. DMSO-d6 was purchased at Cambridge 
Isotope Laboratories. Endoproteinase Glu-C was obtained from BIOKÉ. Trypsin Gold was 
purchased from Promega.
Buffers
pH 5.0 capsid buffer: 50 mM NaOAc, 500 mM NaCl, 10 mM MgCl2, 1 mM EDTA, pH 5.0. 
pH 7.5 dimer buffer: 50 mM Tris·HCl, 500 mM NaCl, 10 mM MgCl2, 1 mM EDTA, pH 7.5.
pH 7.5 capsid buffer: 50 mM Tris·HCl, 2000 mM NaCl, 10 mM MgCl2, 1 mM EDTA, pH 7.5.
Sortase buffer: 50 mM HEPES, 150 mM NaCl, 5 mM CaCl2, pH 7.5.
CalB buffer: 50 mM NaH2PO4, 150 mM NaCl, pH 7.0.
All buffers were filtered over a 0.2 micron filter prior to use.
UV-vis spectroscopy
Protein concentrations were measured on a Varian Cary 50 Conc UV-vis spectrometer 
using a quartz cuvette with a path length of 3 mm. Protein concentrations were calculated 
using the theoretical extinction coefficients.28 Samples were centrifuged prior to the 
measurements.
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Mass	spectrometry
Protein mass characterization was performed by electrospray ionization time-of-flight 
(ESI-TOF) on a JEOL AccuTOF CS. Deconvoluted mass spectra were obtained using 
MagTran 1.03 b2. Isotopically averaged molecular weights were calculated using the 
‘Protein Calculator v3.4’ at http://protcalc.sourceforge.net. Protein samples were desalted 
by spin filtration to MQ (final concentrations 10-150 μM).
Size exclusion chromatography (SEC)
SEC was performed on a Superose 6 10/300 column or a Superdex 75 PC 10/300 column (GE 
Healthcare). Analytical and preparative SEC measurements were executed on a Shimadzu 
LC-2010AHT HPLC and Agilent 1260 bio-inert HPLC, respectively. Samples (10-200 μg) 
were separated on the column with a flow rate of 0.5 mL/min.
Transmission	electron	microscopy	(TEM)
TEM grids (FCF-200-Cu, EMS) were glow-discharged using a Cressington carbon coater 
and power unit. Protein samples (0.2 mg/mL, 5 μL) were applied on the glow-discharged 
grids and incubated for 1 min. The samples were carefully removed using a filter paper and 
the grid was allowed to dry for at least 15 minutes. Then the grid was negatively stained 
by applying 2% uranyl acetate in water (5 μL). The staining solution was removed after 15 
seconds and the grid was allowed to dry for at least 15 minutes. The samples were analyzed 
on a JEOL JEM-1010 TEM.
1H and 13C	NMR
1H and 13C NMR spectra were recorded on a Bruker Avance III 400 (400 MHz) spectrometer 
in DMSO-d6. The NMR solvent residual peak of DMSO-d6 was used as the internal 
reference. Proton coupling constants (Hz) of the phenyl protons were determined by 
computer simulation using MestReNova.
Dynamic	light	scattering	(DLS)
DLS measurements were performed on a Zetasizer Nano S at 25 °C. Samples (1 mg/mL) 
were centrifuged prior to analysis. Organic solvents and buffers were filtered prior to use. 
All measurements were done in triplicate, and the average of the triplicate measurements 
was plotted.
Microplate	reader	experiments
Microplate reader experiments were performed on a Tecan Spark 10 M microplate reader 
at 25 °C. Samples were centrifuged prior to analysis. Buffers were filtered prior to use. The 
readout wavelength was set to 405 nm. All measurements were done in duplicate.
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4.5.2  experimental details
Protein	sequences
Table 4.1	 Amino	acid	sequences	of	the	proteins	used	in	this	chapter.
Name Sequence
H6-SrtA
TGSHHHHHHGSKPHIDNYLHDKDKDEKIEQYDKNVKEQASKDKKQQAKPQIPKDKSKVAGYIEIPDAD
IKEPVYPGPATPEQLNRGVSFAEENESLDDQNISIAGHTFIDRPNYQFTNLKAAKKGSMVYFKVGNET
RKYKMTSIRDVKPTDVGVLDEQKGKDKQLTLITCDDYNEKTGVWEKRKIFVATEVK
G-H6-ELP-CCMV
GHHHHHHVPGVGVPGLGVPGVGVPGLGVPGVGVPGLGVPGGGVPGVGVPGLGLEVVQPVIVEPIASGQ
GKAIKAWTGYSVSKWTASCAAAEAKVTSAITISLPNELSSERNKQLKVGRVLLWLGLLPSVSGTVKSC
VTETQTTAAASFQVALAVADNSKDVVAAMYPEAFKGITLEQLTADLTIYLYSSAALTEGDVIVHLEVE
HVRPTFDDSFTPVY
CalB-H6
MGLPSGSDPAFSQPKSVLDAGLTCQGASPSSVSKPILLVPGTGTTGPQSFDSNWIPLSAQLGYTPCWI
SPPPFMLNDTQVNTEYMVNAITTLYAGSGNNKLPVLTWSQGGLVAQWGLTFFPSIRSKVDRLMAFAPD
YKGTVLAGPLDALAVSAPSVWQQTTGSALTTALRNAGGLTQIVPTTNLYSATDEIVQPQVSNSPLDSS
YLFNGKNVQAQAVCGPLFVIDHAGSLTSQFSYVVGRSALRSTTGQARSADYGITDCNPLPANDLTPEQ
KVAAAALLAPAAAAIVAGPKQNCEPDLMPYARPFAVGKRTCSGIVTPLEHHHHHH
CalB-LPETG-H6
MGLPSGSDPAFSQPKSVLDAGLTCQGASPSSVSKPILLVPGTGTTGPQSFDSNWIPLSAQLGYTPCWI
SPPPFMLNDTQVNTEYMVNAITTLYAGSGNNKLPVLTWSQGGLVAQWGLTFFPSIRSKVDRLMAFAPD
YKGTVLAGPLDALAVSAPSVWQQTTGSALTTALRNAGGLTQIVPTTNLYSATDEIVQPQVSNSPLDSS
YLFNGKNVQAQAVCGPLFVIDHAGSLTSQFSYVVGRSALRSTTGQARSADYGITDCNPLPANDLTPEQ
KVAAAALLAPAAAAIVAGPKQNCEPDLMPYARPFAVGKRTCSGIVTPLPETGGLEHHHHHH
Expression of H6-SrtA
The expression and purification of H6-SrtA were performed as described in Chapter 3.
Expression	of	G-H6-ELP-CCMV
The expression and purification of G-H6-ELP-CCMV were performed as described in 
Chapter 3.
Cloning	of	CalB-LPETG-H6
The pET-22b-wt-CalB vector encoding for bacterial expression of the histidine-tagged 
wild-type CalB protein was previously constructed as described by Schoffelen et al.29 
For the introduction of the LPETG-tag, a set of DNA oligos was designed (Table 4.2). The 
oligos were annealed and the resulting insert encoded for the CalB protein, an LPETGG 
motif and a hexahistidine tag with a 5’ NcoI and a 3’ XhoI restriction site. The product 
after PCR was purified by agarose gel electrophoresis. Both the purified insert and the 
pET-22b-wt-CalB vector were digested with NcoI-HF® and XhoI and the products were 
again purified by agarose gel electrophoresis. Subsequently, the inserts were ligated into 
the digested vector to yield pET-22b-CalB-LPETG-H6. This plasmid was transformed into 
E. coli XL1-BLUE cells, the DNA was extracted and the sequences were confirmed by DNA 
sequencing (Table 4.1). For expression, the plasmid was transformed into E. coli BLR(DE3)
pLysS cells (Novagen, MERCK).
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Table 4.2	 DNA	sequence	of	the	oligos	used	for	the	construction	of	the	required	expression	vectors.
Name Sequence
CalB-LPETG-H6 forward 5’-ATATATCCATGGGACTACCTTCCG
CalB-LPETG-H6 reverse 5’-ATATATCTCGAGGCCGCCGGTTTCCGGCAGGGGGGTGACGATGCC
General	protocol	for	the	expression	of	CalB
The pET-22b-wt-CalB vector encoding for bacterial expression of the histidine-tagged CalB 
protein was previously constructed as described by Schoffelen et al.29 
For a typical expression, LB medium (50 mL), containing ampicillin (100 mg/L) and 
chloramphenicol (50 mg/L), was inoculated with a single colony of E. coli B834(DE3)pLysS 
containing pET-22b-CalB-H6 or BLR(DE3)pLysS containing pET-22b-CalB-LPETG-H6 
and was incubated overnight at 37 °C. This overnight culture was used to inoculate 2x TY 
medium (1 L), supplemented with ampicillin (100 mg/L) and chloramphenicol (50 mg/L). 
The culture was grown at 37 °C and protein expression was induced during logarithmic 
growth (OD600 = 0.4-0.6) by the addition of IPTG (1 mM). After 6 h of expression at 30 °C, 
the cells were harvested by centrifugation (2700 g, 15 min, 4 °C) and the pellets were stored 
overnight at -20 °C. 
After thawing, the cell pellet was resuspended in lysis buffer (50 mM NaH2PO4, 0.5 M 
NaCl, 10 mM imidazole, pH 8.0; 25 mL). The cells were lysed by ultrasonic disruption (5 
times 30 s, 100% duty cycle, output control 3, Branson Sonifier 250, Marius Instruments). 
Then the lysate was centrifuged (16.400 g, 15 min, 4 °C) to remove the cellular debris. 
The supernatant was incubated with Ni-NTA agarose beads (3 mL) for 1 h at 4 °C. The 
suspension was loaded onto a column, the flow-through was collected and the beads were 
washed twice with wash buffer (50 mM NaH2PO4, 0.5 M NaCl, 20 mM imidazole, pH 8.0; 
20 mL). Then, the protein of interest was eluted from the column with elution buffer (50 
mM NaH2PO4, 0.5 M NaCl, 250 mM imidazole, pH 8.0; 1 time 0.5 mL, 7 times 1.5 mL). 
The purification was analyzed by SDS-PAGE. The elution fractions containing CalB were 
combined and concentrated (Amicon® Ultra-4 Centrifugal Filter Device 10.000 NMWL). 
Further purification was performed by preparative SEC using a Superdex 75 PC 10/300 
column and CalB buffer as the eluent. The purity was verified by SDS-PAGE and SEC using 
a Superose 6 10/300 GL column and CalB buffer as the eluent. The yields of the proteins 
after purification and the ESI-TOF results are listed in Table 4.3.
Table 4.3 Expression yields and ESI-TOF results of the CalB variants used in this chapter.
Name Yield ESI-TOF
calculated mw observed mw
CalB-H6 0.9-2.8 mg/L 34269.7 Da 34268.0 Da
CalB-LPETG-H6 2.5-3.8 mg/L 34824.3 Da 34823.8 Da
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Synthesis of substrate 2
p-Nitrophenol (54 mg, 0.39 mmol, 1.5 eq.), MeO-
PEGNHCO-C2H4-COOH MW 802 (203 mg, 0.25 mmol, 
1.0 eq.) and EDC·HCl (77 mg, 0.40 mmol, 1.6 eq.) were 
dissolved in anhydrous CH2Cl2 (20 mL) under Ar and 
stirred overnight at rt. An aqueous 2M HCl solution 
(50 mL) and CH2Cl2 (30 mL) were added, the layers 
were separated, and the aqueous phase was extracted 
again with CH2Cl2 (2x 50 mL). The combined organic 
layers were washed with aqueous 0.5 M K2CO3 (3 x 50 mL) and brine (1 x 50 mL) and dried 
over Na2SO4. The solvent was removed in vacuo yielding ester 2 as a yellow solid (229 mg, 
0.25 mmol, quant.). R
f
 = 0.49 (MeOH/CH2Cl2 1/9, v/v). 
1H NMR (400 MHz, DMSO-d6) δ: 
8.33 – 8.25 (m, 2H), 8.01 (t, J = 5.5 Hz, 1H), 7.42 – 7.36 (m, 2H), 3.49 (m, 66H)*, 3.43 – 3.36 
(m, 4H), 3.22 (s, 3H), 3.21 – 3.16 (m, 2H), 2.78 (t, J = 6.7 Hz, 2H) ppm. 13C NMR (100 MHz, 
DMSO-d6) δ: 170.8, 170.6, 155.5, 144.9, 137.4, 136.4, 125.3, 123.1, 71.3, 69.8 (b) (multiple PEG 
carbons), 69.7, 69.6, 69.1, 58.0, 54.9, 29.7, 29.3 ppm.
* The peak belonging to the PEG protons (66H) did not match with the mass that was given 
by the supplier (~56H). During further experiments, the mass given by the supplier was 
used in the calculations.
Synthesis of substrate 3
p-Nitrophenol (24 mg, 0.17 mmol, 1.6 eq.), MeO-
PEGNHCO-C2H4-COOH MW 1931 (212 mg, 0.11 mmol, 
1.0 eq.) and EDC·HCl (30 mg, 0.16 mmol, 1.4 eq.) were 
dissolved in anhydrous CH2Cl2 (20 mL) under Ar and 
stirred overnight at rt. An aqueous 2M HCl solution 
(50 mL) and CH2Cl2 (30 mL) were added, the layers 
were separated, and the aqueous phase was extracted 
again with CH2Cl2 (2x 50 mL). The combined organic 
layers were washed with aqueous 0.5 M K2CO3 (3 x 50 mL) and brine (1 x 50 mL) and dried 
over Na2SO4. The solvent was removed in vacuo yielding ester 3 as a yellow solid (221 mg, 
0.11 mmol, quant.). R
f
 = 0.47 (MeOH/CH2Cl2 1/9, v/v). 
1H NMR (400 MHz, DMSO-d6) δ: 
8.35 – 8.28 (m, 2H), 8.03 (t, J = 5.5 Hz, 1H), 7.45 – 7.37 (m, 2H), 3.51 (m, 200H)*, 3.44 – 3.38 
(m, 5H), 3.24 (s, 3H), 3.23 – 3.18 (m, 2H), 2.80 (t, J = 6.7 Hz, 2H) ppm. 13C NMR (100 MHz, 
DMSO-d6) δ: 170.8, 170.6, 155.5, 144.9, 125.3, 123.1, 71.3, 69.8 (b) (multiple PEG carbons), 
69.7, 69.6, 69.1, 58.1, 54.9, 29.7, 29.3 ppm.
* The peak belonging to the PEG protons (200H) did not match with the mass that was 
given by the supplier (~160H). During further experiments, the mass given by the supplier 
was used in the calculations.
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Analysis of capsid stability in the presence of organic solvents
DLS analysis: Two solutions of G-H6-ELP-CCMV in pH 7.5 capsid buffer (1 mg/mL, 100 
μL) were prepared. To one solution, DMSO (1 μL) was added, to the other solution, buffer 
(1 μL) was added. The solutions were stored at rt in a cuvette. After 0, 1, 2, 3, and 4 h, the 
solutions were analyzed by DLS.
UV-vis analysis: Two solutions of G-H6-ELP-CCMV in pH 7.5 capsid buffer (1 mg/mL, 300 
μL) were prepared. To one solution, DMSO (3 μL) was added, to the other solution buffer 
(3 μL) was added. The solutions were shaken at 21 °C. After 0, 1, 2, 3, and 4 h, a 50 μL aliquot 
of each solution was removed, centrifuged to precipitate any aggregated material (13.000 
rpm, 1 min, 4 °C) and analyzed by UV-vis spectroscopy.
SrtA-mediated coupling experiments
For a typical SrtA-mediated coupling experiment, stock solutions of SrtA, G-H6-ELP-
CCMV and CalB-LPETG were prepared in Sortase buffer. If a component had been 
dissolved in another buffer, it was spin filtrated to Sortase buffer (10 kDa MWCO, 3 x 10 
min). The components were added together to final concentrations of 0-100 μM SrtA, 50 
μM G-H6-ELP-CCMV and 50 μM CalB-LPETG. The solutions were shaken at 21 °C for 24 h. 
The reaction progress was followed by SDS-PAGE analysis.
SrtA-mediated	coupling	experiments,	followed	by	capsid	purification
For a typical SrtA-mediated coupling experiment, stock solutions of SrtA, G-H6-ELP-CCMV 
and CalB-LPETG were prepared in Sortase buffer. If a component had been dissolved in 
another buffer, it was spin filtrated to Sortase buffer (10 kDa MWCO, 3 x 10 min). The 
components were added together to final concentrations of 0/100 μM SrtA, 50 μM G-H6-
ELP-CCMV and 0/50 μM CalB-LPETG. The solutions were shaken at 21 °C for 3 h. Capsid 
assembly was induced by spin filtration to either pH 5.0 capsid buffer (Buffer B) or pH 
7.5 capsid buffer (Buffer C) (10 kDa MWCO, 3 x 10 min). Subsequently, the capsids were 
isolated using preparative SEC. The capsid fractions were analyzed and used for further 
experiments.
Calculation	capsid	loading	based	on	ImageJ	analysis	of	SDS-PAGE
The capsid loading calculations were performed as described in Chapter 3.
Activity assay of non-encapsulated CalB
The lipase activity of CalB-H6 and CalB-LPETG was analyzed by the hydrolysis of 
p-nitrophenyl acetate (p-NPA). CalB (111.0 nM, 45.0 μL) in the desired buffer (see Table 4.4) 
was added to p-NPA (10 mM in DMSO, 5.0 μL) in triplicate. The background hydrolysis 
was measured by the addition of the desired buffer without CalB to the substrate. The 
production of p-nitrophenol was monitored for 5 minutes at 25 °C by measuring the 
absorbance at 405 nm on a Tecan infinite M200 Pro microplate reader. The slopes of 
the curves were taken as a measure of the hydrolytic activity. Calibration curves of the 
absorbance of p-nitrophenol in the different buffers were measured, in order to convert the 
measured relative activity to U/mg.
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Table 4.4	 Buffers	used	in	the	activity	assay	of	non-encapsulated	CalB.
Name Composition
Buffer A 50 mM NaH2PO4, 150 mM NaCl, pH 7.0
Buffer A + 350 mM NaCl 50 mM NaH2PO4, 500 mM NaCl, pH 7.0
Buffer A + 1.85 M NaCl 50 mM NaH2PO4, 2000 mM NaCl, pH 7.0
Buffer A + 10 mM MgCl2 50 mM NaH2PO4, 150 mM NaCl, 10 mM MgCl2, pH 7.0
Buffer A + 1 mM EDTA 50 mM NaH2PO4, 150 mM NaCl, 1 mM EDTA, pH 7.0
Buffer B 50 mM NaOAc, 500 mM NaCl, 10 mM MgCl2, 1 mM EDTA, pH 5.0
Buffer C 50 mM Tris·HCl, 2000 mM NaCl, 10 mM MgCl2, 1 mM EDTA, pH 7.5
Calculation enzyme activity in U/mg. The enzyme activity was calculated and expressed 
in U/mg. The definition of 1U is:
1U = conversion of 1 µmol  substrate per minute 
The measured slope of background hydrolysis of p-NPA to p-NP was subtracted from 
the CalB-catalyzed conversion and multiplied by a factor of 60, to convert the units into 
minutes instead of seconds:
ΔAbs = (ΔAbs
CalB
 - ΔAbs
BG
) * 60
Next, the calibration curves were used to convert this absorbance difference into an amount 
of converted p-NPA per minute, which is equal to U:
Δsubstrate (µM) = 
                  ΔAbs                    
= Utotal 
 
     slope calibration curve
Finally, Utotal was divided by the amount of CalB present in the reaction mixture to obtain 
the enzyme activity in U/mg:
Activity (U/mg) = 
             Utotal               
                     amount of CalB (mg)
Activity assay of encapsulated CalB
A capsid fraction of CalB-ELP-CCMV capsids (49.5 μL) was added to p-NPA 1, substrate 2 or 
substrate 3 (100 mM in DMSO, 0.5 μL) in duplo. The background hydrolysis was measured 
by the addition of pH 7.5 capsid buffer (Buffer C) to the substrate. The production of 
p-nitrophenol was monitored for 5 minutes at 25 °C by measuring the absorbance at 405 
nm on a Tecan infinite M200 Pro microplate reader. The slopes of the curves were taken as 
a measure of the hydrolytic activity.
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Protease degradation assay
Protease Glu-C (1 μg/μL in MQ, 1.0 μL) and trypsin (1 μg/μL in 50 mM acetic acid, 1.0 
μL) were added to a capsid fraction (2 x 120 μL). As a control, the proteases were added 
to pH 7.5 capsid buffer (Buffer C) (2 x 120 μL) or non-encapsulated CalB-LPETG (same 
concentration as the encapsulated CalB, 2 x 120 μL). The solutions were shaken at 21 °C 
for 5 h. After 0 and 5 h, samples (49.5 μL) were removed and added to p-NPA (100 mM in 
DMSO, 0.5 μL). The production of p-nitrophenol was monitored for 5 minutes at 25 °C by 
measuring the absorbance at 405 nm on a Tecan infinite M200 Pro microplate reader. The 
slopes of the curves were taken as a measure of the hydrolytic activity.
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abSTracT
Virus-like particles are very interesting tools for applications 
in bionanotechnology, due to their monodisperse features and 
biocompatibility. In particular, the cowpea chlorotic mottle virus 
(CCMV) capsid has been studied extensively as it can be assembled 
and disassembled reversibly, facilitating cargo encapsulation. 
CCMV is, however, only stable at physiological conditions when its 
endogenous nucleic acid cargo is present. To gain more flexibility 
in the type of cargo encapsulated and to broaden the window of 
operation, it is interesting to improve the stability of the empty 
virus-like particles. Here, a method is described to utilize the CCMV 
capsid at close to physiological conditions as a stable, enzyme-
filled nanoreactor. As a proof-of-principle, the encapsulation of T4 
lysozyme (T4L) was chosen; this enzyme is a promising antibiotic, 
but its clinical application is hampered by, for example, its cationic 
character. It was shown that four T4L molecules can successfully be 
encapsulated inside CCMV capsids, while remaining catalytically 
active, which could thus improve the enzyme’s application potential.
Stabilization of a VLP and its application as a nanoreactor at physiological conditions
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5.1 inTroDucTion
Virus-like particles (VLPs) are protein-based nanocages composed of a discrete number of 
viral capsid proteins.1 In contrast to some other types of nanoparticles, such as liposomes 
or polymeric vesicles, VLPs are very monodisperse in shape and size. Of special interest 
is the cowpea chlorotic mottle virus (CCMV), an icosahedral plant virus, which normally 
adopts T = 3 symmetry.2 This capsid consists of 180 identical 20 kDa capsid proteins and has 
inner and outer diameters of 18 and 28 nm, respectively.3 The CCMV VLP is able to undergo 
reversible, pH-dependent assembly and disassembly, even in the absence of its viral RNA.4 
At pH 7.5, the capsid disassembles into 90 protein dimers, and by lowering the pH to 5.0, 
the original structure is reformed. This property has been used to encapsulate inorganic 
materials,5,6 negatively charged polymers,7,8 and enzymes9 by adding these molecules to 
the media during the assembly process of the protein dimers.
The endogenous assembly behavior of CCMV VLPs does not allow for their facile 
application in biological settings, as the capsids will disassemble at a physiologically 
neutral pH. Therefore, a modified protein-based block copolymer of the CCMV capsid 
protein, containing an N-terminal elastin-like polypeptide (ELP) block, was previously 
developed in our lab.10 ELPs are stimuli-responsive polymers, derived from elastin, which 
can switch from a water-soluble state to a collapsed, insoluble state, upon a change in 
the environmental conditions, such as temperature, pH, cations, and salt concentration of 
the solution.11,12 ELPs consist of repeats of the Val-Pro-Gly-Xaa-Gly (VPGXG) pentapeptide, 
where X is any natural amino acid except proline. Previously, the stimuli-responsive 
polypeptide block was placed at the N-terminal end of the CCMV capsid protein, replacing 
the cationic RNA-binding domain. The introduction of the ELP resulted in a new assembly 
pathway: ELP-induced assembly led to the formation of T = 1 capsids, consisting of 30 
protein dimers, after an increase of the salt concentration at pH 7.5. Capsids with a T = 3 
symmetry could still be formed via the endogenous pH-induced assembly pathway.
Even though the newly developed ELP-CCMV capsid proteins could assemble at 
physiological pH, a high salt concentration (~2 M NaCl) was still needed to form the 
capsids. Therefore, a third assembly mechanism for the ELP-CCMV capsid proteins was 
introduced, making use of the metal-binding properties of the hexahistidine tags at 
the N-terminus of ELP-CCMV, which had initially been introduced to facilitate protein 
purification through affinity chromatography.13 The addition of divalent ions to H6-ELP-
CCMV, such as nickel or cobalt, resulted in local clustering of the capsid proteins, lowering 
the transition temperature of the ELP blocks and subsequently leading to capsid assembly 
at pH 7.5, without the need for a high salt concentration. This has set the stage to use 
CCMV capsids as enzyme nanoreactors at non-native and physiological conditions.
Lysozyme, specifically T4 lysozyme (T4L) was chosen as the model enzyme to be 
encapsulated in the nanoreactor. This enzyme plays a key role in the human immune system, 
as it protects our body from Gram-positive pathogens, such as Bacillus and Streptococcus. 
It does so by cleaving the core β-(1,4)-glycosidic bond between N-acetylmuramic acid and 
the fourth carbon atom of the N-acetylglucosamine of bacterial cell wall peptidoglycans, 
resulting in bacterial lysis and death.14 Human lysozyme has been successfully applied in 
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Scheme 5.1	 Schematic	 representation	 of	 the	 Sortase	 A-mediated	 N-terminal	 functionalization	 of	 hexahistidine-
tagged	 G-H6-ELP-CCMV	 capsid	 protein	 dimers	 with	 LPETG-modified	 T4	 lysozyme,	 and	 subsequent	 enzyme	
encapsulation	via	capsid	formation.	Capsid	stabilization	with	Ni2+ ions results in capsids which remain assembled at 
low	NaCl	concentrations	and	allows	the	degradation	of	the	cell	wall	of	M.	luteus by lysozyme.
early studies to treat experimentally induced pneumonia using hamster models, which 
has laid the foundation for clinical testing of lysozyme for antibiotic treatments.15,16 The 
enzyme has some disadvantageous properties, however, which hamper its application in 
a clinical setting. For instance, the cationic character of lysozyme can lead to aggregation 
with negatively charged biopolymers, resulting in inhibition of its antibacterial properties. 
Additionally, lysozyme-specific inhibitors exist, which also limits the clinical efficacy of 
lysozyme. So far, only genetic engineering has been used to address these problems.17–20 In 
some cases, the engineered variants did indeed show improved properties. Changing the 
lysozyme genetic sequence, however, has also led to the introduction of new unexpected 
and unfavorable properties.
We set out to encapsulate lysozyme in a nanocage structure, in order to protect it against 
harmful external conditions or molecules, allowing the enzyme to remain active without 
the need for extensive genetic engineering of the T4L sequence. Since the lysozyme activity 
drops significantly upon an increase in ionic strength, a nanoreactor is required which is 
stable under physiological conditions.21,22 We hypothesized that the metal ion-stabilized 
H6-ELP-CCMV particles might be very suitable nanocarriers for this purpose.
In order to encapsulate lysozyme, statistical encapsulation during assembly of the H6-ELP-
CCMV capsids would probably not yield a high enough encapsulation efficiency due to the 
cationic character of lysozyme. Therefore, we chose to use a covalent coupling strategy 
(see Chapters 3 and 4).23,24 Briefly, we used Sortase A (SrtA) to modify the N-terminus of 
H6-ELP-CCMV with different cargoes, which eventually end up at the interior of the VLPs 
(Scheme 5.1). SrtA is present in Gram-positive bacteria, where it anchors surface proteins 
to the bacterial cell wall. It recognizes proteins with the sorting signal LPXTG (where X 
= any amino acid). SrtA cleaves the bond between threonine and glycine, after which an 
N-terminal glycine residue attacks the intermediate.
We aimed to introduce the sorting signal LPETG onto the C-terminus of T4L, using a single 
step of genetic engineering, in order to couple it to the N-terminus of H6-ELP-CCMV using 
SrtA (Scheme 5.1). After optimization of the coupling reaction and subsequent assembly 
and metal ion-mediated stabilization of the capsids, we investigated the activity of 
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lysozyme encapsulated in H6-ELP-CCMV by monitoring the degradation of the cell walls 
of Micrococcus luteus (M. luteus), a Gram-positive bacterium.
5.2 reSuLTS anD DiScuSSion
The H6-ELP-CCMV construct was designed such, that it displayed a glycine residue on 
its N-terminus for the SrtA reaction (G-H6-ELP-CCMV). A T4L construct was modified 
to display the Sortase recognition motif LPETG at its C-terminus (T4L-LPETG). A 
hexahistidine tag was additionally included at the C-terminus of T4L-LPETG, for facile 
purification via affinity chromatography. As a control, a T4L construct was prepared with a 
C-terminal hexahistidine tag, but lacking the LPETG recognition motif. The proteins were 
subsequently expressed in Escherichia coli (E. coli), followed by purification through Ni2+ 
affinity chromatography.
Next, the Sortase-mediated coupling of T4L-LPETG to G-H6-ELP-CCMV was evaluated. 
To this end, different equivalents of SrtA were added to a mixture of T4L-LPETG and 
G-H6-ELP-CCMV. The coupling reaction was followed over time by polyacrylamide gel 
electrophoresis (SDS-PAGE) (Figure 5.1A). Formation of both the intermediate T4L-SrtA 
and the desired product T4L-H6-ELP-CCMV could be observed over time. As expected, 
the addition of higher equivalents of SrtA, compared to the reactants, resulted in a faster 
reaction and more product formation after 24 h, as indicated by quantitative ImageJ 
analysis of the SDS-PAGE results (Figure 5.1B). Product formation was further confirmed 
by electrospray ionization time-of-flight (ESI-TOF) mass spectrometry analysis of the 
reaction mixtures after 24 h (Figure 5.1C). No product formation was observed using SDS-
PAGE analysis when no SrtA was added to the reaction mixture. This was confirmed by 
ESI-TOF results of those reaction mixtures (Figure 5.1D).
A conventional way to monitor lysozyme activity is to follow degradation of lyophilized M. 
luteus cells. In this assay, a decrease in turbidity of the cell wall suspension indicates the 
presence of active lysozyme. Even though this assay has been the benchmark in lysozyme 
activity assays for a long time, the sensitivity and reproducibility of this assay are not 
optimal. In another procedure, the M. luteus cell walls are fluorescently labeled to such a 
degree, that the fluorescence becomes quenched. If now lysozyme-catalyzed degradation 
of the cell walls takes place, a dramatic increase of fluorescence occurs, making this assay 
much more sensitive. We chose to use the fluorescence-based assay for the next series of 
experiments.
First, the activity of hexahistidine-tagged T4L and the LPETG-modified variant were tested 
in the benchmark phosphate buffer pH 7.5, supplied with the substrate kit (Figure 5.2). 
Significant activity was observed for both enzymes under the experimental conditions 
used. A slight decrease in activity was observed as a consequence of the introduction of the 
LPETG sequence in T4L-LPETG. Next, we tested whether T4L would become inactive under 
conditions at which the G-H6-ELP-CCMV capsid proteins are assembled, that is, pH 5.0 
capsid buffer or pH 7.5 capsid buffer with 2.0 M NaCl (Buffer 7 and buffer 4, respectively). 
In neither buffer, activity was observed. Also, in pH 7.5 dimer buffer, containing 500 mM 
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figure 5.1	 Analysis	 of	 the	SrtA-mediated	 coupling	 of	 T4L-LPETG	 to	G-H6-ELP-CCMV.	a)	 SDS-PAGE	analysis	
of	 the	conjugation	over	 time,	with	different	equivalents	of	SrtA.	Protein	bands	were	visualized	by	Coomassie	blue	
staining. b)	Conversions	of	G-H6-ELP-CCMV	to	T4L-LPETG-ELP-CCMV	after	7	and	24	h,	based	on	quantitative	ImageJ	
analysis	of	the	SDS-PAGE	results	shown	in	A.	c) Deconvoluted ESI-TOF mass spectrum of a reaction mixture with 1.0 
equiv	SrtA	after	24	h.	D)	Deconvoluted	ESI-TOF	mass	spectrum	of	a	reaction	mixture	with	0	equiv	SrtA	after	24	h.	The	
expected	molecular	weights	are	21947.5	Da	(SrtA,	blue),	22253.4	Da	(G-H6-ELP-CCMV,	purple),	19904.6/20035.8	Da	
(T4L-LPETG/M-T4L-LPETG,	orange),	and	41203.1/41334.3	Da	(T4L-H6-ELP-CCMV/M-T4L-H6-ELP-CCMV,	pink).
NaCl, hardly any activity was observed (Buffer 2). Reducing the NaCl concentration of 
the pH 7.5 dimer buffer to 150 mM did result in lysozyme activity (Buffer 3). Additionally, 
lowering the Tris·HCl concentration from 50 to 10 mM further increased the activity 
(Buffer 6). At pH 5, no activity was observed at all, even upon lowering the ionic strength 
of the buffer (Buffers 7-10). These results confirm that, in order to ensure activity of the 
encapsulated T4L, further stabilization of the G-H6-ELP-CCMV capsids with metal ions 
is required, as no lysozyme activity was observed in buffers in which the capsids remain 
assembled without additional stabilization.
Subsequently, a protocol was developed for capsid assembly and stabilization from a SrtA 
reaction mixture, containing modified and non-modified G-H6-ELP-CCMV capsid protein 
dimers, SrtA and free T4L-LPETG. This was done based on previous work on both the 
SrtA-mediated modification of the N-terminus of CCMV capsid proteins and Ni2+-induced 
capsid formation of H6-ELP-CCMV.
13,23,24 In the first attempt, Ni2+ ions were directly 
added to the reaction mixture to induce the formation of stabilized capsids, followed by 
preparative size exclusion chromatography (SEC) purification of the assembled capsids. 
This, however, did not lead to the formation of monodisperse capsids, as indicated by 
SEC analysis. Instead, tailing of the capsid peak was observed and a very low amount of 
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figure 5.2 a)	Catalytic	activity	of	T4L-H6	and	T4L-LPETG-H6	in	different	buffers.	The	activity	was	measured	using	
the	EnzChek	lysozyme	assay.	The	initial	slopes	of	the	fluorescence	intensity	curves	were	taken	as	a	measure	of	the	
enzymatic activity. b)	Overview	of	 the	different	buffers	that	were	used	 in	 the	activity	assay.	Buffer	2:	pH	7.5	dimer	
buffer,	buffer	4:	pH	7.5	capsid	buffer,	buffer	6:	reaction	buffer,	buffer	7:	pH	5.0	capsid	buffer.
capsids was obtained. A possible explanation could be that the Ni2+ ions also interact with 
other proteins in the solution with a hexahistidine tag, such as SrtA and free T4L-LPETG. 
Therefore, it was decided to first induce capsid formation from the SrtA reaction mixture 
via either pH-induced assembly or salt-induced assembly, followed by preparative SEC 
purification and subsequent stabilization of the capsids with Ni2+ ions. Both assembly 
methods, that is, lowering the pH of the reaction mixture from 7.5 to 5.0 or increasing 
the NaCl concentration of the reaction mixture from 150 to 2000 mM, were tested, and 
both resulted in the formation of capsids from the reaction mixtures (Figure 5.3A). After 
successful purification of both the T = 3 and T = 1 capsids, it was investigated whether 
these capsids could be stabilized by Ni2+ ions. To this end, the capsids were incubated 
with Ni2+ ions and subsequently dialyzed to the T4L-compatible pH 7.5 dimer buffer 
with reduced NaCl and Tris·HCl concentrations (Buffer 6, will be referred to as reaction 
buffer). DLS analysis showed that the T = 3 capsids fell apart during dialysis, indicating 
that the stabilizing effect of the metal ions is not enough in this case (Figure 5.3B). The T 
= 1 particles, however, could be stabilized by Ni2+: capsids were still present after dialysis 
to the reaction buffer (Figure 5.3C). Transmission electron microscopy (TEM) analysis of 
the particles directly after preparative SEC in pH 7.5 capsid buffer, and after stabilization 
and dialysis to reaction buffer showed equally sized particles of approximately 19.6 nm 
(Figure 5.4). When the Ni2+ ions were left out, disassembly towards the capsid protein 
dimers occurred during dialysis, as expected (Figure 5.3C).
After having developed a successful protocol for the formation and stabilization of 
T4L-modified H6-ELP-CCMV T = 1 capsids, the lysozyme encapsulation efficiency was 
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figure 5.3 a)	Size	exclusion	chromatograms	of	SrtA	reaction	mixtures	after	dialysis	to	either	pH	5.0	capsid	buffer	
(pH-induced, purple line)	or	pH	7.5	capsid	buffer	containing	2.0	M	NaCl	(salt-induced,	blue line). Capsids are observed 
around	an	elution	volume	of	10-13	mL,	with	 the	T = 3 particles eluting earlier due to their larger size. b) Intensity 
distributions of the T	=	3	capsid	fraction	shown	in	A	after	preparative	SEC	purification,	after	subsequent	incubation	
with	Ni2+	ions,	and	after	subsequent	dialysis	to	reaction	buffer,	as	measured	by	DLS.	c) Intensity distributions of the T 
=	1	capsid	fraction	shown	in	A,	after	incubation	with	(solid	line)	or	without	(dashed	line)	Ni2+ ions, followed by dialysis 
to	reaction	buffer,	as	measured	by	DLS.	Capsids	are	expected	around	20-30	nm,	and	dimers	are	expected	below	10	
nm.
figure 5.4	 Uranyl	acetate-stained	TEM	micrographs	of	G-H6-ELP-CCMV	after	reaction	with	T4L-LPETG	(0.2	eq.	
SrtA). Scale bars correspond to 200 nm. a)	Particles	after	dialysis	to	pH	7.5	capsid	buffer	and	subsequent	purification	
using	 preparative	 SEC.	 Size	 =	 19.6	 nm	 ±	 1.3	 nm.	b)	 Particles	 shown	 in	 A,	 after	 stabilization	 with	 Ni2+ ions and 
subsequent	dialysis	to	reaction	buffer.	Size	=	19.6	nm	±	1.4	nm.
determined. To this end, the composition of the isolated capsid fraction was analyzed by 
SDS-PAGE (Figure 5.5A). As a control, capsids were prepared from reaction mixtures lacking 
either SrtA or T4L-LPETG. A band corresponding to G-H6-ELP-CCMV was observed for 
all three capsid samples. As expected, the coupled product T4L-H6-ELP-CCMV was only 
observed when both SrtA and T4L-LPETG had been present during the coupling reaction. 
ImageJ analysis of this gel suggested that each T = 1 capsid contained approximately 4 T4L 
enzymes. This is quite a remarkable amount of enzymes to fit in such a small compartment, 
taking into account that lysozyme has a cationic surface charge.
To investigate the enzymatic activity of T4L after encapsulation in the capsids, the capsids 
in the reaction buffer were exposed to M. luteus cell walls, labeled with fluorophores of 
which the fluorescence was self-quenched (Figure 5.6). Also dimers, obtained from the 
procedure where the Ni2+ ions had been left out before dialysis to reaction buffer, were 
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figure 5.5	 SDS-PAGE	analysis	of	 isolated	capsid	 fractions	after	 the	SrtA-mediated	coupling	of	T4L-LPETG	 to	
G-H6-ELP-CCMV.	a)	Left:	comparison	between	capsids	prepared	 from	reaction	mixtures	containing	both	SrtA	and	
T4L-LPETG	(++),	no	SrtA	(-SrtA),	and	no	T4L-LPETG	(-T4L).	Right:	calibration	curve	of	G-H6-ELP-CCMV.	Protein	bands	
were visualized by Coomassie blue staining. b)	Calibration	curve	of	the	peak	area	observed	on	SDS-PAGE,	related	to	
the	amount	of	G-H6-ELP-CCMV	in	μg.	The	calibration	curve	was	constructed	based	on	the	SDS-PAGE	results	shown	
in A.
added to the M. luteus substrate. As a control, samples were prepared from SrtA reaction 
mixtures deficient of either SrtA or T4L-LPETG. The T4L-LPETG concentration in the 
active capsid and dimer samples was determined based on the ratio of T4L-H6-ELP-CCMV 
and G-H6-ELP-CCMV, determined by SDS-PAGE analysis (Figure 5.5A) and compared to a 
calibration curve of G-H6-ELP-CCMV (Figure 5.5B). Only when both SrtA and T4L-LPETG 
had been present during the reaction, a fluorescence increase was observed. This showed 
that the enzyme was available to react with the substrate after encapsulation, as shown 
previously when Candida antarctica lipase B (CalB) was encapsulated using a similar 
strategy (Chapter 4).24 Free T4L-LPETG, in the same concentration as present in the active 
capsid and dimer samples, was found to be more active (i.e., approximately seven times) 
than T4L-LPETG attached to G-H6-ELP-CCMV (Figure 5.6). Additionally, free T4L-LPETG, 
subjected to the whole assembly protocol, but without SrtA and G-H6-ELP-CCMV present, 
was equally active as T4L-LPETG that had not been subjected to this protocol (data not 
shown). Hence, attachment of H6-ELP-CCMV did affect lysozyme activity to some extent. 
Attempts to disassemble the metal ion-stabilized capsids into capsids by the addition of 
an excess of chelating agent ethylenediaminetetraacetic acid (EDTA) failed. Probably, the 
crowded interior of the loaded capsids did not allow EDTA to reach the metal ions near the 
hexahistidine tags.
Surprisingly, the activities of the T4L-modified dimers and capsids were very similar (Figure 
5.6). Even if the M. luteus cells had been fragmented during lyophilization, resulting in cell 
wall fragments which could more easily come into contact with enzyme molecules, we 
would still expect to see a difference in activity, that is, some effect of diffusion through 
the pores of the T = 1 capsids. To be sure that the addition of the substrate did not result 
in capsid disassembly, DLS measurements were performed on the capsids before and after 
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figure 5.6	 Catalytic	 activity	 of	 capsids	 where	 both	 SrtA	 and	 T4L-LPETG	 had	 been	 present	 during	 the	 SrtA	
reaction	(++)	or	where	either	SrtA	or	T4L-LPETG	had	been	left	out	(-SrtA	and	-T4L-LPETG,	respectively).	The	activity	
was	measured	using	the	EnzChek	lysozyme	assay.	+Ni2+:	nickel	 ions	were	added	before	dialysis	to	reaction	buffer,	
to	 stabilize	 the	 capsids;	 -Ni2+:	 nickel	 ions	were	 not	 added	 before	 dialysis	 to	 reaction	 buffer,	 yielding	 dimers.	 The	
activity	of	the	++	samples	was	compared	to	the	activity	of	non-encapsulated	T4L-LPETG,	in	approximately	the	same	
concentration	as	the	capsid	samples.	As	a	control,	the	background	reaction	in	reaction	buffer	was	measured.
substrate addition. No signs of capsid disassembly were observed, suggesting that the 
capsids remained intact during the activity assay. We could also rule out aspecific adhesion 
of free T4L-LPETG to the outside of the capsids, as no free T4L-LPETG was observed on 
the SDS-PAGE gels after capsid purification (Figure 5.5A). Lastly, the effect of G-H6-ELP-
CCMV itself on T4L activity was investigated by incubating free T4L-LPETG with free 
G-H6-ELP-CCMV, followed by a measurement of the lysozyme activity. No effect of the 
presence of G-H6-ELP-CCMV was observed on the T4L activity. This excludes any effects 
arising from aspecific ionic interactions between lysozyme and the CCMV capsid protein. 
From the experiments above, we can conclude that the T4L enzyme molecules retain their 
activity after encapsulation inside the CCMV capsids and that their activity is somewhat 
reduced compared to free T4L as a result of their fusion to CCMV.
5.3 concLuSionS
We have utilized a protein-based block copolymer of CCMV and its expanded assembly 
profile to create nanoreactors which can function under conditions with similar salt 
concentrations as present in the physiological environment. As a proof-of-principle, T4 
lysozyme was successfully encapsulated via selective attachment to the interior of the 
CCMV capsids. The activity of this enzyme is highly dependent on the salt concentration 
and pH of the environment. Only after addition of metal ions to the CCMV capsids, these 
could remain stable at conditions at which its cargo was also active. A high encapsulation 
efficiency of approximately four enzymes per T = 1 capsid was achieved, indicating that the 
unfavorable interaction between the cationic lysozyme molecules was overcome. Possibly, 
these charges were neutralized by interactions with the interior of the capsids. It was 
shown that on incorporation in the CCMV capsids, the enzyme molecules were available to 
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interact with the substrate and remained active. This opens perspectives to use the shielded 
T4L in antibiotic applications. Attempts to disassemble the capsids by the addition of 
EDTA, which should bind the metal ions, have not been successful so far. Future research 
could focus on methods to disassemble these capsids, and expansion of the assembly/
disassembly cycle towards a switchable nanoreactor. Furthermore, we believe this strategy 
can be applicable to different types of cargo.
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5.5 exPeriMenTaL SecTion
5.5.1  Materials and methods
Materials
Hot start II HF DNA polymerase, dNTPs, restriction enzymes, and T4 DNA ligase were 
obtained from New England Biolabs. The DNA oligos were synthesized by Biolegio. 
Ampicillin was purchased from MP Biomedicals. Chloramphenicol was obtained from 
Sigma-Aldrich. Isopropyl β-d-1-thiogalactopyranoside (IPTG) was purchased from Acros. 
Ni-NTA agarose beads were obtained from Qiagen. The fluorescein conjugated Micrococcus 
luteus was purchased as part of the EnzChek Lysozyme Assay Kit from Fisher Scientific. 
NiCl2 was purchased from Alfa Chemicals.
Buffers
pH 5.0 capsid buffer: 50 mM NaOAc, 500 mM NaCl, 10 mM MgCl2, 1 mM EDTA, pH 5.0. 
pH 7.5 dimer buffer: 50 mM Tris·HCl, 500 mM NaCl, 10 mM MgCl2, 1 mM EDTA, pH 7.5. 
pH 7.5 capsid buffer: 50 mM Tris·HCl, 2000 mM NaCl, 10 mM MgCl2, 1 mM EDTA, pH 7.5. 
PBS buffer: 10 mM Na2HPO4, 1.8 mM KH2PO4, 137 mM NaCl, 2.7 mM KCl, pH 7.2-7.4.
Sortase buffer: 50 mM HEPES, 150 mM NaCl, 5 mM CaCl2, pH 7.5. 
Reaction buffer: 10 mM Tris·HCl, 150 mM NaCl, 10 mM MgCl2, pH 7.5.
All buffers were filtered over a 0.2 micron filter prior to use.
UV-vis spectroscopy
Protein concentrations were measured on a Varian Cary 50 Conc UV-vis spectrometer 
using a quartz cuvette with a path length of 3 mm. Protein concentrations were calculated 
using the theoretical extinction coefficients.25 Samples were centrifuged prior to the 
measurements.
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Mass	spectrometry
Protein mass characterization was performed by electrospray ionization time-of-flight 
(ESI-TOF) on a JEOL AccuTOF CS. Deconvoluted mass spectra were obtained using 
MagTran 1.03 b2. Isotopically averaged molecular weights were calculated using the 
‘Protein Calculator v3.4’ at http://protcalc.sourceforge.net. Protein samples were desalted 
by spin filtration to MQ (final concentrations 20 μM).
Size exclusion chromatography (SEC)
SEC was performed on a Superose 6 10/300 column (GE Healthcare). Analytical and 
preparative SEC measurements were executed on a Shimadzu LC-2010AHT HPLC and 
Agilent 1260 bio-inert HPLC, respectively. Samples (10-200 μg) were separated on the 
column with a flow rate of 0.5 mL/min.
Transmission	electron	microscopy	(TEM)
TEM grids (FCF-200-Cu, EMS) were glow-discharged using a Cressington carbon coater 
and power unit. Protein samples (0.2 mg/mL, 5 μL) were applied on the glow-discharged 
grids and incubated for 1 min. The samples were carefully removed using a filter paper and 
the grid was allowed to dry for at least 15 minutes. Then the grid was negatively stained 
by applying 2% uranyl acetate in water (5 μL). The staining solution was removed after 15 
seconds and the grid was allowed to dry for at least 15 minutes. The samples were analyzed 
on a JEOL JEM-1010 TEM.
Microplate	reader	experiments
Microplate reader experiments were performed on a Tecan Spark 10 M microplate 
reader at 21 °C. Samples were centrifuged prior to analysis. Buffers were filtered prior to 
use. Excitation and emission wavelengths were set to 485 and 530 nm, respectively. All 
measurements were done in triplicate.
Dynamic	light	scattering	(DLS)
DLS measurements were performed on a Zetasizer Nano S at 25 °C. Samples (25-50 μM) 
were centrifuged prior to analysis. Buffers were filtered prior to use. All measurements 
were done in triplicate, and the average of the triplicate measurements was plotted.
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5.5.2  experimental details
Protein	sequences
Table 5.1	 Amino	acid	sequences	of	the	proteins	used	in	this	chapter.
Name Sequence
H6-SrtA
TGSHHHHHHGSKPHIDNYLHDKDKDEKIEQYDKNVKEQASKDKKQQAKPQIPKDKSKVAGYIEIPDAD
IKEPVYPGPATPEQLNRGVSFAEENESLDDQNISIAGHTFIDRPNYQFTNLKAAKKGSMVYFKVGNET
RKYKMTSIRDVKPTDVGVLDEQKGKDKQLTLITCDDYNEKTGVWEKRKIFVATEVK
G-H6-ELP-CCMV
GHHHHHHVPGVGVPGLGVPGVGVPGLGVPGVGVPGLGVPGGGVPGVGVPGLGLEVVQPVIVEPIASGQ
GKAIKAWTGYSVSKWTASCAAAEAKVTSAITISLPNELSSERNKQLKVGRVLLWLGLLPSVSGTVKSC
VTETQTTAAASFQVALAVADNSKDVVAAMYPEAFKGITLEQLTADLTIYLYSSAALTEGDVIVHLEVE
HVRPTFDDSFTPVY
wt-T4L
MNIFEMLRIDEGLRLKIYKDTEGYYTIGIGHLLTKSPSLNAAKSELDKAIGRNTNGVITKDEAEKLFN
QDVDAAVRGILRNAKLKPVYDSLDAVRRAALINMVFQMGETGVAGFTNSLRMLQQKRWDEAAVNLAKS
RWYNQTPNRAKRVITTFRTGTWDAYKNL
T4L-H6
GNIFEMLRIDEGLRLKIYKDTEGYYTIGIGHLLTKSPSLNAAKSELDKAIGRNTNGVITKDEAEKLF
NQDVDAAVRGILRNAKLKPVYDSLDAVRRAALINMVFQMGETGVAGFTNSLRMLQQKRWDEAAVNLA
KSRWYNQTPNRAKRVITTFRTGTWDAYKNLHHHHHH
T4L-LPETG-H6
GNIFEMLRIDEGLRLKIYKDTEGYYTIGIGHLLTKSPSLNAAKSELDKAIGRNTNGVITKDEAEKLF
NQDVDAAVRGILRNAKLKPVYDSLDAVRRAALINMVFQMGETGVAGFTNSLRMLQQKRWDEAAVNLA
KSRWYNQTPNRAKRVITTFRTGTWDAYKNLLPETGGHHHHHH
Expression of H6-SrtA
The expression and purification of H6-SrtA were performed as described in Chapter 3.
Expression	of	G-H6-ELP-CCMV
The expression and purification of G-H6-ELP-CCMV were performed as described in 
Chapter 3.
Cloning	of	T4L-H6	and	T4L-LPETG-H6
T4 Lysozyme WT* was a gift from Brian Matthews (Addgene plasmid #18111). 
For the introduction of a hexahistidine tag and an additional LPETG sequence, a set of DNA 
oligos was designed (Table 5.2). The oligos were annealed and the resulting insert encoded 
for the T4L protein, an LPETGG motif in case of T4L-LPETG and a hexahistidine tag with 
a 5’ NcoI and a 3’ BamHI restriction site. The products after PCR were purified by agarose 
gel electrophoresis. Both the purified inserts and a pET-15b vector were digested with NcoI-
HF® and BamHI-HF® and the products were again purified by agarose gel electrophoresis. 
Subsequently, the inserts were ligated into the digested vector to yield pET-15b-T4L-H6 
and pET-15b-T4L-LPETG-H6. These plasmids were transformed into E. coli XL1-BLUE cells, 
the DNA was extracted and the sequences were confirmed by DNA sequencing (Table 5.1). 
For expression, the plasmids were transformed into E. coli BLR(DE3)pLysS cells (Novagen, 
MERCK).
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Table 5.2	 DNA	sequence	of	the	oligos	used	for	the	construction	of	the	required	expression	vectors.
Name Sequence
T4L-H6 foward 5’-ATATATCCATGGGCAATATATTTGAAATG
T4L-H6 reverse 5’-ATATATGGATCCTTAGTGATGATGATGATGATGTAGATTTTTATACGC
T4L-LPETG-H6 foward 5’-ATATATCCATGGGCAATATATTTGAAATG
T4L-LPETG-H6 reverse
5’-ATATATGGATCCTTAGTGATGATGATGATGATGGCCGCCGGTTTCCGGCAGTAGATTTT
TATACGC
General	protocol	for	the	expression	of	T4	lysozyme
For a typical expression, LB medium (50 mL), containing ampicillin (100 mg/L) and 
chloramphenicol (50 mg/L), was inoculated with a single colony of E. coli BLR(DE3)pLysS 
containing the pET-15b vector encoding for the desired T4 lysozyme protein, and was 
incubated overnight at 37 °C. This overnight culture was used to inoculate 2x TY medium (1 
L), supplemented with ampicillin (100 mg/L) and chloramphenicol (50 mg/L). The culture 
was grown at 37 °C and protein expression was induced during logarithmic growth (OD600 
= 0.4-0.6) by the addition of IPTG (1 mM). After 6 h of expression at 30 °C, the cells were 
harvested by centrifugation (2700 g, 15 min, 4 °C) and the pellets were stored overnight at 
-20 °C. 
After thawing, the cell pellet was resuspended in lysis buffer (50 mM NaH2PO4, 1.5 M 
NaCl, 10 mM imidazole, pH 8.0; 25 mL). The cells were lysed by ultrasonic disruption (3 
times 30 s, 100% duty cycle, output control 3, Branson Sonifier 250, Marius Instruments). 
Then the lysate was centrifuged (16.400 g, 15 min, 4 °C) to remove the cellular debris. 
The supernatant was incubated with Ni-NTA agarose beads (3 mL) for 1 h at 4 °C. The 
suspension was loaded onto a column, the flow-through was collected and the beads were 
washed twice with wash buffer (50 mM NaH2PO4, 1.5 M NaCl, 20 mM imidazole, pH 8.0; 
20 mL). Then, the protein of interest was eluted from the column with elution buffer (50 
mM NaH2PO4, 1.5 M NaCl, 250 mM imidazole, pH 8.0; 1 time 0.5 mL, 7 times 1.5 mL). 
The purification was analyzed by SDS-PAGE. The elution fractions containing the desired 
protein were combined and dialyzed against PBS buffer. The purity was verified by SDS-
PAGE and SEC using a Superose 6 10/300 GL column and PBS buffer as the eluent. The 
yields of the proteins after purification and the ESI-TOF results are listed in Table 5.3. For 
both proteins, also the mass of the desired protein with an additional methionine was 
found, indicating incomplete processing of the N-terminal methionine.
Table 5.3	 Expression	yields	and	ESI-TOF	results	of	the	T4L	variants	used	in	this	chapter.
Name Yield ESI-TOF
calculated mw observed mw
T4L-H6 50 mg/L 19350.0 Da 19349.4 Da
T4L-LPETG-H6 60 mg/L 19904.6 Da 19903.8 Da
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SrtA-mediated coupling experiments
For a typical SrtA-mediated coupling experiment, stock solutions of SrtA, G-H6-ELP-
CCMV, and T4L-LPETG were prepared in Sortase buffer. If a component had been 
dissolved in another buffer, it was spin filtrated to Sortase buffer (10 kDa MWCO, 3 × 10 
min). The components were added together to final concentrations of 0-100 μM SrtA, 50 
μM G-H6-ELP-CCMV, and 50 μM T4L-LPETG. The solutions were shaken at 21 °C for 24 h. 
The reaction progress was followed by SDS-PAGE analysis.
SrtA-mediated	coupling	experiments,	followed	by	capsid	purification
For a typical SrtA-mediated coupling experiment, stock solutions of SrtA, G-H6-ELP-
CCMV, and T4L-LPETG were prepared in Sortase buffer. If a component had been dissolved 
in another buffer, it was spin filtrated to Sortase buffer (10 kDa MWCO, 3 × 10 min). The 
components were added together to final concentrations of 0/10 μM SrtA, 50 μM G-H6-
ELP-CCMV, and 0/50 μM T4L-LPETG. The solutions were shaken at 21 °C for 3 h. Capsids 
assembly was induced by changing the reaction medium to either pH 5.0 capsid buffer by 
spin filtration (10 kDa MWCO, 3 × 10 min) or pH 7.5 capsid buffer by dialysis (Spectra/Por 2 
dialysis tubing, 12-14 kDa MWCO, 25 mm flat width, 3 × 20 min). Subsequently, the capsids 
were isolated using preparative SEC. The combined capsid fractions were concentrated by 
spin filtration, analyzed, and used for further experiments.
Activity	assay	with	non-encapsulated	T4L
Lysozyme activity of free T4L and T4L-LPETG was measured by observing the degradation 
of fluorescently labeled M. luteus cell walls (EnzChek lysozyme assay). An increase in 
fluorescence indicated the presence of active lysozyme, as the degradation of the cell walls 
reduced the quenching of the fluorescent groups. The fluorescently labeled substrate was 
diluted from 1 mg/mL in MQ to 50 μM in the desired buffer. The substrate (50 μL) was 
added to T4L or T4L-LPETG (50 μL, 2 μM in the desired buffer) in triplicate in a 96-well 
plate. The fluorescence intensity was then followed for 60 min at 21 °C with intermediate 
shaking steps on a Tecan Spark 10 M microplate reader (excitation wavelength 485 nm, 
emission wavelength 530 nm). The initial slopes of the curves were taken as a measure of 
the hydrolytic activity.
Activity	assay	with	encapsulated	T4L	(and	related	controls)
The isolated and concentrated capsid fractions (see ‘SrtA-mediated coupling experiments, 
followed by capsid purification’) were diluted to a concentration of approximately 200 μM 
by measuring the OD280 of the concentrated capsid solution and diluting to an OD280 of 
1.4. Subsequently, NiCl2 (900 μM in either pH 5.0 capsid buffer or pH 7.5 capsid buffer) 
or buffer (equal volume as the capsid solution) was added (final protein concentration is 
approximately 100 μM). The mixtures were incubated for 30 min at rt. Subsequently, the 
mixtures were dialyzed to reaction buffer (Spectra/Por 4 dialysis tubing, 12-14 kDa MWCO, 
10 mm flat width, 3 × 20 min; solutions with Ni2+ separately from solutions without Ni2+ 
ions, to prevent potential capsid formation in the control samples during dialysis). The 
activity assay with the capsids was then executed as described in the section ‘activity assay 
with free T4L’, using 50 μL of the capsid solution of approximately 100 μM per reaction.
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Hexahistidines are very common tags used in the affinity 
chromatography purification of recombinant proteins. Although 
these tags are solely applied for their metal-binding properties, 
we found that they are also able to perform ester hydrolysis when 
attached to a protein. For instance, green fluorescent protein (GFP) 
and the cowpea chlorotic mottle virus (CCMV) are able to perform 
catalysis after introduction of the His-tag. By attaching a His-tag 
to an enzyme, a dual-functional catalyst was created, that can 
perform a two-step cascade reaction. These findings show that the 
catalytic properties of the hexahistidine tag should be taken into 
consideration when choosing a suitable protein purification tag.
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6.1 inTroDucTion
Hexahistidine tags (His-tags) are among the most popular affinity purification tags for 
recombinant proteins.1,2 The advantages of these tags over other purification tags for 
recombinant protein purification are that: (i) the tags can be incorporated at both the 
C- and the N-terminus of a protein, (ii) the tags have little interference with the protein 
structure due to their small size and neutral charge at physiological pH values, and (iii) 
the tagged proteins can be eluted under mild conditions after affinity chromatography, 
allowing them to retain their biological activity.
In His-tags, the metal-coordinating properties of histidines are exploited. Metals such as 
nickel, cobalt and copper are known to efficiently bind histidines. This feature is displayed 
in enzymes, for instance, where histidines can be used for metal ion binding in the active 
sites. Histidines, being among the most versatile naturally occurring amino acids, also play 
a role in general acid-base catalysis and can as such regularly be found in the catalytic sites 
of enzymes, whether or not as a part of a catalytic triad.3,4 The versatility of this amino acid 
stems from the imidazole group in its side chain. This group is amphoteric and able to lose 
a proton via its pros nitrogen atom, whereas it can accept a proton via the nitrogen in the 
tele position at pH values close to pH 7.0.5 Its unique properties make that imidazoles, and 
thus histidines, can take part in both nucleophilic and base catalysis, in addition to metal 
coordination.
It is already known for a long time that imidazole by itself is able to catalyze the hydrolysis 
of p-nitrophenyl acetate (p-NPA).6 Since the first report in 1956, the imidazole group in 
histidine has been applied as a catalytic function, e.g. when present in polymers, peptide 
bundles or micelles.7–12 Furthermore, it was shown that imidazoles, and hence histidines, 
can catalyze other types of reactions, such as aldol reactions and RNA cleavage.13–17
We reasoned that the introduction of a His-tag in a protein for purification purposes might 
not be as innocent as previously thought. Since histidines have such unique properties, as 
a consequence of their side chain imidazole functionalities, the introduction of six copies 
of this amino acid could have serious implications on the properties of the resulting tagged 
protein. Here, we will show that the effects of the introduction of a His-tag are indeed 
not negligible, in terms of the catalytic properties of the resulting protein construct. 
This should be taken into consideration when, choosing this protein tag for purification 
purposes.
6.2 reSuLTS anD DiScuSSion
6.2.1  Esterase activity of His-tags
Green fluorescent protein (GFP) was chosen as a model system to study the catalytic 
properties of the His-tag. GFP-H6 was dissolved in PBS buffer and the activity of the His-
tag was measured by recording the conversion of p-NPA to p-nitrophenol (p-NP) and acetic 
acid, using a spectrophotometric assay (Figure 6.1A). It was found that GFP-H6 is indeed 
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figure 6.2 a)	Schematic	representation	of	inhibition	of	the	esterase	activity	of	GFP-H6 by coordination of nickel 
ions to the His-tag. b)	Activity	of	GFP-H6	after	incubation	with	different	equivalents	of	NiCl2. The conversion of p-NPA	
to p-NP	was	measured.
figure 6.1 a)	Schematic	representation	of	the	GFP-H6 catalyzed conversion of p-nitrophenyl acetate (p-NPA)	to	
p-nitrophenol (p-NP).	b)	Activity	of	GFP-H6 in the conversion of p-NPA	to	p-NP,	compared	to	background	hydrolysis	
(BG)	and	the	activity	of	GFP	after	cleavage	of	the	His-tag.
able to hydrolyze p-NPA to p-NP, and that its activity can easily be distinguished from 
the background hydrolysis of p-NPA (Figure 6.1B). It was also observed that the activity is 
linearly dependent on the GFP-H6 concentration, supporting the fact that GFP-H6 indeed 
acts as the catalyst in this reaction (data not shown). The activity of GFP-H6 was compared 
to the activity of GFP, after cleavage of the His-tag using tobacco etch virus (TEV) protease. 
It was found that more than half of the activity was lost upon cleavage of the His-tag (Figure 
6.1B). We believe the activity of the cleaved GFP stems from the nine residual histidines 
in its endogenous sequence, which might also act as catalysts. Comparing the activity of 
GFP-H6 to the activity of esterase Candida antarctica lipase B (CalB) in PBS buffer, it was 
found that the activity of GFP-H6 is a factor of approximately 3000 lower (~14 µmol/min/
mg for GFP-H6 vs. ~40.000 µmol/min/mg for CalB).
To provide definite proof that the His-tags are responsible for the observed activity of 
GFP-H6, we performed the same activity assay, but now the protein was first incubated 
with varying equivalents of NiCl2. If the imidazole groups of the histidines are responsible 
for the conversion, binding of nickel would block the catalytically active groups, inhibiting 
the reaction (Figure 6.2). It was observed that the addition of 10 equivalents of NiCl2 indeed 
reduced the activity of GFP-H6 significantly.
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figure 6.3 a)	Different	classes	of	substrates	that	were	tested	in	the	GFP-H6 activity assay. b)	Activity	of	GFP-H6 
upon	incubation	with	different	substrates.	H2O2 was added to the reactions with ABTS and o-PD. The slope of the 
background reaction was subtracted from the slope of the catalytic reaction. In all cases where catalytic activity was 
observed,	the	background	reaction	was	less	than	10%	of	the	activity	of	the	catalyzed	reaction.
6.2.2  Scope of His-tag catalysis
Next, we investigated whether the His-tag can also hydrolyze other esterase substrates. To 
this end, we tested p-nitrophenyl butyrate (p-NPB), polyethylene glycol MW 800-modified 
p-NPA (p-NPA-PEG) and carboxyfluorescein diacetate (CFDA) (Figure 6.3). In all cases, 
hydrolysis to the corresponding alcohols was observed, and a slower reaction was observed 
for the larger substrates. In a previous study, we observed a similar effect for CalB in 
experiments that were performed under very similar reaction conditions: large substrates 
were converted more slowly than small substrates (Chapter 4).18
After having established that the His-tag is an efficient catalyst in ester hydrolysis, we 
studied the scope of its catalytic activity. Structurally similar reactions were investigated, 
e.g. the hydrolysis of phosphate monoesters (phosphatase activity), reactions that are often 
catalyzed by enzymes with a histidine-containing catalytic triad in their active sites, e.g. 
proteolysis (protease activity), and reactions catalyzed by enzymes in which histidine is 
involved in metal-binding, e.g. hydrogen peroxide oxidation (peroxidase activity) (Figure 
6.3). Surprisingly, the activity of GFP-H6 in the anilide hydrolysis reactions was comparable 
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to the activity in some of the esterase reactions, which is of interest for future studies. In all 
other cases, however, activity was negligible.
6.2.3  Investigation of cooperativity in His-tag catalysis
To investigate whether the activity of the His-tags is enhanced by the close proximity 
of several imidazole groups in the adjacent histidine residues, we decided to study the 
activity of a His-tagged self-assembling protein. We chose the cowpea chlorotic mottle 
virus (CCMV) capsid protein for this purpose. In particular, we used a block copolymer 
variant of the capsid protein, which is equipped with an elastin-like polypeptide (ELP) 
at its N-terminus. The introduction of this stimuli-responsive polymer resulted in new 
assembly properties of the H6-ELP-CCMV capsid protein, as has been shown before.
19 With 
this modified protein, capsid formation can be induced by increasing the salt concentration 
or varying the temperature, aside from the pH-dependent assembly behavior. We used H6-
ELP-CCMV as a catalyst in the conversion of p-NPA to p-NP, both in the dimer state and after 
salt-induced assembly of the capsids (Figure 6.4A). As a control, the non-His-tagged wild-
type CCMV capsid protein (wt-CCMV) was used. Significant activity was observed for H6-
ELP-CCMV compared to the background hydrolysis. Similar to GFP-H6, product formation 
depends linearly on the H6-ELP-CCMV concentration (data not shown). Additionally, the 
activity of H6-ELP-CCMV was inhibited by the addition of NiCl2 (Figure 6.4B). The activity 
in the pH 7.5 capsid buffer, containing 2000 mM NaCl, was higher than in the pH 7.5 dimer 
buffer with 500 mM NaCl (Figure 6.4A). In order to explain this trend, we investigated the 
effect of salt concentration on the catalysis of H6-ELP-CCMV (Figure 6.4C). We found that 
the activity is indeed salt concentration dependent. An increase in activity was especially 
observed between 1750 mM and 2000 mM NaCl. Based on dynamic light scattering (DLS) 
analysis of the assembly state of H6-ELP-CCMV at different salt concentrations, we can 
conclude that this coincides with the formation of capsids around 1700 mM NaCl (Figure 
6.5). In separate experiments, it was found that the activity of GFP-H6 does not depend 
similarly on the NaCl concentration (data not shown).
The control protein without a His-tag, wt-CCMV, showed some activity in the two buffers 
that were used (pH 7.5 dimer buffer and pH 7.5 capsid buffer), compared to the background 
hydrolysis of p-NPA (Figure 6.4A). This small activity is most probably due to the two 
endogenous histidine residues of wt-CCMV. It should be noted that wt-CCMV does not 
form capsids when the salt concentration is increased, i.e. when going from dimer buffer 
to capsid buffer. This might be the reason why we do not observe an increase in activity at 
higher NaCl concentrations for wt-CCMV.
6.2.4  Activity assay with a library of histidine and histidine oligomers
To investigate the histidine catalysis further, we examined the esterase activity of a small 
library of histidine derivatives, consisting of H-His-NH2, H-His6-NH2 and H-His12-NH2 
(Figure 6.6). It was found that longer histidine peptides show higher activity, when 
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figure 6.4 a) Activity of H6-ELP-CCMV	and	wt-CCMV	in	the	conversion	of	p-NPA	to	p-NP,	both	in	pH	7.5	dimer	
buffer	and	pH	7.5	capsid	buffer.	b) Activity of H6-ELP-CCMV	in	both	dimer	and	capsid	buffer	after	 incubation	with	
different	 equivalents	 of	 NiCl2.	 Note:	 upon	 incubation	 of	 H6-ELP-CCMV	with	 NiCl2	 in	 dimer	 buffer,	 capsids	will	 be	
formed.20 c) Activity of H6-ELP-CCMV	in	pH	7.5	dimer	buffer	with	increasing	NaCl	concentrations.
figure 6.5 Intensity distributions of H6-ELP-CCMV	 in	 dimer	 buffer	 without	 EDTA,	 with	 increasing	 NaCl	
concentrations,	as	measured	by	DLS.	All	graphs	are	an	average	of	triplicate	measurements.	Capsids	are	observed	
around 20 nm.
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figure 6.6 Activity assays with a histidine peptide library. a)	Comparison	of	the	activity	of	equimolar	amounts	of	
His1, His6, and His12 peptides. b) Comparison of the activity of His1, His6, and His12 peptides, when the same histidine 
concentration was present in each reaction.
equimolar amounts of the peptides were used. When the concentrations of the catalyst 
were adjusted, such that in each solution the same amounts of imidazole groups were 
present, the differences in catalytic activity were very small. This shows that the catalysis 
is not cooperative: more histidines in close proximity to each other do not necessarily 
increase the activity.
His6 was found to be approximately 2-3 times less active than GFP-H6 and H6-ELP-
CCMV, when used at the same concentrations. In the case of these proteins, the protein 
environment might have a positive effect on the catalytic activity of a His-tag. A possible 
explanation for this effect could be the non-specific binding of the substrate to the protein, 
resulting in a higher local substrate concentration. This might also explain the increase 
that is observed when going from CCMV dimers to capsids: the His-tags are much more 
surrounded by protein material and the hydrophobic aggregated ELPs in the capsid state 
than in the dimer state. Another explanation might be the influence of other types of 
neighboring residues, as it was shown previously that the activity of histidine-containing 
oligopeptides is sequence dependent.21 Of course, the increase in activity of the proteins, 
compared to the free His6, could also simply be due to the presence of additional histidines 
in the proteins.
6.2.5  Application of His-tag catalysis in a dual-active enzyme
Finally, we investigated whether we could convert an enzyme with one active site into 
a dual-active enzyme by introducing a His-tag. To this end, we expressed His-tagged 
phenylacetone monooxygenase (H6-PAMO), which is an oxidoreductase that normally 
catalyzes the conversion of phenylacetone to benzyl acetate.22 We envisioned to use H6-
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figure 6.7 a) Activity of H6-PAMO	in	the	conversion	of	p-NPA	to	p-NP.	b) Activity of H6-PAMO	in	the	cascade	
conversion of p-nitroacetophenone to p-NP	via	p-NPA.
PAMO in a cascade reaction, i.e. the conversion of p-nitroacetophenone to p-NP, via p-NPA. 
First, we tested whether the His-tag of H6-PAMO could catalyze the second step of this 
cascade (Figure 6.7A). It was found that this reaction proceeds well; full conversion was 
reached after a reaction time of approximately 40 minutes. Some background reaction was 
observed, due to the spontaneous hydrolysis of p-NPA to p-NP in aqueous environments. 
Next, His6-PAMO was investigated as a dual-active enzyme in a cascade reaction, by 
introducing p-nitroacetophenone as the substrate. As expected, we observed the formation 
of p-NP with a delay, indicating the formation of an intermediate product. In this case, 
no background reaction was observed, as expected, because this starting material is not 
prone to spontaneous hydrolysis in aqueous environments. Notably, the final absorbance 
in this case was somewhat lower than for the conversion of p-NPA to p-NP. This might be a 
consequence of imine formation between the starting material p-nitroacetophenone and 
amine functions in the protein, resulting in a lower effective substrate concentration and 
hence a lower concentration of the final product. As a control, H6-PAMO was incubated 
with 10 equivalents of NiCl2 before the addition of p-nitroacetophenone. As expected, 
slower p-NP formation was observed due to inhibition of the His-tag activity due to nickel 
binding (data not shown).
6.3 concLuSionS
His-tags are very often attached to recombinant proteins for purification purposes. In 
the abovementioned examples, we have shown that this is not without consequence. In 
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fact, these proteins may now acquire catalytic properties, due to the clustering of several 
imidazole groups at the N- or C-terminus of the protein. More specifically, different 
types of esters can be hydrolyzed by the His-tags. Additionally, preliminary studies have 
indicated that His-tags might also act as proteases in peptide cleavage, which may be worth 
investigating further. 
By studying the activity of a His-tagged self-assembling protein and a small library of 
histidine peptides, it was found that the surrounding protein or neighboring residues 
might influence the catalysis performed by the His-tag in a positive way. Finally, we showed 
that by providing an enzyme with a His-tag, its catalytic properties can be modified such 
that it can now catalyze a two-step cascade reaction.
We believe that the implications of the findings described in this paper are two-fold: 
(i) it might explain the unexpected background reactions that are sometimes observed 
when performing hydrolysis reactions in the presence of His-tagged proteins, and (ii) this 
phenomenon can be used to our advantage, e.g. ester hydrolysis activity can be added to 
the catalytic properties of an enzyme, leading to a two- or even multi-step (enzymatic) 
reaction catalyzed by a single biocatalyst.
6.4 acknowLeDgeMenTS
We thank Mr. Roel J. M. Maas for the collection of the DLS data. Prof. Marco W. Fraaije 
is kindly acknowledged for the donation of the expression vector for H6-PAMO. The wt-
CCMV virus was a kind gift from Prof. Jeroen J. L. M. Cornelissen (University of Twente).
6.5 exPeriMenTaL SecTion
6.5.1  Materials and methods
Materials
Ampicillin was purchased from MP Biomedicals. p-Nitrophenol, p-nitrophenyl acetate, 
p-nitrophenyl butyrate, Ala-pNA and Su-AAPF-pNA were obtained from Sigma-Aldrich. 
CFDA was purchased from VWR International. ABTS was obtained from Fluka. H-His-NH2 
was purchased from Bio Connect. H-His6-NH2 and H-His12-NH2 were ordered at Pepscan. 
p-NPA-PEG MW 800 was synthesized as described previously.18 Ni-NTA agarose beads were 
obtained from Qiagen. NiCl2 was purchased from Alfa Chemicals. p-Nitroacetophenone 
was obtained from Merck. DMSO was purchased from Acros. The wt-CCMV virus was a 
kind gift from Prof. Jeroen J. L. M. Cornelissen (University of Twente).
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Buffers
PBS buffer: 10 mM Na2HPO4, 1.8 mM KH2PO4, 137 mM NaCl, 2.7 mM KCl, pH 7.2-7.4. 
pH 7.5 dimer buffer: 50 mM Tris·HCl, 500 mM NaCl, 10 mM MgCl2, 1 mM EDTA, pH 7.5. 
pH 7.5 capsid buffer: 50 mM Tris·HCl, 2000 mM NaCl, 10 mM MgCl2, 1 mM EDTA, pH 7.5. 
RNA buffer: 50 mM Tris·HCl, 500 mM CaCl2, 1 mM DTT, pH 7.5. 
Clean buffer: 50 mM Tris·HCl, 500 mM NaCl, 1 mM DTT, pH 7.5. 
Storage buffer: 50 mM NaOAc, 1000 mM NaCl, 1 mM NaN3, pH 5.0. 
PAMO buffer: 50 mM Tris·HCl, pH 7.5. 
All buffers were filtered over a 0.2 micron filter prior to use.
UV-vis spectroscopy
Protein concentrations were measured on a Varian Cary 50 Conc UV-vis spectrometer 
using a quartz cuvette with a path length of 3 mm. Protein concentrations were calculated 
using the theoretical extinction coefficients.23 Samples were centrifuged prior to the 
measurements.
Mass	spectrometry
Protein mass characterization was performed by electrospray ionization time-of-flight 
(ESI-TOF) on a JEOL AccuTOF CS. Deconvoluted mass spectra were obtained using 
MagTran 1.03 b2. Isotopically averaged molecular weights were calculated using the 
‘Protein Calculator v3.4’ at http://protcalc.sourceforge.net. Protein samples were desalted 
by spin filtration to MQ (final concentrations ~20 μM).
Size exclusion chromatography (SEC)
SEC was performed on a Superose 6 increase 10/300 column, a Superdex 75 PC 10/300 
column or a Superdex 200 10/300 column (GE Healthcare). Analytical and preparative SEC 
measurements were executed on a Shimadzu LC-2010AHT HPLC and Agilent 1260 bio-
inert HPLC, respectively. Samples (~100 µg) were separated on the column with a flow rate 
of 0.5 mL/min.
Microplate	reader	experiments
Microplate reader experiments were performed on a Tecan Spark 10 M microplate reader 
at 21 °C. Samples were centrifuged prior to analysis. Buffers were filtered prior to use. The 
readout wavelength was set to 405 nm. All measurements were done in triplicate.
Dynamic	light	scattering	(DLS)
DLS measurements were performed on a Zetasizer Nano S at 20 °C. Samples (20 μM) were 
centrifuged prior to analysis. Buffers were filtered prior to use. All measurements were 
done in triplicate, and the average of the triplicate measurements was plotted.
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6.5.2  experimental details
Protein	sequences
Table 6.1	 Amino	acid	sequences	of	the	proteins	used	in	this	chapter.
Name Sequence
GFP-H6
SVSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTGKLPVPWPTLVTTLTYG
VQCFSRYPDHMKQHDFFKSAMPEGYVQERTIFFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKEDGN
ILGHKLEYNYNSHNVYIMADKQKNGIKVNFKIRHNIEDGSVQLADHYQQNTPIGDGPVLLPDNHYLST
QSALSKDPNEKRDHMVLLEFVTAAGITLGMDELYKLPETGENLYFQSLEHHHHHH
wt-CCMV
MSTVGTGKLTRAQRRAAARKNKRNTRVVQPVIVEPIASGQGKAIKAWTGYSVSKWTASCAAAEAKVTS
AITISLPNELSSERNKQLKVGRVLLWLGLLPSVSGTVKSCVTETQTTAAASFQVALAVADNSKDVVAA
MYPEAFKGITLEQLTADLTIYLYSSAALTEGDVIVHLEVEHVRPTFDDSFTPVY
G-H6-ELP-CCMV
GHHHHHHVPGVGVPGLGVPGVGVPGLGVPGVGVPGLGVPGGGVPGVGVPGLGLEVVQPVIVEPIASGQ
GKAIKAWTGYSVSKWTASCAAAEAKVTSAITISLPNELSSERNKQLKVGRVLLWLGLLPSVSGTVKSC
VTETQTTAAASFQVALAVADNSKDVVAAMYPEAFKGITLEQLTADLTIYLYSSAALTEGDVIVHLEVE
HVRPTFDDSFTPVY
H6-PAMO
MGSSHHHHHHSSGLVPRGSHMLPKLVITHRVHEEILQLLAPHCELITNQTDSTLTREEILRRCRDAQA
MMAFMPDRVDADFLQACPELRVIGCALKGFDNFDVDACTARGVWLTFVPDLLTVPTAELAIGLAVGLG
RHLRAADAFVRSGKFRGWQPRFYGTGLDNATVGFLGMGAIGLAMADRLQGWGATLQYHARKALDTQTE
QRLGLRQVACSELFASSDFILLALPLNADTLHLVNAELLALVRPGALLVNPCRGSVVDEAAVLAALER
GQLGGYAADVFEMEDWARADRPQQIDPALLAHPNTLFTPHIGSAVRAVRLEIERCAAQNILQALAGER
PINAVNRLPKANPAADSRSAAGMAGQTTVDSRRQPPEEVDVLVVGAGFSGLYALYRLRELGRSVHVIE
TAGDVGGVWYWNRYPGARCDIESIEYCYSFSEEVLQEWNWTERYASQPEILRYINFVADKFDLRSGIT
FHTTVTAAAFDEATNTWTVDTNHGDRIRARYLIMASGQLSVPQLPNFPGLKDFAGNLYHTGNWPHEPV
DFSGQRVGVIGTGSSGIQVSPQIAKQAAELFVFQRTPHFAVPARNAPLDPEFLADLKKRYAEFREESR
NTPGGTHRYQGPKSALEVSDEELVETLERYWQEGGPDILAAYRDILRDRDANERVAEFIRNKIRNTVR
DPEVAERLVPKGYPFGTKRLILEIDYYEMFNRDNVHLVDTLSAPIETITPRGVRTSEREYELDSLVLA
TGFDALTGALFKIDIRGVGNVALKEKWAAGPRTYLGLSTAGFPNLFFIAGPGSPSALSNMLVSIEQHV
EWVTDHIAYMFKNGLTRSEAVLEKEDEWVEHVNEIADETLYPMTASWYTGANVPGKPRVFMLYVGGFH
RYRQICDEVAAKGYEGFVLT
CalB-H6
MGLPSGSDPAFSQPKSVLDAGLTCQGASPSSVSKPILLVPGTGTTGPQSFDSNWIPLSAQLGYTPCWI
SPPPFMLNDTQVNTEYMVNAITTLYAGSGNNKLPVLTWSQGGLVAQWGLTFFPSIRSKVDRLMAFAPD
YKGTVLAGPLDALAVSAPSVWQQTTGSALTTALRNAGGLTQIVPTTNLYSATDEIVQPQVSNSPLDSS
YLFNGKNVQAQAVCGPLFVIDHAGSLTSQFSYVVGRSALRSTTGQARSADYGITDCNPLPANDLTPEQ
KVAAAALLAPAAAAIVAGPKQNCEPDLMPYARPFAVGKRTCSGIVTPLEHHHHHH
Expression	of	GFP-H6
The expression and purification of GFP-H6 were performed as described in Chapter 3.
Purification	of	wt-CCMV
The wild-type CCMV virus, which was extracted from the cowpea plant, was kindly 
donated to our group by the group of Prof. Jeroen J. L. M. Cornelissen (Biomolecular 
Nanotechnology Department, University of Twente).
The virus (11 mg/mL, 500 µL) was dialyzed against RNA buffer (4 °C, first 2h 200 mL, 
then overnight 800 mL). The precipitated RNA was centrifuged down (4 °C, 13.000 rpm, 
overnight). The supernatant was dialyzed against clean buffer (4 °C, two times 3h 330 
mL, then overnight 330 mL). The proteins were assembled into capsids by dialysis against 
storage buffer (4 °C, three times 3h 330 mL). Pure wt-CCMV capsid protein was obtained in 
a final concentration of 8.67 mg/mL. The purity of the proteins was verified by SDS-PAGE. 
The assembly properties of the capsid proteins and the geometry of the resulting capsids 
were analyzed by SEC using a Superose 6 increase 10/300 column with pH 5.0 capsid buffer 
as the eluent, and TEM. ESI-TOF: calculated 20254.3 Da (acetylated), found 20254.5 Da.
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Expression	of	G-H6-ELP-CCMV
The expression and purification of G-H6-ELP-CCMV were performed as described in 
Chapter 3.
Expression of H6-PAMO
The vector encoding for the hexahistidine-tagged fusion protein H6-BVMO-PAMO was 
previously constructed by the group of Marco W. Fraaije (Department of Biotechnology, 
University of Groningen) and kindly donated to our group.22
For a typical expression, LB medium (50 mL), containing ampicillin (10 mg/L), was 
inoculated with a single colony of E. coli TOP10 containing the vector encoding H6-BVMO-
PAMO and was incubated overnight at 37 °C. This overnight culture was used to inoculate 
TB medium (1 L), supplemented with ampicillin (50 mg/L), l-arabinose (0.02%, v/v) and 
glucose (0.05%, v/v). The culture was grown for 30 h at 24 °C. The cells were harvested by 
centrifugation (2700 g, 15 min, 4 °C) and the pellets were stored overnight at -20 °C.
After thawing, the cell pellet was resuspended in lysis buffer (50 mM Tris·HCl, pH 7.5; 
25 mL). Flavin adenine dinucleotide (FAD) (100 mM stock solution, 25 µL) was added to 
the resuspended cells. The cells were lysed by ultrasonic disruption (7 times 10 s, 100% 
duty cycle, output control 3, Branson Sonifier 250, Marius Instruments). Then the lysate 
was centrifuged (16.400 g, 15 min, 4 °C) to remove the cellular debris. The supernatant was 
incubated with Ni-NTA agarose beads (3 mL) for 1 h at 4 °C. The suspension was loaded 
onto a column, the flow-through was collected and the beads were washed twice with wash 
buffer (50 mM Tris·HCl, 5 mM imidazole, pH 7.5; 20 mL). Then, the protein of interest 
was eluted from the column with elution buffer (50 mM Tris·HCl, 500 mM imidazole, pH 
7.5; 7 times 1.0 mL). The purification was analyzed by SDS-PAGE. The elution fractions 
containing H6-PAMO were combined and dialyzed against PAMO buffer. The pure protein 
was obtained with a yield of 16.7 mg/L of culture. The purity was verified by SDS-PAGE. 
ESI-TOF: calculated 100235.3 Da, found 100230.0 Da.
Expression of CalB-H6
The expression and purification of CalB-H6 were performed as described in Chapter 4.
Spectrophotometric activity assays
General protocol. Esterase activity was analyzed by the hydrolysis of p-nitrophenyl 
acetate (p-NPA). The catalyst (101.0 µM in buffer, 99.0 µL) was added to p-NPA (100 mM 
in DMSO, 1.0 µL) in triplicate. The background hydrolysis was measured by the addition 
of the desired buffer without catalyst to the substrate. The production of p-nitrophenol 
(p-NP) was monitored for 10 minutes at 21 °C by measuring the absorbance at 405 nm on a 
Tecan Spark 10M microplate reader. The slopes of the curves were taken as a measure of the 
hydrolytic activity. Calibration curves of the absorbance of p-nitrophenol in the different 
buffers were measured, in order to convert the measured absorbance to µmol/min. Other 
extinction coefficients were taken from previous studies.24–28
Experiments with GFP-H6. Buffer: PBS buffer, PBS buffer with NaCl concentrations of 
750-2000 mM.
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Experiments with preceding NiCl2 incubation. Experimental: NiCl2 (0 µM / 202 µM 
/ 2.02 mM / 20.2 mM in buffer, 60 µL) was added to the catalyst (202.0 µM in buffer, 60 
µL) in triplicate. The mixtures were incubated at rt for 1 h. Then, the catalyst solution was 
added to the substrate as described in the general protocol. Buffers: pH 7.5 dimer buffer or 
pH 7.5 capsid buffer without EDTA, PBS buffer.
Experiments with different substrate types. Experimental: To the reactions with 
the peroxidase substrates ABTS and o-PD, 1.0% w/w H2O2 was added to the substrates 
prior to the addition of the catalyst. Buffer: PBS buffer. Substrates: p-nitrophenyl acetate 
(p-NPA), p-nitrophenyl butyrate (p-NPB), MeO-PEG-NHCO-C2H4-CO-p-NP (p-NPA-
PEG), carboxyfluorescein diacetate (CFDA), p-nitrophenyl phosphate (p-NPP), l-alanine 
4-nitroanilide (Ala-pNA), N-succinyl-l-alanyl-l-alanyl-l-prolyl-l-phenylalanine 
4-nitroanilide (Su-AAPF-pNA), 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) 
(ABTS), o-phenylenediamine (o-PD). Measured wavelengths: 410 nm (p-NPA, p-NPB, 
p-NPA-PEG, CFDA, p-NPP, Ala-pNA, Su-AAPF-pNA, ABTS), 490 nm (o-PD).
Experiments with G-H6-ELP-CCMV and wt-CCMV. Buffers: pH 7.5 dimer buffer, pH 7.5 
dimer buffer with NaCl concentrations of 750-1750 mM, pH 7.5 capsid buffer.
Experiments with H6-PAMO. Buffer: PAMO buffer supplemented with NADPH (10 mM). 
Substrates: p-NPA, p-nitroacetophenone.
Experiments with CalB-H6. Experimental: a final catalyst concentration of 1.0 µM was 
used, as the reaction was too fast to determine the slope otherwise. Buffer: PBS buffer.
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abSTracT
Virus capsids, i.e. viruses devoid of their genetic material, are 
suitable nanocontainers for applications in e.g. drug delivery and 
diagnostic imaging. To this end, the reliable encapsulation of cargoes 
in such protein nanocages is crucial. Here, N-terminal modification 
of the capsid proteins of the cowpea chlorotic mottle virus (CCMV) 
is described using a straightforward strategy employing modified 
aldehydes. In a first step, a bioorthogonal handle was specifically 
introduced onto the capsid proteins N-termini, allowing the 
hypothetical attachment of any desired cargo, modified with the 
complementary reactive handle. Subsequent application of capsid 
assembly conditions should then lead to the cargo encapsulation, 
as the protein N-termini are located on the capsid interior. Proof-
of-principle experiments showed successful attachment and 
encapsulation of a fluorescent dye using this two-step modification 
protocol. Subsequent studies were aimed at the encapsulation of 
l-proline, a model organocatalyst.
Modular, bioorthogonal strategy for controlled cargo loading of a protein nanocage
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7.1 inTroDucTion
Viruses are associated with terrible diseases all over the world, and therefore they generally 
have a negative reputation.1,2 Nevertheless, viruses have also been recognized as useful 
carrier tools for applications in bionanotechnology and medicine, due to their unique 
ability to protect their nucleic acid cargo and deliver it to cells in their infected host. In 
particular, virus-like particles (VLPs), i.e. viruses devoid of their viral nucleic acids, are 
used for nanocarrier purposes instead of viruses, as they have room on the interior for the 
loading of e.g. catalysts, drugs, or imaging agents.
A remarkable example of a VLP that has proven very suitable as a nanocarrier is the cowpea 
chlorotic mottle virus (CCMV) capsid. In contrast to most other VLPs, CCMV capsids show 
reversible assembly and disassembly behavior, even in the absence of their genetic material. 
At a physiological pH of 7.5, the capsid proteins exist as dimers in solution. When the pH 
is lowered to pH 5.0, 28 nm sized capsids with T = 3 symmetry spontaneously assemble 
out of 90 capsid protein dimers.3,4 In order to make the capsids more stable at neutral pH 
for in vivo applications, an elastin-like polypeptide (ELP) block was previously introduced 
on the N-terminus of the CCMV capsid protein.5 ELPs are derived from the highly elastic 
protein elastin, which is the major component of tissues that require elasticity, such as skin 
and lung tissue.6 They consist of repeating Val-Pro-Gly-Xaa-Gly (VPGXG) pentapeptides, 
containing a guest residue Xaa/X that can be any natural amino acid, except proline.7,8 ELPs 
are stimuli-responsive polypeptides, which can reversibly switch from a water-soluble state 
to a collapsed, hydrophobic state upon a change in the environmental conditions, e.g. an 
increase in the temperature or salt concentration. The introduction of this peptide at the 
N-terminus of the CCMV capsid protein sequence resulted in a new assembly pathway 
(ELP-induced assembly), resulting in smaller T = 1 capsids with a diameter of 18 nm.5 This 
assembly pathway could be triggered by increasing the temperature or salt concentration, 
while the endogenous assembly pathway leading to T = 3 capsids could still be triggered 
by lowering the pH to 5.0. The development of this ELP-CCMV variant resulted in a wider 
range of conditions at which the capsids remained stable, showing promise for in vivo 
applications.
Controlled encapsulation of cargo in the ELP-CCMV capsid interior is crucial for its 
successful application as a nanocarrier. A classical way to encapsulate cargo in CCMV capsids 
is via statistical encapsulation, where cargo is added to the capsid proteins when they are in 
the dimer state, after which assembly conditions are applied to induce capsid formation.9 
To increase the encapsulation efficiency, the cargo can be equipped with negatively 
charged moieties, mimicking the charge of the endogenous nucleic acid cargo and allowing 
interactions with the cationic N-terminal tails of the CCMV capsid proteins.10–12 These 
methods, however, are not applicable for cargo encapsulation in ELP-CCMV capsids, as the 
ELP sequence was inserted at the N-terminus in such a way, that it replaced the cationic 
RNA-binding motif. Alternative methods that have been used for cargo encapsulation in 
CCMV VLPs are: (i) genetic cloning of a target protein onto the N-terminus of the capsid 
proteins,13 (ii) the introduction of an N-terminal domain which can form non-covalent 
interactions with a specific complementary domain,14,15 and (iii) enzymatic modification 
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of the N-terminus using the enzyme Sortase A.16,17 The latter methodology is possibly 
the most optimal for versatile and reproducible cargo encapsulation, since it is modular, 
does not require extensive genetic engineering and yields a robust covalent link between 
the cargo and the capsid proteins. Even though this technique is applicable to any cargo 
that can be equipped with the required Sortase recognition sequence, it lends itself best 
for the encapsulation of peptides and proteins, as these allow facile introduction of the 
recognition peptide. In order to further broaden the possibilities for cargo loading, we set 
out to develop a method for the modification of the ELP-CCMV capsid proteins, which did 
not require the incorporation of a peptide and would be more applicable to other types of 
cargoes, e.g. organocatalysts, imaging agents, etc.
Recently, a non-enzymatic method for specific N-terminal protein modification was 
reported by Francis and co-workers.18 It was found that 2-pyridinecarboxaldehyde 
(2PCA) forms 1:1 condensation products with peptides and proteins, through the two-
step formation of a cyclic imidazolidinone via an imine intermediate. This modification 
reaction could proceed in aqueous environments under mild conditions and was shown 
to be delicate enough to modify a range of different proteins. Additionally, as this method 
does not require a specific amino acid residue at the N-terminus, no genetic engineering 
was required to make this method applicable to a specific protein. The 2PCA moieties 
could also be modified with, in this case, a biotin group, showing the potential of this 
method for the introduction of new functionalities at protein N-termini.
Previous work in our group indicated that CCMV capsid proteins are quite sensitive to 
conditions and reagents associated with some of the typical protein modification strategies, 
for instance, the diazotransfer reaction (unpublished data).19 Therefore, we envisioned to 
test the feasibility of the 2PCA-based modification strategy on these proteins, since this 
method was claimed to be mild and applicable to a range of different proteins. In order to 
keep our strategy modular, we decided to use this method to introduce a bioorthogonal 
handle onto the N-terminus of the CCMV capsid proteins. In a second step, we planned to 
introduce the desired cargo, functionalized with the complementary handle. The reaction 
we chose for this purpose was the inverse electron-demand Diels-Alder reaction between 
vinylboronic acids (VBAs) and tetrazines.20 This reaction was found to be bioorthogonal 
and applicable for the modification of biomolecules. Additionally, the reacting components 
were readily accessible and stable.
Here, we describe the application of the 2PCA modification methodology to ELP-CCMV 
capsid proteins (Scheme 7.1). A 2PCA variant functionalized with a VBA handle was 
synthesized to allow the introduction of a bioorthogonal handle at the capsid protein 
N-termini in this first modification step. As a proof-of-principle, we chose l-proline as 
the cargo, as this organocatalyst requires an hydrophobic environment to be catalytically 
active in aqueous environments, which might be provided by the condensed ELP layer 
on the interior of the assembled capsids.21,22 ELP-CCMV might therefore be an interesting 
nanocarrier for l-proline, in terms of its hydrophobic interior, as well as its protective 
features. To this end, tetrazine was functionalized with l-proline, for modular introduction 
of this organocatalyst. Subsequently, encapsulation of the catalyst through capsid assembly 
and the effect of the encapsulation upon its activity was investigated.
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Scheme 7.1	 Schematic	representation	of	the	two-step	modular	N-terminal	modification	of	H6-ELP-CCMV	capsid	
proteins.	 In	 the	 first	 step,	 2-pyridinecarboxaldehyde	 (2PCA),	 functionalized	with	 a	 vinylboronic	 acid	 (VBA),	 reacts	
specifically	with	the	N-terminus	of	the	capsid	protein.	Subsequently,	a	click	reaction	between	the	introduced	VBA	and	
a	tetrazine,	modified	with	the	desired	cargo,	e.g.	l-proline (Pro), can take place, resulting in covalent attachment of 
the cargo to the capsid proteins. Upon capsid assembly, the cargo is then encapsulated in the interior of the resulting 
H6-ELP-CCMV	capsids.
7.2 reSuLTS anD DiScuSSion
The ELP-CCMV capsid protein, equipped with an N-terminal hexahistidine tag (H6-
ELP-CCMV) for purification purposes, was heterologously expressed in Escherichia coli 
(E. coli). The protein was purified by Ni2+ affinity chromatography and characterized by 
polyacrylamide gel electrophoresis (SDS-PAGE) and electrospray ionization time-of-flight 
(ESI-TOF) mass spectrometry. 
Firstly, it was tested whether the 2PCA-based modification strategy was applicable to the 
H6-ELP-CCMV capsid proteins. To this end, the proteins were incubated with 10 equivalents 
of 2PCA 1 for 24 hours in PBS buffer (Figure 7.1A). No precipitation was observed after 
the reaction, indicating that the protein was stable towards the 2PCA reagent and the 
reaction conditions. SDS-PAGE analysis of this mixture and a control reaction without 
2PCA 1 showed comparable intensities for both protein bands, further indicating that the 
protein remained stable and in solution during the reaction (Figure 7.1B). ESI-TOF analysis 
of the reactions confirmed the formation of the desired product 2PCA-H6-ELP-CCMV, 
demonstrating the applicability of this modification strategy to CCMV capsid proteins 
(Figures 7.1C and D). To determine the highest achievable modification yield, a series of 0, 
1, 5, 10, 50 and 100 equivalents of 2PCA 1 was added to the capsid proteins in duplicate. The 
conversions could not be determined using SDS-PAGE analysis, as this did not show a shift 
of the protein band upon modification with 2PCA 1, due to that fact that the mass difference 
between the non-functionalized and functionalized protein is only 89 Da (Figure 7.1B). 
Therefore, the conversions were estimated using ESI-TOF analysis - even though this is 
not a quantitative analysis technique - as this was the only available method to distinguish 
the product from the starting material. A higher estimated conversion was observed when 
more equivalents of 2PCA 1 were added, as expected (Figure 7.1E). Based on this data, the 
highest achievable conversion seemed to be approximately 65%. Even though for some 
applications this yield should be improved, for our purpose of cargo encapsulation in the 
CCMV capsid interior it is not desired to achieve full conversion, as this might hamper 
capsid formation due to steric hindrance in case of large cargoes. Our results compare 
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figure 7.1	 Proof-of-principle	N-terminal	modification	of	H6-ELP-CCMV	with	2PCA	1. a) Schematic representation 
of	the	N-terminal	modification	of	H6-ELP-CCMV	with	2PCA	1. b)	SDS-PAGE	analysis	of	the	modification	of	H6-ELP-
CCMV	with	2PCA	1	(0	and	10	eq.).	Protein	bands	were	stained	with	Coomassie	blue	staining.	c) Deconvoluted ESI-
TOF	mass	spectrum	of	 the	modification	of	H6-ELP-CCMV	with	2PCA	1	 (10	eq.).	The	expected	molecular	weights	
are	22253.4	Da	(H6-ELP-CCMV,	purple)	and	22342.5	Da	(2PCA-H6-ELP-CCMV,	blue). D)	Multiply	charged	ion	series	
of the deconvoluted ESI-TOF mass spectrum shown in C. e) Estimated conversion of H6-ELP-CCMV	to	2PCA-H6-
ELP-CCMV	in	reactions	with	0,	1,	5,	10,	50	or	100	equivalents	of	2PCA	1, based on ESI-TOF analysis of the reaction 
mixtures. The average of duplicate measurements is plotted.
well with the research conducted by Francis and co-workers on the 2PCA modification, in 
which conversions of 43% to >95% were achieved for different types of proteins.18
After having established that the modification strategy using 2PCA 1 was applicable to the 
CCMV capsid proteins, we continued to use this strategy to introduce a functional VBA 
handle onto the capsid protein N-termini, to allow modular attachment and encapsulation 
of desired cargoes, functionalized with a tetrazine moiety.20 To this end, 2PCA-VBA 2 was 
designed containing the required 2PCA group for protein modification, coupled to a 
pinacol vinylboronic ester via a short linker (Figure 7.2A). The protected boronic ester was 
used instead of the free boronic acid, since the ester is synthetically more accessible, and 
previous research has shown that pinacol boronic esters hydrolyze to the reactive boronic 
acids in aqueous media within 15 minutes.20 2PCA-VBA 2 was synthetized and kindly 
provided by Ms. Selma Eising. The coupling of 2PCA-VBA 2 to the CCMV capsid protein 
was performed under the same conditions used for the coupling of 2PCA 1 (Figure 7.2B). 
Again, the reaction could not be followed using SDS-PAGE, as no shift was observed on gel 
after the reaction. ESI-TOF analysis of the reaction mixtures in this case did not show the 
expected mass corresponding to the desired product VBA-H6-ELP-CCMV. Notably, we did 
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figure 7.2	 N-terminal	modification	of	H6-ELP-CCMV	with	2PCA-VBA	2	and	subsequent	reaction	with	tetrazine-
BODIPY 3. a) Structures of 2-pyridinecarboxaldehyde-vinylboronic acid (2PCA-VBA) 2 and tetrazine-BODIPY 3. 
b)	Schematic	 representation	of	N-terminal	modification	of	H6-ELP-CCMV	with	2PCA-VBA	2,	and	subsequent	click	
reaction of tetrazine-BODIPY 3 to obtain BODIPY-H6-ELP-CCMV.	c)	SDS-PAGE	analysis	of	the	modification	of	H6-
ELP-CCMV	with	2PCA-VBA	2	(10	and	50	eq.),	and	subsequent	reaction	with	tetrazine-BODIPY	3	(0	and	10	eq.).	D) 
SDS-PAGE	analysis	of	the	control	modifications	of	H6-ELP-CCMV	that	were	performed	in	addition	to	the	modification	
shown	in	C.	Left:	modification	of	H6-ELP-CCMV	with	2PCA	1	(10	and	50	eq.),	and	subsequent	addition	of	tetrazine-
BODIPY 3	 (0	and	10	eq.).	Right:	 incubation	of	H6-ELP-CCMV	without	a	2PCA	derivative,	and	subsequent	addition	
of tetrazine-BODIPY 3	 (0	and	10	eq.).	Protein	bands	were	visualized	by	 in-gel	fluorescence	 (top)	and	stained	with	
Coomassie blue staining (bottom).
observe the appearance of a new mass after the reaction, but this was approximately 30 Da 
lower in molecular weight than the expected VBA-H6-ELP-CCMV product with a hydrolyzed 
boronic acid group. Similar observations were made in previous research regarding the 
modification of human serum albumin (HSA), where the mass of the protein after coupling 
of a boronic acid also did not match with the expected product with approximately the 
same mass difference (unpublished data). To prove that the coupling of 2PCA-VBA 2 to 
the CCMV capsid proteins had been successful, we performed a subsequent reaction with 
tetrazine-BODIPY 3, which was also kindly provided by Ms. Selma Eising (Figure 7.2A). 
After the reaction of 2PCA-VBA 2 with H6-ELP-CCMV, the reaction mixtures were dialyzed 
extensively to remove any remaining 2PCA-VBA 2. Then, tetrazine-BODIPY 3 was reacted 
for 1 hour with the protein in PBS buffer (Figure 7.2B). If the modification of the capsid 
proteins with a boronic acid group had been successful, the tetrazine should be able to 
react with the protein to form a dihydropyridazine product. As the final protein after the 
two reactions, BODIPY-H6-ELP-CCMV, should be fluorescently labeled, the final product 
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figure 7.3 SEC chromatogram of H6-ELP-CCMV	in	pH	5.0	capsid	buffer	after	modification	with	2PCA-VBA	2	(50	
eq.),	and	subsequent	reaction	with	tetrazine-Cy5	(10	eq.).
could be visualized by SDS-PAGE combined with in-gel fluorescence analysis (Figure 7.2C). 
When both 2PCA-VBA 2 and tetrazine-BODIPY 3 had been added during the subsequent 
reactions, a fluorescent product was observed, as expected. When tetrazine-BODIPY 3 was 
not added, the observed protein band was not fluorescent. Control reactions in which 
either 2PCA 1 or no 2PCA derivative was used instead of 2PCA-VBA 2 showed no fluorescent 
product, eliminating aspecific reactions of tetrazine-BODIPY 3 with the protein (Figures 
7.2D and E). These results not only prove that 2PCA-VBA 2 can be coupled to the CCMV 
capsid proteins, but also indicate that the coupled boronic acid is available for a subsequent 
reaction with tetrazines. The final product BODIPY-H6-ELP-CCMV could unfortunately 
not be identified using ESI-TOF analysis. Nevertheless, disappearance of the unknown 
mass which probably corresponds to the intermediate VBA-H6-ELP-CCMV product was 
observed, furthermore indicating that this mass indeed corresponds to the VBA-modified 
protein and implying conversion of this intermediate through reaction with the tetrazine. 
Subsequent studies into the assembly behavior of the modified capsid proteins showed 
that capsids could still be formed after the two-step reaction after reducing the pH of the 
solution to 5.0 (Figure 7.3). A signal corresponding to the fluorophore (i.e. Cy5 instead of 
BODIPY in this case) was also observed, further indicating successful attachment of the 
cargo to the capsid proteins.
Next, we designed tetrazine-proline 4 to test the applicability of the modular two-step 
modification strategy for other types of cargoes than a fluorescent dye. This tetrazine 
was kindly synthesized and provided by Ms. Selma Eising (Figure 7.4A). We applied the 
abovementioned reaction conditions, using tetrazine-proline 4 in the second reaction 
step, towards proline-H6-ELP-CCMV (Figure 7.4B). SDS-PAGE analysis of this reaction 
did not show a shift when both 2PCA-VBA 2 and tetrazine-proline 4 were added to the 
protein, compared to reaction mixtures where either 2 or 4 or both reactants were left out 
(Figure 7.4C). This was not surprising, as the coupling of tetrazine-BODIPY 3 also did not 
show a clear shift on gel (Figure 7.2C). To gain more information on the possible product 
formation, we again turned to ESI-TOF analysis. Unfortunately, the product proline-H6-
ELP-CCMV could not be detected, as was the case for BODIPY-H6-ELP-CCMV. Similar 
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figure 7.4	 Two-step	 modification	 of	 H6-ELP-CCMV	 with	 tetrazine-proline	 4 and estimation of the amount of 
modified	protein.	a) Structure of tetrazine-proline 4. b) Schematic representation of the product proline-H6-ELP-CCMV,	
after	N-terminal	modification	of	H6-ELP-CCMV	with	2PCA-VBA	2,	and	subsequent	click	reaction	with	tetrazine-proline	
4. c)	SDS-PAGE	analysis	of	 the	modification	of	H6-ELP-CCMV	with	2PCA-VBA	2	 (0	and	50	eq.),	and	subsequent	
reaction with tetrazine-proline 4	(0	and	10	eq.).	D)	Estimated	quantification	of	the	conversion	of	H6-ELP-CCMV	into	
BODIPY-H6-ELP-CCMV.	Left:	SDS-PAGE	analysis	of	the	modification	of	H6-ELP-CCMV	with	2PCA-VBA	2	(0	and	50	
eq.),	and	subsequent	reaction	with	tetrazine-BODIPY	3	(10	eq.).	Right:	SDS-PAGE	analysis	of	a	dilution	series	of	HSA,	
modified	with	approximately	1	VBA	group	per	protein,	after	reaction	with	tetrazine-BODIPY	3	(10	eq.).	Protein	bands	
were	visualized	by	in-gel	fluorescence.	e)	Calibration	curve	of	BODIPY-HSA,	based	on	the	SDS-PAGE	results	shown	
in D.
to what was observed for coupling of tetrazine-BODIPY 3, however, we did observe the 
disappearance of the abovementioned unknown mass which probably corresponds to the 
intermediate VBA-H6-ELP-CCMV. This indicated that the desired product might indeed 
have been formed from the intermediate. 
To get a feeling for the conversion, i.e. the percentage of capsid proteins modified with 
a cargo, we could not use quantitative analysis of the ratio of the product and starting 
material bands on gel, as these two bands could not be distinguished. Therefore, we once 
more turned to the two-step modification H6-ELP-CCMV with 2PCA-VBA 2 and tetrazine-
BODIPY 3. This reaction was analyzed using SDS-PAGE and on the same gel a dilution series 
was loaded for the determination of a calibration curve (Figure 7.4D). To construct this 
calibration curve, we used HSA which had previously been modified with approximately 
one VBA group per protein.20 If we assume 100% conversion in the reaction of VBA with 
tetrazine, we can assume that each HSA protein was modified with approximately one 
BODIPY after reaction with tetrazine-BODIPY 3. Based on this assumption, a calibration 
curve was constructed of the peak area vs. the BODIPY concentration (Figure 7.4E). Using 
this calibration curve, it was estimated that approximately 5% of all H6-ELP-CCMV proteins 
was modified with a BODIPY group. Again assuming full conversion in the second reaction 
between VBA and tetrazine, also 5% conversion was achieved in the modification step 
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with 50 eq. 2PCA-VBA 2. This is lower than the conversion that was achieved with 2PCA 1 
(Figure 7.1E), suggesting that the addition of the linker and the VBA group to 2PCA 1 had 
an effect on the reactivity of the aldehyde. For our application, however, we do not need a 
high conversion, as mentioned above. Therefore, no attempts were made in this stage to 
achieve higher conversions. Extending these results to the coupling of tetrazine-proline 4 
to VBA-H6-ELP-CCMV, we estimate that the final product also contains approximately 5% 
proline-H6-ELP-CCMV, assuming that tetrazine-BODIPY 3 and tetrazine-proline 4 both 
react to completion with the VBA-modified proteins.
The model reaction that was chosen to investigate the catalytic activity of l-proline, 
after attachment to the capsid proteins, was the asymmetric aldol reaction between 
cyclohexanone 5 and 4-nitrobenzaldehyde 6. It is well-known that l-proline does not 
catalyze this reaction in water. Alternatively, organic solvents have been used, but they 
often require high catalyst loadings. Another approach involves the introduction of a 
hydrophobic environment, in which l-proline can act as a catalyst. Many different examples 
are known of such attempts, including the attachment of hydrophobic substituents on 
the catalyst itself, or the inclusion of the catalyst in a compartment of some form.21,22 In 
our case, we envisioned that the dense ELP layer on the capsid interior might provide the 
hydrophobic environment needed to perform catalysis with the encapsulated l-proline 
catalyst.
Initial experiments, aimed at examining the catalysis of free l-proline and tetrazine-
proline 4 in aqueous environments, including the relevant buffers for CCMV capsid 
protein assembly, showed: (i) as reported in the literature, l-proline is not active in MQ, 
but shows activity in DMSO, (ii) no l-proline activity was observed in pH 5.0 capsid 
buffer, (iii) surprisingly, l-proline and tetrazine-proline 4 did show activity in pH 7.5 
dimer buffer, containing 500 mM NaCl, 10 mM MgCl2 and 1 mM EDTA, (iv) the addition 
of increasing NaCl concentrations to the pH 7.5 buffer reduced the l-proline activity, and 
(v) the introduction of the tetrazine moiety onto l-proline did not affect its activity to a 
great extent. These observations optimistically showed activity in relevant buffer systems. 
For our initial catalysis studies, we envisioned to use a buffer in which some activity of 
free l-proline was observed, so that we could also safely expect to observe some activity 
after encapsulation of this catalyst. The observed effects of the reaction medium on 
catalytic activity therefore had implications for the possible assembly pathways towards 
assembled CCMV capsids. The endogenous assembly behavior of the capsid proteins 
could not be exploited, as no l-proline activity was observed at pH 5.0. Additionally, high 
NaCl concentrations were found incompatible with the catalysis, eliminating salt-induced 
assembly of H6-ELP-CCMV towards T = 1 capsids. Therefore, we decided to exploit metal 
ion-induced capsid assembly, making use of the N-terminal hexahistidine tags attached 
to the ELP-CCMV capsid proteins.23 It was previously found that divalent ions, such as 
Ni2+, which have an affinity for the H6-tag, are not only useful in purification of these 
proteins via affinity chromatography. They can also be used to bind several hexahistidine 
tags after purification, resulting in local clustering of the capsid proteins and lowering 
of the transition temperature of the ELP blocks, which can subsequently lead to capsid 
assembly at pH 7.5 and at low NaCl concentrations (assembly buffer). To test whether 
these capsids could remain assembled during l-proline catalysis, i.e. whether the Ni2+ ions 
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Table 7.1 Investigation of the tetrazine-proline 4-catalyzed asymmetric aldol reaction between cyclohexanone 5 
and 4-nitrobenzaldehyde 6,	and	the	influence	of	the	addition	of	H6-ELP-CCMV	capsid	protein	dimers	or	capsids.
Entry [4] (mM) Additive Conversion1 (%) d.e. antia (%) e.e. antia (%) e.e. syna (%)
1 2.0 - 13 25 -27 36
2 2.0 H6-ELP-CCMV -Ni
2+ 25 30 14 20
3 - H6-ELP-CCMV -Ni
2+ 15 29 23 19
4 2.0 H6-ELP-CCMV +Ni
2+ 17 33 12 18
5b 2.0 H6-ELP-CCMV +Ni
2+ 14 31 10 20
6 - H6-ELP-CCMV +Ni
2+ 7 36 7 3
7 - - 4 40 12 18
Standard	reaction	conditions:	2.0	mM	tetrazine-proline	4,	1.0	mM	4-nitrobenzaldehyde	6,	20.0	mM	cyclohexanone	5	(20	eq.),	assembly	
buffer	with	1%	DMSO,	21	°C,	24	h.	Additives:	198	µM	H6-ELP-CCMV,	either	without	Ni
2+	 ions	added	(dimers)	or	with	Ni2+ ions added 
(capsids). a Determined	by	chiral	HPLC	analysis.	b Catalyst 4	was	added	to	the	capsid	proteins	before	the	addition	of	Ni2+ ions.
would remain bound upon the addition of the required components, the capsid stability 
was followed by DLS in the presence of l-proline, cyclohexanone 5 or 4-nitrobenzaldehyde 
6. These measurements indicated that the capsids remain stable for at least 24 hours in the 
presence of relevant concentrations of each of these compounds, making this assembly 
pathway suitable for the encapsulation of l-proline.
Next, it was tested whether the addition of H6-ELP-CCMV capsids to l-proline would 
improve its catalytic efficiency, due to the presence of a hydrophobic environment. To 
this end, the tetrazine-proline 4-catalyzed aldol reaction between cyclohexanone 5 and 
4-nitrobenzaldehyde 6 was examined in the presence or absence of H6-ELP-CCMV dimers 
or Ni2+-induced capsids, using chiral HPLC analysis (Table 7.1). Free tetrazine-proline 4 
yielded a conversion of 13% and e.e. values around 30% (entry 1). The addition of capsid 
protein dimers to the catalyst had an impact on both the conversion and the e.e. values 
obtained after the reaction (entry 2). For instance, in this case the e.e. value for the anti 
products was in favor of the (1R,2S) product, in contrast to the tetrazine-proline 4-catalyzed 
reaction, which was in favor of the (1S,2R) product. Additionally, an increase of the 
conversion to 25% was observed upon the addition of H6-ELP-CCMV dimers. The activity 
of tetrazine-proline 4 could have been increased due to the presence of a hydrophobic 
environment, but the observed activity could also well be a combination of the activity of 
free tetrazine-proline 4 and the observed activity in the control reaction with only capsid 
protein dimers and no tetrazine-proline 4 (entry 3). The obtained e.e. values, and more 
specifically the e.e. observed for the anti products, however, indicate that the activity of 
tetrazine-proline 4 is affected by the presence of the capsid protein dimers, as a simple 
combination of both free components would have most likely resulted in a net e.e. of the 
anti products of approximately zero. The addition of assembled H6-ELP-CCMV capsids, 
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Table 7.2 Investigation of the asymmetric aldol reaction between cyclohexanone 5 and 4-nitrobenzaldehyde 
6, catalyzed by H6-ELP-CCMV	capsid	protein	dimers	or	capsids	which	had	been	reacted	with	2PCA-VBA	2	and/or	
tetrazine-proline 4.
Entry [4] (mM) Additive Conversion1 (%) d.e. antia (%) e.e. antia (%) e.e. syna (%)
1 2.0 - 13 25 -27 36
2 2.0 H6-ELP-CCMV -Ni
2+ 25 30 14 20
3 - H6-ELP-CCMV -Ni
2+ 15 29 23 19
4 2.0 H6-ELP-CCMV +Ni
2+ 17 33 12 18
5b 2.0 H6-ELP-CCMV +Ni
2+ 14 31 10 20
6 - H6-ELP-CCMV +Ni
2+ 7 36 7 3
7 - - 4 40 12 18
Standard	reaction	conditions:	90	µM	H6-ELP-CCMV,	1.0	mM	4-nitrobenzaldehyde	6,	30.0	mM	cyclohexanone	5	(30	eq.),	assembly	buffer	
with	1%	DMSO,	21	°C,	24	h.	a Determined	by	chiral	HPLC	analysis.	b No	protein	was	added	to	this	reaction	mixture.
i.e. capsid proteins incubated with Ni2+ ions, only slightly improved the conversion of the 
tetrazine-proline 4-catalyzed reaction (entry 4). The e.e. value of the anti product was again 
in favor of the (1R,2S) product, however, suggesting some form of interaction between the 
catalyst and the capsids in this reaction. Addition of tetrazine-proline 4 during incubation 
of the capsid proteins with the Ni2+ ions, resulting in possible encapsulation of the catalyst 
did not change the outcome of this reaction much (entry 5). This could indicate that free 
tetrazine-proline 4 is able to diffuse into the capsids through their pores, after being added 
to the exterior of the capsids, or that substrate diffusion over the capsid barrier is quite 
efficient. Finally, comparing the abovementioned reactions with a non-catalyzed reaction 
(entry 7), we can conclude that most reactions show a higher conversion, indicating active 
catalysis taking place. On the other hand, some of these reactions do not distinguish 
themselves from the background reaction in terms of the enantiomeric outcome of these 
reactions, leaving some room for improvement. 
Subsequent activity assays were aimed at investigating the activity of l-proline after 
attachment to the H6-ELP-CCMV capsid proteins. To this end, three batches of protein 
were prepared which had been subjected to either 2PCA-VBA 2 or tetrazine-proline 4, or 
both. The latter should be the only protein which is catalytically active, whereas the other 
two serve as controls, e.g. for aspecific reaction of tetrazine-proline 4 with the protein. After 
the protein modification, each batch was split into two equal parts and either Ni2+ ions or 
buffer was added, resulting in assembled and disassembled samples for each protein batch. 
Assuming 5% conversion of the capsid proteins, as mentioned above, approximately three 
proline moieties should be present per assembled T = 1 capsid. After preparation of the 
protein samples, the substrates were added and the reactions were followed by chiral HPLC 
(Table 7.2). As these samples contained a relatively low l-proline concentration compared 
to the abovementioned reactions (~450 times lower than the reactions listed in Table 7.1), 
a higher excess of cyclohexanone 5 over 4-nitrobenzaldehyde 6 was used to still be able to 
observe a distinct conversion of the starting material to the products. Compared to the 
background reaction (entry 7), a distinct conversion was only observed for the protein 
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sample which has been subjected to both 2PCA-VBA 2 and tetrazine-proline 4 and which 
was not assembled through the addition of Ni2+ ions (entry 1). All other samples showed 
similar conversions to the background reaction, indicating that both 2PCA-VBA 2 and 
tetrazine-proline 4 are indeed required to modify the protein. Notably, no conversion 
was observed for the proline-modified protein which had been assembled through Ni2+-
induced assembly (entry 2). This could indicate that substrate diffusion into the capsid is 
the rate-limiting step in this reaction.
7.3 concLuSionS
N-terminal modification of the CCMV capsid proteins has proven to be challenging, due to 
the fact that these proteins are not very stable and will precipitate upon exposure to reaction 
conditions that are too harsh. This has previously excluded the use of some of the most 
common protein modification strategies to functionalize the capsid proteins. Here, it was 
shown that the mild modification method using 2-pyridinecarboxaldehydes is suitable for 
the modification of the CCMV capsid proteins. No protein instability was observed during 
the reactions, while up to 65% of the proteins could be modified using this strategy. We 
applied this to attach a modular vinylboronic acid handle, which could be further modified 
with a cargo, modified with a tetrazine moiety. Proof-of-principle reactions with tetrazine-
BODIPY showed that this modular two-step modification strategy was successful.
The attachment of tetrazine-proline using this strategy could not be proven by SDS-
PAGE analysis, and ESI-TOF measurements only gave indirect evidence for the successful 
coupling. Nevertheless, some activity of the capsid proteins dimers was observed after the 
two-step reaction with this proline moiety, indicating successful attachment. This activity, 
however, was still quite low and should be improved in further studies. Since the reaction 
conditions of the aldol reaction, e.g. the substrate concentrations and the substrate ratio’s, 
were already varied and optimized to some extent, we should probably focus on achieving 
higher conversions in the protein modification step, in order to obtain higher conversions 
in the asymmetric aldol reaction. The N-terminus of the capsid proteins could, for instance, 
be modified to display another N-terminal amino acid than glycine, since previous research 
has shown that this can improve the modification efficiency.18
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7.5 exPeriMenTaL SecTion
7.5.1  Materials and methods
Materials
2PCA 1 was obtained from Aldrich. 2PCA-VBA 2, tetrazine-BODIPY 3, tetrazine-
Cy5, and tetrazine-proline 4 were provided by Ms. Selma Eising. Cyclohexanone 5 and 
4-nitrobenzaldehyde 6 were obtained from Fluorochem. NiCl2 was purchased from Alfa 
Chemicals. DMSO was obtained from Acros.
Buffers
PBS buffer: 10 mM Na2HPO4, 1.8 mM KH2PO4, 137 mM NaCl, 2.7 mM KCl, pH 7.2-7.4. 
pH 5.0 capsid buffer: 50 mM NaOAc, 500 mM NaCl, 10 mM MgCl2, 1 mM EDTA, pH 5.0. 
pH 7.5 dimer buffer: 50 mM Tris·HCl, 500 mM NaCl, 10 mM MgCl2, 1 mM EDTA, pH 7.5. 
Assembly buffer: 50 mM Tris·HCl, 300 mM NaCl, 10 mM MgCl2, pH 7.5.
All buffers were filtered over a 0.2 micron filter prior to use.
UV-vis spectroscopy
Protein concentrations were measured on a Varian Cary 50 Conc UV-vis spectrometer 
using a quartz cuvette with a path length of 3 mm. Protein concentrations were calculated 
using the theoretical extinction coefficients.24 Samples were centrifuged prior to the 
measurements.
Mass	spectrometry
Protein mass characterization was performed by electrospray ionization time-of-flight 
(ESI-TOF) on a JEOL AccuTOF CS. Deconvoluted mass spectra were obtained using 
MagTran 1.03 b2. Isotopically averaged molecular weights were calculated using the 
‘Protein Calculator v3.4’ at http://protcalc.sourceforge.net. Protein samples were desalted 
by spin filtration to MQ (final concentrations 20-50 μM).
Chiral	HPLC
Chiral HPLC was performed on a Shimadzu LC-2010C with an AD-H column (Chiralpak, 
250 x 4.6 mm). Method: n-heptane/isopropanol 95/5 (v/v), 1.0 mL/min, 5 µL sample 
injected, 254 nm absorbance read-out.
7.5.2  experimental details
Protein	sequences
Table 7.1	 Amino	acid	sequences	of	the	proteins	used	in	this	chapter.
Name Sequence
G-H6-ELP-CCMV
GHHHHHHVPGVGVPGLGVPGVGVPGLGVPGVGVPGLGVPGGGVPGVGVPGLGLEVVQPVIVEPIASGQ
GKAIKAWTGYSVSKWTASCAAAEAKVTSAITISLPNELSSERNKQLKVGRVLLWLGLLPSVSGTVKSC
VTETQTTAAASFQVALAVADNSKDVVAAMYPEAFKGITLEQLTADLTIYLYSSAALTEGDVIVHLEVE
HVRPTFDDSFTPVY
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Expression	of	G-H6-ELP-CCMV
The expression and purification of G-H6-ELP-CCMV were performed as described in 
Chapter 3.
Protein	modification	with	2PCA	derivatives
For a typical modification using 2PCA 1 or a derivative thereof, a stock solution of the 
desired protein in PBS buffer was prepared by spin filtration to this buffer (10 kDa MWCO, 
3 x 10 min). A 100x stock solution of the 2PCA derivative in DMSO was prepared, to keep 
the final DMSO concentration in the reaction mixture at a maximum of 1%. The protein (50 
µM) and the 2PCA compound (500/2500 µM) were combined in PBS buffer and incubated 
at 21 °C for 24 h.
Protein	modification	with	2PCA	derivatives,	followed	by	tetrazine	ligation
For a typical modification using 2PCA 1 or a derivative thereof, a stock solution of the 
desired protein in PBS buffer was prepared by spin filtration to this buffer (10 kDa MWCO, 
3 x 10 min). A 100x stock solution of the 2PCA derivative in DMSO was prepared, to keep 
the final DMSO concentration in the reaction mixture at a maximum of 1%. The protein (50 
µM) and the 2PCA compound (500/2500 µM) were combined in PBS buffer and incubated 
at 21 °C for 24 h, after which it was dialyzed with PBS buffer to remove the excess 2PCA 
compound (Spectra/Por 4 dialysis tubing, 12-14 kDa MWCO, 10 mm flat width, 3 × 60 min). 
A 100x stock solution of the desired tetrazine derivative in DMSO was prepared, to keep 
the final DMSO concentration in the reaction mixture at a maximum of 1%. The protein 
(10 µM) and the tetrazine compound (100 µM) were combined in PBS buffer and incubated 
at 21 °C for 1 hour.
Ni2+-induced capsid assembly
G-H6-ELP-CCMV was spin filtrated to assembly buffer (10 kDa MWCO, 3 x 10 min) and 
diluted back to 850 µM (~20 mg/mL). G-H6-ELP-CCMV (425 µM) and NiCl2 (425 µM) were 
combined in assembly buffer and incubated at rt for 30 minutes.
Ni2+-induced capsid assembly after tetrazine ligation
A tetrazine ligation reaction mixture was dialyzed to assembly buffer to remove the excess 
tetrazine compound (Spectra/Por 2 dialysis tubing, 12-14 kDa MWCO, 25 mm flat width, 
3 × 60 min). The solution was concentrated 20 times by spin filtration, to obtain a protein 
concentration of 200 µM (10 kDa MWCO, 3 x 10 min). The protein (100 µM) and NiCl2 (1800 
µM) were combined in assembly buffer and incubated at rt for 30 minutes. The mixture was 
dialyzed to assembly buffer to remove the excess NiCl2 (Spectra/Por 4 dialysis tubing, 12-14 
kDa MWCO, 10 mm flat width, 3 × 60 min).
Aldol reaction
A stock solution of 4-nitrobenzaldehyde 6 (100 mM, DMSO) was prepared. 
4-Nitrobenzaldehyde 6 (1 mM), cyclohexanone 5 (20/30 mM, 20/30 eq.) and catalyst (e.g. 
tetrazine-proline 4 (2 mM, 2.0 eq.) or protein (90 µM)) were combined in assembly buffer 
(final volume 40-100 µL). The mixture was incubated at 21 °C for 24 h. The products and 
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remaining reactants were extracted with Et2O (2 times 100 µL). The organic layers were 
combined and the solvent was evaporated using an N2 flow. The remainders were dissolved 
in n-heptane/isopropanol 95/5 (v/v) (30-50 µL) for chiral HPLC analysis.
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abSTracT
Viruses are sophisticated structures, which are able to replicate 
inside living cells of their host after infection. The viral nucleic acid 
material carrying the required genetic information for replication is 
usually encapsulated in a protective mantle, i.e. a protein capsid. In 
our research towards the construction of nanoreactors based on virus 
capsids, we envisioned to use a strategy based on the endogenous 
viral structure. Here, we describe our attempts to encapsulate DNA-
based catalysts in the capsid of the cowpea chlorotic mottle virus 
(CCMV). Systematic studies were executed to both investigate the 
encapsulation of nucleic acid carriers in the CCMV capsids, and 
evaluate potentially suitable DNA-based catalysts and their catalytic 
reactions for their potential to be combined with the CCMV capsids.
Encapsulation of a DNA-based catalyst inside virus-like particles
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8.1 inTroDucTion
A lot of inspiration in the development of nanotechnological structures is obtained from 
nature, e.g. from the threedimensional organization of nucleic acids and proteins. Viruses 
are beautiful examples of complex supramolecular structures, combining both proteins 
and nucleic acids. Their core consists of viral DNA or RNA, which allows replication of 
the virus after infection of a host. The nucleic acid material is surrounded by a capsid 
protein shell, resulting in a well-defined and stable supramolecular complex. Our research 
has focused mostly on the cowpea chlorotic mottle virus (CCMV), which is icosahedrally 
shaped and consists of 180 identical 20 kDa capsid proteins. These virus particles have 
inner and outer diameters of 18 and 28 nm, respectively.1,2 An interesting feature of the 
CCMV virus is its ability to undergo reversible, pH-dependent assembly and disassembly, 
even without its viral RNA present.3 This makes these particles particularly interesting for 
nanotechnological applications, as the interior of the capsids can be filled with a cargo.
In our research towards CCMV-based nanoreactors, we would like to achieve a controlled 
encapsulation of catalytically active species. This can be achieved by covalent attachment 
of the catalyst to the N-terminus of CCMV, as we have shown earlier (Chapters 3, 4, 5 
and 7).4,5,6 In addition, we would like to develop a CCMV nanoreactor without covalently 
attaching the catalyst, as this makes the introduction of functional handles on both the 
CCMV proteins and the catalyst, and a subsequent coupling reaction unnecessary. Inspired 
by nature, where virus capsids are loaded with DNA and RNA, much research has focused 
on the encapsulation of negatively charged cargo in CCMV particles. The N-terminus of the 
CCMV capsid protein, which is located on the inside of the particles, is positively charged 
and therefore has ionic interactions with negatively charged molecules. Consequently, 
negatively charged cargo can be encapsulated in a controlled way and the cargo loading 
will exceed the loading that is expected for a purely statistical encapsulation. Examples of 
negative cargo that has been encapsulated in VLPs in this way are polymers7–11 and nucleic 
acids.12,13
Inspired by the native CCMV virus, we attempted to encapsulate a DNA-based catalyst in 
the empty CCMV capsids. DNA-based catalysis has proven to be a very suitable approach 
for asymmetric chemical transformations in aqueous systems.14 Generally, the catalytic 
species (e.g. copper(II)) is bound to a ligand, which is able to bind or position itself in close 
proximity to the DNA helix.15 High enantioselectivities have been achieved by performing 
catalysis in the chiral environment of DNA, and this approach has been applied in 
several important reactions, such as Diels-Alder reactions16–18, Friedel-Crafts alkylations19, 
Michael additions20,21, cyclopropanations22, fluorinations23, enone hydrations24, and allylic 
aminations25.
In this study, we investigated the encapsulation of a DNA-based catalyst inside CCMV, 
with the aim of comparing the performance of the catalyst inside CCMV with that of 
the free catalyst (Scheme 8.1). Encapsulation of the DNA-based catalysts could impart 
protection from degradation by DNases. Additionally, the additional chiral shell around 
the catalytic system could potentially enhance the enantioselective properties of the 
catalytic conversions.
138
Chapter 8
Scheme 8.1	 Schematic	representation	of	the	formation	of	an	encapsulated	DNA-based	catalyst.	First,	a	transition	
metal	complex,	based	on	a	non-chiral	ligand,	is	non-covalently	bound	to	double-stranded	DNA.	CCMV	capsids	can	
be	disassembled	by	increasing	the	pH	of	the	buffer	to	7.5,	resulting	in	protein	dimers.	Then,	encapsulation	of	the	DNA-
based	catalyst	is	achieved	by	lowering	the	pH	back	to	5.0,	yielding	catalytically	active	nanocompartments,	which	are	
able to convert a prochiral substrate into a chiral product.
8.2 reSuLTS anD DiScuSSion
8.2.1  Dna encapsulation during capsid assembly
We aimed to encapsulate DNA based on electrostatic interactions between the negatively 
charged nucleic acid and the positively charged N-terminal part of the H6-CCMV capsid 
proteins. Initial studies were performed using salmon testes DNA (st-DNA), which is most 
commonly used for the construction of DNA-based catalysts. st-DNA is cheap and readily 
available as a mixture of duplex fragments of approximately 2000 base pairs in length. 
Unfortunately, addition of this DNA to H6-CCMV capsid protein dimers in pH 7.5 dimer 
buffer, followed by dialysis to assembly buffer (50 mM MES, 500 mM NaCl, 10 mM MgCl2, 
pH 5.0), resulted in visual precipitation of what seemed to be both the protein and st-
DNA. Moreover, a low degree of st-DNA encapsulation was observed in the remaining 
capsids in size exclusion chromatography (SEC) measurements.
As an alternative to salmon testes DNA, catalysis could also be performed using a short 
DNA fragment as the DNA source.18,19,21,24 Inspired by these nucleic acid sequences, we 
designed the self-complementary DNA sequence 5’-CAAAAATTTTTGCAAAAATTTTTG-3’ 
(DNA-1), with a 6-carboxyfluorescein label attached to the 5’ end. Again, the DNA was 
added to the disassembled H6-CCMV capsid proteins, after which capsid formation was 
induced by dialyzing to assembly buffer. In this case, no precipitation was observed. SEC 
measurements indicated encapsulation of DNA-1 in the capsids, as the UV absorption of 
the capsids, eluting at approximately 10 mL, at 260 nm was significantly higher than at 280 
nm (Figure 8.1A). Some residual capsid protein and DNA-1 were also still observed, eluting 
at approximately 17 mL and 20 mL, respectively. The absorption of the capsids at 494 nm, 
which could be attributed to the 6-carboxyfluorescein label attached to DNA-1, confirmed 
encapsulation of the DNA. A subsequent stability experiment showed that the capsids 
remained stable in MES buffer for at least 30 hours. This indicated that these capsids can 
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figure 8.1 SEC chromatograms of H6-CCMV	after	disassembly	and	pH-induced	re-assembly	in	the	a) presence, 
or b) absence of Dna-1.	Capsids	are	expected	around	an	elution	volume	of	10	mL,	capsid	protein	dimers	around	17	
mL	and	free	DNA	around	20	mL.
be used in catalytic test experiments, which are normally performed in MES or MOPS 
buffers.
At the protein concentrations used in these experiments, no capsid assembly was observed 
when no DNA had been added before lowering the pH of the environment (Figure 8.1B). 
This indicates that the negatively charged nucleic acids are able to aid in the capsid 
assembly process, probably due to electrostatic interactions with the N-termini of the 
capsid proteins.
The 260 to 280 nm absorption ratio of the capsids with encapsulated DNA-1 was used to 
estimate the ratio of encapsulated DNA-1 and capsid protein, making use of their average 
extinction coefficients ε (Figure 8.1A) (see experimental section for calculations). It was 
found that approximately 10% of the sample consisted of nucleic acid and 90% of protein. 
This corresponds to an encapsulation of 20 short DNA-1 fragments per T = 3 capsid.
Empty capsids and capsids with encapsulated DNA-1 were further investigated using multi-
angle laser light scattering (MALLS) in combination with SEC (Figure 8.2A). In both cases, 
capsids were observed around 10 mL. The mass of the DNA-filled capsids was, however, 
higher than the mass of the empty capsids (4.0 vs. 3.4 MDa), suggesting that a significant 
amount of DNA-1 was encapsulated. Assuming that approximately 20 DNA-1 molecules 
were encapsulated, a mass difference of 0.16 MDa would have been expected. We believe 
the observed mass difference of ~0.6 MDa might be explained by the fact that the capsids 
are on the lower size limit for reliable analysis, based on angular-dependent scattering. The 
results from the UV absorption measurements are therefore expected to be more reliable.
From the MALLS measurements, an estimation of the radius of gyration (Rg) of the 
capsids could also be made (Figure 8.2B). A lower Rg was observed for the filled particles, 
confirming successful DNA-1 encapsulation. As expected, little difference was observed 
in the hydrodynamic radii (Rh) of the capsids, which were determined using quasi-elastic 
light scattering (QELS) (Figure 8.2B). From these data, the shape parameter Rg/Rh was 
estimated for both particles, which was 0.74 for filled and 0.78 for empty particles, whereas 
expected values for monodisperse, filled spheres and empty spheres were 0.78 and 1.00, 
respectively. This difference, especially for the empty spheres, can be explained by the 
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figure 8.2 a)	 Normalized	 SEC-MALLS	 chromatograms	 of	 empty	 H6-CCMV	 capsids	 (blue line) and H6-CCMV	
capsids with Dna-1 encapsulated (purple line). b) Experimentally determined hydrodynamic radii (Rh) and radii of 
gyration (Rg) of the capsids shown in A.
fact that the protein capsids have a rather thick protein wall, and their morphology can 
therefore be more regarded as core-shell architectures with a relatively high core density.
8.2.2  Conjugate addition of water to enones
To investigate the possibility of using DNA fragments encapsulated in H6-CCMV capsids 
as a catalytic platform, three different DNA-catalyzed reactions were tested against the 
following criteria: (i) the reaction should proceed in a buffer that allows CCMV assembly, 
containing e.g. relatively high NaCl concentrations, (ii) there should be a significant 
difference in conversion and e.e. between the background reaction in buffer and the 
catalyzed reaction, to allow reliable detection of catalysis after encapsulation of the DNA-
based catalyst, and (iii) if one of the components of the DNA-based catalyst is missing, the 
reaction should be reduced to background level, allowing reliable detection of assembly of 
the complete catalyst in the CCMV interior.
The conjugate addition of water to enones was the first reaction that was investigated for its 
potential to be combined with CCMV (Table 8.1).24 As water is one of the substrates in this 
reaction, only diffusion of the enone into the capsid can be rate limiting. Additionally, even 
though decent enantioselectivities were reported in literature with the unencapsulated 
DNA-based catalytic system,24 we saw room for improvement on the enantioselective 
outcome of the reaction, facilitated by the chiral H6-CCMV capsid after encapsulation of 
the catalytic system.
Firstly, the hydration reaction was investigated with the non-encapsulated catalytic 
system, based on st-DNA. To this end, the DNA was dissolved and incubated with ligand 3 
and Cu(NO3)2, followed by the addition of unsaturated ketone substrate 1 (Table 8.1). After 
incubation at 4 °C for 24 hours, the products and remaining reactants were extracted with 
Et2O and analyzed by chiral HPLC. For enone 1a, and especially for enone 1b, a significant 
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Table 8.1 Investigation of st-Dna-catalyzed	conjugate	addition	of	water	to	enone	substrates.
Entry Starting material Product st-DNA Ligand 3 Cu(NO3)2 Conversion
a (%) e.e.a (%)
1 1a 2a + + + 65 21
2 1a 2a - + + 73 -7
3 1a 2a + - + 33 9
4 1a 2a + + - 0 n/a
5 1b 2b + + + 45 31
6 1b 2b - + + 62 1
7 1b 2b + - + 30 2
8 1b 2b + + - 0 n/a
Standard	reaction	conditions:	1.3	mg/mL	st-Dna	(2.0	mM	DNA	basepairs),	0.39	mM	ligand	3,	0.3	mM	Cu(NO3)2,	1.0	mM	substrate	1a/1b, 
50	mM	MES	+	500	mM	NaCl	+	10	mM	MgCl2	pH	5.0	buffer,	4	°C,	24	h.	
a Determined	by	chiral	HPLC	analysis.	n/a	=	not	applicable.
conversion and e.e. were observed. Compared to the published results, the conversions 
and e.e. values were slightly lower in our hands, which could be due to the small scale at 
which our reactions were performed.23 When st-DNA or ligand 3 was left out from the 
reaction, a low e.e. was observed, suggesting that product 2 had not been formed in a chiral 
environment in these mixtures. When Cu(NO3)2 was left out, no conversion was observed 
at all, showing that the presence of Cu(NO3)2 is essential for the reaction to proceed.
After having established the st-DNA-catalyzed hydration of enones, we examined the 
performance of DNA-1 in the same reaction. Initially, no effect of the addition of DNA 
on the reaction was observed for DNA-1 with a 6-carboxyfluorescein label. When non-
labeled DNA-1 was used, however, an effect could be observed, meaning that the labeled 
variant could probably not hybridize towards a double-stranded DNA fragment. Varying 
results were obtained when enones 1a and 1b were subjected to the DNA-1-based catalyst 
(Table 8.2). For substrate 1b, an e.e. was only observed when DNA was present, as expected. 
Surprisingly, however, in this case the other enantiomer was preferred, compared to the 
st-DNA-catalyzed reaction (Table 8.1). No e.e. was observed for substrate 1a, even when 
DNA-1 had been present. These results might indicate a different catalytic mechanism in 
the reactions catalyzed by the short DNA-1 fragment.
This catalytic system poses a number of problems, which makes it less useful for studying the 
effect of encapsulation on catalytic performance. The conversion and e.e. values obtained 
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Table 8.2 Investigation of Dna-1-catalyzed	conjugate	addition	of	water	to	enone	substrates.
Entry Starting material Product DNA-1 Ligand 3 Cu(NO3)2 Conversion
a (%) e.e.a (%)
1 1a 2a + + + 44 9
2 1a 2a - + + 56 -7
3 1b 2b + + + 29 -30
4 1b 2b - + + 36 4
Standard	reaction	conditions:	1.3	mg/mL	Dna-1,	0.39	mM	ligand	3,	0.3	mM	Cu(NO3)2,	1.0	mM	substrate	1a/1b,	50	mM	MES	+	500	mM	
NaCl	+	10	mM	MgCl2	pH	5.0	buffer,	4	°C,	24	h.	
a Determined	by	chiral	HPLC	analysis.
in the reaction without DNA are, in some cases, comparable to the results obtained in 
the DNA-catalyzed reactions. When combining the DNA-based catalytic system with the 
H6-CCMV capsid, a conversion should ideally only be observed when the whole catalyst 
is assembled inside the capsid and once the remaining parts of the catalytic system are 
washed away. In this system, however, conversion is already observed when Cu(NO3)2 
is added to the starting materials. These findings might make it hard to distinguish the 
activity arising from the encapsulated catalyst from e.g. free Cu remaining in solution or 
partially assembled catalyst.
8.2.3  cyclopropanation reaction
A DNA-catalyzed reaction that should be more suitable for our purpose, in the sense 
that conversion should only be observed when the catalyst is assembled as a whole, is the 
carbene-transfer reaction.22 In this reaction, an iron porphyrin complex associates with 
double-stranded DNA, after which it can catalyze the enantioselective cyclopropanation 
of 2-vinylanisole 4 with ethyl diazoacetate 5.
Firstly, the performance of st-DNA in the cyclopropanation reaction was tested in 50 mM 
MES pH 5.0 buffer (Table 8.3). Compared to the reported reaction in MOPS pH 6.5 buffer, 
the yield was slightly lower, while the enantioselectivity was retained.22 When no DNA was 
added, no conversion was observed, as expected. With these results, we continued and tested 
the influence of several additives, such as NaCl, MgCl2 and ethylenediaminetetraacetic 
acid (EDTA), which are commonly used in the storage buffers for H6-CCMV. The addition 
of increasing amounts of NaCl resulted in a decrease of the e.e. values. A buffer with 150 
mM NaCl, however, still resulted in acceptable e.e. values. There was little influence of 10 
mM MgCl2 and 1 mM EDTA on the st-DNA-catalyzed reaction. Combining the additives 
slightly reduced the conversions and e.e. values further. In all cases, a background reaction 
was observed in the absence of st-DNA, as a consequence of the addition of the additive 
to the buffer. This effect was also observed before for the hydration of enones (see section 
8.2.2).
Since st-DNA cannot be used as a carrier for the DNA-based catalyst, when combined 
with H6-CCMV capsids, we decided to check whether a background reaction would also 
be observed for short DNA fragments after the addition of additives to the reaction buffer. 
Firstly, the performance of several short DNA fragments was tested in the cyclopropanation 
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Table 8.3	 Investigation	of	the	influence	of	additives	on	the	st-Dna-catalyzed cyclopropanation of 2-vinylanisole 
4 with ethyl diazoacetate 5.
Entry st-DNA [NaCl] 
(mM)
[MgCl2] 
(mM)
[EDTA] 
(mM)
Conversiona (%) d.e. transa 
(%)
e.e. transa 
(%)
e.e. cisa 
(%)
1 - - - - 0 n/a n/a n/a
2 + - - - 8 61 46 3
3 - 150 - - 10 81 0 -6
4 + 150 - - 11 80 27 20
5 - 500 - - 7 78 0 2
6 + 500 - - 5 76 -8 1
7 - - 10 - 19 81 0 2
8 + - 10 - 11 79 30 12
9 - - - 1 18 80 0 0
10 + - - 1 8 82 38 25
11 - 150 10 - 11 80 0 1
12 + 150 10 - 16 77 15 -3
13 - 150 10 1 8 80 -1 1
14 + 150 10 1 11 80 7 7
Standard	reaction	conditions:	4.0	mg/mL	st-Dna	(6.0	mM	DNA	basepairs),	37.5	µM	FeIII porphyrin 7,	5.0	mM	substrate	4	(750	mM	stock	
solution	in	MeCN),	50.0	mM	substrate	5	(1875	mM	stock	solution	in	MeCN),	buffer:	50	mM	MES	with	additives	as	given	in	the	table,	pH	
5.0,	4	°C,	5	min.	a Determined	by	chiral	HPLC	analysis.	n/a	=	not	applicable.
of 2-vinylanisole with ethyl diazoacetate (Table 8.4). Five DNA sequences were chosen, 
based on unpublished results from the Roelfes group (DNA-2 - DNA-5). To test the effect 
of the length of the DNA, also the double-sized DNA sequences DNA-7 - DNA-11 were 
tested. It was found that the longer fragments performed slightly better; higher yields and 
e.e. values were observed for the double-sized DNA fragments. This is probably due to the 
fact that relatively more ligands can associate with the DNA and that the DNA can exert 
more influence on the catalysis, respectively. From the short fragments, DNA-4 performed 
the best.
A selection of four DNA fragments was made (DNA-4, DNA-7, DNA-8 and DNA-9), 
with which the cyclopropanation reaction was performed again, now in the presence of 
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Table 8.4 Investigation of the cyclopropanation of 2-vinylanisole 4 with ethyl diazoacetate 5, catalyzed by short 
DNA	fragments.
Entry DNA DNA sequence Conversiona 
(%)
d.e. transa 
(%)
e.e. transa 
(%)
e.e. cisa 
(%)
1 DNA-2 5’-TATATATATATA 3 89 17 7
2 DNA-3 5’-ATATATATATAT 3 83 -10 20
3 DNA-4 5’-AAAAAATTTTTT 31 83 10 7
4 DNA-5 5’-GCGCTATAGCGC 11 83 10 13
5 DNA-6 5’-GCGCATATGCGC 4 81 10 6
6 DNA-7 5’-TATATATATATATATATATATATA 17 85 35 20
7 DNA-8 5’-ATATATATATATATATATATATAT 19 86 39 20
8 DNA-9 5’-AAAAAATTTTTTAAAAAATTTTTT 30 83 25 10
9 DNA-10 5’-GCGCTATAGCGCGCGCTATAGCGC 21 80 14 4
10 DNA-11 5’-GCGCATATGCGCGCGCATATGCGC 20 83 19 10
Standard	reaction	conditions:	9.0	mM	DNA	basepairs,	37.5	µM	FeIII porphyrin 7,	5.0	mM	substrate	4	(750	mM	stock	solution	in	MeCN),	
50.0	mM	substrate	5	(1875	mM	stock	solution	in	MeCN),	50	mM	MES	pH	5.0	buffer,	4	°C,	5	min.	a Determined	by	chiral	HPLC	analysis.
Table 8.5	 Investigation	 of	 the	 influence	 of	 additives	 on	 the	 cyclopropanation	 of	 2-vinylanisole	 4 with ethyl 
diazoacetate 5,	catalyzed	by	short	DNA	fragments.
Entry DNA [NaCl] 
(mM)
[MgCl2] 
(mM)
[EDTA] 
(mM)
Conversiona (%) d.e. transa 
(%)
e.e. transa 
(%)
e.e. cisa 
(%)
1 DNA-7 150 10 - 12 87 16 11
2 DNA-8 150 10 - 17 85 15 2
3 DNA-9 150 10 - 22 83 4 1
4 - 150 10 - 27 81 1 0
5 DNA-4 150 10 1 30 82 0 1
6 DNA-7 150 10 1 32 83 9 5
7 DNA-8 150 10 1 18 83 15 9
8 DNA-9 150 10 1 25 83 2 -1
9 - 150 10 1 23 80 -2 -1
Standard	reaction	conditions:	9.0	mM	DNA,	37.5	µM	FeIII porphyrin 7,	5.0	mM	substrate	4	(750	mM	stock	solution	in	MeCN),	50.0	mM	
substrate 5	(1875	mM	stock	solution	in	MeCN),	buffer:	50	mM	MES	with	additives	as	given	in	the	table,	pH	5.0,	4	°C,	5	min.	a Determined 
by	chiral	HPLC	analysis.
additives (Table 8.5). First, the influence of the addition of 150 mM NaCl and 10 mM MgCl2 
was investigated. It was found that, compared to a control reaction without DNA, lower 
conversions and higher e.e. values were obtained for the DNA-catalyzed reactions. When 
EDTA was also added as an additive, the conversions increased slightly. For DNA-4 and 
DNA-9, very low e.e. values were observed, suggesting that the DNA hardly played a role 
in these reactions.
As is the case with the previously investigated hydration of enones (see section 8.2.2), the 
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cyclopropanation background reaction was increased upon the addition of additives to 
the reaction buffer. Additionally, the e.e. values of the DNA-based catalytic reactions were 
significantly reduced. Therefore, we set out to find a more suitable reaction.
8.2.4  Friedel-Crafts alkylation
In order to be able to better distinguish DNA-catalyzed reactions from background 
reactions, we decided to investigate the Friedel-Crafts alkylation between enone 1a and 
5-methoxyindole 8.19 This reaction has shown promising results, e.g. high yields and e.e. 
values were obtained. We investigated the Friedel-Crafts alkylation catalyzed by DNA-12: 
5’-TCAGGGCCCTGA-3’, bearing a 1-aminohexane-modified phosphate functionality at the 
5’ end of the sequence. This functional handle was introduced to offer the possibility of 
covalent attachment of the DNA to the H6-CCMV capsid protein.
Without any additives, it was found that the addition of DNA accelerates the reaction, as 
higher conversions were obtained in the presence of DNA-12 (Table 8.6). Only when all 
components of the catalyst were present, an e.e. was obtained. The addition of increasing 
amounts of NaCl reduced both the conversions and e.e. values. The addition of MgCl2 
to the reaction had the same effect. An even bigger decrease of conversion and e.e. was 
observed upon the addition of 1 mM of EDTA. This can probably be explained by the fact 
that EDTA can coordinate CuII ions and will compete for the binding with the 4,4’-dimethyl-
2,2’-bipyridine (dmbpy) ligand. Combining the NaCl and MgCl2 additives, it was found 
that with both 150 mM NaCl and 500 mM NaCl satisfactory conversions and e.e. values 
were obtained. Additionally, compared to the two previously investigated DNA-catalyzed 
reactions, the difference between the reactions with and without DNA was most profound 
in this case: a big difference in e.e. values was observed for the reactions with and without 
DNA, while maintaining good yields.
8.2.5  Encapsulation of a DNA-based catalyst
To investigate the encapsulation of the DNA-based catalyst, used in the Friedel-Crafts 
alkylation in CCMV capsids, H6-CCMV capsid proteins were incubated with DNA-12 and 
CuII-dmbpy 10 in pH 7.5 dimer buffer, followed by dialysis to either 20 mM MES + 150 mM 
NaCl pH 5.0 buffer, or 20 mM MES + 500 mM NaCl pH 5.0 buffer (data not shown). No 
protein was observed in the size exclusion chromatograms after dialysis to the 150 mM 
NaCl buffer, indicating that all protein precipitated in this buffer. First dialyzing to pH 
5.0 capsid buffer, followed by dialysis to the 150 mM NaCl MES buffer yielded the same 
results (Figure 8.3). In contrast, when 500 mM NaCl was used, capsids were observed. 
Encapsulation of DNA in this buffer was confirmed by the 260/280 ratio of the capsid 
peaks, being approximately 1.0. As a control, DNA-12 and CuII-dmbpy 10 were left out of 
the mixture. In this case, capsids were obtained with a much lower 260/280 ratio.
After having established a protocol for the encapsulation of DNA-12, the capsids were 
purified by preparative SEC. These fractions were then used as the catalyst in the Friedel-
Crafts alkylation (Table 8.7). When CuII-dmbpy 10 was co-encapsulated with DNA-12 in 
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Table 8.6	 Investigation	of	the	influence	of	additives	on	the	Dna-12-catalyzed Friedel-Crafts alkylation between 
enone 1a	and	5-methoxyindole	8.
Entry DNA-12 [NaCl] (mM) [MgCl2] (mM) [EDTA] (mM) Conversion
a (%) e.e.a (%)
1 - - - - 78 0
2 + - - - 100 89
3 - 150 - - 62 0
4 + 150 - - 99 84
5 - 500 - - 66 1
6 + 500 - - 86 60
7 - - 10 - 61 0
8 + - 10 - 94 67
9 - - - 1 8 3
10 + - - 1 36 75
11 - 150 10 - 78 0
12 + 150 10 - 98 65
13 - 500 10 - 78 1
14 + 500 10 - 94 51
Standard	reaction	conditions:	1.3	mg/mL	Dna-12	(2.0	mM	DNA	basepairs),	0.3	mM	CuII-dmbpy 10,	1.6	mM	substrate	1a	(82	mM	stock	
solution	in	DMSO),	1.2	mM	substrate	8	(61	mM	stock	solution	in	DMSO),	buffer:	20	mM	MES	with	additives	as	given	in	the	table,	pH	5.0,	
4	°C,	24	h.	a Determined	by	chiral	HPLC	analysis.
H6-CCMV capsids, a very low conversion was observed (entry 1). The conversions were 
similar when no CuII-dmbpy 10 was added, or when no DNA was encapsulated in the 
CCMV capsids (entries 3 and 5, respectively). These results suggest that copper or CuII-
dmbpy 10 was lost during capsid formation and purification, or that substrate diffusion is 
limiting in this reaction. 
To exclude potential copper-loss during dialysis steps, in a second approach CuII-dmbpy 
10 was added after capsid purification (entries 2 and 4). Using this strategy, however, the 
ligand should be able to diffuse through the pores of the H6-CCMV capsid in order to bind 
the encapsulated DNA and form the active catalyst complex. In this case, a conversion 
was observed, but no e.e., suggesting the catalyst was not assembled in this reaction. 
Possible explanations in this case could be insufficient diffusion of CuII-dmbpy 10 over the 
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figure 8.3 SEC chromatograms of H6-CCMV	after	disassembly,	pH-induced	re-assembly	and	subsequent	dialysis	
to	in	20	mM	MES	+	150	mM	NaCl	pH	5.0	buffer	(purple line)	or	re-assembly	in	20	mM	MES	+	500	mM	NaCl	pH	5.0	
buffer	in	the	presence	(blue line) or absence (orange line) of Dna-12 and CuII-dmbpy 10.
Table 8.7 Investigation of the Friedel-Crafts alkylation between enone 1a	and	5-methoxyindole	8, catalyzed by 
Dna-12	encapsulated	in	CCMV	capsids.
Entry CCMV DNA-12 CuII-dmbpy 10 Conversiona (%) e.e.a (%)
1b H6-CCMV + in 6 4
2b H6-CCMV + out 48 0
3b H6-CCMV + - 6 7
4b H6-CCMV - out 49 0
5b H6-CCMV - - 5 2
6 wt-CCMV + in 7 14
7 wt-CCMV + out 60 0
8 wt-CCMV + - 9 4
Standard	reaction	conditions:	Dna-12	was	encapsulated	in	CCMV	capsid	proteins	in	a	ratio	of	5:1	protein:DNA,	according	to	the	protocol	
(see experimental details). In some cases, CuII-dmbpy 10	(DNA:CuII-dmbpy	=	1.1:1)	was	also	added	during	DNA	encapsulation	(in).	50	
µL	capsid	solution	(prep.	SEC	fraction	containing	capsids),	16.7	µL	CuII-dmbpy 10	(0.9	mM,	MQ)	(out),	1.0	µL	substrate	1a	(82	mM	stock	
solution	in	DMSO),	1.0	µL	substrate	8	(61	mM	stock	solution	in	DMSO),	20	mM	MES	+	500	mM	NaCl	+	10	mM	MgCl2	pH	5.0	buffer,	4	°C,	
24 h. a Determined	by	chiral	HPLC	analysis.	b	Reaction	time	=	16	h.
capsid barrier, or weak coordination of CuII to the ligand, allowing CuII to e.g. bind to the 
hexahistidine tags at the N-termini of the H6-CCMV capsid proteins. The latter explanation 
would also explain the results obtained in the experiments where CuII-dmbpy 10 was added 
before capsid assembly.
To test whether CuII coordination to the hexahistidine tags of the H6 -CCMV capsid proteins 
interfered with the catalysis, the catalytic experiments were repeated with wt-CCMV capsid 
proteins without His-tag, which were extracted and purified from infected cowpea plants 
(Table 8.7, entries 6-8). The results obtained were very similar to when H6-CCMV capsids 
were used: a significant conversion, but no e.e. was only observed when CuII-dmbpy was 
added to the reaction mixture after purification of the capsids. This suggests that, even 
though binding of CuII to the hexahistidine tags might play a role, this is not the main 
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reason why catalysis is not observed.
To investigate further the CuII loss in the samples where was CuII-dmbpy 10 was co-
encapsulated, the CuII loading in wt-CCMV capsids was investigated using inductively 
coupled plasma mass spectrometry (ICP-MS). To this end, three batches of wt-CCMV 
were prepared. Firstly, wt-CCMV capsids were disassembled and the capsid proteins 
were incubated with DNA-12 and either 0, 0.9 or 1.8 eq. CuII-dmbpy 10, relative to DNA-
12. Subsequently, the capsids were assembled in 20 mM MES + 500 mM NaCl + 10 mM 
MgCl2 pH 5.0 buffer and purified using preparative SEC. If Cu
II would have been able to 
stay coordinated to its ligand throughout this procedure, ICP-MS analysis of the capsid 
fractions would show an increasing CuII concentration with increasing equivalents of CuII-
dmbpy 10 added to the capsid proteins. No significant differences in the CuII concentration 
could be detected, however, indicating that CuII diffused out of the wt-CCMV capsids 
during the dialysis and preparative SEC steps.
8.3 concLuSionS
The encapsulation of a DNA-based catalyst in CCMV viral capsids, and subsequently 
the catalytic action of the encapsulated catalytic system was investigated. Statistical 
encapsulation of a 24 nucleotide-long double-stranded DNA resulted in the encapsulation 
of approximately 20 pieces of DNA per T = 3 capsid. The degree of encapsulation could 
possibly be improved further by covalently attaching the DNA to the N-terminus of the 
CCMV capsid proteins, facilitating spontaneous encapsulation upon capsid assembly. For 
this, both the Sortase methodology (Chapters 3,4 and 5) and the 2-pyridinecarboxaldehyde 
chemistry (Chapter 7) might be suitable.4,5,6
Three reactions, catalyzed by different types of DNA-based catalysts, were evaluated for 
their potential to be encapsulated inside CCMV capsids. The conjugate addition of water to 
enones and the cyclopropanation reaction were not found to be suitable for combination 
with CCMV capsids. In these reactions, the difference between the DNA-catalyzed reaction 
and the background reaction, i.e. reactions with and without DNA present, were small. 
This makes it hard to distinguish the systems where catalysis takes place inside the capsids 
by the intact DNA-based catalyst from possible side reactions. For instance, it could also 
well be possible that the metal-chelated ligand associates to the outside of the capsids, 
where the protein might also slightly influence the enantiomeric outcome of the reaction. 
From the three evaluated reactions, the Friedel-Crafts alkylation is thought to be the most 
suitable reaction for studying the effect of encapsulation in CCMV capsids. Even though 
a background reaction is still observed without DNA being present, the e.e. values are 
sufficiently different to tell whether catalysis takes place in close proximity of the DNA. Since 
the e.e. values are not optimal yet, the CCMV capsid might be able to further enhance the 
e.e. after encapsulation of the catalytic system, besides offering a protective environment. 
So far, however, we observed leakage of the CuII ions out of the DNA-encapsulated capsids, 
which has prevented the capsids to act as efficient catalysts in the Friedel-Crafts alkylation 
reaction. This should be investigated further, as it is unknown from the collected data 
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whether CuII loss is due to weak coordination of the metal to its ligand. Additionally, it is 
essential to further investigate the proposed leakage of the CuII ions during assembly and 
purification of the DNA-encapsulated capsids, and other additional issues that might play 
a role in the formation of the assembled DNA-based catalysts inside the CCMV capsids.
8.4 acknowLeDgeMenTS
Ms. Dowine de Bruijn, Dr. Ana Rioz-Martínez and Prof. Gerard Roelfes are kindly 
acknowledged for fruitful discussions and the synthesis and purification of several 
compounds needed for this study. We thank Ms. Ilva Klomp for her work on the 
cyclopropanation reaction. Mr. Stan J. Maassen and Prof. Jeroen J. L. M. Cornelissen are 
kindly acknowledged for the donation of the wt-CCMV virus and fruitful discussions.
8.5 exPeriMenTaL SecTion
8.5.1  Materials and methods
Materials
Salmon testes DNA sodium salt (st-DNA), 2-vinylanisole 4, ethyl diazoacetate 5, 
5-methoxyindole 8 and copper nitrate were purchased from Sigma-Aldrich. DNA-1 - DNA-
11 were synthesized by Biolegio. DNA-12 was synthesized by Integrated DNA Technologies. 
Enones 1a and 1b, ligand 3 and CuII-dmbpy 10 were synthesized and purified by Dowine de 
Bruijn (Roelfes group, RUG). FeIII porphyrin 7 was synthesized and purified by Ana Rioz-
Martínez (Roelfes group, RUG). DMSO was obtained from Acros Organics. CH3CN was 
purchased from Biosolve B.V.
Buffers
pH 5.0 capsid buffer: 50 mM NaOAc, 500 mM NaCl, 10 mM MgCl2, 1 mM EDTA, pH 5.0. 
pH 7.5 dimer buffer: 50 mM Tris·HCl, 500 mM NaCl, 10 mM MgCl2, 1 mM EDTA, pH 7.5. 
Assembly buffer: 50 mM MES, 500 mM NaCl, 10 mM MgCl2, pH 5.0. 
All buffers were filtered over a 0.2 micron filter prior to use.
UV-vis spectroscopy
Protein concentrations were measured on a Varian Cary 50 Conc UV-vis spectrometer 
using a quartz cuvette with a path length of 3 mm. Protein concentrations were calculated 
using the theoretical extinction coefficients.26 Samples were centrifuged prior to the 
measurements.
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Size exclusion chromatography (SEC)
SEC was performed on a Superose 6 10/300 column (GE Healthcare). Analytical and 
preparative SEC measurements were executed on a Shimadzu LC-2010AHT HPLC and 
Agilent 1260 bio-inert HPLC, respectively. Samples (70-200 μg) were separated with a flow 
rate of 0.5 mL/min.
SEC-multi-angle	laser	light	scattering	(SEC-MALLS)
SEC-MALLS was performed on a Superose 6 10/300 column (GE Healthcare). Samples (~200 
μg) were separated with a flow rate of 0.5 mL/min. The column was connected to a series 
of detectors: a Wyatt DAWN HELEOS II light scattering detector, using a laser operated 
at 664.5 nm, a Wyatt Optilab Rex refractive index detector and a Shimadzu SPD20A UV-
vis detector. The system was flushed overnight with buffer. Before the measurement, a 
calibration was performed using bovine serum albumin (BSA).
Chiral	HPLC
Chiral HPLC was performed on a Shimadzu LC-2010C with a Cellulose 1 column 
(Phenomenex, 250 x 4.6 mm). Conjugate addition of water to enones: n-heptane/
isopropanol 90/10 (v/v), 0.5 mL/min, 20 µL sample injected, 275 nm absorbance read-out. 
Cyclopropanation: n-heptane/isopropanol 98/2 (v/v), 0.5 mL/min, 5 µL sample injected, 
271 nm absorbance read-out. Friedel-Crafts alkylation: n-heptane/isopropanol 90/10 (v/v), 
0.5 mL/min, 5 µL sample injected, 275 nm absorbance read-out.
8.5.2  experimental details
Protein	sequences
Table 8.8	 Amino	acid	sequences	of	the	proteins	used	in	this	chapter.
Name Sequence
wt-CCMV
MSTVGTGKLTRAQRRAAARKNKRNTRVVQPVIVEPIASGQGKAIKAWTGYSVSKWTASCAAAEAKVTS
AITISLPNELSSERNKQLKVGRVLLWLGLLPSVSGTVKSCVTETQTTAAASFQVALAVADNSKDVVAA
MYPEAFKGITLEQLTADLTIYLYSSAALTEGDVIVHLEVEHVRPTFDDSFTPVY
G-H6-CCMV
GSSHHHHHHSSGLVPRGSHMMSTVGTGKLTRAQRRAAARKNKRNTRVVQPVIVEPIASGQGKAIKAWT
GYSVSKWTASCAAAEAKVTSAITISLPNELSSERNKQLKVGRVLLWLGLLPSVSGTVKSCVTETQTTA
AASFQVALAVADNSKDVVAAMYPEAFKGITLEQLTADLTIYLYSSAALTEGDVIVHLEVEHVRPTFDD
SFTPVY
Purification	of	wt-CCMV
The purification of wt-CCMV was performed as described in Chapter 6.
Expression	of	G-H6-CCMV
The expression and purification of G-H6-CCMV were performed as described in Chapter 3.
DNA	encapsulation	in	CCMV	capsids
For a typical DNA encapsulation experiment, CCMV capsid proteins were dialyzed to pH 
7.5 dimer buffer (Spectra/Por dialysis tubing, 12-14 kDa MWCO). A stock solution of the 
DNA in MQ was added such, that the desired protein:DNA ratio was obtained. Typically, 
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a protein:DNA ratio of 10:1 was used. As a control, only MQ was added. The mixtures were 
incubated at 4 °C for 30 minutes. Then, the solutions were dialyzed to the desired assembly 
buffer (Spectra/Por dialysis tubing, for DNA removal: 12-14 kDa MWCO, otherwise: 3.5 kDa 
MWCO).
Calculation	DNA	encapsulation	efficiency	based	on	260/280	absorption	ratio
The absorbance of a material depends on its molar extinction coefficient and concentration, 
according to the Lambert-Beer law:
Absorbance = ε·c·l 
The ratio between the absorbance at 260 nm and 280 nm can thus be expressed as:
A260 = 
ε260·c·l = 
ε260·c 
 
A280    ε280·c·l    ε280·c
A mixture in which both nucleic acids (N) and proteins (P) are present, will behave as 
follows:
A260 = 
ε
260,N
·cN + ε260,P·cP = 
20·cN + 0.57·cP 
 
A280    ε280,N·cN + ε280,P·cP      10·cN + 1·cP    
For a certain, measured A260/A280 ratio, the ratio between the nucleic acid concentration 
and protein concentration can thus be calculated.
Conjugate	addition	of	water	to	enones
st-DNA was dissolved overnight at 4 °C (4 mg/mL, MQ) (400 rpm). DNA-1 was dissolved 
(7.9 mg/mL, 1.0 mM, MQ), annealed by heating to 95 °C for 5 minutes and slowly cooled 
back to rt. The DNA (1.3 mg/mL), ligand 3 (0.39 mM) and Cu(NO3)2 (0.3 mM) were 
combined in 50 mM MES + 500 mM NaCl + 10 mM MgCl2 pH 5.0 buffer (final volume = 
14 µL) and incubated at 4 °C for 30 minutes. The desired substrate was added (15.0 mM in 
MeCN, to a final concentration of 1.0 mM). The mixture was incubated at 4 °C for 24 h. The 
products and remaining reactants were extracted with Et2O (2 times 100 µL). The organic 
layers were combined and the solvent was evaporated using an Ar flow. The remainders 
were dissolved in n-heptane/isopropanol 90/10 (v/v) (100 µL) for chiral HPLC analysis.
Cyclopropanation reaction with st-Dna
st-DNA was dissolved overnight at 4 °C under continuous inversion (6 mg/mL, 50 mM MES 
pH 5.0 buffer). FeIII porphyrin was dissolved (~3 mg/mL, 50 mM MES pH 5.0 buffer) and the 
exact concentration was determined by measuring the absorbance of the resulting solution 
at 395 nm (ε
395
 = 128824 M-1 cm-1). The DNA (4 mg/mL) and FeIII porphyrin 7 (37.5 µM) were 
combined in 50 mM MES pH 5.0 buffer (final volume = 7.25 mL) and continuously inverted 
at 4 °C for 30 minutes. Then, 2-vinylanisole 4 (750 mM in MeCN, to a final concentration of 
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5.0 mM) and ethyl diazoacetate 5 (1875 mM in MeCN, to a final concentration of 50.0 mM) 
were added in that order. The mixture was continuously inverted at 4 °C for 5 min. The 
products and remaining reactants were extracted with Et2O (3 times 5 mL). The organic 
layers were combined, washed with brine, dried over Na2SO4 and concentrated in vacuo. 
The remainders were dissolved in isopropanol (2.5 mL) containing an internal standard 
(1.29 mM 2-methylanisole) for chiral HPLC analysis.
Cyclopropanation	reaction	with	DNA	fragments	Dna-2 - Dna-11
The short DNA fragments DNA-2 - DNA-11 were dissolved (13.5 mM, MQ), annealed by 
heating to 95 °C for 5 minutes and slowly cooled back to rt. FeIII porphyrin was dissolved 
(~3 mg/mL, 50 mM MES pH 5.0 buffer) and the exact concentration was determined by 
measuring the absorbance of the resulting solution at 395 nm (ε
395
 = 128824 M-1 cm-1). The 
DNA (9.0 mM) and FeIII porphyrin 7 (37.5 µM) were combined in 50 mM MES pH 5.0 buffer 
(final volume = 37.5 µL) and continuously inverted at 4 °C for 30 minutes. A 10x buffer (500 
mM MES pH 5.0 buffer) was added to this mixture, to compensate the addition of DNA 
in MQ. Then, 2-vinylanisole 4 (750 mM in MeCN, to a final concentration of 5.0 mM) and 
ethyl diazoacetate 5 (1875 mM in MeCN, to a final concentration of 50.0 mM) were added 
in that order. The mixture was continuously inverted at 4 °C for 5 min. The products and 
remaining reactants were extracted with Et2O (3 times 100 µL). The organic layers were 
combined, washed with brine, dried over Na2SO4 and concentrated using an Ar flow. The 
remainders were dissolved in isopropanol (25 µL) containing an internal standard (1.29 
mM 2-methylanisole) for chiral HPLC analysis.
Friedel-Crafts alkylation
DNA-12 was dissolved (3.8 mg/mL, 1.0 mM, MQ), annealed by heating to 95 °C for 5 
minutes and slowly cooled back to rt. The DNA (1.3 mg/mL) and CuII-dmbpy 10 (0.3 mM) 
were combined in 20 mM MES pH 5.0 buffer (final volume = 50 µL). A 10x buffer (200 
mM MES pH 5.0 buffer) was added to this mixture, to compensate the addition of DNA in 
MQ. The mixture was incubated at 4 °C for 1 h. Substrate 8 was added (61 mM in DMSO, 
to a final concentration of 1.2 mM), followed by substrate 1a (82 mM in DMSO, to a final 
concentration of 1.6 mM). The mixture was incubated at 4 °C for 24 h. The products and 
remaining reactants were extracted with Et2O (2 times 100 µL). The organic layers were 
combined and the solvent was evaporated using an Ar flow. The remainders were dissolved 
in n-heptane/isopropanol 90/10 (v/v) (20 µL) for chiral HPLC analysis.
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abSTracT
The cowpea chlorotic mottle virus (CCMV) is a nanoparticle that 
holds promise for diagnostic and therapeutic applications. The 
empty virus-like particle, however, is not stable under physiological 
conditions. Here, we describe a systematic study into the expansion 
of the assembly properties of a protein-based block copolymer of 
the CCMV capsid protein and an elastin-like polypeptide (ELP). 
By systematically changing the hydrophobicity of the stimulus-
responsive ELP block, assembly of the capsid proteins could be 
achieved at close to physiological conditions. This strategy may 
prove useful in the development of a physiologically stable CCMV 
capsid variant.
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9.1 inTroDucTion
Nanoparticles are important tools in the development of diagnostic and therapeutic tests 
for applications in medicine. In particular, virus-like particles (VLPs), i.e. viruses without 
their endogenous genetic material, are interesting scaffolds.1 They are biocompatible, as 
their building blocks are proteins, and monodisperse and well-defined, due to the fact that 
they are always built up from a specific number of capsid proteins. In vivo studies on their 
use as drug carriers and other biomedical applications have already been performed, e.g. 
with the M13 bacteriophage, bacteriophage P22, tobacco mosaic virus (TMV), potato virus 
X (PVX), and cowpea mosaic virus (CPMV).2–5 Even though these types of VLPs show great 
promise as imaging agents and drug delivery vehicles, they lack flexibility with regard to 
their encapsulation and modification properties, as they cannot be reversibly assembled 
and disassembled. The capsid proteins of the cowpea chlorotic mottle virus (CCMV), on the 
other hand, are able to reversibly assemble and disassemble, without their genetic material 
being present. The CCMV VLP assembles when the pH of the environment is lowered to 
5.0. This results in icosahedral capsids with T = 3 symmetry and inner and outer diameters 
of 18 and 28 nm, respectively.6,7 When the pH is increased to 7.5, the capsids fall apart 
into capsid protein dimers. These dimers arise from interdimer interactions, involving the 
N- and C-termini of the capsid proteins.7 The reversible assembly of CCMV capsids has 
previously been used to encapsulate different types of cargoes, e.g. MRI contrast agents 
and proteins.8,9
Even though no toxicity has been observed after injection of CCMV particles in mice, the 
capsids have not been applied frequently for in vivo studies.10 This is due to the fact that, in 
order for CCMV to be stable under physiological conditions, it has to be held together by a 
negatively charged cargo polymer, e.g. nucleic acids.10 Since this restricts the incorporation 
of a cargo, and thus the application of CCMV in the medical field, we set out to improve 
the stability of the CCMV capsid. More specifically, we would like to expand the window of 
operation under which empty CCMV VLPs can be applied towards physiological conditions.
Previously, we developed a protein-based block copolymer of the CCMV capsid protein 
and an elastin-like polypeptide (ELP).11 Elastin-like polypeptides are stimuli-responsive 
compounds, derived from the naturally occurring, highly elastic protein elastin.12 They 
consist of repeating Val-Pro-Gly-Xaa-Gly (VPGXP) pentapeptides, where the guest residue 
Xaa/X can be any natural amino acid except proline. ELPs can be reversibly switched 
from a water-soluble state to a hydrophobic, collapsed state, in response to changes in 
the environmental conditions, such as an increase in temperature or salt concentration. 
The guest residue furthermore plays an important role in the transition process; a more 
hydrophobic amino acid will shift the transition temperature (Tt) to lower values, whereas 
a more hydrophilic moiety will increase the Tt. A short ELP, consisting of nine pentapeptide 
repeats, was attached to the N-termini of CCMV capsid proteins, which are located in 
close proximity to each other in the interior of the VLPs. By introducing the ELPs, a new 
assembly pathway towards CCMV capsids was introduced.11 T = 3 VLPs could still be formed 
using pH-induced assembly, whereas the new ELP-induced assembly pathway resulted in 
smaller particles with T = 1 icosahedral symmetry. The latter pathway could be initiated 
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by an increase in the environmental temperature or salt concentration, leading to a higher 
local concentration of ELPs and subsequent assembly of the capsid proteins towards ELP-
CCMV VLPs.
The development of the ELP-CCMV construct improved the assembly properties of the 
CCMV capsid protein such, that capsid formation could be induced at pH 7.5. Even though 
this is closer to physiologically relevant conditions, a high sodium chloride concentration 
(~2 M) was still needed at room temperature to induce capsid formation. Here, we will 
introduce mutations in the guest residues of the short N-terminal ELP, in order to render 
this more hydrophobic. This should lead to ELP-CCMV constructs, which are able to 
assemble at lower salt concentrations at pH 7.5. In order to understand the effect of the 
mutations, these will be introduced in a systematic and controlled way. In this way, we 
hope to establish whether the switchable assembly behavior of the ELP-CCMV capsid 
proteins can be predictably controlled by the hydrophobicity of the ELP.
9.2 reSuLTS anD DiScuSSion
In order to introduce more hydrophobic residues in the ELP of the ELP-CCMV construct, 
we started with the native ELP-CCMV construct: H6-ELP-CCMV(ΔN26). This construct 
has an N-terminal hexahistidine tag for purification purposes, followed by an ELP block, 
replacing the RNA-binding domain of the wild-type CCMV capsid protein. The native ELP 
sequence is VPGVG-VPGLG-VPGVG-VPGLG-VPGVG-VPGLG-VPGGG-VPGVG-VPGLG, 
containing four valine guest residues, four leucine guest residues, and one glycine guest 
residue. In short, this ELP can be described using the general notation ELP[V4L4G1-9], 
where all guest residues and their ratios are given, followed by the total number of 
pentapeptide repeats.
We decided to target the valine and leucine residues and mutate them to either tyrosines 
or tryptophans to introduce more hydrophobic residues in the ELP (Table 9.1). A valine to 
tyrosine mutation can be done in the 1st position (first pentapeptide at the N-terminus), 
3rd position, 5th position, and 8th position. We decided to compare a single mutation from 
valine to tyrosine on both the 1st and 8th position (VY1 and VY8, respectively), to investigate 
whether there would be a positional effect of the mutation. Additionally, two or three 
valine to tyrosine mutations could give information about the linearity of the effect of 
the hydrophobicity of the guest residues and the assembly behavior of the ELP-CCMV 
construct. To this end, we envisioned to make the VY1-VY8, and VY1-VY5-VY8 mutants. 
To see if valine to tryptophan mutations would have an even bigger effect, we also aimed 
at creating the VW1, VW1-VW8, and VW1-VW5-VW8 mutants. Lastly, to confirm the 
relationship between the hydrophobicity of the ELP and the assembly behavior of ELP-
CCMV, we envisioned to mutate leucine residues to more hydrophobic residues and 
compare these constructs to the abovementioned ones. To this end, we designed LY2, LY9, 
and LW2 mutants.
In order to relate these ELPs in terms of hydrophobicity, we used a hydrophobicity scale 
developed by Urry.13 In this paper, the change in Gibbs free energy upon hydrophobic 
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Table 9.1	 Overview	of	the	designed	ELP-CCMV	variants	and	their	calculated	hydrophobicity	factors.
Variant ELP notation ELP guest residues Hydrophobicity factor13
Native ELP[V4L4G1-9] VLVLVLGVL 19.9 °C
LY2 ELP[V4L3G1Y1-9] VYVLVLGVL 11.0 °C
LY9 ELP[V4L3G1Y1-9] VLVLVLGVY 11.0 °C
VY1 ELP[V3L4G1Y1-9] YLVLVLGVL 8.7 °C
VY8 ELP[V3L4G1Y1-9] VLVLVLGYL 8.7 °C
LW2 ELP[V4L3G1W1-9] VWVLVLGVL 7.7 °C
VW1 ELP[V3L4G1W1-9] WLVLVLGVL 5.3 °C
VY1-VY8 ELP[V2L4G1Y2-9] YLVLVLGYL -2.6 °C
VW1-VW8 ELP[V2L4G1W2-9] WLVLVLGWL -9.2 °C
VY1-VY5-VY8 ELP[V1L4G1Y3-9] YLVLYLGYL -13.8 °C
VW1-VW5-VW8 ELP[V1L4G1W3-9] WLVLWLGWL -23.8 °C
association was derived for a series of ELPs with different natural amino acid guest residues. 
To this end, transition temperatures of each possible guest residue in an ELP sequence 
were experimentally determined. Note that these Tt values highly depend on e.g. the salt 
concentration of the buffer and the concentration of the ELP itself. Nevertheless, we could 
use these values to calculate a hydrophobicity factor of all proposed ELP-CCMV mutants, 
by averaging the Tt’s of all nine guest residues (Table 9.1).
Next, we cloned all the designed constructs, starting from the original H6-ELP[V4L4G1-
9]-CCMV(ΔN26) vector. We envisioned to use PCR driven mutagenesis to introduce the 
mutations in the 1st, 8th and 9th positions. All other guest residues could not be mutated 
using this strategy, as the required primers would have exceeded a length of 50 nucleotides. 
Not only would this have led to problems due to secondary structure formation in the 
primers, but also the chance of mismatches would have been high due the highly repetitive 
sequence of the ELP. Therefore, full-length DNA sequences were ordered for LY2, LW2, 
VY1-VY5-VY8, and VW1-VW5-VW8 and annealed in the desired vector. All other constructs 
were cloned, starting with PCR driven mutagenesis with the corresponding primers, and 
annealed into the expression vector.
After successful cloning of all ten ELP-CCMV mutants, we tested whether these variants 
could be expressed in Escherichia coli (E. coli). To this end, all vectors were transformed into 
BLR(DE3) pLysS cells and small scale test expressions were performed. Polyacrylamide gel 
electrophoresis (SDS-PAGE) analysis of the lysates confirmed IPTG-induced expression of 
seven of the mutants; LW2, VY1-VY5-VY8, and VW1-VW5-VW8 were not expressed under 
the conditions tested (Figure 9.1). Subsequently, the remaining seven variants and native 
ELP-CCMV were produced in a large scale expression, followed by purification via Ni2+ 
affinity chromatography. SDS-PAGE and electrospray ionization time-of-flight (ESI-TOF) 
mass spectrometry analysis confirmed successful expression of the proteins.
In order to investigate the assembly behavior of the ELP-CCMV variants, we set out to 
determine the salt concentration at which each variant would start to assemble, at a certain 
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figure 9.1	 SDS-PAGE	analysis	of	the	expression	of	native	ELP-CCMV	and	ten	ELP-CCMV	variants	in	E. coli, with 
and	without	IPTG	to	induce	protein	expression.	Protein	bands	were	visualized	by	Coomassie	blue	staining.
protein concentration and temperature. In our studies, we chose to vary the concentration of 
sodium chloride and determine the transition NaCl concentration at certain temperatures.
For the first experiments, the fluorescent molecular probe 8-anilino-1-naphthalenesulfonic 
acid (ANS) was used as a read-out system for capsid assembly. The fluorescence intensity 
of this probe increases when it binds to hydrophobic regions of proteins. We used this 
dye to monitor the aggregation of the ELPs at certain NaCl concentrations (Figure 9.2). 
A sudden increase of fluorescence intensity could be linked to ELP aggregation, which 
is the driving force for capsid assembly. This assay was used to determine the transition 
NaCl concentration of native ELP-CCMV and the 7 variants thereof at four different 
temperatures. As a control, only buffer was added to the ANS dye. As expected, for all 
NaCl concentrations ranging from 0.15 to 2.0 M, the same emission intensity was measured 
in plain buffer (data not shown). For native ELP-CCMV, LY2, LY9, VY1, and VY8, a clear 
transition NaCl concentration could be observed, where the emission maximum stopped 
from being constant (Figure 9.2). From this point on towards higher NaCl concentrations, 
a linear increase in the emission maximum was observed, corresponding to the continuous 
release of water from the aggregated ELP structures.
When the collected data for each of these proteins at 20, 24, 28, and 32 °C was compared, 
a linear relationship between the transition NaCl concentration and the temperature was 
observed (Figure 9.3A). When the same data was plotted slightly differently, there also 
seemed to be a linear trend between the transition NaCl concentration and the calculated 
hydrophobicity factor of the ELP (Figure 9.3B). This indicates that the behavior of an ELP-
CCMV construct is predictable, based on the hydrophobicity factor of the short N-terminal 
ELP. This data also shows that there is a slight difference in the behavior of LY2 and LY9, 
and of VY1 and VY8. In both cases, the mutation at the C-terminal end of the ELP seems to 
have the greatest effect on the assembly behavior of the ELP-CCMV construct. This might 
be explained by the fact that a mutation closer to the CCMV capsid protein will have more 
effect on its assembly behavior. Furthermore, it can be noted that there does not seem to 
be a clear difference between a mutation of a leucine or valine residue; the hydrophobicity 
factor of the ELP is most influential when it comes to the resulting assembly behavior of 
the ELP-CCMV variant.
The behavior of the three most hydrophobic ELP-CCMV variants, namely VW1, VY1-VY8 
and VW1-VW8 could not be measured under these experimental conditions. Instead of a 
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figure 9.2	 ANS	assay	with	native	ELP-CCMV	and	variants	LY2,	LY9,	VY1,	VY8,	VW1,	VY1-VY8,	and	VW1-VW8.
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figure 9.3	 Transition	NaCl	concentrations	of	native	ELP-CCMV	and	four	ELP-CCMV	variants,	measured	using	the	
ANS	assay,	at	a	final	protein	concentration	of	20	mM.	a)	Transition	NaCl	concentration	plotted	against	the	experimental	
temperature, per protein variant. b)	Transition	NaCl	concentration	plotted	against	the	calculated	hydrophobicity	factor	
(Table	9.1),	per	experimental	temperature.	The	linear	fits	were	added	to	aid	visualisation	of	the	observed	trends.
figure 9.4 a) Intensity distributions and b)	Number	distributions	of	LY2	ELP-CCMV	at	different	NaCl	concentrations,	
as	measured	by	DLS.	Capsids	are	expected	around	20-30	nm,	and	dimers	are	expected	below	10	nm.
sharp transition in the fluorescence emission maximum, a subtle increase in the emission 
was observed going from 150 mM NaCl to 2000 mM NaCl (Figure 9.2). This indicates that 
these variants were probably already assembled at 150 mM NaCl and that an increase in the 
NaCl concentration in this case only leads to additional loss of water from the aggregated 
ELP core of the capsids.
In order to confirm that the increase in the emission maximum observed in the ANS assay 
corresponds to a transition of ELP-CCMV dimers to capsids, the assembly was further 
investigated using dynamic light scattering (DLS). DLS can be used to distinguish between 
capsid protein dimers, which normally show a peak around 8 nm in DLS distribution plots, 
and capsids, which are normally observed around 20-30 nm in DLS distributions. Firstly, 
the assembly behavior of ELP-CCMV variant LY2 was fully characterized at 20 °C. In both 
the intensity distribution (Figure 9.4A) and the number distribution (Figure 9.4B), dimers 
were observed at NaCl concentrations below 1500 mM. At 1500 mM NaCl and higher, 
capsids were visible. This data therefore confirms that the ANS assay is able to distinguish 
between capsid protein dimers and capsids.
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figure 9.5 a) Intensity distributions and b)	Number	distributions	at	600	mM	or	150	mM	and	1700	mM	NaCl,	as	
measured	by	DLS,	at	a	final	protein	concentration	of	20	mM,	of	native	ELP-CCMV,	LY9,	VY1-VY8	and	VW1-VW8.	
Capsids are expected around 20-30 nm, and dimers are expected below 10 nm.
Next, we checked the behavior of native ELP-CCMV and variants LY9, VY1-VY8, and 
VW1-VW8 using DLS (Figure 9.5). As expected, we observed a transition from dimers to 
capsids for native and LY9 ELP-CCMV, going from 600 mM NaCl to 1700 mM NaCl. For 
VY1-VY8 and VW1-VW8, we did not observe any transition in the ANS assay, which led us 
to suggest that these proteins might be in the capsid state at all NaCl concentrations that 
were tested. This was indeed confirmed by the DLS data measured at 150 mM and 1700 mM 
NaCl. For both these proteins, only capsids and no dimers were observed at these NaCl 
concentrations.
When the DLS data was compared to the data obtained in the ANS assay, it was found that 
the transition NaCl concentrations observed in the DLS distribution plots were consistently 
higher than the transition NaCl concentrations determined by the ANS assay. For instance, 
for LY2 a transition NaCl concentration of 1.23 M NaCl was determined by the ANS assay 
at 20 °C, whereas capsids were only observed starting from 1.5 M in the DLS distribution 
plots, as shown above. We believe that the ANS assay is more sensitive to changes in 
hydrophobicity and the subsequent onset of assembly. Furthermore, the experimental 
set-up of the ANS assay allowed for more controlled experimental conditions, such as 
temperature, incubation times, and waiting times in between measurements than the DLS 
procedure. We therefore think that the ANS data is more reliable than the DLS data. The 
observed trends, however, are similar for the two techniques.
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9.3 concLuSionS
We have described a systematic study into the effect of the guest residues in a short 
N-terminal ELP sequence, attached to the CCMV capsid protein. We found that the 
assembly behavior of the capsid protein depends in a predictable, linear way on the 
hydrophobicity of the ELP. ELP-CCMV variants were developed which could assemble at 
much lower NaCl concentrations than the native ELP-CCMV capsid protein. These results 
allow the construction of ELP-CCMV proteins which have the desired switchable assembly 
behavior. In our lab, studies are ongoing to find out whether the systematic variations in the 
ELP-CCMV construct can be applied to produce physiologically stable ELP-CCMV capsids.
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9.5 exPeriMenTaL SecTion
9.5.1  Materials and methods
Materials
Hot start II HF DNA polymerase, dNTPs, restriction enzymes, and T4 DNA ligase were 
obtained from New England Biolabs. The DNA oligos were synthesized by Integrated DNA 
Technologies. 8-Anilino-1-naphthalenesulfonic acid (ANS) was obtained from Sigma-
Aldrich.
Buffers
pH 7.5 150 mM NaCl buffer: 50 mM Tris·HCl, 150 mM NaCl, 10 mM MgCl2, 1 mM EDTA, 
pH 7.5. 
pH 7.5 3000 mM NaCl buffer: 50 mM Tris·HCl, 3000 mM NaCl, 10 mM MgCl2, 1 mM 
EDTA, pH 7.5.
All buffers were filtered over a 0.2 micron filter prior to use.
UV-vis spectroscopy
Protein concentrations were measured on a Varian Cary 50 Conc UV-vis spectrometer 
using a quartz cuvette with a path length of 3 mm. Protein concentrations were calculated 
using the theoretical extinction coefficients.14 Samples were centrifuged prior to the 
measurements.
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Mass	spectrometry
Protein mass characterization was performed by electrospray ionization time-of-flight 
(ESI-TOF) on a JEOL AccuTOF CS. Deconvoluted mass spectra were obtained using 
MagTran 1.03 b2. Isotopically averaged molecular weights were calculated using the 
‘Protein Calculator v3.4’ at http://protcalc.sourceforge.net. Protein samples were desalted 
by spin filtration to MQ (final concentrations ~20 μM).
Dynamic	light	scattering	(DLS)
DLS measurements were performed on a Zetasizer Nano S at 20 °C. Samples (20 µM) were 
centrifuged prior to analysis. Buffers were filtered prior to use. All measurements were 
done in triplicate, and the average of the triplicate measurements was plotted.
Microplate	reader	experiments
Microplate reader experiments were performed on a Tecan Spark 10M microplate reader 
at the specified temperatures. Samples (20 µM) were centrifuged prior to analysis. Buffers 
were filtered prior to use. Samples were incubated at the experimental temperature for 15 
minutes prior to the measurement. Excitation and emission wavelengths were set to 380 
nm and 430-520 nm, respectively. All measurements were done in triplicate.
9.5.2  experimental details
Protein	sequences
Table 9.2	 Amino	acid	sequences	of	the	proteins	used	in	this	chapter.
Name Sequence
Native ELP-CCMV
GHHHHHHVPGVGVPGLGVPGVGVPGLGVPGVGVPGLGVPGGGVPGVGVPGLGLEVVQPVI
VEPIASGQGKAIKAWTGYSVSKWTASCAAAEAKVTSAITISLPNELSSERNKQLKVGRVL
LWLGLLPSVSGTVKSCVTETQTTAAASFQVALAVADNSKDVVAAMYPEAFKGITLEQLTA
DLTIYLYSSAALTEGDVIVHLEVEHVRPTFDDSFTPVY
LY2 ELP-CCMV
GHHHHHHVPGVGVPGYGVPGVGVPGLGVPGVGVPGLGVPGGGVPGVGVPGLGLEVVQPVI
VEPIASGQGKAIKAWTGYSVSKWTASCAAAEAKVTSAITISLPNELSSERNKQLKVGRVL
LWLGLLPSVSGTVKSCVTETQTTAAASFQVALAVADNSKDVVAAMYPEAFKGITLEQLTA
DLTIYLYSSAALTEGDVIVHLEVEHVRPTFDDSFTPVY
LY9 ELP-CCMV
GHHHHHHVPGVGVPGLGVPGVGVPGLGVPGVGVPGLGVPGGGVPGVGVPGYGLEVVQPVI
VEPIASGQGKAIKAWTGYSVSKWTASCAAAEAKVTSAITISLPNELSSERNKQLKVGRVL
LWLGLLPSVSGTVKSCVTETQTTAAASFQVALAVADNSKDVVAAMYPEAFKGITLEQLTA
DLTIYLYSSAALTEGDVIVHLEVEHVRPTFDDSFTPVY
VY1 ELP-CCMV
GHHHHHHVPGYGVPGLGVPGVGVPGLGVPGVGVPGLGVPGGGVPGVGVPGLGLEVVQPVI
VEPIASGQGKAIKAWTGYSVSKWTASCAAAEAKVTSAITISLPNELSSERNKQLKVGRVL
LWLGLLPSVSGTVKSCVTETQTTAAASFQVALAVADNSKDVVAAMYPEAFKGITLEQLTA
DLTIYLYSSAALTEGDVIVHLEVEHVRPTFDDSFTPVY
VY8 ELP-CCMV
GHHHHHHVPGVGVPGLGVPGVGVPGLGVPGVGVPGLGVPGGGVPGYGVPGLGLEVVQPVI
VEPIASGQGKAIKAWTGYSVSKWTASCAAAEAKVTSAITISLPNELSSERNKQLKVGRVL
LWLGLLPSVSGTVKSCVTETQTTAAASFQVALAVADNSKDVVAAMYPEAFKGITLEQLTA
DLTIYLYSSAALTEGDVIVHLEVEHVRPTFDDSFTPVY
LW2 ELP-CCMV
GHHHHHHVPGVGVPGWGVPGVGVPGLGVPGVGVPGLGVPGGGVPGVGVPGLGLEVVQPVI
VEPIASGQGKAIKAWTGYSVSKWTASCAAAEAKVTSAITISLPNELSSERNKQLKVGRVL
LWLGLLPSVSGTVKSCVTETQTTAAASFQVALAVADNSKDVVAAMYPEAFKGITLEQLTA
DLTIYLYSSAALTEGDVIVHLEVEHVRPTFDDSFTPVY
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Name Sequence
VW1 ELP-CCMV
GHHHHHHVPGWGVPGLGVPGVGVPGLGVPGVGVPGLGVPGGGVPGVGVPGLGLEVVQPVI
VEPIASGQGKAIKAWTGYSVSKWTASCAAAEAKVTSAITISLPNELSSERNKQLKVGRVL
LWLGLLPSVSGTVKSCVTETQTTAAASFQVALAVADNSKDVVAAMYPEAFKGITLEQLTA
DLTIYLYSSAALTEGDVIVHLEVEHVRPTFDDSFTPVY
VY1-VY8 ELP-CCMV
GHHHHHHVPGYGVPGLGVPGVGVPGLGVPGVGVPGLGVPGGGVPGYGVPGLGLEVVQPVI
VEPIASGQGKAIKAWTGYSVSKWTASCAAAEAKVTSAITISLPNELSSERNKQLKVGRVL
LWLGLLPSVSGTVKSCVTETQTTAAASFQVALAVADNSKDVVAAMYPEAFKGITLEQLTA
DLTIYLYSSAALTEGDVIVHLEVEHVRPTFDDSFTPVY
VW1-VW8 ELP-CCMV
GHHHHHHVPGWGVPGLGVPGVGVPGLGVPGVGVPGLGVPGGGVPGWGVPGLGLEVVQPVI
VEPIASGQGKAIKAWTGYSVSKWTASCAAAEAKVTSAITISLPNELSSERNKQLKVGRVL
LWLGLLPSVSGTVKSCVTETQTTAAASFQVALAVADNSKDVVAAMYPEAFKGITLEQLTA
DLTIYLYSSAALTEGDVIVHLEVEHVRPTFDDSFTPVY
VY1-VY5-VY8 ELP-CCMV
GHHHHHHVPGYGVPGLGVPGVGVPGLGVPGYGVPGLGVPGGGVPGYGVPGLGLEVVQPVI
VEPIASGQGKAIKAWTGYSVSKWTASCAAAEAKVTSAITISLPNELSSERNKQLKVGRVL
LWLGLLPSVSGTVKSCVTETQTTAAASFQVALAVADNSKDVVAAMYPEAFKGITLEQLTA
DLTIYLYSSAALTEGDVIVHLEVEHVRPTFDDSFTPVY
VW1-VW5-VW8 ELP-CCMV
GHHHHHHVPGWGVPGLGVPGVGVPGLGVPGWGVPGLGVPGGGVPGWGVPGLGLEVVQPVI
VEPIASGQGKAIKAWTGYSVSKWTASCAAAEAKVTSAITISLPNELSSERNKQLKVGRVL
LWLGLLPSVSGTVKSCVTETQTTAAASFQVALAVADNSKDVVAAMYPEAFKGITLEQLTA
DLTIYLYSSAALTEGDVIVHLEVEHVRPTFDDSFTPVY
Cloning	of	all	ELP-CCMV	variants
The pET-15b-G-H6-[V4L4G1-9]-CCMV(ΔN26) vector encoding for the hexahistidine-tagged 
ELP-CCMV protein was previously constructed as described by van Eldijk et al.11
For the introduction of the point mutations towards LY9, VY1, VY8, VW1, VY1-VY8 and 
VW1-VW8, a set of DNA oligos was designed per variant (Table 9.3). The oligos were 
annealed at 95 °C and the resulting inserts encoded for a hexahistidine tag and 9 ELP 
repeats with a 5’ NcoI and a 3’ XhoI restriction site. The products after PCR were purified by 
agarose gel electrophoresis. Both the purified inserts and the pET-15b vector were digested 
with NcoI and XhoI and the products were again purified by agarose gel electrophoresis. 
Subsequently, the inserts were ligated into the digested vector. These plasmids were 
transformed into E. coli XL1-BLUE cells, the DNA was extracted and the sequences were 
confirmed by DNA sequencing (Table 9.2). For expression, the plasmids were transformed 
into E. coli BLR(DE3)pLysS cells (Novagen, MERCK).
For the introduction of the point mutations towards LY2, LW2, VY1-VY5-VY8 and VW1-
VW5-VW8, a set of DNA oligos, encoding for the entire ELP insert was designed and 
ordered (Table 9.4). These oligo’s were annealed at 95 °C and the resulting inserts encoded 
for a hexahistidine tag and 9 ELP repeats with sticky ends compatible with 5’ NcoI and 
3’ XhoI annealing. The pET-15b vector was digested with NcoI and XhoI and the product 
was purified by agarose gel electrophoresis. Subsequently, the inserts were ligated into 
the digested vector. These plasmids were transformed into E. coli XL1-BLUE cells, the 
DNA was extracted and the sequences were confirmed by DNA sequencing (Table 9.2). 
For expression, the plasmids were transformed into E. coli BLR(DE3)pLysS cells (Novagen, 
MERCK).
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Table 9.3	 DNA	sequence	of	the	oligos	used	for	PCR	driven	mutagenesis	towards	the	expression	vectors	of	LY9,	
VY1,	VY8,	VW1,	VY1-VY8	and	VW1-VW8.
Name Sequence
LY9 forward 5’TATACCATGGGCCATCATCATCATCATCACGTTCCGGGCGTCGGT
LY9 reverse 5’CCACCTCGAGACCATAACCAGGAACTCCCACACCAGGA
VY1 forward 5’TATACCATGGGCCATCATCATCATCATCACGTTCCGGGCTACGGTGTTCC
VY1 reverse 5’CCACCTCGAGACCTAAACCAGGAACTCCCACACCAGGA
VY8 forward 5’TATACCATGGGCCATCATCATCATCATCACGTTCCGGGCGTCGGT
VY8 reverse 5’CCACCTCGAGACCTAAACCAGGAACTCCGTAACCAGGAACACC
VW1 forward 5’TATACCATGGGCCATCATCATCATCATCACGTTCCGGGCTGGGGTGTTCC
VW1 reverse 5’CCACCTCGAGACCTAAACCAGGAACTCCCACACCAGGA
VY1-VY8 forward 5’TATACCATGGGCCATCATCATCATCATCACGTTCCGGGCTACGGTGTTCC
VY1-VY8 reverse 5’CCACCTCGAGACCTAAACCAGGAACTCCGTAACCAGGAACACC
VW1-VW8 forward 5’TATACCATGGGCCATCATCATCATCATCACGTTCCGGGCTGGGGTGTTCC
VW1-VW8 reverse 5’CCACCTCGAGACCTAAACCAGGAACTCCCCAACCAGGAACACC
Table 9.4	 DNA	sequence	of	the	ordered	oligos	used	for	the	construction	of	the	expression	vectors	of	LY2,	LW2,	
VY1-VY5-VY8	and	VW1-VW5-VW8.
Name Sequence
LY2-1
5’CATGGGCCATCATCATCATCATCACGTTCCGGGCGTCGGTGTTCCTGGATATGGTGTTCC
AGGTGTAGGTGTTCCAGGACTCGGTGTTCCTGGTGTAGGTGTTCCTGGTTTAGGTGTTCCAG
GTGGCGGTGTTCCTGGTGTGGGAGTTCCTGGTTTAGGTC
LY2-2
5’TCGAGACCTAAACCAGGAACTCCCACACCAGGAACACCGCCACCTGGAACACCTAAACCA
GGAACACCTACACCAGGAACACCGAGTCCTGGAACACCTACACCTGGAACACCATATCCAGG
AACACCGACGCCCGGAACGTGATGATGATGATGATGGCC
LW2-1
5’CATGGGCCATCATCATCATCATCACGTTCCGGGCGTCGGTGTTCCTGGATGGGGTGTTCC
AGGTGTAGGTGTTCCAGGACTCGGTGTTCCTGGTGTAGGTGTTCCTGGTTTAGGTGTTCCAG
GTGGCGGTGTTCCTGGTGTGGGAGTTCCTGGTTTAGGTC
LW2-2
5’TCGAGACCTAAACCAGGAACTCCCACACCAGGAACACCGCCACCTGGAACACCTAAACCA
GGAACACCTACACCAGGAACACCGAGTCCTGGAACACCTACACCTGGAACACCCCATCCAGG
AACACCGACGCCCGGAACGTGATGATGATGATGATGGCC
VY1-VY5-VY8-1
5’CATGGGCCATCATCATCATCATCACGTTCCGGGCTACGGTGTTCCTGGATTAGGTGTTCC
AGGTGTAGGTGTTCCAGGACTCGGTGTTCCTGGTTATGGTGTTCCTGGTTTAGGTGTTCCAG
GTGGCGGTGTTCCTGGTTACGGAGTTCCTGGTTTAGGTC
VY1-VY5-VY8-2
5’TCGAGACCTAAACCAGGAACTCCGTAACCAGGAACACCGCCACCTGGAACACCTAAACCA
GGAACACCATAACCAGGAACACCGAGTCCTGGAACACCTACACCTGGAACACCTAATCCAGG
AACACCGTAGCCCGGAACGTGATGATGATGATGATGGCC
VW1-VW5-VW8-1
5’CATGGGCCATCATCATCATCATCACGTTCCGGGCTGGGGTGTTCCTGGATTAGGTGTTCC
AGGTGTAGGTGTTCCAGGACTCGGTGTTCCTGGTTGGGGTGTTCCTGGTTTAGGTGTTCCAG
GTGGCGGTGTTCCTGGTTGGGGAGTTCCTGGTTTAGGTC
VW1-VW5-VW8-2
5’TCGAGACCTAAACCAGGAACTCCCCAACCAGGAACACCGCCACCTGGAACACCTAAACCA
GGAACACCCCAACCAGGAACACCGAGTCCTGGAACACCTACACCTGGAACACCTAATCCAGG
AACACCCCAGCCCGGAACGTGATGATGATGATGATGGCC
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Expression	of	the	ELP-CCMV	variants
The expression and purification of the ELP-CCMV variants were performed as described 
in Chapter 3. The yields of the proteins after purification and the ESI-TOF results are listed 
in Table 9.5.
Table 9.5	 Expression	yields	and	ESI-TOF	results	of	LY2,	LY9,	VY1,	VY8,	VW1,	VY1-VY8	and	VW1-VW8.
Name Yield ESI-TOF
calculated mw observed mw
LY2 ELP-CCMV 28 mg/L 22303.5 Da 22306.6 Da
LY9 ELP-CCMV 78 mg/L 22303.5 Da 22306.6 Da
VY1 ELP-CCMV 60 mg/L 22317.5 Da 22320.7 Da
VY8 ELP-CCMV 56 mg/L 22317.5 Da 22320.4 Da
VW1 ELP-CCMV 43 mg/L 22340.5 Da 22343.7 Da
VY1-VY8 ELP-CCMV 44 mg/L 22381.5 Da 22384.2 Da
VW1-VW8 ELP-CCMV 40 mg/L 22427.6 Da 22430.6 Da
DLS	assay
For a typical DLS assay, an ELP-CCMV variant was spin filtrated to pH 7.5 150 mM NaCl 
buffer (10 kDa MWCO, 3 x 10 min). A stock solution of 150 µM protein in pH 7.5 150 mM 
NaCl buffer was prepared. Mixtures of 100 µL were prepared in vials, containing pH 7.5 150 
mM NaCl buffer, pH 7.5 3000 mM NaCl buffer and the ELP-CCMV variant (20 µM). The 
desired final NaCl concentration was achieved by using different ratios of pH 7.5 150 mM 
NaCl buffer and pH 7.5 3000 mM NaCl buffer. ELP-CCMV was added last to these mixtures, 
to ensure that the protein was added to the correct NaCl concentration. These samples 
were then analyzed by DLS in triplicate. The average of these three measurements was 
calculated and plotted.
ANS	fluorescence	assay
For a typical ANS fluorescence assay, an ELP-CCMV variant was spin filtrated to pH 7.5 150 
mM NaCl buffer (10 kDa MWCO, 3 x 10 min). A stock solution of 150 µM protein in pH 7.5 
150 mM NaCl buffer was prepared. ANS was dissolved in pH 7.5 150 mM NaCl buffer (200 
µM). Mixtures of 100 µL were prepared in a 96 microwell plate, containing ANS (20 µM), 
pH 7.5 150 mM NaCl buffer, pH 7.5 3000 mM NaCl buffer and the ELP-CCMV variant (20 
µM). The desired final NaCl concentration was achieved by using different ratios of pH 
7.5 150 mM NaCl buffer and pH 7.5 3000 mM NaCl buffer. ELP-CCMV was added last to 
these mixtures, to ensure that the protein was added to the correct NaCl concentration. All 
samples were prepared in triplicate. The fluorescence of the ANS probe was measured using 
a microplate reader. The average of each triplicate measurement at each salt concentration 
was calculated. Next, the maximum of the emission intensity was determined and plotted.
We defined the transition NaCl concentration as the point in these curves, where the 
emission intensity maximum started to increase. The data before and after this point can 
be fitted with a linear fit. In order to determine the transition NaCl concentration in an 
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unbiased way, a Matlab script was developed which fitted all possible combinations of 
two linear fits to each data set. The transition NaCl concentration was then defined as the 
point, where the linear fits before and after this point had the lowest combined R2 value.
Matlab script
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
% Authors: Jack Wever & Lise Schoonen %
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
 
clc
clear all
close all
 
% Read data
Dat     = xlsread(‘LS0661.xlsx’);
 
% Define data set analyzed from excel
data    = 1;
x       = Dat(1:20,1);
y       = Dat(1:20,3*data);
L       = length(x);
 
% Initialize parameters
Rsq     = zeros(1,L);
Rsq1    = zeros(1,L);
Rsq2    = zeros(1,L);
slope   = zeros(5,L);
 
% Plot raw data
scatter(x,y)
hold on
grid on
cc=hsv(L); % color string
% Vary place of data cut and derive parameters for linear fit
for cut= 3:L-3
x1 = x(1:cut);
x2 = x(cut+1:L);
y1 = y(1:cut);
y2 = y(cut+1:L);
 
X1           = [ones(length(x1),1) x1];
X2           = [ones(length(x2),1) x2];
b1           = X1\y1;
b2           = X2\y2;
yCalc1       = X1*b1;
yCalc2       = X2*b2;     
slope(1,cut) = b1(1,1);
slope(2,cut) = b1(2,1);
slope(3,cut) = b2(1,1);
slope(4,cut) = b2(2,1);
slope(5,cut) = (b2(1,1)-b1(1,1))/(b1(2,1)-b2(2,1));
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% Calculate total goodness of the fit
Rsq1(cut)    = 1 - sum((y1 - yCalc1).^2)/sum((y1 - mean(y1)).^2);
Rsq2(cut)    = 1 - sum((y2 - yCalc2).^2)/sum((y2 - mean(y2)).^2);
Rsq(cut)     = Rsq1(cut) + Rsq2(cut);
 
plot(x1,yCalc1,’color’,cc(cut-2,:)); hold on
plot(x2,yCalc2,’color’,cc(cut-2,:));
xlabel(‘NaCl concentration [M]’)
ylabel(‘Emission maximum [Au]’)
end
% Plot R^2 
figure(2)
plot(x(3:L-3),Rsq1(3:L-3),’color’,’r’); hold on
plot(x(3:L-3),Rsq2(3:L-3)); 
plot(x(3:L-3),Rsq(3:L-3),’color’,’black’); 
legend(‘R^2_{left}’,’R^2_{right}’,’R^2_{left} + R^2_{right}’);
xlabel(‘Cut-off NaCl concentration [M]’)
ylabel(‘R^2’)
 
% Give concentration for which R^2_{left} + R^2{right} ) is maximum
disp([‘Cut-off NaCl Concentration resulting in best fit = ‘ 
num2str(x(find(Rsq==max(Rsq)))) ‘ M’])
disp([‘Transition NaCl concentration = ‘ num2str(slope(5,find(Rsq==max(R
sq)))) ‘ M’])
disp([‘ ‘])
disp([‘Slope 1: y = ‘ num2str(slope(2,find(Rsq==max(Rsq)))) ‘ x + ‘ num2str(s
lope(1,find(Rsq==max(Rsq))))])
disp([‘Slope 2: y = ‘ num2str(slope(4,find(Rsq==max(Rsq)))) ‘ x + ‘ num2str(s
lope(3,find(Rsq==max(Rsq))))])
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Biological hydrogels display strain-stiffening properties, i.e. they 
become stronger when an external force is applied. Mimicking 
this unique ability to respond and adapt to the mechanical input 
from their surroundings in synthetic systems is challenging. 
Furthermore, introducing new functionalities such as drug loading 
capabilities or stress response features to a synthetic hydrogel is 
difficult. Here, we describe the expansion of the advantageous 
properties of a previously reported synthetic strain-stiffening 
hydrogel based on polyisocyanopeptides, by introducing virus-like 
particles as supramolecular crosslinkers. We show that by changing 
the functionalization degree and crosslinker concentration the 
mechanical behavior of the gel can be tuned. Rheology experiments 
suggest that deterioration of the crosslinkers leads to energy 
dissipation at high stress levels, as also observed for fibrin gels. 
This offers possibilities for future applications of these crosslinked 
hydrogels, e.g. as drug delivery vehicles or as stress sensors.
Biomimetic strain-stiffening hydrogels with virus-like particles as crosslinkers
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10.1 inTroDucTion
Mechano-responsive hydrogels play an important role in nature and are crucial for many 
mechanical cellular processes.1,2 These gels mostly consist of polypeptides and proteins, 
e.g. collagen, actin, or intermediate filaments, which are crosslinked by proteins and metal 
ions. An interesting example of such a natural gel is fibrin, one of the main structural 
proteins in blood clots.3,4 Upon vascular injury, an assembled structure consisting of 
proteins, i.e. a fibrin gel, is formed, which is one of the most resilient materials known 
due to its hierarchical architecture of crosslinked fibers. The fibrin gel is capable of 
withstanding severe mechanical stresses, because the stiffness of the gel increases upon 
increasing stress (strain-stiffening behavior). Even though increasing levels of stress result 
in disruption of the crosslinkers between the fibers in this network, pulling the different 
subunits apart, the overall architecture of the gel remains intact.5,6
Biological hydrogels are very interesting for biomedical applications, because of their 
biocompatibility, mechanical stability, and bioreactivity.7 Synthetic alternatives to these 
types of networks, which mimic the architectural and mechanical properties of natural 
hydrogels as closely as possible, are relatively rare.8 They would be very useful as they allow, 
for instance, the fine-tuning of the properties of the gels and the introduction of functional 
groups. In particular, crosslinked (bio)polymer networks are often used as biomimetic 
hydrogels because they are biocompatible and versatile.9,10
Recently, we reported a fully synthetic hydrogel which shows strain-stiffening behavior 
similar to biological hydrogels.11,12 This gel is composed of polyisocyanopeptides (PICs) 
modified with oligo(ethylene glycol) side chains. These polymers possess a stiff and 
helical backbone and display a lower critical solution temperature (LCST) in water, above 
which a branched, bundled hydrogel is formed. The mechanical properties of PIC gels 
can be tuned, e.g. by varying the polymer length or the polymer concentration, and by 
the addition of salts.13 This material combines the architecture of biological gels with the 
flexibility of synthetic gels, making it very interesting for applications in e.g. immunology 
and regenerative medicine.14-16
Even though the architecture of PIC hydrogels is similar to e.g. fibrin gels, the material is only 
marginally able to dissipate stress in its network. This means that, although the PIC gels are 
strain-stiffening, they gels are also relatively brittle compared to their natural counterparts. 
Advances have been made in toughening biocompatible hydrogels, e.g. by synthesizing 
double network hydrogels,17,18 biosynthetic hybrids,6,19 or filled nanocomposite gels.20,21 In 
these kinds of materials, however, biomimicry in terms of architecture is often sacrificed 
for high polymer density, or synthetic flexibility is lost by improving the biocompatibility 
(e.g. by making hybrid gels). In another example, the tobacco mosaic virus (TMV) was 
mixed with alginate hydrogels, which improved cell attachment and introduced a non-
linear response to compression in these systems.22,23 This approach, however, simply 
involved mixing the two components without a covalent interaction between the polymers 
and the virus particles.
Crosslinking with non-compliant, sacrificial crosslinkers on the other hand, can increase 
the rigidity of synthetic hydrogels by providing a mechanism for energy dissipation, similar 
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Scheme 10.1 Schematic overview showing the crosslinking of an azide-functionalized polyisocyanopeptide (PIC) 
hydrogel	 with	 DBCO-functionalized	 CCMV	 capsids.	 The	 PIC	 polymers	 are	 built	 up	 from	 3%	 azide-functionalized	
monomers,	20%	tetra(ethylene	glycol)	monomers,	and	77%	tri(ethylene	glycol)	monomers.	The	CCMV	capsids	are	
assembled	from	capsid	protein	dimers	which	have	partially	been	reacted	with	DBCO-PEG4-NHS	ester.
to the natural fibrin gel. Additionally, new functionalities can be introduced, at least in 
principle, by crosslinking with functional supramolecular crosslinking agents.24 This has 
previously been shown for ionic crosslinks and crosslinkers from a biological origin, such 
as DNA-based crosslinkers, or small protein- and oligo-peptide-based crosslinkers.10,19,25-28 
The latter have the intrinsic advantage of biocompatibility, making them suitable for in 
vivo applications. Nevertheless, these typically divalent crosslinks are often stabilized by 
only a small amount of non-covalent interactions, making the system relatively sensitive to 
environmental conditions, which limits its flexibility.
To our best of knowledge, the use of a biological supramolecular crosslinking node in 
a hydrogel that can form multivalent crosslinks, stabilized by many supramolecular 
interactions, has not yet been described in the literature. We believe that this type of 
crosslink could not only stabilize a hydrogel in an efficient and flexible way, but could 
also introduce new functionalities and dissipate stress in the system. We envisioned to 
use protein-based nanocages for this purpose, as they are monodisperse, biocompatible, 
and robust. The cowpea chlorotic mottle virus (CCMV) capsid, i.e. the empty protein 
shell of the CCMV virus without the endogenous viral RNA, is a particularly interesting 
protein-based nanoparticle. CCMV is a plant virus with an outer and inner diameter 
of 28 and 18 nm, respectively.29 It is composed of 180 identical capsid proteins together 
forming a icosahedral capsid with a Caspar and Klug triangulation number T = 3.30 This 
virus is especially interesting, as its capsid proteins are able to reversibly assemble into 
the T = 3 capsids and disassemble back into protein dimers by changing the pH of the 
buffer solution, even without the viral RNA being present.31 This pH-sensitive behavior 
allows for the creation of highly symmetric and monodisperse particles which can be used 
as nanocarriers for functional cargoes. CCMV capsids have also proven to be useful for 
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applications in materials science, e.g. as components of metamaterials.32,33
Here, we report on the crosslinking of PIC hydrogels with virus-like particles, i.e. cowpea 
chlorotic mottle virus capsids, which act as supramolecular crosslink nodes. They are 
attached to the hydrogel by linking some of the capsid proteins covalently to the polymer 
fibers via click chemistry (Scheme 10.1). We show that the strength of the crosslinked gel 
can be varied by changing the functionalization degree of the particles, as well as the 
amount of particles added to the polymer. Additionally, the strain-stiffening properties of 
the crosslinked gel are investigated with the objective of determining the energy dissipation 
capabilities of the supramolecularly crosslinked hydrogel.
10.2 reSuLTS anD DiScuSSion
10.2.1  Material synthesis
To form a covalent link between the PIC polymers and the CCMV capsid nodes, we planned 
a strategy based on strain-promoted click chemistry. We used PIC copolymers containing 
a small percentage of azide-functionalized monomers. We aimed for polymers with an 
LCST between 10 °C and 20 °C in the physiological buffer solutions, so that experiments 
can be started below 10 °C (on ice), while crosslinking can be performed in the gel state. 
The polymers were synthesized by polymerizing of approximately 3% azide-functionalized 
monomers, 20% tetra(ethylene glycol)-grafted monomers, and 77% tri(ethylene glycol)-
grafted monomers, using nickel(II) as a catalyst (Scheme 10.1).16 We prepared two 
polymers, one with Mv = 486 kDa (1a) and one with Mv = 585 kDa (1b). The addition of the 
tetra(ethylene glycol) monomer raised the gelation temperature of both polymers to 12 °C 
in the salty buffer solution required for CCMV assembly.13,34 The molecular weights of 1a and 
1b were determined by viscometry and the polymers were further characterized by infrared 
spectroscopy. The mechanical properties of the hydrogels were studied by rheology.
As the reaction partner for the click reaction, dibenzocyclooctyne (DBCO) was chosen, 
as this group reacts efficiently and selectively with azides, without the need for a catalyst. 
To this end, we functionalized ELP-CCMV capsids with DBCO groups (Scheme 10.1). 
Recombinant ELP-CCMV capsid proteins were expressed in Escherichia coli (E. coli), 
followed by purification through Ni2+ affinity chromatography. Subsequently, the lysines 
of the capsid protein dimers were aspecifically modified with dibenzocyclooctyne-PEG4-
N-hydroxysuccinimidyl ester (DBCO-PEG4-NHS), such that a mixture of non-, mono- 
and bis-DBCO-functionalized capsid protein monomers was obtained (Figure 10.1).35 
As the capsid proteins are, however, always present as dimers in a neutral environment, 
this resulted in a statistical mixture of dimers 2 with 0-4 DBCO groups per dimer. After 
assembly of the dimers 2 into capsid particles (capsids 3), the available DBCO groups on 
the exterior could be used as reaction partners in a click reaction with azide-functionalized 
polymers 1a and 1b. Part of the introduced DBCO groups (on average approximately 90 
per particle), however, was probably not accessible after assembly, because they were for 
instance located on the capsid interior.
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figure 10.1	 DBCO-functionalization	 of	 ELP-CCMV	 capsid	 proteins.	 a) Representative SEC chromatogram of 
DBCO-modified	ELP-CCMV	in	pH	5.0	capsid	buffer.	b)	Representative	UV-vis	absorption	spectrum	of	DBCO-modified	
ELP-CCMV. c)	 Representative	 ESI-TOF	mass	 spectrum	 of	 DBCO-modified	 ELP-CCMV.	 Deconvoluted	 total	mass	
spectrum	 (left)	and	multiply	charged	 ion	series	 (right).	The	expected	molecular	weights	are	22253.4	Da	 (0 DBCO), 
22788.0	Da	(1 DBCO)	and	23322.6	Da	(2 DBCO).
10.2.2  Low stress mechanical properties
Rheology experiments were carried out to evaluate the mechanical properties of the 
crosslinked hydrogels. For the crosslinking experiments, a pre-cooled solution of either 
ELP-CCMV-DBCO dimers 2 or capsids 3 in a pH 7.5 buffer or pH 5.0 buffer, respectively, 
was mixed with a cold solution of PIC-N3 1a in the same buffer (Figure 10.2A). Both the 
DBCO-functionalized capsids 3 and ELP-CCMV capsid protein dimers 2 functionalized 
with two or more DBCO groups should be able to act as crosslinkers in the PIC network. 
This dimer-crosslinked PIC network was included in our initial studies, as a suitable model 
system of a crosslinked network in which the supramolecular ELP-CCMV capsids have 
been deteriorated by high levels of stress.
After combining the polymer and the crosslinker, the mixture was transferred to the 
rheometer and the solution was immediately heated to 25 °C to induce gelation. The click 
reaction was allowed to proceed for one hour at this temperature, while in the meantime 
the storage modulus G’ was measured (Figure 10.2B). Both the samples containing ELP-
CCMV (dimers; pink line and capsids; orange line) and the control samples without the 
crosslinker (dimer buffer; blue line and capsid buffer; purple line) clearly formed elastic 
gels at 25 °C. The presence of the crosslinker had a negligible effect on the storage moduli at 
temperatures above the LCST. When cooled to 5 °C, the crosslinked samples remained a gel 
(tan δ < 0.2), albeit relatively weak. The G’ of the dimer-crosslinked gel was approximately 
ten times higher than the G’ of the capsid-crosslinked gel. To estimate the concentration 
of crosslinks in the resulting gels, we compared the obtained data to prior work, in which 
the concentration of a divalent crosslinker was varied and the storage moduli G’ of the 
resulting crosslinked gels were measured.34 This data was fitted, and based on the obtained 
179
Biomimetic strain-stiffening hydrogels with virus-like particles as crosslinkers
figure 10.2 a) Schematic representation of the four types of PIC gels that were analyzed using rheology. Blue:	
polymer 1	 in	pH	7.5	buffer;	Pink:	polymer	1	+	ELP-CCMV-DBCO	capsid	protein	dimers	2	 in	pH	7.5	buffer;	Purple:	
polymer 1	in	pH	5.0	buffer;	Orange:	polymer	1	+	ELP-CCMV-DBCO	capsids	3	in	pH	5.0	buffer.	b) Rheological analysis 
of the PIC gels depicted in Figure A. The storage modulus G’ is plotted as a function of the time. Over time, the 
temperature of the samples was changed as indicated in the graph. The color coding of the curves corresponds to the 
situation depicted in Figure A. c) Dimer- (pink) and capsid-crosslinked (orange) PIC hydrogels, and a non-crosslinked 
PIC	solution	at	pH	5.0	(purple).	All	pictures	were	taken	at	5	°C	(II	and	IV	coincide	with	the	temperature	zones	in	B),	and	
the	gels	were	stained	with	6.7	µM	Rhodamine	B.
G’ values of the capsid-crosslinked gels and dimer-crosslinked gels, the approximate 
crosslink concentrations were estimated to be approximately 8 µM and 25 µM for capsid 
and dimers crosslinks, respectively. This difference can partly be explained by the fact 
that, even though the same protein concentration was used in both the dimer and capsid 
samples, the effective crosslinker concentration in the dimer-crosslinker gel is higher than 
in the capsid-crosslinker gel, as each virus capsid contains 90 dimers, effectively reducing 
the crosslinker concentration compared to the dimers. An additional factor that plays 
a role is that not each dimer can act as a crosslinker, as some dimers have less than 2 
DBCO groups attached. The G’ of the crosslinked gels at 5 °C was more than an order of 
magnitude higher than the control samples without crosslinker present, which returned 
to a viscous solution state (tan δ ≈ 0.95) under the LCST (Figure 10.2C). Next, the samples 
were heated to 37 °C to induce the formation of a stiffer gel and to further improve on 
the chemical crosslinking reaction, which would lead to a stronger crosslinked network 
at temperatures below the LCST. After applying the second heating and cooling cycle, the 
difference between the crosslinked samples and the blanks became even more apparent. At 
5 °C, storage moduli of G’ ≈ 9 Pa for the gel with capsid crosslinks 3 and G’ ≈ 80 Pa for the 
gel with dimer crosslinks 2 were obtained.
The higher stiffness of the dimer-crosslinked gel is probably the result of a higher crosslinker 
density. To further investigate the effect of crosslinker concentration, we performed two more 
experiments for which we prepared three batches of DBCO-functionalized capsids. Each 
of these batches had a different degree of DBCO-functionalization, which was controlled 
by varying the time that the functionalization reaction was allowed to proceed (Figure 
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figure 10.3	 Estimated	 crosslink	 concentration	 of	 PIC	 gels,	 crosslinked	 with	 different	 amounts	 of	 ELP-CCMV	
capsids	with	different	 functionalization	degrees.	a) Comparison of three gels, in which the total DBCO and capsid 
concentrations	were	kept	constant,	while	varying	the	amount	of	DBCO-modified	capsids	(crosslinkers).	As	a	reference,	
the estimated crosslink concentration of dimer-crosslinked gels is depicted. b) Comparison of three gels, in which the 
amount	of	DBCO-modified	capsids	(crosslinkers)	and	total	capsid	concentration	were	kept	constant,	while	varying	the	
degree of DBCO functionalization.
10.3). Note that the conversions are an estimation and based on DBCO-functionalization 
degrees in the dimer state; some of these DBCO moieties might not be available on the 
exterior of the capsids after assembly of the capsid proteins. In the first experiment, the 
amount of available crosslinkers (functionalized capsids) was varied while keeping the 
total capsid concentration equal in each sample (Figure 10.3A). To do so, the pre-formed 
functionalized capsids, with three different functionalization degrees were diluted with 
non-functionalized capsids to obtain the same capsid concentration in each sample. After 
performing the abovementioned heating-cooling protocol, the crosslink concentration 
in the resulting gels was estimated based on previous work, as explained above.34 We 
observed a significant increase in estimated crosslink concentration when more DBCO-
functionalized capsids were present with fewer DBCO groups per capsids. When equal 
concentrations of each capsid batch -with different degrees of functionalization- were 
used, only very small variations in estimated crosslink concentration were observed after 
crosslinking (Figure 10.3B). This confirms our hypothesis that the crosslink density, and 
not the degree of functionalization of the crosslinker, is crucial for the efficiency with 
which the network is crosslinked.
10.2.3  non-linear mechanics
As the PIC hydrogels have a bundled architecture, they show strain-stiffening behavior 
at low stresses.2,36 In this non-linear regime, the differential modulus, K’ = ∂σ/∂γ (where 
σ is the applied stress and γ is the resulting strain) is used to describe the mechanical 
behavior of the material. At low stresses, K’ = G’. When the stress is increased beyond 
a critical value σc, however, the differential modulus becomes stress-dependent: K’ ~ 
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σm. Rheology measurements were done to investigate the strain-stiffening properties of 
the capsid-crosslinked gels, as these are most promising for future applications. These 
experiments revealed that the crosslinked PIC gels indeed show strain-stiffening behavior 
above the same critical stress value as observed for a non-functionalized PIC hydrogel. 
Additionally, both the non-functionalized and crosslinked gels had the same stiffening 
index m = 1.4 (Figure 10.4A). When the stress on the capsid-crosslinked gel was further 
increased a plateau was observed for K’ between σ = 140 Pa and σ = 200 Pa (Figure 10.4A). 
Gels containing a small molecular crosslinker, i.e. DBCO-PEG4-DBCO, survive the high 
stress but do not show a plateau as we found in separate experiments.34 A plateau similar 
to the one observed in the capsid-crosslinked gel has been observed for fibrin hydrogels, 
where it was attributed to breaking of the intra-bundular crosslinks.4,5 Fibrin is unique 
in this aspect; to the best of our knowledge, no other natural or synthetic gels have been 
shown to feature this kind of behavior. The presence of the plateau in our case implies 
that the bundles are no longer being stretched at the applied stresses and that the energy 
is dissipated in another way in the hydrogel. We hypothesize that the observed energy 
dissipation is linked to the disassembly or deterioration of the ELP-CCMV capsids in 
response to the high applied stress. 
In an additional rheology experiment, the capsid-crosslinked gel was first subjected to 
a stepwise increasing stress until a value above the plateau was reached (Figure 10.5). 
Subsequently, the stress was decreased stepwise while measuring K’. The plateau was not 
observed in this case, which implicates that it involves a permanent change in the network 
structure, for instance the rupture of the virus capsids. Next, the gel was subjected again 
to a stepwise increasing stress. Now, a new plateau was observed at much higher applied 
stress value, σ = 450 Pa. This suggests that the remaining capsids, capsid fragments, and/
or dimers had rearranged to form a different crosslinked architecture, which can dissipate 
stress once again.
Subsequent experiments were aimed at further unravelling the effect of high and low stress 
on the crosslinked network. To this end, samples were subjected to stresses just below or 
above the plateau, i.e. to stress values of σ = 120 Pa or 320 Pa, respectively (Figure 10.4A, 
indicated by the arrows). After the stress was removed, the stiffness in the linear visco-
elastic (LVE) regime of the gel was measured and compared to the initial stiffness before 
the application of the stress (Figure 10.4B). At 25 °C, gels which had been subjected to 
a stress of σ = 120 Pa regained their original stiffness. Gels stressed above the plateau, 
however, showed a small decrease in stiffness after the application of stress. This could 
be a result of a decrease in the effective crosslink concentration, since the crosslinks are 
broken due to the high stress. These results confirm that the energy dissipation causes a 
permanent change in the network architecture.
We hypothesize that the capsids are pulled apart when the crosslinked gel is subjected to 
high stresses. Since the resulting capsid protein dimers 2 can form more crosslinks than 
the original capsids themselves, the gel stiffness is expected to increase when the material 
is allowed to reorganize by lowering the temperature below the LCST. To investigate this, 
the gel was allowed to reorganize at low T after being stressed above the plateau (Figure 
10.4C). In these experiments, again stresses just below or above the plateau were applied. 
An interesting effect was observed after applying a stress of σ = 320 Pa, above the plateau: 
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figure 10.5	 Differential	 modulus	 K’	 as	 a	 function	 of	 stress	 σ	 for	 DBCO-functionalized	 ELP-CCMV	 capsid	 3 
crosslinked	PIC	gels.	The	crosslinked	gel	was	first	subjected	to	a	constant	pre-stress	σ0	from	60	Pa	to	320	Pa	(loading), 
after	which	the	pre-stress	was	decreased	from	320	Pa	to	60	Pa	(unloading).	Subsequently,	the	stress	was	increased	
again	from	60	Pa	to	900	Pa	(reloading).
figure 10.4 a)	 Differential	modulus	 K’	 as	 a	 function	 of	 stress	 σ	 for	 crosslinked	PIC	 gels.	 DBCO-functionalized	
capsid	crosslinkers	are	compared	to	a	short	DBCO-PEG4-DBCO	crosslinker.	As	a	control,	 the	behavior	of	the	PIC	
gel	without	crosslinker	was	measured.	The	stiffening	index	was	calculated	by	fitting	the	curve	of	the	non-crosslinked	
gel to formula y = a * xm. b) Recovery of the storage modulus G’ after applying stresses σ	just	below	or	above	the	
observed	plateau	(see	Figure	A)	for	DBCO-functionalized	ELP-CCMV	capsid	crosslinkers,	at	a	temperature	of	25	°C.	
c) Recovery of the storage modulus G’ after applying stresses σ	just	below	or	above	the	observed	plateau	(see	Figure	
A)	for	DBCO-functionalized	ELP-CCMV	capsid	crosslinkers	after	cooling	to	5	°C.
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a much higher stiffness was observed than before a stress was applied. This effect was also 
observed when the materials were stressed below the plateau, but much less pronounced. 
If indeed the capsids are broken when the materials are stressed above the plateau, the 
newly formed capsid fractions might be able to form additional crosslinks, crosslinking 
the network more efficiently and effectively raising the G’ at low T, which was not possible 
when these DBCO groups were present on a single particle.
10.3 concLuSionS
We have described a new supramolecular crosslinking strategy towards biomimetic 
hydrogels, using protein-based viral capsids as hierarchical crosslinks. The mechanical 
properties of the crosslinked gel could be tuned by changing the functionalization degree 
and the concentration of the crosslinker. Additionally, similar to the strong natural fibrin 
gels, energy dissipation was observed in the strain-stiffening regime, which is probably 
caused by (partial) disassembly of the capsid crosslinks. These findings may lay the 
foundation for the application of these types of biomimetic hydrogels, e.g. as stress sensors 
or drug delivery vehicles. Further studies in this direction are aimed at investigating the 
release of cargo from the interior of the capsids upon the application of high stresses to the 
crosslinked gel.
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10.5 exPeriMenTaL SecTion
10.5.1  Materials and methods
Materials
DBCO-PEG4-NHS ester was purchased from Click Chemistry Tools. DMSO was purchased 
from Acros. Isocyanide monomers were purchased from Chiralix. All other solutions and 
materials were obtained from Sigma-Aldrich.
Buffers
pH 7.5 dimer buffer: 50 mM Tris·HCl, 500 mM NaCl, 10 mM MgCl2, 1 mM EDTA, pH 7.5. 
pH 5.0 capsid buffer: 50 mM NaOAc, 500 mM NaCl, 10 mM MgCl2, 1 mM EDTA, pH 5.0. 
Phosphate buffer: 100 mM NaH2PO4, 150 mM NaCl, pH 7.5. 
PBS buffer: 10 mM Na2HPO4, 1.8 mM KH2PO4, 137 mM NaCl, 2.7 mM KCl, pH 7.2-7.4.
184
Chapter 10
All buffers were filtered over a 0.2 micron filter prior to use.
Viscometry
For viscometry measurements the polymers were dissolved in CH3CN (0.1-0.6 mg/mL) 
and the intrinsic viscosity of these solutions was measured at 25 °C. The average viscosity 
molecular weight, Mv, of the polymers was calculated using the empirical Mark–Houwink 
equation: [η] = KMv
a . Where [η] is the intrinsic viscosity of the polymer solution as 
determined from viscometry measurements and Mark–Houwink parameters K and a 
depend on solvent and polymer characteristics. We used parameter values that were 
previously determined for other polyisocyanides: K = 1.4 × 10−9 and a = 1.75.37
Rheology
Rheological measurements were carried out on a TA Instruments Dynamic Hybrid 
Rheometer 1 or 2 fitted with a 40 mm aluminum or stainless steel parallel plate geometry. 
A geometry gap of 500 µm was used. All non-linear measurements were carried out using 
a 40 mm aluminum parallel plate geometry.
UV-vis spectroscopy
Protein concentrations were measured on a Varian Cary 50 Conc UV-vis spectrometer 
using a quartz cuvette with a path length of 3 mm. Protein concentrations were calculated 
using the theoretical extinction coefficients.38 Samples were centrifuged prior to the 
measurements.
Mass	spectrometry
Protein mass characterization was performed by electrospray ionization time-of-flight 
(ESI-TOF) on a JEOL AccuTOF CS. Deconvoluted mass spectra were obtained using 
MagTran 1.03 b2. Isotopically averaged molecular weights were calculated using the 
‘Protein Calculator v3.4’ at http://protcalc.sourceforge.net. Protein samples were desalted 
by spin filtration to MQ (final concentrations 50-100 μM).
Size exclusion chromatography (SEC)
SEC was performed on a Superose 6 10/300 column (GE Healthcare). Analytical SEC 
measurements were executed on a Shimadzu LC-2010AHT HPLC. Samples (100 μg) were 
separated on the column with a flow rate of 0.5 mL/min.
10.5.2  experimental details
Protein	sequences
Table 10.1	 Amino	acid	sequences	of	the	proteins	used	in	this	chapter.
Name Sequence
G-H6-ELP-CCMV
GHHHHHHVPGVGVPGLGVPGVGVPGLGVPGVGVPGLGVPGGGVPGVGVPGLGLEVVQPVIVEPIASGQ
GKAIKAWTGYSVSKWTASCAAAEAKVTSAITISLPNELSSERNKQLKVGRVLLWLGLLPSVSGTVKSC
VTETQTTAAASFQVALAVADNSKDVVAAMYPEAFKGITLEQLTADLTIYLYSSAALTEGDVIVHLEVE
HVRPTFDDSFTPVY
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Expression	of	G-H6-ELP-CCMV
The expression and purification of G-H6-ELP-CCMV were performed as described in 
Chapter 3.
General	procedure	for	the	synthesis	of	polyisocyanide	polymers
PIC polymers 1 were synthesized following a previously described protocol.12,16 The tri-
ethylene glycol monomer, tetra-ethylene glycol monomer, and azide-functionalized 
monomer were dissolved in freshly distilled toluene. A solution of Ni(ClO4)2·6H2O (1 
mM) in freshly distilled EtOH/toluene 1/9 (v/v) was prepared. The required amount of 
catalyst stock solution was diluted to 1 mL using freshly distilled toluene and added to the 
monomer solution. The resulting mixture was stirred for 48 h at rt. The reaction mixture 
was diluted with CH2Cl2 (5 mL) and the product was precipitated in diisopropyl ether (100 
mL). After filtration, the polymer was re-dissolved in CH2Cl2 (5 mL) and re-precipitated in 
diisopropyl ether (100 mL). This procedure was repeated once more.
Polymer 1a. The general procedure described above was followed. An amount of 251 mg 
(0.79 mmol) of the tri-ethylene glycol monomer, 75.9 mg (0.21 mmol) of the tetra-ethylene 
glycol monomer, and 14.5 mg (39 µmol) of the azide-functionalized monomer (14.5 mg, 
39 µmol) were dissolved in 6.5 mL of freshly distilled toluene. An amount of 257 µL of the 
catalyst stock solution was diluted to 1 mL using freshly distilled toluene and added to the 
abovementioned solution. Yield: 287 mg (84 %) of a pale yellow solid. FT-IR ν
max
 film (cm-
1): 3268, 2876, 1742, 1657, 1532, 1455, 1264, 1217, 1065, 729, 703. Mv = 486 kDa. Tgel (pH 5.0 
capsid buffer) = 12 °C. The Tgel of this polymer was determined from a measurement of the 
storage modulus as a function of temperature.
Polymer 1b. The general procedure described above was followed. An amount of 197 mg 
(0.62 mmol) of the tri-ethylene glycol monomer, 59 mg (0.17 mmol) of the tetra-ethylene 
glycol monomer, and 10 mg (28 µmol) of the azide-functionalized monomer (14.5 mg, 39 
µmol) were dissolved in 6.5 mL of freshly distilled toluene. An amount of 137 µL of the 
catalyst stock solution was diluted to 1 mL using freshly distilled toluene and added to this 
solution. Yield: 264 mg (97 %) of a pale yellow solid. FT-IR ν
max
 film (cm-1): 3268, 2876, 
1742, 1657, 1533, 1455, 1352, 1272, 1246, 1204, 1111, 1065, 853, 755, 530. Mv = 585 kDa. Tgel (pH 
5.0 capsid buffer) = 12 °C. The Tgel of this polymer was determined from a measurement of 
the storage modulus as a function of temperature. This polymer was used for all non-linear 
rheology experiments.
DBCO-functionalization	of	G-H6-ELP-CCMV
G-H6-ELP-CCMV was spin filtrated to phosphate buffer (10 kDa MWCO, 3x), after which the 
protein concentration was determined by UV-vis spectroscopy. DBCO-PEG4-NHS ester was 
dissolved in DMSO (10 mM). G-H6-ELP-CCMV (105 µM final concentration) and DBCO-
PEG4-NHS (157.5 µM final concentration, 1.5 eq.) were combined in phosphate buffer and 
incubated at 21 °C for 10-30 minutes, depending on the desired functionalization degree 
(500 rpm). The reaction mixture was dialyzed against PBS buffer, and subsequently pH 
5.0 capsid buffer at 4 °C to remove the excess of DBCO-PEG4-NHS (Spectra/Por 2, 12-
14 kDa MWCO) (3x 100 mL for 30 minutes per buffer). Then, the protein solution was 
concentrated approximately ten times by spin filtration (10 kDa MWCO) to induce capsid 
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formation. The protein concentration was determined by UV-vis spectroscopy and the 
solution was diluted back to 126 µM. DBCO-functionalization was qualitatively verified 
by UV-vis spectroscopy. The degree of functionalization was estimated using electrospray 
ionization time-of-flight (ESI-TOF) mass spectrometry. Successful capsid assembly after 
DBCO-modification was confirmed using SEC. The DBCO-modified ELP-CCMV capsids 
were stored at 4 °C until further use.
PIC	crosslinking	with	CCMV-DBCO
PIC polymer 1 was dissolved in pH 5.0 capsid buffer or pH 7.5 dimer buffer (4 mg/mL) at 
4 °C overnight, with occasional shaking. The solutions were stored at -20°C until further 
use. The solution of DBCO-modified ELP-CCMV capsids 3 was prepared according to 
the protocol described in the section ‘DBCO-functionalization of H6-ELP-CCMV’. For 
crosslinking experiments with DBCO-modified ELP-CCMV dimers 2, the capsid solution 
was first dialyzed to pH 7.5 dimer buffer (Spectra/Por 2, 12-14 kDa MWCO) (3x 100 mL 
for 30 minutes). Fresh, cold solutions of ELP-CCMV-DBCO dimers 2 or capsids 3 and PIC 
polymer 1 were combined on ice and immediately loaded into the rheometer in the liquid 
state at a temperature of 5 °C.
Rheology experiments
To measure the linear regime (G0), the sample was heated to the desired temperature, 
and after a short waiting period for equilibration the complex modulus G* was measured 
by applying an oscillating deformation of amplitude γ = 0.04 at frequency f = 1 Hz. 
Temperature-dependent measurements were carried out at a 1 °C/min or 3 °C/min ramp 
rate. For non-linear measurements, after isothermal time sweeps at 25 °C and at 5 °C, the 
pre-stress protocol described by Broedersz et al. was used with a pre-stress increasing from 
20 Pa to the desired pre-stress in steps of 20 Pa.3
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11.1 TowarDS aPPLicaTion of ccMV in bionanoTechnoLogy 
Nanoparticles have gained increasing attention in the field of bionanotechnology as tools 
for e.g. drug delivery or diagnostic imaging. Virus capsids are an interesting example 
with many advantageous properties, such as their highly monodisperse and symmetric 
structure, robustness, stability, and biocompatibility.1 The fact that many differently 
sized and shaped viruses exist, has allowed scientists to choose the desired virus capsid, 
based on the size and shape that is desired for a certain application. For our studies, we 
utilized the capsid of the cowpea chlorotic mottle virus (CCMV), which is an icosahedrally 
shaped particle with an outer diameter of 28 nm in its T = 3 form.2,3 We focused on the 
application of CCMV virus-like particles (VLPs), i.e. CCMV capsids without encapsulated 
genetic material, as artificial organelles or drug delivery vehicles in bionanotechnological 
applications. More specifically, we investigated three aspects we deemed important 
towards these types of applications, namely: (i) selective N-terminal modification of the 
capsid proteins for encapsulation of specific cargoes, (ii) the influence of encapsulation of 
a cargo upon its functionality, and (iii) possibilities for expansion of the assembly profile of 
the capsid proteins, towards physiological conditions.
11.1.1  ccMV as a versatile nanocontainer
The CCMV capsid is a unique VLP with some very advantageous properties for 
nanotechnological applications. In contrast to many other viruses, the CCMV capsid can 
be reversibly assembled and disassembled into protein dimers, by a simple shift in pH of 
the surrounding solution. Additionally, the capsid proteins are able to form stable particles 
after precipitation of the viral nucleic acids, resulting in empty particles which can be used 
as nanocontainers through encapsulation of cargoes. Traditionally, the virus is produced 
in and extracted from cowpea plants. Even though this protocol yields high amounts of 
capsid protein, a protocol was recently developed for the heterologous expression of the 
CCMV capsid proteins in Escherichia coli (E. coli), offering the possibility of genetically 
altering the capsid protein sequence for specific purposes. The native virus is composed 
of 180 capsid proteins, which are arranged in an icosahedral shell with T = 3 symmetry.2 
Alternatively, T = 1 particles or pseudo T = 2 particles, comprising 60 and 120 capsid 
proteins, respectively, can be formed if the N-terminus of the capsid proteins is truncated.4 
Thus, using the same capsid proteins, three differently sized capsids can be formed. The 
N-terminus of the capsid proteins is located on the interior of the capsids after assembly. 
This offers a selective handle which can be used for the encapsulation of cargoes.
11.1.2  Selective N-terminal modification of CCMV capsid proteins
A straightforward way to encapsulate cargo in CCMV capsids is via statistical encapsulation. 
In this method, the cargo is added to a solution of capsid protein dimers, after which 
conditions are applied to induce capsid formation.5 If needed, the encapsulation efficiency 
can be increased by introducing negative charges on the desired cargo, allowing ionic 
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interactions with the cationic N-terminal tails of the CCMV capsid proteins.6–10 Better 
control over encapsulation can be obtained via the selective modification of the interior 
of the CCMV capsids. Two previously utilized modification strategies are: genetic cloning 
of the target protein onto the CCMV capsid protein N-terminus towards a fusion protein 
construct11, and the introduction of a domain at the N-terminus that can form non-covalent 
interactions with a specific complementary domain.12,13 These studies have proven valuable 
for the encapsulation of proteins and enzymes.
We believe the ideal interior modification strategy should be modular, applicable to 
different types of cargo, and achievable without extensive genetic engineering. Additionally, 
covalent encapsulation allows for more controlled cargo encapsulation with higher yields, 
as previously shown.11 The abovementioned methods do not comply with some of these 
requirements. For instance, genetic fusion of a target protein to the CCMV N-terminus 
only applies to proteinaceous cargoes and requires extensive genetic engineering before 
being applicable for a specific cargo. On the other hand, non-covalent encapsulation 
using complementary domains will intrinsically be sensitive to disassembly conditions 
disturbing the interactions between the two domains.
We therefore set out to find a compatible method for selective N-terminal modification 
of the CCMV capsid proteins, based on established protein modification strategies. 
Previous, unpublished research in our group had already shown that the capsid proteins 
are quite sensitive and will precipitate easily upon exposure to e.g. diazotransfer conditions 
and reagents, which hampers the application of click chemistry methods for capsid 
modification.14,15 To this end, we applied a mild, enzymatic method for the N-terminal 
modification of the capsid proteins, making use of the enzyme Sortase A (Chapters 3, 4 
and 5).16,17,18 This enzyme allowed selective modification of the N-terminus of the proteins, 
while being robust towards the nature of the substrates that were attached, as long as they 
are equipped with an LPETG peptide tag. A general disadvantage of the Sortase enzyme 
is the low yield that can be reached as the procedures involves an equilibrium reaction. 
This has previously been solved by e.g. performing the reaction under dialysis conditions, 
allowing removal of one of the reaction products, or using depsipeptides, which do 
not release nucleophilic products after the Sortase reaction.19,20 Ironically, however, the 
intrinsic low yielding nature of this reaction is an advantage for our purpose of interior 
functionalization of the CCMV capsids, as we were not aiming at using capsid proteins 
which were 100% functionalized, making the interior too crowded or not allowing capsid 
assembly at all due to steric hindrance. Thus, by changing the amount of enzyme added, 
we could alter the ratio between functionalized and non-functionalized capsid proteins to 
a desired degree, after which capsids could be assembled. Other downsides of the Sortase 
system are the high catalyst loading that is required to achieve reasonable conversions 
and its dependency on a Ca2+ cofactor. Fortunately, recent research has shown potential in 
engineering Sortase sequences, to circumvent some of these disadvantages.21–26
In addition to the Sortase A-methodology, we set out to develop a method more suitable 
for small, organic, non-proteinaceous molecules, without the need for the introduction 
of a peptide to incorporate the Sortase recognition sequence. To this end, we investigated 
the applicability of the mild, selective, N-terminal protein modification strategy using 
2-pyridinecarboxaldehydes (Chapter 7).27 In contrast to our previous attempts to chemically 
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modify the CCMV capsid proteins, this method was found to be mild enough for the 
reaction with these proteins. In addition, the 2-pyridinecarboxaldehyde moiety could be 
functionalized, allowing for the introduction of desired cargo. We chose to introduce a click 
handle, making this a modular approach for the introduction of cargoes functionalized 
with the complementary click moiety. A downside of this modification strategy was 
the instability of the aldehyde moiety, which is crucial during both the synthesis of the 
desired compounds, as well as the long-term storage of these compounds. Additionally, the 
obtained modification yields could be further improved. As explained above, however, in 
our system we are not looking for 100% modification, so this was not an insuperable issue 
in our case.
11.1.3  Investigation of cargo encapsulation in CCMV VLPs
Introducing cargo inside the CCMV capsids is a crucial step towards the application of 
these particles in bionanotechnology. Using the two abovementioned described methods, 
we introduced a range of different cargoes into the interior of the capsules, i.e. fluorescently 
labeled peptides, fluorescent proteins and enzymes (among which a challenging enzyme 
carrying a net positive charge). These studies showed that CCMV capsids are suitable 
containers for the encapsulation of different types of cargoes, with different characteristics, 
without significant loss in the functionality of the cargo. Additionally, it was found that 
high encapsulation efficiencies can be achieved, in case of the SrtA-mediated coupling 
of the cargoes to the N-terminus of the capsid proteins. When assembly conditions are 
applied to a mixture of capsid proteins with a higher percentage of N-terminally modified 
proteins than the final achievable percentage of those proteins in an assembled capsid (due 
to interior steric hindrance), a high encapsulation efficiency is consistently achieved. This 
approach is especially useful in case of the encapsulation of charged cargoes, as these do 
not lend themselves to statistical encapsulation, due to unfavorable ionic intermolecular 
repulsion.
11.1.4  Investigation of cargo encapsulation in CCMV VLPs
The inherent assembly profile of the native CCMV capsid proteins poses a challenge for 
their application in biological systems, as the capsids are only stable under physiological 
conditions when in their native viral form, i.e. encapsulating their viral RNA, or when 
held together by a negatively charged polymer, mimicking the viral RNA.28,29 We aimed 
to modify the capsid proteins such, that they would be stable at physiological conditions, 
without the aid of an encapsulated cargo. A first step towards this goal was previously 
made with the development of the ELP-CCMV fusion protein, allowing capsid formation 
at a physiologically relevant pH of 7.5.30 Further improvements were made with the 
introduction of Ni-induced capsid assembly, making use of the hexahistidine tags present 
in the protein construct for purification purposes.31 This assembly mechanism allowed 
assembly at pH 7.5 with significantly reduced NaCl concentrations, compared to ELP-
induced assembly. Ni-stabilized capsids, however, were proven to be unstable in DMEM 
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cell culture medium, probably due to the presence of e.g. free histidines in the medium, 
which can compete for Ni2+-binding with the hexahistidine tags attached to the capsid 
proteins (unpublished data).
Based on these results, and the fact that we would ideally like to only use a variant of the 
CCMV capsid protein that does not require any additives for biological applications, we 
decided to focus on ELP-induced assembly instead of Ni-induced assembly. We introduced 
point mutations in the short N-terminal ELP sequence, with the aim of making the guest 
residues more hydrophobic and lowering the lower critical transition temperature (LCST) 
of the ELP, and thereby the amount of salt needed for the assembly of the fusion protein 
(Chapter 9).32 A small library of ELP-CCMV capsid protein variants was prepared, which 
showed predictable assembly behavior, when taking the theoretical hydrophobicity of the 
mutated ELP into account. This work has laid a foundation for further research into the use 
of the more hydrophobic variants under physiological conditions.
11.2 ouTLook
The work presented in this thesis has contributed to the potential application of CCMV 
capsids in biological systems. One of the newly described hydrophobic ELP-CCMV variants 
might be suitable for these kinds of experiments, after careful optimization of all protocols 
in terms of the protein concentration, temperature and salt concentration, as these have a 
significant influence on the behavior of the ELPs. The fact that we have gained control over 
both the stability and the loading of the ELP-CCMV capsids, has opened the door for the 
use of these nanoparticles for in vivo applications. An important aspect that we have not 
yet touched upon, however, is the influence of the exterior of the particles. To control the 
immune response, circulation time and cell uptake of the particles, it is crucial to control 
the interactions of the particles with their surroundings. Important aspects that play a role 
in this respect and influence the fate of the nanoparticles in a biological system, are their 
shape and charge:33,34
i) Shape: a wide variety of differently shaped VLPs exist, which can each prove useful 
for different kinds of applications. It has been shown that non-spherical particles have 
better margination towards blood vessel walls and stronger interactions due to the larger 
surface area. Spherical VLPs, on the other hand, have proven useful for in situ vaccination 
applications.
ii) Surface charge: there is evidence that neutral and negatively charged nanoparticles 
have longer circulation times than cationic nanoparticles, due to the adsorption of serum 
proteins.35 The opposite trend has been observed, however, for virus-based particles: 
negatively charged VLPs, such as CCMV, have been shown to have shorter blood circulation 
times than positively charged VLPs. In addition, positively charged VLPs have been shown 
to possess enhanced tumor tissue penetration and binding and uptake by mammalian 
cells. 
Both of these aspects play an important role in the application of CCMV capsids as either 
artificial organelles or drug delivery vehicles. Previous research has rendered spherical 
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capsids, such as CCMV, more suitable for in situ vaccination applications. Even though 
this is an interesting area, which can be further explored using CCMV capsid nanocarriers, 
it would also be interesting to see whether the interactions with mammalian cells and 
margination properties can be improved, to make the particles more suitable for e.g. tumor 
targeting. One approach towards increasing the aspect ratio of the capsids could be to 
link several CCMV capsids together, similar to work performed on CPMV.36 An alternative 
approach might be the creation of a Janus particle, with large polymers (e.g. PEG) on one 
end to increase the aspect ratio of the particles.37,38
The negative charge of the outer surface of the CCMV capsids poses another challenge 
for their in vivo application. Neutralization of the charge is probably required at least, to 
increase the half-life to a significant level. Inversion of the charge to create a positive outer 
surface, however, would be even more advantageous, as this should allow better interaction 
and uptake by mammalian cells. Additional modifications on the capsid exterior could 
be the introduction of additional PEG chains, which should reduce non-specific uptake, 
the introduction of specific targeting moieties, depending on the specific application, and 
functionalities which can aid in directing the cell uptake mechanism.39
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SuMMary
Nature has developed many intricate and elegant solutions to challenging problems over 
the course of many centuries of evolution. Therefore, she serves as an bottomless pool of 
inspiration for scientists from different research areas. In our case, we were drawn to the 
fascinating systems that are viruses. They have developed in such a way, that they are able 
to reproduce using solely the reproduction machinery of the host they infected. They do 
so by injecting their viral genetic material into a host cell, after which the cell starts to 
produce new viruses via transcription and translation. Of particular interest is the protein 
nanocompartment that contains the viral genetic material, as this is responsible for both 
the transportation and protection of its DNA/RNA cargo, and the interaction with cells 
of its host and delivery of its cargo to these cells. These types of nanocontainers thus have 
some interesting features, which could prove useful in bionanotechnological applications.
The work described in this thesis mainly focused on the cowpea chlorotic mottle virus (CCMV) 
protein capsid. Initial studies were aimed at further expanding the existing technologies 
for cargo encapsulation in these particles. We aimed to develop a straightforward, reliable 
and modular strategy for covalent modification inside the capsids, which would be suitable 
for a range of different cargoes. To this end, we applied Sortase A (SrtA), an enzyme which 
is present in Gram-positive bacteria, to specifically modify the N-terminus of the CCMV 
capsid proteins, which is present in the interior of the capsids after assembly. In Chapter 
3, the development of this method is described and demonstrated with a fluorescently 
labeled peptide and a model protein, both containing the required Sortase recognition 
peptide. High encapsulation efficiencies were achieved, which motivated us to apply this 
strategy for the encapsulation of a model enzyme, Candida antarctica lipase B (CalB) 
(Chapter 4). It was shown that the encapsulation did not affect the performance of the 
enzyme: no loss of activity was observed and no signs of rate-limiting substrate diffusion 
were observed. Additionally, it was shown that the capsid is able to protect the enzyme 
from proteases. In Chapter 5, the Sortase strategy was applied for the encapsulation of 
a more challenging enzyme: T4 lysozyme (T4L). As this enzyme was found to be inactive 
under any of the conditions that would normally be required to achieve assembled capsids, 
the assembly protocol had to be expanded based on previous studies. This lead to particles 
containing a high loading of the T4L enzyme, which remained stable under conditions 
similar to physiological conditions, and could act as catalytically active nanoreactors.
While performing activity assays with functionalized CCMV capsid proteins, we began 
to notice background reactions that could not be explained by the presence of a trace 
amount of residual catalyst. After further investigation, it was surprisingly found that 
the hexahistidine tag, which was introduced at the N-terminus of the capsid proteins 
for affinity purification purposes, was actually responsible for the observed background 
activity (Chapter 6). Additionally, it was found that this phenomenon occurred with 
several different types of proteins that were modified with a hexahistidine. As a proof-of-
principle, the activity of a hexahistidine-tagged enzyme was investigated. As expected, 
this enzyme was now able to catalyze a two-step cascade reaction. This example clearly 
illustrated the potential (unwanted) side effects of the introduction of a hexahistidine tag, 
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which might be intended solely for purification purposes.
In Chapter 7, an additional method for the selective N-terminal modification of the CCMV 
capsid proteins was investigated. In contrast to the Sortase methodology, this method did 
not require the introduction of a recognition peptide onto the desired cargo. Instead, a 
small reactive group containing an aldehyde functionality was used, which selectively 
cyclizes to protein N-termini. To make this methodology applicable to different cargoes, 
we decided to use a two-step approach. This involved the introduction of a functional 
bioorthogonal handle modified with the aldehyde in the first step, after which the protein 
could be reacted with the complementary bioorthogonal group, attached to a desired cargo. 
This reaction was successfully used to couple a fluorophore to the CCMV capsid protein, as 
a proof-of-principle. Additional studies into the attachment of an organocatalyst indicated 
that the coupling might have been successful, although this could not be shown through 
direct measurements. Future experiments should be aimed at directly proving successful 
coupling and measuring the catalytic activity of the resulting nanoreactors.
In contrast to the previous methods for cargo encapsulation, which were aimed at covalent 
attachment of the cargo to the N-terminus of the CCMV capsid proteins, we also investigated 
an approach in which cargo was encapsulated in a non-covalent way (Chapter 8). We were 
inspired by the fact that the capsid proteins naturally encapsulate nucleic acids. Therefore, 
we tried to encapsulate a DNA-based catalyst, towards the fabrication of another type of 
nanoreactor. Although the encapsulation of short strands of double-stranded DNA did 
not pose any problems, the entrapment of an assembled DNA-based catalyst was found to 
be more challenging. For instance, leakage of the catalytic metal center of the catalyst was 
probably observed, leading to an ineffective catalyst. 
Besides cargo encapsulation, an aspect we deemed important towards the application of 
CCMV for bionanotechnological purposes was the improvement of the stability of the 
capsids at physiological conditions. The approach we chose was to further improve the 
protein-based fusion between the CCMV capsid protein and a short elastin-like polypeptide 
(ELP), which was previously developed in our group. This variant could be assembled at 
physiological conditions, but still required salt concentrations which were far higher than 
physiologically relevant. In the study described in Chapter 9, we systematically changed 
the ELP-part of the fusion protein to lower the amount of salt required to let this protein 
assemble. It was found that the assembly behavior of the protein is quite predictable, based 
on the hydrophobicity of the short ELP. Additionally, improvements were made such that 
assembly could be achieved at close to physiological conditions.
Finally, in Chapter 10 an application of CCMV capsids in material science is described. 
The capsids were used as crosslinking nodes in biomimetic hydrogels, to introduce new 
functionalities to the gel. By changing the functionalization degree and concentration of 
the capsids, the mechanical behavior of the gel could be tuned. Additionally, rheology 
experiments at high stress levels indicated that the crosslinkers could be selectively 
deteriorated, offering possibilities for cargo release in future applications.
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SaMenVaTTing
De natuur grossiert in efficiënte en slimme oplossingen voor problemen. Dit komt omdat 
dieren en planten miljoenen jaren de tijd hebben gehad om processen te optimaliseren 
door middel van evolutie en natuurlijke selectie. Neem de opslag van ons DNA: hoewel het 
humane DNA enkele meters lang is, is het opgeslagen in een kleine celkern die qua grootte 
met het blote oog niet eens zichtbaar is.
Wetenschappers maken dankbaar gebruik van dit soort slimme oplossingen: veel inspiratie 
voor hedendaagse technologie is voortgekomen uit het bestuderen van de natuur en haar 
creativiteit in het oplossen van problemen. Een simpel voorbeeld is de verwerking van 
spinnenzijde in kogelwerende vesten om ze nog sterker te maken. Een volgende stap zou 
zijn om spinnenzijde na te kunnen maken, omdat we hierdoor het materiaal nog beter 
leren begrijpen en wellicht zelfs kunnen verbeteren voor bepaalde toepassingen.
Virussen zijn ook zo’n bron van inspiratie. We kennen virussen allemaal als de grote 
boosdoeners achter ziekten als Zika en HIV/AIDS. En ben je verkouden? Ook dat is de 
schuld van een virus. Je zou dus zeggen dat virussen alleen maar ellende veroorzaken. Toch 
kunnen we veel van ze leren en ze zelfs gebruiken voor nuttige toepassingen. Een interessant 
aspect van virussen is dat ze gebruikmaken van de bestaande lichaamsprocessen van hun 
gastheer, bijvoorbeeld de geïnfecteerde mens, om zichzelf voort te planten. Ze doen dit 
door hun genetisch materiaal, DNA of RNA, te injecteren in een cel van de gastheer, 
waarna de gastheer zelf nieuwe virussen gaat maken. Om het genetische materiaal veilig 
op de juiste plaats te krijgen zit het opgesloten in een mantel (capside), bestaande uit 
zogenaamde capside eiwitten. Doordat het hierin opgesloten zit, kan het onderweg niet 
aangetast worden en wordt het op de juiste plaats afgeleverd. Het feit dat deze typen 
eiwitmantels dus zo goed zijn in het beschermen van hun lading en het afleveren hiervan 
op een bepaalde locatie, maakt dat we ze ook voor andere doeleinden zouden kunnen 
gebruiken, bijvoorbeeld voor het afleveren van medicijnen op een bepaalde plaats in het 
lichaam. Voor de medische wetenschap is dit van groot belang. Hoe preciezer je kunt zijn 
in het sturen van medicijn naar de zieke delen van het lichaam, hoe effectiever dat medicijn 
zal zijn. En als je preciezer kunt zijn in de toediening, zijn ook de bijwerkingen minder.
Voor het onderzoek dat wordt beschreven in dit proefschrift hebben we in detail gekeken 
naar het capside van het plantenvirus ‘cowpea chlorotic mottle virus’ (CCMV). Dit is een 
virus dat de kousenband plant (cowpea) infecteert, wat duidelijk te zien is doordat de 
bladeren van de planten gele vlekken (chlorotic mottle) ontwikkelen. We hebben ervoor 
gekozen om met een plantenvirus te werken, omdat dit mogelijk minder snel reacties 
zal oproepen na het inbrengen in een menselijk lichaam, en dus minder giftig is voor de 
mens. Daarnaast heeft CCMV een aantal specifieke gunstige eigenschappen. Zo kunnen 
de capside eiwitten relatief makkelijk in het lab geproduceerd worden, terwijl andere 
virussen vaak uit een geïnfecteerde plant geëxtraheerd moeten worden, wat een tijdrovend 
proces is. Nog belangrijker is dat de capside eiwitten spontaan in capsiden assembleren in 
een zure omgeving, een omgeving met een lage pH, en dat ze ook weer uit elkaar gehaald 
kunnen worden door de zuurgraad te neutraliseren tot 7.5. Dit is chemisch weergegeven 
in Figuur 1. Deze bijzondere eigenschap geeft mogelijkheden om de capsiden een lading 
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figuur 1	 Capside	eiwitten	van	het	plantenvirus	CCMV	(links)	kunnen	onder	de	 juiste	omstandigheden	samen	
een	CCMV	capside	vormen,	een	hol	bolletje	met	een	eiwitwand	(rechts).	Deze	reactie	is	omkeerbaar:	de	capside	kan	
ook	weer	worden	geopend	waarbij	de	losse	capside	eiwitten	worden	verkregen.	Dit	proces	wordt	gestuurd	door	de	
zuurgraad	van	de	omgeving.	Bij	een	hoge	zuurgaad	(lage	pH)	zullen	voornamelijk	capsiden	aanwezig	zijn,	en	bij	een	
lage	zuurgraad	(hoge	pH)	zijn	voornamelijk	de	vrije	capside	eiwitten	aanwezig.
mee te geven, aangezien de deeltjes ‘open’ en ‘dicht’ gemaakt kunnen worden. Veel andere 
plantenvirussen hebben deze eigenschap niet. Die zijn alleen stabiel met hun virale DNA 
of RNA als lading, dat deze de capside eiwitten bij elkaar gebonden houdt. Dit heeft tot 
gevolg dat je minder makkelijk lading in kunt brengen, omdat deze deeltjes niet geopend 
kunnen worden én omdat de deeltjes al gevuld zijn met hun eigen genetisch materiaal en 
dus weinig ruimte over hebben voor extra lading.
Om de CCMV capsiden goed te kunnen gebruiken voor toepassingen zoals hierboven 
beschreven, hebben we naar een aantal aspecten gekeken: (i) betrouwbare manieren om 
lading in de deeltjes te stoppen, (ii) het behoud van de functionaliteit van de lading na het 
insluiten in de eiwitmantels, en (iii) het verbeteren van de stabiliteit van de deeltjes, opdat 
ze intact kunnen blijven in een menselijk lichaam.
De eerste projecten waren erop gericht de CCMV capsiden te voorzien van een lading. We 
hebben ervoor gekozen de lading vast te maken aan de binnenkant van de deeltjes, om 
zeker te weten dat de lading binnenin zou blijven zitten en om de hoeveelheid belading 
goed te kunnen regelen. In de hoofdstukken 3, 4 en 5 beschrijven we een methode die 
we hiervoor hebben toegepast, waarbij we gebruik hebben gemaakt van een enzym dat in 
bepaalde bacteriën kan ingrijpen op de samenstelling van het buitenoppervlak. Dit enzym 
hebben we gebruikt om verschillende ladingen aan de binnenkant van de capsiden vast 
te maken op een betrouwbare en reproduceerbare manier. Daarbij hebben we kunnen 
aantonen dat deze lading zijn functionaliteit behoudt.
In hoofdstuk 7 hebben we een alternatieve methode getest om aanpassingen aan de 
binnenkant van de CCMV capsiden te doen om die geschikt te maken voor het dragen 
van een lading. In dit geval was er geen toevoeging van een enzym nodig, wat de reactie 
wat eenvoudiger maakt. Ook leent deze methode zich beter voor andere typen lading, 
waardoor het een mooie aanvulling is op de eerder beschreven enzymatische methode.
Daarnaast was een belangrijk doel de stabiliteit van de deeltjes te verbeteren. In planten 
zijn de CCMV virussen stabiel, omdat ze gestabiliseerd worden door hun virale RNA. 
Aangezien wij andere ladingen willen insluiten, werken we met capsiden zonder RNA. 
Deze capsiden missen dus de noodzakelijke aantrekking tot hun lading die ervoor zorgt 
dat ze stabiel blijven.
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figuur 2	 De	CCMV	 capside	 eiwitten	 zijn	 nu	 voorzien	 van	 een	 verlenging,	 een	 extra	 stukje	 eiwit.	 Dit	 zijn	 de	
rode	staarten	(ELP)	links.	Met	de	juiste	prikkels	kunnen	die	verlengingen	worden	aangezet	elkaar	vast	te	pakken	en	
daarmee de capsiden te vormen en stabiliteit te geven (rechts).
Hiermee zijn de grote lijnen van mijn onderzoek hopelijk voor een ieder helder geworden. 
Houd er rekening mee dat deze samenvatting op een aantal punten is gesimplificeerd 
omwille de begrijpelijkheid. Meer details zijn te vinden in de Engelstalige samenvatting, 
en natuurlijk in de overige hoofdstukken van dit proefschrift.
Nu is het al wel gebleken dat stabiele deeltjes gemaakt kunnen worden door het insluiten 
van een lading die soortgelijke eigenschappen heeft als RNA. Dit werkt echter niet 
voor alle ladingen, omdat die nu eenmaal niet allemaal deze gunstige eigenschappen 
hebben. Daarom hebben we gezocht naar een algemeen toepasbare manier om de 
deeltjes te stabiliseren. Onze oplossing lag in werk dat eerder uitgevoerd was in onze 
onderzoeksgroep, waarin de capside eiwitten werden verlengd met een stukje eiwit (ELP). 
Die stukjes eiwit gaan onder invloed van de juiste externe stimuli opeenhopen met andere 
ELP fragmenten. Door dit eiwit aan de binnenkant van de capsiden te zetten, kon het 
samenkomen van deze ELPs de capsiden stabiliseren, ook onder omstandigheden waarin 
ze normaal niet stabiel zouden blijven. Deze truc wordt schematisch weergegeven in 
Figuur 2. In hoofdstuk 9 hebben we dit werk verder uitgebreid door de ELP’s systematisch 
aan te passen, om zo steeds stabielere deeltjes te vormen. Hierbij hebben we toegewerkt 
naar deeltjes die stabiel zijn in een omgeving die vergelijkbaar is met de omstandigheden 
in ons lichaam, zogenaamde fysiologische omstandigheden. Dit werk kan de basis vormen 
voor toekomstige experimenten, waarin de CCMV capsiden kunnen worden beproefd als 
drager van medicijnen in een lichaam.
207
Samenvatting
208
Addendum
LiST of abbreViaTionS
2PCA 2-Pyridinecarboxaldehyde
AaLS Aquifex aeolicus lumazine synthase
ABTS 2,2'-Azino-bis(3-ethylbenzothiazoline-6-sulfonic acid)
AHA l-Azidohomoalanine
Anl Azido-l-norleucine
ANS 8-Anilino-1-naphthalenesulfonic acid
ATRP Atom transfer radical polymerization
β-CD β-cyclodextrin
BG Background
BMV Brome mosaic virus
BSA Bovine serum albumin
BVMO Baeyer-Villiger monooxygenase
CalB Candida antarctica lipase B
CCMV Cowpea chlorotic mottle virus
CFDA Carboxyfluorescein diacetate
CMV Cucumber mosaic virus
CPMV Cowpea mosaic virus
CYP Cytochrome P450
d.e. Diastereomeric excess
DBCO Dibenzocyclooctyne
Dec Decorating protein
DIPCDI N,N'-diisopropylcarbodiimide
DLS Dynamic light scattering
dmbpy 4,4’-Dimethyl-2,2’-bipyridine
DMF Dimethylformamide
DMSO Dimethylsulfoxide
DNA Deoxyribonucleic acid
dNTP Deoxynucleotide
Dox Doxorubicin
DTT 1,4-Dithiothreitol
E. coli Escherichia coli
e.e. Enantiomeric excess
EDC N-ethyl-N’-(3-dimethylaminopropyl)-carbodiimide
EDTA Ethylenediaminetetraacetic acid
EGFP Enhanced green fluorescent protein
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EGFR Epidermal growth factor receptor
ELP Elastin-like polypeptide
ESI-TOF Electrospray ionization time-of-flight
Eut Ethanolamine utilization
FA Folic acid
FAD Flavin adenine dinucleotide
FITC Fluorescein isothiocyanate
FT-IR Fourier-transform infrared spectroscopy
G’ Storage modulus
GFP Green fluorescent protein
HBV Human hepatitis B virus
HCC Hepatocellular carcinoma
HCRSV Hibiscus chlorotic ringspot virus
HEPES 4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid)
HF High-fidelity
HFn Human ferritin
HOBt 1-Hydroxybenzotriazole
HPG l-Homopropargylglycine
HPLC High-performance liquid chromatography
HSA Human serum albumin
ICP-MS Inductively coupled plasma mass spectrometry
IPTG Isopropyl β-d-1-thiogalactopyranoside
K' Differential modulus
LB Lysogeny broth
LC-MS Liquid chromatography-mass spectrometry
LCST Lower critical solution temperature
LiDps Listeria innocua DNA-binding protein from starved cells
LVE Linear visco-elastic
m Stiffening index
M.	luteus Micrococcus luteus
MALLS Multi-angle laser light scattering
MES 2-(N-morpholino)ethanesulfonic acid
MjHsp Methanococcus jannaschii small heat-shock protein
MQ Milli-Q water
MW Molecular weight
MWCO Molecular weight cut-off
NADPH Nicotinamide adenine dinucleotide phosphate
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NHS N-hydroxysuccinimide
NMR Nuclear magnetic resonance
NTA Nitrilotriacetic acid
o-PD o-Phenylenediamine
OD Optical density
p-NP p-Nitrophenol
p-NPA p-Nitrophenyl acetate
p-NPB p-Nitrophenyl butyrate
p-NPP p-Nitrophenyl phosphate
pAF p-Amino-l-phenylalanine
PAMO Phenylacetone monooxygenase
PBS Phosphate buffered saline
PCR Polymerase chain reaction
PDB Protein data bank
PDT Photodynamic therapy
PEG Polyethylene glycol
PfFn Pyrococcus furiosus ferritin
PIC Polyisocyanopeptide
pNA p-Nitroanilide
ppm Parts per million
Pro Proline
PVX Potato virus X
QELS Quasi-elastic light scattering
RCNMV Red clover necrotic mosaic virus
Rf Retention factor
Rg Radius of gyration
Rh Hydrodynamic radius
RNA Ribonucleic acid
rpm Rounds per minute
S. aureus Staphylococcus aureus
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis
SEC Size exclusion chromatography
sHsp Small heat-shock protein
SP Scaffolding protein
SPPS Solid-phase peptide synthesis
SrtA Sortase A
st-DNA Salmon testes DNA
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SV40 Simian vacuolating virus 40
T4L T4 lysozyme
TEM Transmission electron microscopy
TEV Tobacco etch virus
Tfn Transferrin
THS Thermoplasma acidophilum thermosome
TMV Tobacco mosaic virus
Tris Tris(hydroxymethyl)aminomethane
Tt Transition temperature
TYMV Turnip yellow mosaic virus
UV-vis Ultraviolet-visible
VBA Vinylboronic acid
VLP Virus-like particle
wt Wild-type
ZYMV Zucchini yellow mosaic virus
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DankwoorD
Iedereen zegt het, maar het is ook echt zo: vier jaar lijkt een lange tijd, maar het vliegt 
voorbij! Na het meten van zo'n 900 UV-vis spectra, het maken van 500 SDS-PAGE gels 
en het dialyseren van zo’n 600 AccuTOF samples, en daarbij nog een heleboel andere 
metingen, ligt hier dan het resultaat. Deze metingen heb ik grotendeels zelf uitgevoerd, 
maar dat had ik nooit kunnen doen zonder de hulp van de talloze mensen die op de één of 
andere manier hebben bijgedragen aan dit onderzoek. Ik zou hierbij graag gebruik maken 
van de gelegenheid om hen hiervoor te bedanken. Daarnaast zou ik nog een aantal mensen 
in het bijzonder willen noemen.
Jan, bedankt dat je me vier jaar geleden de kans hebt gegeven om aan dit geweldige 
onderzoek te werken. Ik ben blij dat je me het vertrouwen gaf dit project over te nemen, 
ook al had ik nog geen enkele ervaring op het gebied van eiwitexpressie of biochemische 
experimenten. Ik waardeer het dat je me altijd de vrijheid hebt gegeven om eigen ideeën 
in te brengen en zelf projecten op te starten. Ik heb ontzettend veel geleerd de afgelopen 
jaren, en dat is mede dankzij het vertrouwen en de vrijheid die je me gegeven hebt.
Roeland, bedankt voor je betrokkenheid bij het virus project. Het was motiverend om 
te merken hoe enthousiast je nog altijd over dit onderwerp bent, en dat heeft me zeker 
geholpen op de momenten dat het wat minder ging.
I would like to thank the doctoral thesis committee, consisting of Prof. Ger Pruijn, Prof. 
Mauri Kostiainen and Prof. Maarten Merkx, for critically reading and correcting this 
thesis. Ook ben ik Prof. Jeroen Cornelissen, Prof. Gerard Roelfes en Dr. Kim Bonger 
dankbaar voor hun deelname aan mijn promotiecommissie. 
Dit onderzoek is gefinancierd door, en uitgevoerd als onderdeel van het Research Center 
for Functional Molecular Systems, in samenwerking met de TU/e en de Rijksuniversiteit 
Groningen. Ik zou graag alle betrokkenen willen bedanken voor hun input bij de jaarlijkse 
bijeenkomsten. Deze waren altijd zeer inspirerend en interessant en gaven vaak stof tot 
nadenken. Daarnaast wil ik graag Marta bedanken voor haar rol als project manager bij 
het FMS, en toevalligerwijs ook haar eerdere werk aan CCMV.
Ik ben me ervan bewust dat er een heleboel dingen zijn geweest waar ik me niet druk 
over hoefde te maken, omdat die allemaal achter de schermen geregeld werden. Marieke, 
heel erg bedankt voor de administratieve ondersteuning, gezellige bijklets-momentjes en 
natuurlijk het gezamenlijk organiseren van de kerstborrel (een traditie die we toch een 
aantal jaren staande hebben mogen houden!). Ook Desiree (nog zo'n vroege vogel!) 
Jacky en Paula wil ik graag bedanken voor de administratieve hulp. Daarnaast zou ik 
graag Marjo willen bedanken voor de hulp bij de verhuizing naar Eindhoven. Ook al ben 
ik niet echt officieel verhuisd, ik ben dankbaar voor alles wat je hebt geregeld, zodat ik toch 
makkelijk op bezoek kon komen bij de groep.
Peter (van Dijk), sjah... waar beginnen we?! Misschien dekt dit de lading wel het beste: 
bedankt voor alles! Het is ongelofelijk hoe onvermoeibaar je bent en hoe je altijd voor 
iedereen klaarstaat om te helpen wanneer nodig. Naast de oneindige hoeveelheid 
praktische hulp zal ik onze gesprekken zeker het meeste missen.
Jan (Dommerholt), dankjewel voor je hulp bij bestellingen, het achter de broek zitten 
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van verkopende partijen en nog veel meer regel-dingen. Ik vind het bijzonder hoe je dit 
altijd zo onuitputtelijk hebt kunnen doen, ook al kwam het soms wel voor dat je me voor 
de vijfde keer moest uitleggen hoe Labservant nou ook alweer werkte als ik zo’n gekke 
biochemische kit wilde bestellen...
Daarnaast wil ik graag bedanken: Peter (van Galen) voor de (regelmatige) technische 
ondersteuning bij de ESI-TOF, Helene voor het meerdere malen te hulp schieten bij HPLC 
problemen, Paul (White) voor het fantastisch uitbreiden van de NMR faciliteiten, Dani 
voor hulp bij chemische vraagstukken, Hans voor het synthetiseren van enkele peptiden 
voor verschillende projecten, Geert-Jan voor technische ondersteuning bij de TEM, 
Liesbeth voor het gezamenlijk aankopen en onderhoud aan de platereader, Paul (van der 
Ven) voor een aantal ICP-MS metingen, en Thea, Nelly en Ronald van het LEM voor het 
faciliteren van het ML-I werk dat ik heb gedaan op het RIMLS.
Ik begon al tijdens mijn bachelorstage op het lab in vleugel 1 op de 3e, waarbij ik zowel 
van de Synthetische Organische Chemie groep en de Bio-Organische Chemie groep deel 
mocht uitmaken. Dit beviel zo goed, dat ik hier ook het grootste deel van mijn master heb 
doorgebracht. Jorgen, bedankt voor je begeleiding tijdens deze periode, waarin ik voor 
het eerst echt kennismaakte met onderzoek. Dit heeft me gemotiveerd om te beginnen 
met een promotie! Ook wil ik graag Henri en Marjoke bedanken, van wie ik een aantal 
belangrijke lessen heb geleerd die ik nog altijd niet vergeten ben. Ik ben blij dat de traditie 
van de streepjesborrels, waar ik in deze periode al van heb mogen genieten, ook in de 
van Hest groep hoog in het vaandel heeft gestaan! Ik zou ook graag Timo en Dr. Peter 
Quaedflieg willen bedanken voor hun begeleiding tijdens mijn tweede masterstage, waar 
ik aan een heel nieuw onderwerp mocht werken en ook enorm van het onderzoek heb 
genoten.
En toen kwam het moment dat ik van de synthetische chemie weg ging en de biochemie 
in dook. Mark, dit was nooit zo soepel gelopen zonder jouw hulp! Van klonering en 
eiwitexpressie, tot size-exclusion chromatografie en TEM, ik heb het allemaal van jou 
geleerd! Heel erg bedankt voor je begeleiding, geduld en meedenken tijdens de eerste 
maanden van mijn PhD (en ook lange tijd daarna). Het was ontzettend fijn om op deze 
manier te beginnen en langzaam het project over te nemen toen jouw tijd erop zat.
Lianne, wij kenden elkaar al enkele jaren toen we collega’s werden, omdat we ook al samen 
gestudeerd hadden. Ons gezamenlijk enthousiasme voor muziek heeft ons gedurende 
die tijd, maar vooral de laatste jaren, vaak samen op concerten en festivals gebracht, een 
traditie die we zeker nog een tijd vol gaan houden! Toch wel handig als ik je zocht, want als 
er De Staat of Todd Terje op het lab aanstond, wist ik dat je niet ver weg kon zijn! En ook 
bedankt voor het overdragen van je passie voor motorrijden, misschien heeft dat me wel 
over de streep getrokken om zelf ook mijn rijbewijs te gaan halen!
Imke, helaas hebben we in Nijmegen weinig overlap gehad omdat je al snel naar Eindhoven 
verhuisde, maar desalniettemin was het ontzettend fijn om je als college te hebben. Je 
was er altijd om mee te lachen, maar ook als luisterend oor wanneer nodig. Bedankt voor 
alle gezelligheid als buurvrouw in Eindhoven, maar ook tijdens BBQ’s, borrels, winkelen 
(dat kunnen we misschien iets te goed samen, aldus de ING!), wijntjes, panda's kijken, 
concerten, festivals, en wellicht ook nog wel motorrijden in de toekomst… Lianne en Imke, 
ontzettend bedankt dat jullie me tijdens mijn verdediging willen bijstaan als paranimfen!
214
Addendum
I would like to thank all colleagues from the Van Hest, Rutjes and other groups for 
the nice time I had during my PhD: Abbas, Albert, Alejandra, Alex, Amy, Angelique, 
Anika, Annelies, Annika, Bastiaan (leuk dat we uiteindelijk van studiegenoten ook nog 
collega’s, én natuurlijk leden van Jack & the Daniels zijn geworden), Bram, Britta, Chiara, 
Daan, Daniël, Danny, Dave, David (bedankt voor de mede-organisatie van het groepsuitje 
naar Gent), Dennis, Emilia (it was nice to have you as a buddy who could relate to all 
problems occurring when working on proteins), Fei, Ferdi, Fleur, Guizhi, Hailong, Hidde, 
Ilmar, Ilia, Imke, Ivan, Jaleesa (het was een beetje jammer dat je in Oss werkte, maar 
toch leuk dat we officieel lollie-collega’s zijn geweest!), Jan (Pille) (bedankt voor de vele 
inhoudelijke discussies en onze nog doorlopende samenwerking), Jianzhi, Jingxin, Joep, 
Jorge, Lianne, Loai, Marcel, Mariëlle, Mark, Marlies, Mathijs, Mona, Nanda (bedankt 
voor alle hulp tijdens mijn eerste maanden, en daarnaast natuurlijk voor alle gezelligheid 
tijdens borrels en etentjes), Pascal (wellicht starten we ooit nog wel een eigen pineapple 
motorclubje!), Petra, Pim, René, Rens, Rinske, Roel, Roger, Roxane, Ruud, Ryan, Sanne, 
Saskia (bedankt voor de gezellige pauze’s en de sollicitatie tips!), Selma (bedankt voor 
alle gezelligheid de afgelopen jaren, tijdens borrels, EHBO cursussen en pilates lessen, en 
daarnaast ook bedankt voor onze samenwerking, waarvan het resultaat beschreven staat in 
hoofdstuk 7), Shoupeng, Silvie, Sjoerd, Stefan (bedankt voor de gezamenlije (nachtelijke) 
motortochtjes), Stijn (bedankt voor je motiverende woorden en gezelligheid), Suzanne, 
Teresa, Ton, Torben, Victor, Yingfeng, Yongjun and Zhipeng.
Buiten het lab was het altijd gezellig in ons ‘U-tje’, waarvan de samenstelling over de jaren 
nogal wat veranderd is. Mark, Nanda, Zhipeng, Annika, Ryan, Jan, Selma, Lianne, 
Imke en Fleur, bedankt voor alle maandagochtend bijklets sessies, interesse, koffiepauze’s, 
wandelingetjes door het park, én snoepjes natuurlijk. 
Ook zou ik graag de Biomoleculaire Chemie groep willen bedanken, voor het altijd terecht 
kunnen met ‘bio-vragen’, een stukje taart of wat gezelligheid tijdens een bezoekje aan het 
RIMLS (de overkant), met in het bijzonder: Bas, Cynthia, Fleur, Ger, Ilmar, Merel, 
Wilbert en Wilma. En als er dan problemen waren op de 2e verdieping op het RIMLS, dan 
was Siebe er altijd om ze op te lossen, zelfs op de vroege ochtend. Bedankt daarvoor.
During my PhD project, I’ve had the chance to collaborate with a number of people and 
research groups on varying projects. I would like to thank Dowine, Ana and Gerard 
from the Rijksuniversiteit Groningen for our long-lasting collaboration, of which the 
results have been described in Chapter 8. Ik ben het grootste deel van mijn PhD traject 
als enige in de groep met CCMV bezig geweest, maar gelukkig was ik niet de enige in de 
omgeving. Stan, Mark, Robin, Jeroen en de rest van de groep uit Enschede, bedankt 
voor de nuttige discussies, het af en toe opsturen van wild-type CCMV en de gezelligheid 
(o.a. alle potjes boerenbridge/’farmersbridge’) op de GRC in Italië. Daarnaast zou ik graag 
Daniël, Paul en Alan willen bedanken voor de samenwerking die heeft geleid tot de 
resultaten die beschreven staan in hoofdstuk 10. I would like to thank Joe Wang from the 
EM Center in Bloomington and Paul Bomans from the TU/e for their help with cryo-
TEM measurements. Furthermore, I would like to acknowledge Salla Välimäki and Prof. 
Mauri Kostiainen from the Aalto University for our still ongoing collaboration. Lastly, I 
would like to thank Dr. Chunqiu Zhang and Prof. Rein Ulijn from the City University of 
New York for the joint project. Unfortunately, the original idea didn’t work, but the project 
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did yield some unexpected and interesting results (see Chapter 6). 
Naast deze samenwerkingen heb ik ook een aantal studenten mogen begeleiden tijdens de 
afgelopen vier jaar. Jochem en Daan, bedankt voor jullie bijdragen tijdens de beginfase 
van mijn PhD. Sjors, je was meteen erg handig op het lab en dit heeft er mede voor 
gezorgd dat je hebt kunnen bijdragen aan het onderzoek beschreven in hoofdstuk 5. Ilva, 
je stage was maar kort, maar toch heb je een deel van de data van hoofdstuk 8 kunnen 
verzamelen. Succes met het afronden van je master! Margo, jij kreeg een uitdagend project 
voorgeschoteld met voornamelijk ingewikkelde synthese, maar je hebt het nooit opgegeven. 
Dankjewel voor alle energie die je in het project hebt gestoken! Dit heeft ervoor gezorgd dat 
we hiermee door hebben kunnen gaan en de resultaten hebben behaald die in hoofdstuk 
7 beschreven staan. Martin, jij begon als BSc student aan het uitdagende project, waarin 
we PIC hydrogels wilden combineren met CCMV. Wat fijn dat je bent blijven hangen als 
MSc student, om het project tot een goed einde te brengen (zie hoofdstuk 10). Roel, jij 
wilde een moeilijk project, en dat heb je gekregen! Maar dat was voor jou helemaal geen 
probleem, en je hebt een stevige basis gelegd voor het werk beschreven in hoofdstuk 9. Ik 
weet zeker dat je het geweldig gaat doen tijdens je eigen promotieonderzoek. Kayleigh, 
jij kwam als Honours student stage lopen, wat betekende dat je ook een deel van je stage 
in het buitenland moest doen. Gelukkig hadden we daar een zeer geschikt project voor 
liggen, waardoor je tijdens het tweede deel van je stage af kon reizen naar New York. Je hebt 
ontzettend hard gewerkt, en ook al werkte het originele idee niet, er zijn zeer interessante 
resultaten uit gekomen die we hebben kunnen uitbreiden tot de resultaten beschreven in 
hoofdstuk 6. Nathalie, op de valreep wilde jij komen werken aan een project dat Jan (Pille) 
en ikzelf al jaren in ons achterhoofd hadden, maar nooit echt de tijd voor hadden gehad. 
Ik ben zeer benieuwd naar de toekomstige resultaten!
I’ve been lucky enough to be able to hand over the CCMV project to new talented PhD 
students, while finishing up my own PhD. Suzanne, Daan and Chiara, thank you for 
continuing the CCMV research in Eindhoven. I wish you the best of luck with the research, 
and, of course, lots of fun with the Bio-Organic Chemistry group!
Naast alle collega’s zou ik ook graag mijn (schoon)familie en vrienden willen noemen. 
Bedankt voor de gezelligheid, interesse en afleiding wanneer nodig. Jullie hebben me 
altijd gesteund in de keuzes die ik maakte en dat heb ik zeker gewaardeerd. Een speciaal 
bedankje gaat uit naar Elke: dankjewel dat je de opmaak van dit proefschrift op je hebt 
willen nemen. Wat bof ik toch met zo’n creatieve zus!
Tot slot, Jack, bedankt dat je altijd voor me klaarstaat. Je hebt me gesteund tijdens de 
dalletjes in de afgelopen vier jaar, maar ook vooral gevierd tijdens de hoogtepunten. In het 
vervolg moeten we toch maar een nieuwe reden verzinnen om naar ons favoriete restaurant 
te gaan (en misschien ook maar meteen een nieuwe Rotterdamse equivalent zoeken...)! 
Lieve Jack, ik hou van je, en ik kijk enorm uit naar onze toekomst samen!
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